<SEC-DOCUMENT>0001193125-24-090862.txt : 20240409
<SEC-HEADER>0001193125-24-090862.hdr.sgml : 20240409
<ACCEPTANCE-DATETIME>20240409162816
ACCESSION NUMBER:		0001193125-24-090862
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240409
DATE AS OF CHANGE:		20240409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			biote Corp.
		CENTRAL INDEX KEY:			0001819253
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851791125
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266433
		FILM NUMBER:		24833064

	BUSINESS ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038
		BUSINESS PHONE:		972-486-9346

	MAIL ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Haymaker Acquisition Corp. III
		DATE OF NAME CHANGE:	20200727
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d822744d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR> Registration No. 333-266433<BR> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>biote Corp. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to
5,000,000 Shares of Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale of up to 5,000,000 shares (the &#147;Shares&#148;) of our Class&nbsp;A common stock, $0.0001 par value
per share (the &#147;Class&nbsp;A common stock&#148;), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the &#147;Selling Securityholder&#148;). The shares included in this prospectus consist of shares of Class&nbsp;A common stock
that we have issued or that we may, in our discretion, elect to issue and sell to the Selling Securityholder, from time to time after the date of this prospectus, pursuant to a standby equity purchase agreement we entered into with the Selling
Securityholder on July&nbsp;27, 2022 (the &#147;Purchase Agreement&#148;), in which the Selling Securityholder has committed to purchase from us, at our direction, up to 5,000,000 shares our Class&nbsp;A common stock, subject to terms and conditions
specified in the Purchase Agreement. Concurrently to the Purchase Agreement, we issued 25,000 shares of Class&nbsp;A common stock to the Selling Securityholder on July&nbsp;27, 2022 as consideration for its irrevocable commitment to purchase shares
of our Class&nbsp;A common stock at our election in our discretion, from time to time after the date of this prospectus, upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement. See the section entitled
&#147;Committed Equity Financing&#148; for a description of the Purchase Agreement and the section entitled &#147;Selling Securityholder&#148; for additional information regarding the Selling Securityholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registration of the securities covered by this prospectus does not mean that the Selling Securityholder will offer or sell any of the
shares of Class&nbsp;A common stock. The Selling Securityholder may offer, sell or distribute all or a portion of their shares of Class&nbsp;A common stock publicly or through private transactions at prevailing market prices or at negotiated prices.
We will not receive any proceeds from the sale of shares of Class&nbsp;A common stock by the Selling Securityholder pursuant to this prospectus. However, we expect to receive proceeds from sales of Class&nbsp;A common stock that we may elect to make
to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. See &#147;Committed Equity Financing&#148; for a description of how the price we may sell shares of Class&nbsp;A common stock to the
Selling Securityholder is calculated pursuant to the Purchase Agreement. We provide more information about how the Selling Securityholder may sell or otherwise dispose of the shares of our Class&nbsp;A common stock in the section entitled &#147;Plan
of Distribution.&#148; The Selling Securityholder is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;) and a &#147;smaller reporting company&#148; as defined in Section&nbsp;10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and are subject to reduced public company reporting
requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A
common stock is quoted on the Nasdaq Stock Market LLC under the symbol &#147;BTMD&#148;. On April&nbsp;8, 2024, the last reported sales price of our Class&nbsp;A common stock was $5.93. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See the section entitled &#147;<U><A HREF="#toc822744_5">Risk Factors</A>&#148;
beginning on page 16 of this prospectus to read about factors you should consider before buying our securities. </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is April&nbsp;9, 2024. </B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_6">COMMITTED EQUITY FINANCING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_8">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_9">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_13">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_14">PRINCIPAL SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_15">SELLING SECURITYHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_16">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_17">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_18">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_19">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_20">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc822744_21">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information provided in this prospectus, as well as the information
incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the Selling Securityholder have authorized anyone to provide you with different information. Neither we nor the Selling Securityholder are making
an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable
document. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </B></P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) using the &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Securityholder may, from time to time, sell the securities offered by them described in this prospectus.
We will not receive any proceeds from the sale of the securities offered by the Selling Securityholder described in this prospectus. However, we expect to receive proceeds from sales of Class&nbsp;A common stock that we may elect to make to the
Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. The net proceeds from sales, if any, under the Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common
Stock to the Selling Securityholder after the date of this prospectus. See &#147;Committed Equity Financing&#148; for a description of how the price we may sell shares of Class&nbsp;A common stock to the Selling Securityholder is calculated pursuant
to the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder have authorized anyone to provide you with any information or to
make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling
Securityholder take responsibility for, or provide any assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholder will make an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration
statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the
additional information to which we refer you in the sections of this prospectus entitled &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;26, 2022 (the &#147;Closing Date&#148;), Haymaker Acquisition Corp. III, a Delaware corporation (&#147;HYAC&#148;), completed the
transactions contemplated by that certain Business Combination Agreement, dated as of December&nbsp;13, 2021 (the &#147;Business Combination Agreement&#148;), by and among HYAC (the &#147;Sponsor&#148;), BioTE Holdings, LLC, a Nevada limited
liability company (&#147;Biote&#148; and, together with its direct and indirect subsidiaries, the &#147;Biote Companies&#148;), BioTE Management, LLC, a Nevada limited liability company, Dr.&nbsp;Gary Donovitz, in his individual capacity, and Teresa
S. Weber, in her capacity as the members&#146; representative (in such capacity, the &#147;Members&#146; Representative&#148;) of the members of Biote immediately prior to the closing (the &#147;Closing&#148;) of the transactions contemplated by the
Business Combination Agreement (collectively, the &#147;Members&#148;). A description of the Business Combination (as defined below) and the terms of the Business Combination Agreement are included in the definitive proxy statement (File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-40128)</FONT> (the &#147;Proxy Statement&#148;) filed by HYAC with the SEC on May&nbsp;5, 2022 in the section titled &#147;Proposal No. <FONT STYLE="white-space:nowrap">1-The</FONT> Business Combination
Proposal.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, (i)&nbsp;Biote transferred to the Company (as defined below) 9,161,771 Class&nbsp;A common units of Biote
(&#147;Biote Units&#148;), which was equal to the number of shares of HYAC&#146;s Class&nbsp;A common stock, par value $0.0001 per share (&#147;HYAC Class&nbsp;A Common Stock&#148;), issued and outstanding as of immediately prior to the Closing
(after giving effect to redemptions by HYAC&#146;s public stockholders of 30,525,729 shares of HYAC Class&nbsp;A Common Stock prior to the Closing and the conversion of HYAC&#146;s Class&nbsp;B common stock, par value $0.0001 per share (&#147;HYAC
Class&nbsp;B Common Stock&#148;)) into shares of HYAC Class&nbsp;A Common Stock and (ii)&nbsp;HYAC issuance of 58,565,824 shares of newly authorized Class&nbsp;V voting stock, par value $0.0001 per share (&#147;Class&nbsp;V voting stock&#148; and,
together with the Class&nbsp;A common stock, the &#147;Common Stock&#148;), which number of shares of Class&nbsp;V voting stock was equal to the number of Biote Units retained by the Members immediately following the Closing (the &#147;Retained
Biote Units&#148;), and which shares of Class&nbsp;V voting stock were distributed to Biote&#146;s Members, resulting in the Combined Company being organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure. The transactions
contemplated by the Business Combination Agreement are referred to herein as the &#147;Business Combination.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also at Closing, (x)&nbsp;in exchange for Biote issuing to the Company 9,161,771 Biote Units
(the &#147;Closing Biote Units&#148;), HYAC transferred cash in an amount equal to (i)&nbsp;the cash in the trust account and any cash held by HYAC outside of the trust account, less (ii)&nbsp;the amounts required by the redemptions of Class&nbsp;A
common stock by the public stockholders, which was equal to $305.5&nbsp;million and (y)&nbsp;the Biote Companies received aggregate proceeds of $125.0&nbsp;million from the Debt Financing (as defined below) (the aggregate amounts described in
(x)&nbsp;and (y) of $137.3&nbsp;million, are referred to as the &#147;Closing Date Cash&#148;) in accordance with and in the priority set forth in the Business Combination Agreement and as described further in the Proxy Statement. There was no cash
consideration paid to Members at Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Closing, HYAC as the registrant changed its name to &#147;biote Corp.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, the terms &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; and the &#147;Company&#148; refers to biote
Corp. and its consolidated subsidiaries, including Biote, following the Closing, and references to &#147;HYAC&#148; refer to Haymaker Acquisition Corp. III at or prior to the Closing. All references herein to the &#147;Board&#148; refer to the board
of directors of the Company after giving effect to the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN DEFINED TERMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, the following terms have the following meanings when used in this prospectus: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Affiliate</I>&#148; of any particular Person means any other Person controlling, controlled by, or under common control with such
Person, where &#147;<I>control</I>&#148; means the possession, directly or indirectly, of the power to direct the management and policies of a Person, whether through the ownership of voting securities, its capacity as a sole or managing member, or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Biote&#148;</I> means BioTE Holdings, LLC, unless otherwise noted, a Delaware limited liability company after the
plan of conversion filed with the Nevada Secretary of State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Biote A&amp;R OA</I>&#148; means the Second Amended and Restated
Operating Agreement of entered into at the Closing by and among the Combined Company, Biote and the Members, which, among other things, permitted the issuance and ownership of Biote Units as contemplated to be issued and owned following the Closing,
designate the Combined Company as the sole manager of Biote, provide for the Exchange Rights, set forth the rights and preferences of the Biote Units, and establish the ownership of the Biote Units by the persons or entities indicated in the Biote
A&amp;R OA, in each case, as more fully described in the Biote A&amp;R OA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Biote Companies</I>&#148; means Biote, together with
all of its direct and indirect subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Biote Medical</I>&#148; means BioTE Medical, LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Bylaws</I>&#148; means the amended and restated bylaws of the Company, dated as of February&nbsp;21, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Charter</I>&#148; means the second amended and restated certificate of incorporation of the Company, dated as of the Closing Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Class</I><I></I><I>&nbsp;A Units</I>&#148; means the Class&nbsp;A Units (as defined in the Biote A&amp;R OA) issued and
outstanding immediately prior to the consummation of the Recapitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Class</I><I></I><I>&nbsp;AA Units</I>&#148; means the
Class&nbsp;AA Units (as defined in the Biote A&amp;R OA) issued and outstanding immediately prior to the consummation of the Recapitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Class</I><I></I><I>&nbsp;AAA Units</I>&#148; means the Class&nbsp;AAA Units (as defined in the Biote A&amp;R OA) issued and
outstanding immediately prior to the consummation of the Recapitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Class</I><I></I><I>&nbsp;AAAA Units</I>&#148; means
the Class&nbsp;AAAA Units (as defined in the Biote A&amp;R OA) issued and outstanding immediately prior to the consummation of the Recapitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Class</I><I></I><I>&nbsp;B Common Stock Conversion</I>&#148; means, in connection with the Closing, the conversion of all
then-outstanding shares of Class&nbsp;B common stock into shares of Class&nbsp;A common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Closing Date</I>&#148; means May&nbsp;26, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Combined Company</I>&#148; means biote Corp. and its consolidated subsidiaries, including Biote, following the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Common Stock</I>&#148; means the Class&nbsp;A common stock and Class&nbsp;V voting stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Credit Agreement</I>&#148; means the Credit Agreement, dated as of May&nbsp;26,
2022, by and among BioTE Medical, Biote, the guarantors identified therein, the lenders party thereto from time to time, Truist Bank, as Administrative Agent, Swingline Lender and Issuing Bank, Bank of America, N.A. and Wells Fargo Bank, National
Association, as <FONT STYLE="white-space:nowrap">Co-Syndication</FONT> Agents, Truist Securities, Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Debt Financing</I>&#148; means the Term Loan, the Revolving Loans and the Credit Agreement, collectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Earnout Voting Shares</I>&#148; means 10,000,000 shares of Class&nbsp;V voting stock distributed to the Members by Biote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Exchange Rights</I>&#148; means, beginning on the six month anniversary of the Closing, the rights of the Members to have their
Retained Biote Units redeemed, together with one share of Class&nbsp;V voting stock and subject to certain conditions, in exchange for either one share of Class&nbsp;A common stock or in certain circumstances, at the election of the Company in its
capacity as the sole manager of Biote, the cash equivalent of the market value of one share of Class&nbsp;A common stock, pursuant to the terms and conditions of the Biote A&amp;R OA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Equity Securities</I>&#148; means, with respect to any Person, all of the shares of capital stock or equity of (or other ownership or
profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock or equity of (or other ownership or profit interests in) such Person, all of the securities
convertible into or exchangeable for shares of capital stock or equity of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares or equity (or such other
interests), restricted stock awards, restricted stock units, equity appreciation rights, phantom equity rights, profit participation and all of the other ownership or profit interests of such Person (including partnership or member interests
therein), whether voting or nonvoting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Founder Holders</I>&#148; means each of the Sponsor, Steven J. Heyer and Andrew R. Heyer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Founder Shares</I>&#148; means the shares of Class&nbsp;B common stock held by the Founder Holders, which such shares of
Class&nbsp;B common stock automatically converted into an equal number of shares of Class&nbsp;A common stock in connection with the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Governmental Entity</I>&#148; means any nation or government, any state, province, county, municipal or other political subdivision
thereof, any entity exercising executive, legislative, tribal, judicial, regulatory or administrative functions of or pertaining to government, including any court, arbitrator (public or private) or other body or administrative, regulatory or
quasi-judicial authority, agency, department, board, commission or instrumentality of any federal, state, local or foreign jurisdiction, or any self-regulated organization or other <FONT STYLE="white-space:nowrap">non-governmental</FONT> regulatory
authority (to the extent that the rules, regulations or orders of such organization or authority have the force of law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>HYAC</I>&#148; means Haymaker Acquisition Corp. III prior to the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Initial Shares</I>&#148; means an aggregate of 58,565,824 Retained Biote Units (and any Equity Securities into which such units may
be exchanged), proportionately amongst the Members based on their respective percentage interests held in Biote as of immediately after the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Investor Rights Agreement</I>&#148; means the Investor Rights Agreement entered into at the Closing, by and among the Company, the
Sponsor, the Members&#146; Representative and certain other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>IPO</I>&#148; means Haymaker Acquisition Corp. III.&#146;s initial public offering,
consummated on March&nbsp;4, 2021, through the sale of 31,750,000 units at $10.00 per unit (including 1,750,000 units that were issued upon the partial exercise of the IPO underwriters&#146; overallotment option, which closed on March&nbsp;5, 2021).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Member Earnout Units</I>&#148; means the 10,000,000 Retained Biote Units held by the Members at the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Nasdaq Independent</I>&#148; means a person who shall qualify as an &#147;independent director&#148; as such term is defined under
Nasdaq Stock Market Rule 5605(a)(2) (or any successor rule) and applicable SEC rules and regulations, as of (i)&nbsp;the time of the nomination of such director pursuant to Section&nbsp;2.1 and (ii)&nbsp;the time of any vote, decision or
recommendation made by such director as a member of the board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Person</I>&#148; means any natural person, sole proprietorship,
partnership, joint venture, trust, unincorporated association, corporation, limited liability company, entity or Governmental Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Phantom Equity Acknowledgement</I>&#148; means the acknowledgement that each Phantom Equity Holder entered into effective as of the
Closing, which, among other things, confirms the number of shares of Class&nbsp;A common stock to be issued to such Phantom Equity Holder pursuant to biote Corp. 2022 Equity Incentive Plan (the &#147;Incentive Plan&#148;) in satisfaction of his or
her phantom equity rights and the vesting schedule for such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Phantom Equity Holder</I>&#148; means each holder of phantom
equity in any of Biote or its direct or indirect subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Purchase Agreement</I>&#148; means that certain standby equity
purchase agreement, by and between biote Corp. and YA II PN, LTD. dated as of July&nbsp;27, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;Recapitalization&#148;</I>
means the recapitalization that occurred immediately prior the Closing, pursuant to which all its Class&nbsp;A Units, Class&nbsp;AA Units, Class&nbsp;AAA Units and Class&nbsp;AAAA Units held by the Members were to be converted or exchanged (whether
by direct exchange, merger or otherwise) into a number of equity interests in Biote designated as &#147;Class&nbsp;A Common Units&#148; resulting in the Members holding a single class of Biote Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Revolving Loans</I>&#148; means the $50,000,000 senior secured revolving credit facility provided for in the Credit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Sponsor Earnout Shares</I>&#148; means 1,587,500 shares of Class&nbsp;A common stock held by the Sponsor after giving effect to the
Class&nbsp;B Common Stock Conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Tax Receivable Agreement</I>&#148; means the tax receivable agreement entered into
simultaneously with the Closing by and among the Combined Company, Biote, the Members and the Members&#146; Representative, which provides for, among other things, payment by the Combined Company to the Members of 85% of the U.S. federal, state and
local income tax savings realized by the Combined Company as a result of the increases in tax basis and certain other tax benefits related to the transactions contemplated under the Business Combination Agreement and the redemption of Retained Biote
Units in exchange for Class&nbsp;A common stock or cash (as more fully described in the Tax Receivable Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Term
Loan</I>&#148; means the $125,000,000 senior secured term loan A credit facility provided for in the Credit Agreement, which was borrowed in full on the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Underwriter Units</I>&#148; means the 1,750,000 units issued to the Underwriters in a concurrent private placement in connection with
the IPO. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Underwriters</I>&#148; means Citigroup Global Markets Inc. and Cantor
Fitzgerald&nbsp;&amp; Co., as representatives of the several underwriters in the IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Working Capital Loans</I>&#148; means
funds that the Sponsor or an affiliate of the Sponsor, or certain of the HYAC&#146;s officers and directors may, but are not obligated to, loan HYAC as may be required in order to finance transaction costs in connection with the Business
Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<I>Yorkville</I>&#148; means YA II PN, LTD., a Cayman Islands exempt limited partnership. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This registration statement contains forward-looking statements. These forward-looking statements relate to expectations for future financial
performance, business strategies, or expectations for the Company&#146;s business. These forward-looking statements include, but are not limited to, statements regarding the Company&#146;s or its management team&#146;s expectations, hopes, beliefs,
intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The
forward-looking statements are contained principally in the sections titled &#147;Prospectus Summary&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148;
&#147;Business&#148; and elsewhere in this registration statement. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;can,&#148; &#147;should,&#148; &#147;will,&#148; &#147;estimate,&#148;
&#147;plan,&#148; &#147;project,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;expect,&#148; &#147;hope,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;seek,&#148; &#147;target,&#148; &#147;continue,&#148; &#147;could,&#148;
&#147;might,&#148; &#147;ongoing,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;would&#148; or similar expressions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
forward-looking statements are based on information available as of the date of this prospectus, and our management&#146;s current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly,
forward-looking statements should not be relied upon as representing the Company&#146;s views as of any subsequent date. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the
date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties,
the Company&#146;s actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and
their patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our customers&#146; reliance on certain third parties to support the manufacturing of <FONT
STYLE="white-space:nowrap">bio-identical</FONT> hormones for prescribers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our and our customers&#146; sensitivity to regulatory, economic, environmental and competitive conditions in
certain geographic regions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate
or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to grow our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the significant competition we face in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our limited operating history; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the heavy regulatory oversight in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in applicable laws or regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to profitably expand in existing markets and into new markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that we may be adversely impacted by other economic, business and/or competitive factors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future exchange and interest rates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties indicated in this registration statement, including those under &#147;Risk
Factors&#148; herein, and other filings the Company has made, or will make, with the Securities and Exchange Commission (the &#147;SEC&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary highlights selected information contained elsewhere in this registration statement and does not contain all of the
information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included in this
prospectus and the information set forth under the headings &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate a high-growth
practice-building business within the hormone optimization space. Similar to a franchise model, we provide the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to
optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> practice building platform that
provides Biote-certified practitioners with the following components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management
software, and information regarding available hormone replacement therapy (&#147;HRT&#148;) products, as well as digital and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> marketing support. We also
sell a complementary Biote-branded line of dietary supplements. We generate revenues by charging the Biote-partnered clinics fees associated with the support Biote provides for HRT and from the sale of Biote-branded dietary supplements. By virtue of
our historical performance over the 12 years ended December&nbsp;31, 2023, we believe that our business model has been successful, remains differentiated, and is well positioned for future growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By incorporating the Biote Method in their practices, we enable practitioners to participate in the large and growing hormone optimization
space. Bioidentical hormone therapy, which is offered by Biote-certified practitioners, is one segment of the large HRT market. It is estimated that, as of 2020, the total U.S. market opportunity for HRT products, available in various forms, exceeds
$7&nbsp;billion and is expected to grow 7% annually through 2026. We believe our business opportunity in providing educational and practice management services is large and will similarly grow. Growth in this field is expected to be fueled by
&#147;aging&#148; demographics and expanding consumer demand for medical information and treatment options to address hormonal imbalances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient symptoms associated with menopause in women and andropause in men, such as hot flashes, night sweats, depressed mood, low libido,
weight gain, and issues with concentration and focus, while negatively impacting quality of life, may also be associated with higher risks for chronic diseases attributable to declining hormone levels, including cardiovascular disease, osteoporosis
and breast cancer. Approximately 20&nbsp;million men over age 45 in the United States are affected by hypogonadism and only about 10&nbsp;million (12%) of those affected undergo testosterone treatment. An average of 27&nbsp;million women between the
ages of 45 and 64, or 20% of the American workforce, experience menopause every year. Despite the prevalence of <FONT STYLE="white-space:nowrap">symptoms-84%</FONT> of women report menopausal symptoms that interfere with their lives-only 58% have
discussed menopause with a health provider, and only 28%, or approximately 13&nbsp;million, undergo HRT (and of that 28%, only 31%, or approximately 4&nbsp;million, undergo bioidentical HRT). By 2030, over 1.2&nbsp;billion women, 14% of the global
population, will be in menopause or post-menopause. Yet, despite the growing number of women experiencing menopause, they remain an underserved population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One key driver of this unmet medical need is the lack of knowledge and experience of treating physicians. For many practitioners, the last
time they received meaningful instruction on treating menopause and andropause was during medical school. Based on a 2018 article by Jennifer Wolff, entitled &#147;What Doctors Don&#146;t Know About Menopause,&#148; among newer doctors surveyed in
2015, 80% of medical residents reported feeling &#147;barely comfortable&#148; discussing or treating menopause. While this knowledge gap applies to training, we believe it also applies to the understanding of treatment alternatives, access to new
therapies, methods to drive efficiencies in a hormone optimization practice and finally, how to profitably treat this growing population. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To capitalize on this large and underserved market opportunity, we developed a highly
differentiated practice-building platform to enable practitioners to treat the hormone imbalance symptoms experienced by their patients. The Biote Method has been designed specifically for practitioners who focus on treating perimenopause in women;
post-menopause in women; and andropause/hypogonadism in men. It is constructed to bridge the existing gaps which exist in education and treatment options, while improving the efficiency of practitioners&#146; business operations and the hormone
health of their aging patient base. Over the past 12 years, we have built our platform to provide highly differentiated education and training, practice support resources and inventory management tools that would be difficult for a practice to
otherwise attain on their own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We empower Biote-certified practitioners by requiring rigorous
<FONT STYLE="white-space:nowrap">in-person</FONT> training, testing and certification for all Biote-certified practitioners and office staff wishing to use the Biote Method in their practice. Our practitioner instructors are among the nation&#146;s
most experienced clinical experts in hormonal therapy, including multiple modalities of HRT such as creams, gels, patches, pills, injections and compounded bioidentical hormone pellets. We teach clinicians how to identify early indicators of
hormone-related aging conditions, and we believe we are the top practitioner educators by virtue of our experience over 12 years, with approximately four million hormone optimization procedures performed by Biote-certified practitioners to date,
including approximately 393,000 active patients. We offer training centrally and regionally to provide consistent and ongoing technical education. On an ongoing basis, we provide access to clinical and technical support for Biote-certified
practitioners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To offer a turnkey platform, we leverage the data Biote-certified practitioners collect using our BioTracker software for
regulatory and record management to seamlessly assess a simple procedure-based revenue model that encompasses fees for the education, training, <FONT STYLE="white-space:nowrap">re-training,</FONT> comprehensive administrative services and support
and pass-through cost of pellets that practitioners may choose to provide as part of the Biote Method. We believe our revenue model represents an objective method to assess fees across the varying size and sophistication of our Biote-certified
practitioners and clinics beginning with the first day of training and continuing throughout the treatment of each practitioner&#146;s patient. Additionally, this revenue model provides our Biote-certified practitioners with consistency and
predictability, notwithstanding the variability in services required to support their practices during any given period. Our revenue model also offers efficiency and transparency for inventory management, as each procedure is electronically recorded
through our technology platform without requiring additional workflow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method&#146;s proprietary clinical decision support
(&#147;CDS&#148;) software assists physicians in establishing individualized dosing for patients. Our BioTracker software and business tools allow practitioners to efficiently manage the record management, product acquisition, inventory logistics
and the business end of a robust hormone optimization practice. We provide Biote-partnered clinics access to <FONT STYLE="white-space:nowrap">FDA-registered</FONT> outsourcing facilities that can supply a wide array of hormone optimization products
for Biote-certified practitioner patients. We provide information to Biote-certified practitioners regarding how to integrate with our BioTracker software. Our BioTracker software allows Biote-certified practitioners to manage orders and maintain
accurate inventory records to keep their regulatory and business systems up to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the breadth and depth of our commercial and
operational platform, the Biote name has achieved strong brand recognition among practitioners and patients in the communities we serve, as illustrated by QY Research&#146;s market research publication entitled &#147;South&nbsp;&amp; North America
Hormone Replacement Therapy Market Insights and Forecast to 2026.&#148; Practitioners undertaking the Biote Method can be confident that our exclusive training and practice building tools will prepare them to provide excellent and differentiated
care to patients. This has led to high practitioner satisfaction and a retention rate of approximately 95% among Biote-certified practitioners. We are contracted with and provide comprehensive support to over 7,100 practitioners that have adopted
the Biote Method in their practices. Leveraging our brand strength, we offer marketing assistance, including office signage and patient education materials, to every Biote-certified practitioner within our network. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe by virtue of their participation in our robust training and practice
certification, Biote-certified practitioners are well informed on all aspects of hormone optimization. We believe our brand advantage with both practitioners and patients is a key element of our commercial growth strategy, and an asset that we
intend to leverage to expand our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complementing the Biote Method is our expanding line of private-labeled dietary supplements to
address hormone, vitamin, and physiological deficiencies that regularly manifest in an aging population. This business segment appeals to practitioners&#146; patient demographic and enables patients the opportunity to receive
practitioner-recommended Biote-branded dietary supplements to support healthy aging. By leveraging our existing Biote-certified practitioner base to sell and distribute our Biote-branded dietary supplements, we believe we have created an efficient
and complementary business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also designed the Biote Method to permit beneficial practice economics for our Biote-partnered clinics.
Our educational training and practice management platform helps enable Biote-partnered clinics to execute this <FONT STYLE="white-space:nowrap">all-cash</FONT> model with minimal reimbursement risk. This contrasts to consistently decreasing
reimbursement rates for most other treatments and therapies offered by physician offices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a track record of consistently
achieving accelerated and highly profitable growth. Our four-year procedure revenue compound annual growth rate (&#147;CAGR&#148;) from 2019-2023 was 11.8%. Our revenue was $185.4&nbsp;million and $165.0&nbsp;million for the years ended
December&nbsp;31, 2023 and 2022, respectively. Net loss was $2.8&nbsp;million and net income was $1.3&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HYAC was
incorporated in the State of Delaware on July&nbsp;6, 2020 as a special purpose acquisition company under the name Haymaker Acquisition Corp. III. Holdings is a Delaware limited liability company formed on March&nbsp;31, 2019. On March&nbsp;4, 2021,
HYAC completed its IPO. On May&nbsp;26, 2022, the Business Combination with Holdings was consummated, resulting in Biote being organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure, and HYAC as the registrant changed its
name to &#147;biote Corp<I>.</I>&#148; Biote&#146;s headquarters are located at 1875 W. Walnut Hill Ln #100 Irving, Texas 75038. Our telephone number is (844) <FONT STYLE="white-space:nowrap">604-1246,</FONT> and our website address is
<U>www.biote.com</U>. The information contained on, or that can be accessed through, our website is not incorporated by reference in this prospectus and does not form a part of this prospectus. The reference to our website address does not
constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committed Equity Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;27, 2022, we entered into the Purchase Agreement, with Yorkville. Pursuant to the Purchase Agreement, we have the right to sell to Yorkville up to 5,000,000 shares of our Class&nbsp;A common stock, subject to certain limitations and
conditions set forth in the Purchase Agreement, from time to time during the term of the Purchase Agreement. Sales of Class&nbsp;A common stock to Yorkville under the Purchase Agreement, and the timing of any such sales, are at our option, and we
are under no obligation to sell any securities to Yorkville under the Purchase Agreement. In accordance with our obligations under the Purchase Agreement, we have filed the registration statement that includes this prospectus with the SEC to
register under the Securities Act the resale by Yorkville of up to 5,000,000 shares of Class&nbsp;A common stock, consisting of 25,000 shares of Class&nbsp;A common stock that we issued to Yorkville in consideration of its commitment to purchase
shares of Class&nbsp;A common stock at our election under to the Purchase Agreement (the &#147;Commitment Shares&#148;), and up to 4,975,000 shares of Class&nbsp;A common stock that we may elect, in our sole discretion, to issue and sell to
Yorkville, from time to time under the Purchase Agreement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to Yorkville&#146;s purchase obligation set forth in
the Purchase Agreement, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC, we will have the right, but not the obligation,
from time to time at our discretion until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> period after the date of the Purchase Agreement, to direct Yorkville to purchase a specified amount of shares of
Class&nbsp;A common stock (each such sale, an &#147;Advance&#148;) by delivering written notice to Yorkville (each, an &#147;Advance Notice&#148;). While there is no mandatory minimum amount for any Advance, it may not exceed the greater of
(i)&nbsp;an amount equal to thirty percent (30%) of the Daily Volume Traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The per share purchase price for the shares of Class&nbsp;A common stock, if any, that we elect to sell to the Selling Securityholder in an
Advance pursuant to the Purchase Agreement will be determined by reference to the volume weighted average price of our Class&nbsp;A common stock (the &#147;VWAP&#148;) and calculated in accordance with the Purchase Agreement, less a variable
discount of 3%, provided however that the Company may establish a minimum acceptable price in each Advance Notice below which it shall not be obligated to make any sales to the Selling Securityholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that Yorkville could be obligated to pay for the Class&nbsp;A common stock we may elect to sell
to it in any Advance. The purchase price per share of Class&nbsp;A common stock that we may elect to sell to Yorkville in an Advance under the Purchase Agreement will be equitably adjusted for any reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the
timing and amount of any sales of Class&nbsp;A common stock to Yorkville. Actual sales of shares of our Class&nbsp;A common stock to Yorkville under the Purchase Agreement will depend on a variety of factors to be determined by us from time to time,
which may include, among other things, market conditions, the trading price of our Class&nbsp;A common stock and determinations by us as to the appropriate sources of funding for our business and its operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not issue or sell any shares of Class&nbsp;A common stock to Yorkville under the Purchase Agreement which, when aggregated with all
other shares of Class&nbsp;A common stock then beneficially owned by Yorkville and its Affiliates (as calculated pursuant to Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended, and Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in Yorkville beneficially owning more than 4.99% of the outstanding shares of Class&nbsp;A common stock (the &#147;Beneficial Ownership Limitation&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds under the Purchase Agreement to us will depend on the frequency and prices at which we sell shares of our stock to Yorkville.
We expect that any proceeds received by us from such sales to Yorkville will be used for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has agreed that it and its Affiliates will not engage in any short sales of the Class&nbsp;A common stock nor enter into any
transaction that establishes a net short position in the Class&nbsp;A common stock during the term of the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Purchase Agreement will automatically terminate on the earliest to occur of (i)&nbsp;the first day of the month next following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date of the Purchase Agreement or (ii)&nbsp;the
date on which the Selling Securityholder shall have purchased from us under the Purchase Agreement 5,000,000 shares of our Class&nbsp;A common stock. We have the right to terminate the Purchase Agreement at no cost or penalty upon five
(5)&nbsp;trading days&#146; prior written notice to Yorkville, provided that there are no outstanding Advance Notices and all outstanding amounts owed to Yorkville are repaid. We and Yorkville may also agree to terminate the Purchase Agreement by
mutual written consent. Neither we nor Yorkville may assign or transfer our respective rights and obligations under the Purchase Agreement, and no provision of the Purchase Agreement may be modified or waived by us or Yorkville other than by an
instrument in writing signed by both parties. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#146;s commitment to purchase shares of Class&nbsp;A common
stock at our direction upon the terms and subject to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, we issued 25,000 shares of Class&nbsp;A common stock to Yorkville. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. The
representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed
upon by the contracting parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;28, 2022, excluding the Commitment Shares, there were 67,727,595 shares of common stock
outstanding, consisting of 9,161,771 shares of our Class&nbsp;A common stock and 58,565,824 shares of our Class&nbsp;V voting stock, of which 9,515,519 shares of common stock were held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT>
consisting of 5,301,991 shares of our Class&nbsp;A common stock and 4,213,528 shares of our Class&nbsp;V voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all of the
5,000,000 shares offered by Yorkville for resale under the registration statement that includes this prospectus were issued and outstanding as of the date hereof (without taking into account the 4.99% Beneficial Ownership Limitation), such shares
would represent approximately 6.9% of the total number of shares of our Common Stock outstanding and approximately 52.5% of the total number of outstanding shares held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> in each case as of
July&nbsp;28, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are substantial risks to our stockholders as a result of the sale and issuance of Class&nbsp;A common stock to
Yorkville under the Purchase Agreement. These risks include the potential for substantial dilution and significant declines in our stock price. See the section entitled &#147;Risk Factors.&#148; Issuances of our Class&nbsp;A common stock in this
offering will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any such issuance. Although the number of shares of
Class&nbsp;A common stock that our existing stockholders own will not decrease as a result of sales, if any, under the Purchase Agreement, the shares owned by our existing stockholders will represent a smaller percentage of our total outstanding
shares after any such issuance to Yorkville. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more detailed information regarding the Purchase Agreement, see the section entitled
&#147;Committed Equity Financing.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company<I>,</I>&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act, and
we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor
attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended
the &#147;Exchange Act&#148;), are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT
STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has
different application dates for </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of
our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences
in accounting standards used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year
(a)&nbsp;following the fifth anniversary of the completion of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market
value of our Class&nbsp;A common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equaled or exceeded $700&nbsp;million as of the prior June&nbsp;30, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a
&#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things,
providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1)&nbsp;the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> equaled or exceeded $250&nbsp;million as of the end of the prior June 30th, or (2)&nbsp;our annual revenues equaled or exceeded $100&nbsp;million during such completed fiscal year and the market
value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equaled or exceeded $700&nbsp;million as of the prior June 30th. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>biote Corp. (f/k/a Haymaker Acquisition Corporation III). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Class&nbsp;A common stock Offered by the Selling Securityholder </P></TD>
<TD>5,000,000 shares of Class&nbsp;A common stock, consisting of (i) 25,000 Commitment Shares; and (ii)&nbsp;up to 4,975,000 shares that we have already issued and sold or may elect, in our discretion, to issue and sell to the Selling Securityholder
under the Purchase Agreement from time to time. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Outstanding </P></TD>
<TD>35,712,492 shares of Class&nbsp;A common stock (and includes 130,559 shares of Class&nbsp;A common stock issued and sold to the Selling Stockholder under the Purchase Agreement from time to time since the commencement of this offering) and
38,819,066 shares of Class&nbsp;V voting stock (as of March&nbsp;11, 2024). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Outstanding After Giving Effect to the Issuance of the Shares Registered for Resale
Hereunder </P></TD>
<TD>40,581,933 shares of Class&nbsp;A common stock and 38,819,066 shares of Class&nbsp;V voting stock (based on total shares outstanding as of March&nbsp;11, 2024). </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the resale of shares of Class&nbsp;A common stock included in this prospectus by the Selling Securityholder. However, we expect to receive proceeds from sales of Class&nbsp;A common stock that we may elect
to make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. The net proceeds from sales, if any, under the Purchase Agreement, will depend on the frequency and prices at which we sell shares
of Common Stock to the Selling Securityholder after the date of this prospectus. See &#147;Committed Equity Financing&#148; for a description of how the price we may sell shares of Class&nbsp;A common stock to the Selling Securityholder is
calculated pursuant to the Purchase Agreement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to use the net proceeds that we receive from sales of our Class&nbsp;A common stock to the Selling Securityholder, if any, under the Purchase Agreement for working capital and general corporate purposes. See
the section titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for Class&nbsp;A common stock </P></TD>
<TD>Our Class&nbsp;A common stock is listed on the Nasdaq Stock Market LLC under the symbol &#147;BTMD&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>See the section entitled &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors you should consider before investing in our securities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock to be outstanding is based on 74,531,558 shares of
Common Stock outstanding as of March&nbsp;11, 2024 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">12,232,987 shares of Class&nbsp;A common stock available for future issuance under the Incentive Plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,359,468 shares available for future issuance under the biote Corp. 2022 Employee Stock Purchase Plan (the
&#147;ESPP&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,869,441 shares of Class&nbsp;A common stock that we may elect, in our sole discretion, to issue and sell to
Yorkville, from time to time under the Purchase Agreement. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves risks. You should consider carefully the risks and uncertainties described below, together with all of
the other information in this prospectus, including the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the financial statements and notes to the financial statements included
herein, before deciding whether to purchase any of our securities. If any of these risks actually occur, our business, results of operations, financial condition, and prospects could be materially and adversely affected. Unless otherwise indicated,
references in these risk factors to our business being harmed will include harm to our business, reputation, brand, financial condition, results of operations, and prospects. In such event, the market price of our securities could decline, and you
could lose all or part of your investment. You should carefully consider the following risk factors in addition to the other information included in this prospectus, including matters addressed in the section entitled &#147;Cautionary Note Regarding
Forward-Looking Statements.&#148; We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial, which may also impair our business or financial condition. The following discussion should be
read in conjunction with the financial statements and notes to the financial statements included herein. Unless otherwise indicated or the context otherwise requires, references in this section to &#147;we&#148;, &#147;us&#148; and &#147;our&#148;
generally refer to Biote in the present tense or the Combined Company from and after the Business Combination. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the risk factors our business faces. The list below is not exhaustive, and investors should read this &#147;Risk
Factors&#148; section in full. Some of the risks we face include: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Risks Related to this Offering </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the
Selling Securityholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the Purchase Agreement with the Selling Securityholder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The sale and issuance of our Class&nbsp;A common stock to the Selling Securityholder will cause dilution to our
existing stockholders, and the sale of the shares of Class&nbsp;A common stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Class&nbsp;A common stock to fall.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investors who buy shares of Class&nbsp;A common stock at different times will likely pay different prices.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of
Class&nbsp;A common stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Risks Related to Our Industry and Business </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our success will depend upon whether the Biote Method and our Biote-branded dietary supplements attain
significant market acceptance among clinics, practitioners and their patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Outsourcing facilities that produce bioidentical hormone pellets that we offer training on in the Biote Method
and failure by those parties to adequately perform their obligations could harm our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and Biote-certified practitioners and Biote-partnered clinics are reliant on AnazaoHealth Corporation, Right
Value Drug Stores, LLC, and F.H. Investments, Inc. to support the manufacturing of <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormones for prescribers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Biote-certified practitioners and Biote-partnered clinics are concentrated in certain geographic regions, which
makes us sensitive to regulatory, economic, environmental and competitive conditions in those regions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The frequency of use by practitioners and clinics of the Biote Method may not increase at the rate that we
anticipate or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adoption of the Biote Method depends upon appropriate practitioner training, and inadequate training may lead to
negative patient outcomes and adversely affect our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The continuing development of our training depends upon our maintaining strong working relationships with
Biote-certified practitioners and other medical personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We believe our long-term value as a company will be greater if we focus on growth, which may negatively impact
our results of operations in the near term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or
maintain expected levels of market penetration and market share, which could have a material adverse effect on our business, financial condition and results of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited history operating a practice-building business for practitioners in the hormone optimization
space, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Risks Related to Intellectual Property </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain patent protection for any products or methods we develop, or if the scope
of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our Biote-branded dietary supplements, and our ability to successfully commercialize any products we may
develop may be adversely affected. If we are not able to maintain freedom to operate for our products from third-party intellectual property rights, our ability to commercialize products may be limited unless we secure a license to such rights.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may become a party to intellectual property litigation or administrative proceedings that could be costly and
could interfere with our ability to sell and market the Biote Method and our Biote-branded dietary supplements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to protect the confidentiality of our other proprietary information, our business and
competitive position may be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be subject to claims that we or our employees, consultants or contractors have wrongfully used, disclosed
or otherwise misappropriated the intellectual property of a third-party, including trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> agreements with our competitors or claims asserting an ownership interest in intellectual property we regard as our own. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be subject to claims challenging our intellectual property. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our trademarks and trade names are not adequately protected, then we may not be able to build brand
recognition in our markets and our business may be adversely affected. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Risks Related to Regulation </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We market dietary supplements and convenience kits, which are regulated by the U.S. Food and Drug Administration
(the &#147;FDA&#148;) and are subject to certain requirements under the Federal Food, Drug, and Cosmetic Act (the &#147;FDCA&#148;) and the laws enforced by the Federal Trade Commission (the &#147;FTC&#148;). Our failure to meet those requirements
could cause us to cease certain of our business activities and may involve the payment of financial penalties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have developed and market a method and training program where the practitioner may prescribe a compounded
bioidentical hormone. Compounded drugs are regulated by the FDA and are subject to certain requirements under the FDCA. Failure of compounding entities to meet those requirements could cause us to cease certain of our business activities and may
involve the payment of financial penalties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compounded preparations and the pharmacy compounding industry are subject to regulatory scrutiny, which may
impair our growth and sales. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If a compounded drug formulation provided through a compounding pharmacy or an outsourcing facility leads to
patient injury or death or results in a product recall, we may be exposed to significant liabilities and reputational harm. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the FDA takes regulatory action to implement any of the National Academies of Sciences, Engineering, and
Medicine (the &#147;NASEM&#148;) recommendations for compounded bioidentical hormones, this may have a substantial effect on the ability of the outsourcing facilities to compound the hormone pellets utilized by Biote-certified practitioners, which
would have a substantially negative impact on Biote&#146;s revenue and business operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our internal controls over financial reporting currently do not meet all of the standards contemplated by
Section&nbsp;404 of the Sarbanes-Oxley Act, and a material weakness resulted in the restatement of previously issued financial statements. Failure to achieve and maintain an effective system of disclosure controls and internal control over financial
reporting could impair our ability to produce timely and accurate financial statements or comply with applicable regulations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to maintain our listing on the Nasdaq Stock Market LLC (&#147;Nasdaq&#148;), it could become
more difficult to sell our Class&nbsp;A common stock in the public market. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Risks Related to Ownership of Our
Securities </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because there are no current plans to pay cash dividends on our Class&nbsp;A common stock for the foreseeable
future, you may not receive any return on investment unless you sell our Class&nbsp;A common stock for a price greater than that which you paid for it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may require additional capital to support business growth, and if capital is not available to us or is
available only by diluting existing stockholders, our business, operating results and financial condition may suffer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anti-takeover provisions contained in the second amended and restated certificate of incorporation (the
&#147;Charter&#148;) and amended and restated bylaws (the &#147;Bylaws&#148;), as well as provisions of Delaware law, could impair a takeover attempt. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Future sales, or the perception of future sales, by the Company or its stockholders in the public market, the
issuance of rights to purchase the Company&#146;s Class&nbsp;A common stock, including pursuant to the 2022 Equity Incentive Plan (the &#147;Incentive Plan&#148;) and the 2022 Employee Stock Purchase Plan (the &#147;ESPP&#148;), and future exercises
of registration rights could result in the additional dilution of the percentage ownership of the Company&#146;s stockholders and cause the market price for the Company&#146;s Class&nbsp;A common stock to decline. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Securities of companies formed through a special purpose acquisition company (&#147;SPAC&#148;) business
combination such as ours may experience a material decline in price relative to the share price of the SPAC prior to the business combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be subject to periodic claims and litigation, including the Donovitz Litigation (as defined herein), that
could result in unexpected expenses and could ultimately be resolved against us. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the Selling Securityholder, or the actual gross
proceeds resulting from those sales. Further, we may not have access to the full amount available under the Purchase Agreement with the Selling Securityholder. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;27, 2022, we entered into the Purchase Agreement with the Selling Securityholder, pursuant to which the Selling Securityholder has
committed to purchase up to 5,000,000 shares of our Class&nbsp;A common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock, subject to certain limitations and conditions set forth in the Purchase Agreement. The shares of our Class&nbsp;A common stock that may be issued under the Purchase Agreement may be sold
by us to the Selling Securityholder at our discretion from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally have the right to control the timing and amount of
any sales of our shares of Class&nbsp;A common stock to the Selling Securityholder under the Purchase Agreement. Sales of our Class&nbsp;A common stock, if any, to the Selling Securityholder under the Purchase Agreement will depend upon market
conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some or none of the shares of our Class&nbsp;A common stock that may be available for us to sell to the Selling Securityholder
pursuant to the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of
Class&nbsp;A common stock that we may elect to sell to the Selling Securityholder under the Purchase Agreement, if any, will fluctuate based on the market prices of our Class&nbsp;A common stock prior to each Advance made pursuant to the Purchase
Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of Class&nbsp;A common stock that we will sell to the Selling Securityholder under the Purchase Agreement,
the purchase price per share that the Selling Securityholder will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by the Selling Securityholder under the
Purchase Agreement, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not required or permitted to issue any shares of Class&nbsp;A common stock under the Purchase
Agreement if such issuance would breach our obligations under the rules or regulations of our Trading Market. In addition, the Selling Securityholder will not be required to purchase any shares of our Class&nbsp;A common stock if such sale would
result in the Selling Securityholder&#146;s beneficial ownership exceeding 4.99% of the then issued and outstanding Class&nbsp;A common stock. Our inability to access a part or all of the amount available under the Purchase Agreement, in the absence
of any other financing sources, could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sale and issuance of our Class&nbsp;A common stock to the
Selling Securityholder will cause dilution to our existing stockholders, and the sale of the shares of Class&nbsp;A common stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our
Class&nbsp;A common stock to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price for the shares that we may sell to the Selling Securityholder under the
Purchase Agreement will fluctuate based on the price of our Class&nbsp;A common stock. Depending on a number of factors, including market liquidity, sales of such shares may cause the trading price of our Class&nbsp;A common stock to fall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to the Selling Securityholder, the Selling Securityholder may resell all, some, or none of those shares at its
discretion, subject to the terms of the Purchase Agreement. Therefore, sales to the Selling Securityholder by us could result in substantial dilution to the interests of other holders of our Class&nbsp;A common stock. Additionally, the sale of a
substantial number of shares of our Class&nbsp;A common stock to the Selling Securityholder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and
price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors who buy shares of Class&nbsp;A common stock at different times will likely pay different prices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement, we control the timing and amount of any sales of Class&nbsp;A common stock to the Selling Securityholder.
If and when we do elect to sell shares of our Class&nbsp;A common stock to the Selling Securityholder pursuant to the Purchase Agreement, the Selling Securityholder may resell all, some or none of such shares in its discretion and at different
prices, subject to the terms of the Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different
levels of dilution and in some cases </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this
offering as a result of future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder
under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related
securities in the future at a desirable time and price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team will have broad discretion over the use of the net proceeds from our
sale of shares of Class&nbsp;A common stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team will have broad discretion as to the use of the net proceeds from our sale of shares of Class&nbsp;A common stock to the
Selling Securityholder, if any, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management team with regard to the use of
those net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does
not yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Industry and Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
success will depend upon whether the Biote Method and our Biote-branded dietary supplements attain significant market acceptance among clinics, practitioners and their patients. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend on the acceptance of the hormone optimization methods we teach in our training. We cannot predict how quickly clinics,
practitioners or their patients will accept the Biote Method (as further described in the section entitled &#147;Business&#148;) or, if accepted, how frequently it will be used. The methods that we currently recommend and any methods we recommend in
the future may never gain broad market acceptance. Demonstrated HRT health risks or side effects, as well as negative publicity relating to the same, could negatively impact the perception of patient benefit and generate resistance and opposition
from practitioners, which could limit adoption of the Biote Method and have a material adverse impact on our business. To date, a substantial majority of our sales and revenue have been derived from a limited number of clinics and independent,
third-party physicians and nurse practitioners who are certified under our training program (the &#147;Biote-certified practitioners&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future growth and profitability will largely depend on our ability to increase practitioner awareness of our practice-building platform as
well as our Biote-branded dietary supplements, and on the willingness of clinics, practitioners and their patients to adopt them. Practitioners may not adopt the Biote Method unless they determine, based on experience, clinical data, medical society
recommendations and other analyses, that our methods and the Biote-branded dietary supplements are appropriate for their patients. Healthcare practitioners must believe that our practice-building platform and Biote-branded dietary supplements offer
benefits over alternatives. Even if we are able to raise awareness, practitioners may be slow in changing their medical treatment practices and may be hesitant to use the Biote Method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Practitioners independently determine the type of treatment that will be utilized and provided to their patients. We focus our sales,
marketing and education efforts primarily in the hormone optimization space and aim to educate Biote-certified practitioners regarding the patient population that would benefit from the Biote Method. Despite our efforts, we cannot assure you that we
will achieve broad market acceptance among these practitioners or, more generally, that practitioners will adopt the Biote Method at all. Further, changes in the regulatory or enforcement landscape may be a factor in practitioners choosing certain
methods for their patients, for example, medication compounded by a compounding pharmacy or outsourcing facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, some Biote-certified practitioners may choose to utilize the Biote Method and
our Biote-branded dietary supplements on only a subset of their total patient population or may not adopt our offerings at all. If we are not able to effectively demonstrate that the use of the Biote Method and our Biote-branded dietary supplements
is beneficial in a broad range of their patients, adoption of our offerings will be limited and may not occur as rapidly as we anticipate or at all, which would have a material adverse effect on our business, financial condition and results of
operations. We cannot assure you that the Biote Method or our Biote-branded dietary supplements will achieve broad market acceptance among clinics and practitioners. Additionally, even if the Biote Method and our Biote-branded dietary supplements
achieve initial market acceptance, they may not maintain that market acceptance over time if competing methods, procedures or technologies are considered more cost-effective or otherwise superior. Any failure of our offerings to generate sufficient
demand or to achieve meaningful market acceptance and penetration will harm our future prospects and have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if the Biote Method or our Biote-branded dietary supplements do not generate sufficient patient demand for the Biote-certified
practitioners or clinics we partner with (&#147;Biote-partnered clinics&#148;), we may be unable to attract or retain contracts with practitioners or clinics to use the Biote Method or sell our Biote-branded dietary supplements. If we are unable to
attract or retain contracts with practitioners or clinics, our business, results of operations and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outsourcing facilities that produce bioidentical hormone pellets that we offer training on in the Biote Method and failure by those parties to
adequately perform their obligations could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outsourcing facilities manufacture the products that we recommend as
part of our training. The facilities used to compound and distribute bioidentical hormone pellets, which may be prescribed by Biote-certified practitioners, are registered with the FDA as 503B outsourcing facilities. We do not control or direct the
compounding or manufacturing processes used by these outsourcing facilities. We use contract manufacturers to produce the formulations of the dietary supplements we develop and sell under Biote&#146;s private label, and we rely on those
manufacturers for compliance with the applicable regulatory requirements. As such, we have no control over the ability of third parties to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable
international regulatory authority does not approve these facilities for the manufacture of these products or if it withdraws any such approval in the future, we may need to identify alternative manufacturing facilities, which would significantly
impact our ability to meet consumer demand. In addition, our inability to identify or enter into satisfactory arrangements with any such alternative manufacturing facilities may result in a material adverse effect on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our reliance on third-party dietary supplement contract manufacturers entails risks,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to meet certain product specifications and quality requirements consistently; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay or inability to procure or expand sufficient manufacturing capacity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issues related to <FONT STYLE="white-space:nowrap">scale-up</FONT> of manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and validation of new equipment and facilities required for
<FONT STYLE="white-space:nowrap">scale-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party manufacturers may not be able to execute necessary manufacturing procedures and other logistical
support requirements appropriately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party manufacturers may fail to comply with current good manufacturing practice (&#147;cGMP&#148;)
requirements and other requirements by the FDA or other comparable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability for us to negotiate manufacturing agreements with third parties under commercially reasonable terms, if
at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach, termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of manufacturing agreements with third
parties in a manner or at a time that is costly or damaging to us or Biote-certified practitioners and Biote-partnered clinics; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party manufacturers may not devote sufficient resources to our Biote-branded dietary supplements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not own, or may have to share, the intellectual property rights to any improvements made by third-party
manufacturers in the manufacturing process for our Biote-branded dietary supplements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operations of third-party manufacturers or our suppliers could be disrupted by conditions unrelated to our
business or operations, including the bankruptcy of the manufacturer or supplier; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">logistics carrier disruptions or increased costs that are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any adverse developments affecting manufacturing operations for our Biote-branded dietary supplements may result in lot failures, inventory
shortages, shipment delays, product withdrawals or recalls or other interruptions in the supply of these products, which could prevent their delivery to Biote-certified practitioners or Biote-partnered clinics. We may also have to write off
inventory, incur other charges and expenses to replace dietary supplements that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could impact our ability to successfully commercialize any future products that we recommend as part of our training and
our current or any future Biote-branded dietary supplements. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and Biote-certified practitioners and Biote-partnered clinics are reliant on AnazaoHealth Corporation, Right Value Drug Stores, LLC, and F.H.
Investments, Inc. to support the manufacturing of <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormones for prescribers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a Pharmacy Services Agreement with AnazaoHealth Corporation, or AnazaoHealth, on October&nbsp;30, 2020 (the &#147;AnazaoHealth
Pharmacy Services Agreement&#148;), an Outsourcing Facility Services Agreement with Right Value Drug Stores, LLC d/b/a Carie Boyd&#146;s Prescription Shop, or Carie Boyd&#146;s, on August&nbsp;1, 2020 (the &#147;Outsourcing Facility Services
Agreement&#148;), and a Pharmacy Services Agreement with F.H. Investments, Inc. d/b/a Asteria Health, Asteria Health, on October&nbsp;28, 2021, which was subsequently amended and restated in its entirety on October&nbsp;19, 2023, to build
relationships to support Biote-certified practitioners by offering an option for the compounded bioidentical hormones that the practitioners may order or prescribe (the &#147;Asteria Health Pharmacy Services Agreement&#148;). AnazaoHealth, Carie
Boyd&#146;s, and Asteria Health are operators of <FONT STYLE="white-space:nowrap">FDA-registered</FONT> 503B outsourcing facilities. While Biote-certified practitioners have the option to use a variety of different outsourcing facilities,
AnazaoHealth, Carie Boyd&#146;s and Asteria Health are the primary outsourcing facilities of the compound testosterone and estradiol implantable subcutaneous pellets used by Biote-certified practitioners as part of the Biote Method. However, we do
not control or direct the compounding or manufacturing processes of these 503B outsourcing facilities. We also do not control the time and resources AnazaoHealth, Carie Boyd&#146;s or Asteria Health devotes to compounding of testosterone and
estradiol implantable subcutaneous pellets. If AnazaoHealth, Carie Boyd&#146;s or Asteria Health are unable to successfully fulfill a Biote-certified practitioner&#146;s product orders, or if the state licenses held by AnazaoHealth, Carie
Boyd&#146;s or Asteria Health to ship medications for office use throughout the United States are revoked, expire or otherwise not maintained, it could adversely impact the practices of Biote-certified Practitioners or Biote-partnered clinics, which
could in turn have a material adverse effect on our business, financial condition and results of operations. The FDCA prohibits selling or transferring a drug compounded by an outsourcing facility by an entity other than the outsourcing facility
that compounded the drug. In June 2023, the FDA released guidance, &#147;Prohibition on Wholesaling Under Section&nbsp;503B of the Federal Food, Drug, and Cosmetic Act&#148; clarifying its interpretation of this prohibition. If the FDA determines
that we are selling or transferring a drug compounded by an outsourcing facility, we may be subject to penalties under the FDCA. Other changes in state and federal regulatory and enforcement with respect to compounded drugs may also affect
AnazaoHealth, Carie Boyd&#146;s and Asteria Health, and, in turn, have the potential to harm the practices of Biote-certified practitioners or Biote-partnered clinics or our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any termination of the AnazaoHealth Pharmacy Services Agreement, the Outsourcing Facility
Services Agreement, or the Asteria Health Pharmacy Services Agreement could have an adverse effect on the practices of Biote-certified Practitioners or Biote-partnered clinics, our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may also seek to develop relationships with other outsourcing facilities to support the manufacturing of bioidentical
hormones for Biote-certified practitioners and Biote-partnered clinics in the United States and internationally. We already have a presence in Puerto Rico, Mexico, and the Dominican Republic, where we hope to continue growing our business, and also
hope to expand into Argentina, Brazil, Colombia, and Canada, as permitted by law, in the future. If we fail to develop new relationships with any other outsourcing facilities we seek to engage, including in new markets in the United States and
internationally, fail to manage or incentivize these facilities effectively, or if these facilities are not successful in their sales and marketing efforts, our ability to support to Biote-certified practitioners and Biote-partnered clinics, and to
generate revenue, cash flow and earnings growth could suffer, which could have a material adverse effect on our business, financial condition and results of operations. Moreover, these agreements may be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> and some of these facilities may also have cooperative relationships with certain of our competitors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biote-certified practitioners and Biote-partnered clinics are concentrated in certain geographic regions, which makes us sensitive to regulatory,
economic, environmental and competitive conditions in those regions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generate revenues by charging the Biote-partnered clinics
fees associated with the support Biote provides for HRT and from the sale of Biote-branded dietary supplements. During the year ended December&nbsp;31, 2023, approximately 60% of our revenue was generated in Texas, Oklahoma, New Mexico, Colorado,
Arkansas, Louisiana, Mississippi, Alabama, Georgia and Florida. Such geographic concentration makes us particularly sensitive to regulatory, economic, environmental and competitive conditions in those states. Any material changes in those factors in
those states could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be
successful in expanding into new geographic areas within the United States or internationally. In addition, as we expand into new geographic areas, we may not be able to dedicate enough time or resources to maintain our market share in our core
geographic areas, and our business may be negatively impacted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The frequency of use by practitioners and clinics of the Biote Method may not
increase at the rate that we anticipate or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our key objectives is to continue to increase utilization, or the
adoption and frequency of use, of both the Biote Method and our Biote-branded dietary supplements by new and existing Biote-certified practitioners and Biote-partnered clinics. If utilization by our existing and newly trained Biote-certified
practitioners of the Biote Method and the Biote-branded dietary supplements we sell does not occur or does not occur as quickly as we anticipate, we could experience a material adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adoption of the Biote Method depends upon appropriate practitioner training, and inadequate training may lead to negative patient
outcomes and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on the patient selection criteria of Biote-certified
practitioners and proper execution of methods discussed in training sessions conducted by our training faculty. However, the practice of medicine is the domain of the Biote-certified practitioners, who rely on their previous medical training and
experience, and we cannot guarantee that Biote-certified practitioners will effectively utilize the Biote Method. Patient outcomes may not be consistent across Biote-certified practitioners and Biote-partnered clinics. This result may negatively
impact the perception of patient benefit and limit adoption of the Biote Method, and could result in litigation against us, in each case which would have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The continuing development of our training depends upon our maintaining strong working relationships
with Biote-certified practitioners and other medical personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development, marketing and sale of our training depend upon
our maintaining working relationships with Biote-certified practitioners and other medical personnel. We rely on these relationships to provide us with considerable knowledge and experience regarding the development, marketing and sale of our
training. For example, Biote-certified practitioners assist us in marketing and as researchers, consultants and public speakers. If we cannot maintain our strong working relationships and continue to receive such advice and input, the development
and marketing of our training could suffer, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We believe our long-term value as a company will be greater if we focus on growth, which may negatively impact our results of operations in the near
term. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our long-term value as a company will be greater if we focus on longer-term growth over short-term results. As a
result, our results of operations may be negatively impacted in the near term relative to a strategy focused on maximizing short-term profitability. Significant expenditures on marketing efforts, acquisitions and international expansion may not
ultimately grow our business or lead to expected long-term results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced substantial growth in our operations, and we
expect to experience continued growth in our business. This growth has placed, and will continue to place, significant demands on our management and our operational infrastructure. Any growth that we experience in the future could require us to
expand our sales and marketing personnel and general and administrative infrastructure. In addition to the need to scale our organization, future growth will impose significant added responsibilities on management, including the need to identify,
recruit, train and integrate additional employees. We cannot assure you that any increases in scale will be successfully implemented or that we will be able to hire additional personnel or that appropriate personnel will be available to facilitate
the growth of our business. Rapid expansion in personnel could mean that less experienced people market and sell the Biote Method and our Biote-branded dietary supplements, which could result in inefficiencies and unanticipated costs, lowered
quality standards and disruptions to our operations. Rapid and significant growth may strain our administrative and operational infrastructure and could require significant capital expenditures that may divert financial resources from other
projects, such as research and development of potential future offerings. In addition, our ability to grow may be adversely impacted due to factors beyond our control, which could have a material adverse effect on our business, reputation, financial
performance, financial condition and results of operations, and could expose us to liability. Our failure to manage growth effectively could have a material and adverse effect on our business, financial condition and results of operations. To manage
the growth of our operations, we must establish appropriate and scalable operational and financial systems, procedures and controls and build and maintain a qualified finance, administrative and operations staff. If we are unable to manage our
growth effectively, including by failing to implement necessary procedures, transition to new processes or hire necessary personnel, we may fail to execute our business strategy which would have a material adverse effect on our business, results of
operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or
maintain expected levels of market penetration and market share, which could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical practice-building market and dietary supplement industry are highly competitive, subject to rapid change and significantly affected
by new offerings and other market activities of industry participants. For example, in the dietary supplement space, we are competing with more than 30 brands of dietary supplements, including that of Evexipel, Pellecome, <FONT
STYLE="white-space:nowrap">Pro-Pell,</FONT> Sottopelle, HTCA and Nature&#146;s Way, which are either available direct to consumer online, through more conventional retailers and department stores and/or sold through practitioners. If we are unable
to compete effectively, we will not be able to establish our training and Biote-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
branded dietary supplements in the marketplace, which would have a material adverse effect on our business, financial condition and results of operations. Further, large, well-capitalized
pharmaceutical companies may enter the medical practice-building market in the hormone optimization space or dietary supplements market and would be able to spend more on development of their offerings, marketing, sales, compliance and other
initiatives than we can. Some of our competitors may have: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly greater name recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broader or deeper relations with healthcare professionals and clinics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more established dietary supplement distribution networks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional lines of dietary supplements and the ability to offer rebates or bundle products to offer greater
discounts or other incentives to gain a competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater experience in conducting research and development, and marketing for their products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater financial and human resources for development, sales and marketing and patent prosecution of our
offerings. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Our continued success depends on our ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop innovative training as well as Biote-branded dietary supplements that aim to address patient needs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adapt to regulatory and enforcement changes over time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our sales force across key markets to increase the number of Biote-certified practitioners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">leverage our Biote-branded dietary supplements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accelerate the expansion of our business into new markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain skilled research, development, sales and clinical personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effectively market and sell our training and our Biote-branded dietary supplements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, enforce and defend our intellectual property rights and operate our business without
infringing, misappropriating or otherwise violating the intellectual property rights of others. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can provide no
assurance that we will be successful in developing new training, methods, or Biote-branded dietary supplements or commercializing them in ways that achieve market acceptance. Moreover, any significant delays in the development or commercialization
of new training, methods or dietary supplements may significantly impede our ability to enter or compete in a given market and may reduce the sales that we are able to generate, which could have a material adverse effect on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited history operating a practice-building business for practitioners in the hormone optimization
space, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited history operating a practice-building business for practitioners in the hormone optimization space. We commenced operations
in 2012, and our operations to date have been largely focused on organizing and staffing our company, business planning, raising capital, developing the Biote Method and our training, refining our relationships with outsourcing facilities that can
compound the bioidentical hormone pellet products that Biote-certified practitioners may prescribe, as well as manufacturers who produce our Biote-branded dietary supplements. Our limited operating history and evolving business make it difficult to
evaluate our current business and future prospects and increase the risk of your investment. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or a history of commercializing the Biote Method and our Biote-branded dietary supplements. In addition, as an early-stage company with a limited operating history, we may encounter unforeseen
expenses, difficulties, complications, delays and other known and unknown factors which may result in our inability to maintain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
quarterly results may fluctuate significantly and may not fully reflect the underlying performance of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of
operations and key metrics discussed elsewhere in this registration statement may vary significantly in the future and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparisons of our operating
results and key metrics may not provide a full picture of our performance. Accordingly, the results of any one quarter or year should not be relied upon as an indication of future performance. Our quarterly financial results and metrics may
fluctuate as a result of a variety of factors, many of which are outside of our control, and as a result they may not fully reflect the underlying performance of our business. These quarterly fluctuations may negatively affect the value of our
securities. Factors that may cause these fluctuations include, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for either the Biote Method or our Biote-branded dietary supplements, which may vary
significantly from period to period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract new Biote-partnered clinics and Biote-certified practitioners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the addition or loss of one or more of our Biote-partnered clinics or Biote-certified practitioners, including as
the result of acquisitions or consolidations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of recognition of revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount and timing of operating expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions, both domestically and internationally, including any economic
downturns and adverse impacts resulting from public health crises, increases in inflation and interest rates and/or international conflicts such as the military conflict between Russia and Ukraine and the Israel-Hamas war; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our billing and collections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Biote-partnered clinic and Biote-certified practitioner renewal, expansion, and adoption rates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increases or decreases in the number of patients that are served by Biote-certified practitioners or
Biote-partnered clinics, or pricing changes upon any renewals of Biote-certified practitioner or Biote-partnered clinic agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our pricing policies or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success of new offerings by us or our competitors or any other change in the competitive dynamics
of our industry, including consolidation among competitors, practitioners, clinics or outsourcing facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extraordinary expenses such as litigation or other dispute-related expenses or settlement payments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales tax and other tax determinations by authorities in the jurisdictions in which we conduct business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of new accounting pronouncements and the adoption thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in stock-based compensation expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses in connection with mergers, acquisitions or other strategic transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory and licensing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount and timing of expenses related to our expansion to markets outside the United States; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of expenses related to the development or acquisition of technologies or businesses and potential
future charges for impairment of goodwill or intangibles from acquired companies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in future periods, our
revenue growth could slow or our revenues could decline for a number of reasons, including slowing demand for either the Biote Method or our Biote-branded dietary supplements, increasing competition, a decrease in the growth of our overall market,
or our failure, for any reason, to continue to capitalize on growth opportunities. In addition, our growth rate may slow in the future as our market penetration rates increase. As a result, our revenues, operating results and cash flows may
fluctuate significantly on a quarterly basis and revenue growth rates may not be sustainable and may decline in the future, and we may not be able to achieve or sustain profitability in future periods, which could harm our business and cause the
market price of our Class&nbsp;A common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to attract and retain executive officers, key employees and other
qualified personnel, or are unable to attract and retain contracts with Biote-certified practitioners, our ability to compete could be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to attract and retain our executive officers, key employees and other qualified personnel, and as a
relatively small company with key talent residing in a limited number of employees, our operations and prospects may be severely disrupted if we lost any one or more of their services. As we build our brand, expand into new domestic and
international territories and become more well known, there is increased risk that competitors or other companies will seek to hire our personnel. While some of our employees are bound by <FONT STYLE="white-space:nowrap">non-competition</FONT>
agreements, these may prove to be unenforceable. The failure to attract, integrate, train, motivate and retain these personnel could seriously harm our business and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are highly dependent on the services of several of our executive officers and other senior technical and management personnel,
including Teresa S. Weber, our Chief Executive Officer, Marc D. Beer, our Executive Chairman, Robert C. Peterson, our Chief Financial Officer, Dr.&nbsp;Ross McQuivey, our Chief Medical Officer, Mary Elizabeth Conlon, our Vice President, Business
Development and General Counsel, and Mary Puncochar, our Chief Commercial Officer, who would be difficult to replace. If these or other key personnel were to depart, we may not be able to successfully attract and retain senior leadership necessary
to grow our business. We do not maintain key person life insurance with respect to any member of management or other employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
our success depends in part upon our ability to attract, train and retain contracts with practitioners and clinics. We have invested substantial time and resources in building our base of Biote-certified practitioners and Biote-partnered clinics. If
we are unable to attract and retain contracts with practitioners and clinics capable of meeting our business needs and expectations, our business and brand image may be impaired. Any failure to grow our practitioner base of Biote-certified
practitioners or any material increase in turnover rates of our Biote-certified practitioners may adversely affect our business, results of operations and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in our business and operations, as well as organizational changes, have placed, and may continue to place, significant demands on our management
and infrastructure. If we fail to manage these changes effectively, we may be unable to execute our business plan, maintain high levels of service, or address competitive challenges adequately. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past 12 months, we have experienced organizational changes, including the recent appointment of new executives, including a new Chief
Financial Officer and a new Chief People Officer, and the promotion, addition, or departure of members of our senior management team. These organizational changes have placed, and will continue to place, a significant strain on our management,
administrative, operational and financial infrastructure. Our success will depend in part upon the ability of our senior management team to manage these changes effectively. If we fail to manage these changes effectively, we may be unable to execute
our business plan, maintain high levels of service or address competitive challenges adequately. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The healthcare industry is highly regulated, and government authorities may determine that we have
failed to comply with applicable laws, rules or regulations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare industry, including the healthcare and other services
that we and Biote-certified practitioners provide, are subject to extensive and complex federal, state and local laws, rules and regulations, compliance with which imposes substantial costs on us. Of particular importance are the provisions
summarized as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal laws (including the False Claims Act, 31 U.S.C. &#167; 3729 (the &#147;False Claims Act&#148;)) that
prohibit entities and individuals from intentionally (or with reckless disregard or deliberate ignorance) presenting or causing to be presented false or fraudulent claims to government-funded programs, or improperly retaining known overpayments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision of the Social Security Act of 1935, as amended, commonly referred to as the federal Anti-Kickback
Statute, as amended (the &#147;federal Anti-Kickback Statute&#148;), that prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration, in cash or in kind, in return for the referral
or recommendation of patients for, or for the purchasing, leasing, ordering or arranging for, items and services for which payment may be made, in whole or in part, by federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar state law provisions pertaining to anti-kickback, fee splitting, self-referral and false claims, and
other fraud and abuse issues which typically are not limited to relationships involving government-funded programs. In some cases these laws prohibit or regulate additional conduct beyond what federal law affects, including applicability to items
and services paid by commercial insurers and private pay patients. Penalties for violating these laws can range from fines to criminal sanctions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provisions of 18 U.S.C. &#167; 1347 that prohibit knowingly and willfully executing a scheme or artifice to
defraud a healthcare benefit program or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or
services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA marketing and promotion restrictions, as well as several other types of state and federal healthcare fraud
and abuse laws have been applied in recent years to restrict certain marketing practices in the healthcare industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal and state laws related to confidentiality, privacy and security of personal information such as Health
Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), including protected health information (&#147;PHI&#148;), that limit the manner in which we may use and disclose that information, impose obligations to safeguard that
information and require that we notify our customers in the event of a breach; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State corporate practice of &#147;medicine&#148; prohibitions that restrict unlicensed persons from engaging
licensed professionals to render professional services to the public or from interfering with or influencing a licensed practitioner&#146;s professional judgment. Certain activities other than those directly related to the delivery of healthcare
services to patients may be considered an element of the practice of medicine in many states; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State <FONT STYLE="white-space:nowrap">fee-splitting</FONT> prohibitions, which prohibit licensed healthcare
professionals from sharing a portion of their professional fees collected from their professional services with unlicensed third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#147;HITECH&#148;)
and their implementing regulations, also imposes obligations, including mandatory contractual terms, on covered entities, which are health plans, healthcare clearing houses, and certain healthcare providers, as those terms are defined by HIPAA, and
their respective business associates and their subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully
interpreted by the regulatory authorities or the courts, and their provisions are open </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant
legal expenses and reputational harm and divert our management&#146;s attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty
associated with the violation, including significant administrative, civil and criminal penalties, damages, fines, sanctions, disgorgement, imprisonment, exclusion from participation in federal healthcare programs, refunding of payments received by
us, integrity oversight and reporting obligations, and curtailment or cessation of our operations. Any of the foregoing consequences could seriously harm our business and our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Biote does not bill or receive any reimbursement from any third-party payor, to the extent that any Biote-certified practitioners and
Biote-partnered clinic with whom we partner accepts health insurance for their services, we could be subject to additional laws, including without limitation the federal Anti-Kickback Statute, False Claims Act and the healthcare fraud provisions of
HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our relationships with Biote-certified practitioners and Biote-partnered clinics, and, therefore, our
operations are subject to federal and state healthcare fraud and abuse, referral and reimbursement laws and regulations. If our operations are found to be in violation of any of the federal and state healthcare laws or any other current or future
fraud and abuse or other healthcare laws and regulations that apply to us, including applicable healthcare fraud statutes, we may be subject to penalties. Penalties under these laws may be severe, and include without limitation treble damages,
significant criminal, civil and administrative penalties, attorneys&#146; fees and fines, injunctions, as well as contractual damages and reputational harm. We could also be required to modify, curtail or cease our operations. Any of the foregoing
consequences could seriously harm our business and our financial results and enforcement of the foregoing laws could have a material adverse effect on our business. Also, these measures may be interpreted or applied by a prosecutorial, regulatory or
judicial authority in a manner that could require us to make changes in our operations or incur substantial defense and settlement expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the complexity of statutory and regulatory exemptions, it is possible that some of our activities
could be subject to challenge under one or more of such laws. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our
management&#146;s attention from the operation of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a regulatory climate that is uncertain, our operations may be subject
to direct and indirect adoption, expansion or reinterpretation of various healthcare laws and regulations. Compliance with these and/or future healthcare laws and regulations may require us to change our practices at an undeterminable and possibly
significant initial monetary and annual expense. These additional monetary expenditures may increase future overhead, which could have a material adverse effect on our results of operations. Additionally, the introduction of new training, and
Biote-branded dietary supplements may require us to comply with additional laws and regulations. Compliance may require obtaining appropriate licenses or certificates, increasing our security measures, and expending additional resources to monitor
developments in applicable rules and ensure compliance. The failure to adequately comply with these and/or future healthcare laws and regulations may delay or possibly prevent any new training and products from being offered to Biote-certified
practitioners, Biote-partnered clinics and their patients, which could have a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other
obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and
penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure,
dispose of, transmit, and share (collectively, process) personal data and other sensitive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, and other sensitive data the Company may process, e.g.,
business plans, transactions, or financial information. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and
security policies, contractual requirements, and other obligations relating to data privacy and security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, HIPAA, as amended
by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable protected health information. In addition, over the past few years, numerous U.S. states-including California, Virginia,
Colorado, Connecticut, and Utah-have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their
personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain data processing activities, such as targeted advertising,
profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting
data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (&#147;CPRA&#148;), (collectively,
&#147;CCPA&#148;) applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to
exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Similar laws are being considered in
several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments further complicate compliance efforts and increase legal risk and compliance costs for us and the
third parties upon whom we rely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security laws, we are contractually subject to industry standards
adopted by industry groups and, we are, or may become subject to such obligations in the future. For example, we are subject to the Payment Card Industry Data Security Standard (&#147;PCI DSS&#148;). The PCI DSS requires companies to adopt certain
measures to ensure the security of cardholder information, including using and maintaining firewalls, adopting proper password protections for certain devices and software, and restricting data access. Noncompliance with <FONT
STYLE="white-space:nowrap">PCI-DSS</FONT> can result in penalties ranging from $5,000 to $100,000 per month by credit card companies, litigation, damage to our reputation, and revenue losses. We also rely on vendors to process payment card data, who
may be subject to PCI DSS, and our business may be negatively affected if our vendors are fined or suffer other consequences as a result of PCI DSS noncompliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and data privacy
laws and regulations will involve substantial ongoing costs and may require us to undertake or implement additional policies or measures. The scope of the foregoing state laws and the interpretations of them vary by jurisdiction and are enforced by
local courts and regulatory authorities, each with broad discretion. We may face claims and proceedings by private parties, and claims, investigations and other proceedings by governmental authorities, relating to allegations that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations, and it is possible that courts or governmental authorities may conclude that our
arrangements with the Biote-certified practitioners, Biote-partnered clinics or our sales force are not consistent with such laws, or that we may find it necessary or appropriate to settle any such claims or other proceedings. In connection with any
such claims, proceedings, or settlements, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare
programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such
actions can be costly, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our
business may be impaired. Further, if any Biote-certified practitioners or Biote-partnered clinics with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in the United States and some foreign jurisdictions there have been, and continue to be, several legislative and
regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care. These reform initiatives may, among other things, result in modifications to the aforementioned laws and/or
the implementation of new laws affecting the healthcare industry, which could have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We plan to expand our
operations to new markets outside the United States, creating a variety of operational challenges. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently work with
numerous clinics that are multi-national in scope, our current business is primarily focused on clinics and practitioners in the United States. A component of our growth strategy involves expanding our operations outside the United States, including
expansion into Puerto Rico, Argentina, Brazil, Colombia, Mexico, Canada and the Dominican Republic, as permitted by law. We may face difficulties as we expand our operations into new domestic and international markets in which we have limited or no
prior operating experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our growth strategy for expanding our operations outside the United States will require significant resources
and management attention and will subject us to regulatory, economic and political risks that are different from those in the United States, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to localize and adapt our platform for specific countries, including translation into foreign languages
and obtaining local regulatory and legal guidance with associated expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">data privacy laws that require customer data to be stored and processed in a designated territory;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in staffing and managing international operations and working with international partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different pricing environments, longer sales cycles and longer accounts receivable payment cycles and collections
issues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new and different sources of competition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">weaker protection for intellectual property and other legal rights than in the United States and practical
difficulties in enforcing intellectual property and other rights outside of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laws and business practices favoring local competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance challenges related to the complexity of multiple, conflicting and changing governmental laws and
regulations, including employment, tax, privacy and data protection laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased financial accounting and reporting burdens and complexities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the transfer of funds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in currency exchange rates, which could increase the price of the products that we recommend as part
of our training and of our Biote-branded dietary supplements outside of the United States, increase the expenses of our international operations and expose us to international currency exchange rate risk; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse tax consequences; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unstable regional and economic political conditions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, due to potential costs from any international expansion efforts and potentially
higher supplier costs outside of the United States, our international operations may operate with a lower margin profile. As a result, our margins may fluctuate as we expand our operations internationally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we move to expand our business into Central and South America, our success will depend, in large part, on our ability to identify and work
with international distributors. If our international distributors are unable to expand our business or are unable to provide an adequate training program, our business could be harmed. Our failure to manage any of these risks successfully, or to
comply with these laws and regulations, could harm our operations, reduce our sales and harm our business, operating results and financial condition. For example, in certain countries, particularly those with developing economies, certain business
practices that are prohibited by laws and regulations applicable to us, such as the Foreign Corrupt Practices Act, may be more commonplace. Although we have policies and procedures designed to ensure compliance with these laws and regulations, our
employees, contractors and agents, as well as partners involved in our international sales, may take actions in violation of our policies. Any such violation could have an adverse effect on our business and reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the outsourcing facilities we work with also have international operations and are subject to the risks described above. Even if we
are able to successfully manage the risks of international operations, our business may be adversely affected if these facilities are not able to successfully manage these risks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to achieve or maintain satisfactory pricing and margins for our training and the Biote Method or the Biote-branded dietary
supplements we sell. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies in our industry have a history of price competition, and we can give no assurance that we will be
able to achieve satisfactory prices for the Biote Method, or our Biote-branded dietary supplements, or maintain prices at the levels we have historically achieved. If we are forced to lower the price we charge for the Biote Method or our
Biote-branded dietary supplements, our revenue and gross margins will decrease, which will adversely affect our ability to invest in and grow our business. If we are unable to maintain our prices, or if our costs increase and we are unable to offset
such increase with an increase in our prices, our margins could erode. We will continue to be subject to significant pricing pressure, which could materially and adversely impact our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unforeseen and unpredictable factors affecting the operations of the FDA, U.S. Drug Enforcement Administration (the &#147;DEA&#148;) and other
government agencies, such as changes in funding for the FDA, DEA and other government agencies, could hinder their ability to hire and retain key leadership and other personnel, or otherwise delay inspections of the 503B outsourcing facilities of
our third-party dietary supplement contract manufacturers, which could negatively impact practitioners and our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ability of the FDA, the DEA and other governmental agencies to conduct their regulatory duties and activities, including reviewing and approving future products, can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review and response times at the agency have fluctuated in recent years as a result. In addition, government
funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or comparable international regulatory
authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or comparable international regulatory authorities to timely inspect the facilities of our
third-party suppliers, which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The size of the markets for our current and future offerings has not been established with precision
and may be smaller than we estimate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners primarily focus their treatments on women experiencing symptoms
due to hormonal imbalance before, during, and after menopause, and men experiencing symptoms of hypogonadism and male sex hormone deficiency. It is estimated that, as of 2020, the total U.S. market opportunity for HRT products, available in various
forms, exceeds $7&nbsp;billion and is expected to grow 7% annually through 2026. We believe our business opportunity in providing educational and practice management services is large and will similarly grow. Our estimates of our total addressable
markets for our current offerings and those under development are based on a number of internal and third-party estimates, including, without limitation, the number of practitioners we can offer our training and Biote-branded dietary supplements to
and the assumed prices at which we can sell offerings in markets that have not been established or that we have not yet entered. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates
may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these estimates. As a result, our estimates of the total addressable market for our current or future
offerings may prove to be incorrect. If the actual number of a Biote-certified practitioner&#146;s or Biote-partnered clinic&#146;s patients who would benefit from the Biote Method or our Biote-branded dietary supplements, the price at which we can
sell training and Biote-branded dietary supplements, or the total addressable market for the Biote Method or our Biote-branded dietary supplements is smaller than we have estimated, it may impair our sales growth and have a material adverse impact
on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our forecasted operating and financial results rely upon assumptions and analyses
developed by us. If these assumptions and analyses prove to be incorrect, our actual operating and financial results may be significantly below our forecasts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether actual operating and financial results and business developments will be consistent with our expectations, assumptions and analyses as
reflected in our forecasted operating and financial results depends on a number of factors, many of which are outside of our control, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we can obtain sufficient capital to grow our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we can manage relationships with 503B outsourcing facilities and dietary supplement contract
manufacturers, and other key suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demand for the Biote Method and our Biote-branded dietary supplements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and costs of new and existing marketing and promotional efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition, including from established and future competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain existing key management, to integrate recent hires and to attract, retain and motivate
qualified personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the overall strength and stability of the economies in the markets in which we operate or intend to operate in
the future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory, legislative and political changes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our
business, prospects, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our estimates or judgments relating to our critical accounting policies
prove to be incorrect, our results of operations could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in
conformity with U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;) requires management to make estimates and assumptions that affect the amounts reported in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consolidated financial statements and accompanying notes appearing elsewhere in this registration statement. We base our estimates on historical experience and on various other assumptions that
we believe to be reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenue and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are described in Note 2 to our audited consolidated financial statements included elsewhere in this
registration statement. We believe that the accounting policies described reflect our most critical accounting policies and estimates (including with respect to revenue recognition and the valuation of inventory), which represent those that involve
a significant degree of judgment and complexity. Accordingly, we believe these policies are critical in fully understanding and evaluating our reported financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions,
which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Off-label</FONT> promotion may result in civil and criminal fines and other penalties, as well as product liability
suits, which could be costly to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote does not manufacture or distribute any drug products. Nevertheless, if the FDA
determines that our practitioner training, including our paid consultants&#146; educational materials, constitutes <FONT STYLE="white-space:nowrap">off-label</FONT> drug promotion, it could subject us or our business partners to enforcement action,
including warning letters, untitled letters, fines and penalties, including criminal fines and/or prosecution. If we are found to have inappropriately marketed or promoted any drugs, we may become subject to significant liability. The federal
government has levied large civil and criminal fines and/or other penalties against companies for alleged improper promotion and has investigated, prosecuted and/or enjoined several companies from engaging in
<FONT STYLE="white-space:nowrap">off-label</FONT> promotion. If we become subject to civil or criminal fines or other penalties, or product liability suits, such fines, penalties or lawsuits could have a material adverse effect on our business,
financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain direct and indirect subsidiaries of Biote entered into that certain credit agreement which
contains affirmative, negative and financial covenants that may limit its flexibility in operating its businesses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;26,
2022, certain direct and indirect subsidiaries of Biote entered into that certain Credit Agreement (the &#147;Credit Agreement&#148;) with BioTE Medical, LLC (the &#147;BioTE Medical&#148;) as borrower, and Truist Bank, as administrative agent, in
connection with the Closing of the Business Combination. The Credit Agreement provides to borrower a $125.0&nbsp;million five-year senior secured term loan A facility (the &#147;Term Loan&#148;) and a $50.0&nbsp;million revolving line of credit. The
proceeds of the Credit Agreement have been used to repay existing debt, pay fees and expenses in connection with the Business Combination, and for general corporate purposes. The Credit Agreement contains affirmative, negative and financial
covenants that could limit the manner in which Biote conducts its business, and Biote may be unable to expand or fully pursue its business strategies, engage in favorable business activities, or finance future operations or capital needs.
Biote&#146;s ability to comply with the covenants under the Credit Agreement may be affected by events beyond its control, and it may not be able to comply with those covenants. A breach of any of the covenants contained in the Credit Agreement
could result in a default under the Credit Agreement, which could cause all of the outstanding indebtedness under the facility to become immediately due and payable if not waived by the lender. Biote failed to timely deliver a budget for the fiscal
year ending December&nbsp;31, 2023, resulting in an event of default as of June&nbsp;30, 2023. On July&nbsp;27, 2023, the lender waived the event of default. As of December&nbsp;31, 2023, the Company was in compliance with all required covenants
associated with the Credit Agreement. If Biote is unable to generate sufficient cash to repay its debt obligations under the Credit Agreement when they become due and payable, either as such obligations become due, when they mature, or in the event
of a default, Biote may not be able to obtain additional debt or equity financing on favorable terms, if at all, which could have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, borrowings under the Credit Agreement are at variable rates of interest and expose
us to interest rate risk. In recent months, global inflation and other factors have resulted in an increase in interest rates generally, which has impacted our borrowing costs. If interest rates were to continue to increase, our debt service
obligations on the variable rate indebtedness referred to above would increase even if the principal amount borrowed remained the same, and our net income and cash flows will correspondingly decrease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we offer or
may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure. If we cannot successfully defend ourselves against claims
that the products that we recommend as part of our training or our Biote-branded dietary supplements caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for the Biote Method and our Biote-branded dietary supplements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any new methods, training, or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation, including the risk that any Biote-certified practitioners who
may face such related litigation may in turn seek to recover from us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards paid to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of any available insurance and our capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced resources for our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any methods, training, or products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur and
we may need to increase our insurance coverage. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a Biote-certified practitioner&#146;s failure to follow our training and the Biote Method, or accepted medical practices in any stage
of treatment may result in lawsuits against us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in strategic transactions that could impact our liquidity, increase our expenses and
present significant distractions to our management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic transactions, such as
acquisitions of companies, asset purchases and <FONT STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies. Any future transactions could increase
our near and long-term expenditures, result in potentially dilutive issuances of our securities, including our Class&nbsp;A common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a
variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not
be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our
existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our
business, results of operations, financial condition and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and only protect us from some business
risks, which will leave us exposed to significant uninsured liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry business interruption coverage to mitigate
certain potential losses, but this insurance is limited in amount and may not be sufficient in type or amount to cover us against claims related to our operations. We cannot be certain that such potential losses will not exceed our policy limits,
insurance will continue to be available to us on economically reasonable terms, or at all, or any insurer will not deny coverage as to any future claim. In addition, we may be subject to changes in our insurance policies, including premium increases
or the imposition of large deductible or <FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we do not carry
insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include products and completed operations liability, business personal property and directors&#146; and officers&#146; insurance. We do
not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would materially and adversely affect our business, financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, Biote-certified practitioners, Biote-partnered clinics,
medical advisors and suppliers may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with professional and regulatory standards and requirements, which could have a material adverse
effect on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants, Biote-certified
practitioners, Biote-partnered clinics, medical advisors and suppliers may engage in misconduct or other improper activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized
activities to us that violates: (i)&nbsp;FDA laws and regulations or those of comparable international regulatory authorities, including those laws that require the reporting of true, complete and accurate information to the FDA,
(ii)&nbsp;compounding and manufacturing standards, (iii)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations established and enforced by comparable international regulatory authorities, or
(iv)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.
Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Extreme weather conditions, natural disasters, and other catastrophic events, including those caused by climate change, could negatively impact our
results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extreme weather conditions and volatile changes in weather conditions in the areas
in which our offices, suppliers, Biote-partnered clinics, dietary supplement third-party manufacturers, and suppliers are located could adversely affect our results of operations and financial condition. Moreover, natural disasters such as
earthquakes, hurricanes, tsunamis, floods, monsoons or wildfires, public health crises, such as pandemics and epidemics (including, for example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic), political crises, such as terrorist
attacks, war and other political instability, or other catastrophic events, whether occurring in the United States or abroad, and their related consequences and effects, including energy shortages, could disrupt our operations, the operations of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vendors and other suppliers or result in economic instability that could negatively impact practitioner or clinic spending, any or all of which would negatively impact our results of operations
and financial condition. In particular, these types of events could impact our global supply chain, including the ability of manufacturers to produce our Biote-branded dietary supplement products to Biote-partnered clinics or Biote-certified
practitioners from or to the impacted region(s). For instance, in 2022 we experienced hurricane-related closures of 140 medical clinics in Florida and Puerto Rico, two of our key markets. If such closures continue or we experience similar closures
in the future, there could be a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adverse developments
affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or <FONT STYLE="white-space:nowrap">non-performance</FONT> by financial institutions could adversely affect our results of operations and
financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Events involving limited liquidity, defaults, <FONT STYLE="white-space:nowrap">non-performance</FONT> or
other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any such events or other
similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&nbsp;10, 2023, the Federal Deposit Insurance Corporation (&#147;FDIC&#148;) took control and was appointed as the receiver of Silicon
Valley Bank. Similarly, on March&nbsp;12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although the FDIC announced that all deposits with these banks would be fully insured, there continues to be uncertainty
in the markets regarding the stability of regional banks and the safety of deposits in excess of the FDIC insured deposit limits. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial
conditions affecting the banking system and financial markets, our ability to access our existing cash may be threatened. The FDIC only insures accounts in amounts up to $250,000 per depositor per insured bank, and we currently have cash deposited
in certain financial institutions significantly in excess of FDIC insured levels. If any of the banking institutions in which we have deposited funds ultimately fails, we may lose our deposits over $250,000. The loss of our deposits may have a
material adverse effect on our business and financial condition. The ultimate outcome of these events cannot be predicted, but these events could have a material adverse effect on our business. Additionally, weakness and volatility in capital
markets and the economy, in general or as a result of bank failures or macroeconomic conditions such as high inflation, could limit our access to capital markets and increase our costs of borrowing. If adequate funds are not available on acceptable
terms, we may be unable to invest in future growth opportunities, which could harm our business, operating results and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market
and economic conditions may negatively impact the Company&#146;s business, financial condition and stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concerns over
inflation, energy costs, geopolitical issues, including the ongoing conflict between Russia and Ukraine and the Israel-Hamas war, unstable global credit markets and financial conditions, and volatile oil prices could lead to periods of significant
economic instability, diminished liquidity and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic growth going forward. For
example, in December 2023, the U.S. Consumer Price Index (&#147;CPI&#148;), which measures a wide-ranging basket of goods and services, rose 3.4% from the same month a year ago. The Company&#146;s general business strategy may be adversely affected
by any such inflationary fluctuations, economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions. Additionally, rising costs of goods and services purchased by the Company, including
its raw materials used in manufacturing its product, may have an adverse effect on the Company&#146;s gross margins and profitability in future periods. Increased inflation rates can adversely affect us by increasing our costs, including labor and
employee benefit costs. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition. If economic and market conditions continue to
deteriorate or do not improve, it may make any necessary debt or equity financing more difficult to complete, more costly and more dilutive to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s stockholders. Failure to secure any necessary financing in a timely manner or on favorable terms could have a material adverse effect on the Company&#146;s financial performance
and stock price or could require the Company to delay or abandon development other business plans. In addition, there is a risk that one or more of the Company&#146;s current and future service providers, manufacturers, suppliers, and other
facilities, and other partners could be negatively affected by such difficult economic factors, which could adversely affect the Company&#146;s ability to attain its operating goals on schedule and on budget or meet its business and financial
objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent protection for any products or methods we develop, or if the scope of the patent protection obtained is
not sufficiently broad, our competitors could develop and commercialize products similar or identical to our Biote-branded dietary supplements, and our ability to successfully commercialize any products we may develop may be adversely affected. If
we are not able to maintain freedom to operate for our products from third-party intellectual property rights, our ability to commercialize products may be limited unless we secure a license to such rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and
other countries with respect to our Biote-branded dietary supplements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a combination of contractual provisions,
confidentiality procedures and copyright, trademark, trade secret and other intellectual property rights to protect the proprietary aspects of our brands, technologies, and data. These legal measures afford only limited protection, and competitors
or others may gain access to or use our intellectual property and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and <FONT STYLE="white-space:nowrap">know-how,</FONT>
obtaining and maintaining patents and obtaining other intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to obtain and maintain
intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. For example, our trade secrets, data and <FONT STYLE="white-space:nowrap">know-how</FONT> could be subject to
unauthorized use, misappropriation or disclosure to unauthorized parties, despite our efforts to enter into confidentiality agreements with our employees, consultants, contractors, clients and other vendors who have access to such information and
could otherwise become known or be independently discovered by third parties. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary
or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our intellectual property at all. Despite our efforts to protect
our intellectual property, unauthorized parties may be able to obtain and use information that we regard as proprietary. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain
patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our
employees, consultants, contractors, collaborators, Biote-certified practitioners, Biote-partnered clinics, vendors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is
filed, thereby jeopardizing our ability to seek patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our other intellectual property, including our trademarks, could also
be challenged, invalidated, infringed and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks, in which case we could be forced to
<FONT STYLE="white-space:nowrap">re-brand</FONT> our Biote-branded dietary supplements, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third
parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future
also be subject to claims by our former employees, consultants or contractors asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Although we generally require all of our employees, consultants, contractors and any other collaborators who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT>
information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our
agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain and maintain patents, trademarks and other intellectual property rights necessary to our business and failure to protect,
monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United
States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property, and may
not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results
of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become a party to intellectual property litigation or administrative proceedings that could be costly and could
interfere with our ability to sell and market the Biote Method and our Biote-branded dietary supplements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has been
characterized by extensive litigation regarding patents, trademarks, trade secrets and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that
we may be accused of misappropriating third parties&#146; trade secrets. Additionally, our Biote-branded dietary supplements are produced by third-party vendors and may include components that are outside of our direct control. Our competitors may
have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to use and sell the Biote Method, or use, sell and/or export our Biote-branded dietary
supplements, or our ability to use product names. Moreover, in recent years, individuals and groups that are <FONT STYLE="white-space:nowrap">non-practicing</FONT> entities, commonly referred to as &#147;patent trolls,&#148; have purchased patents
and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#147;invitations to license,&#148; or may be the subject of
claims that the Biote Method, our Biote-branded dietary supplements and business operations infringe or violate the intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert
management&#146;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments. Vendors from whom we purchase products may not indemnify us in the event that such products accused
of infringing a third-party&#146;s patent or trademark or of misappropriating a third-party&#146;s trade secret, or any indemnification granted by such vendors may not be sufficient to address any liability and costs we incur as a result of such
claims. Additionally, we may be obligated to indemnify Biote-partnered clinics, Biote-certified practitioners or business partners in connection with litigation and to obtain licenses, which could further exhaust our resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we believe a third-party&#146;s intellectual property claims are without merit, there is no assurance that a court would find in our
favor, including on questions of infringement, validity, enforceability or priority of patents. The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted
patents. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any products or technology we may develop and any
other products or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one
requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Conversely, the patent owner
need only prove infringement by a preponderance of the evidence, which is a lower burden of proof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if patents, trademarks or trade secrets are successfully asserted against us, this
may harm our business and result in injunctions preventing us from selling the Biote Method and our Biote-branded dietary supplements, or result in obligations to pay license fees, damages, attorney fees and court costs, which could be significant.
In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although patent, trademark, trade secret and other intellectual property disputes have often been settled through licensing or similar
arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses, if any, on satisfactory terms, if at all. In addition, if any license we obtain is <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> we may not be able to prevent our competitors and other third parties from using the intellectual property or technology covered by such license to compete with us. Any of these events could
materially and adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, interference or derivation
proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office (the &#147;USPTO&#148;), may be necessary to determine priority with respect to our patents, patent applications, trademarks or trademark applications. We may
also become involved in other proceedings, such as reexamination, <I>inter partes</I> review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual
property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent third-party suppliers from manufacturing our Biote-branded dietary supplements, which would have a
significant adverse impact on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have filed and may in the
future file lawsuits or initiate other proceedings to protect or enforce our intellectual property rights, which could be expensive, time consuming and unsuccessful. We are currently party to two open litigation matters involving terminated
practices and practitioners who we filed suit against to enforce post-termination contractual obligations where the defendants offered a competing hormone pellet therapy within the contractual <FONT STYLE="white-space:nowrap">two-year</FONT>
restrictive period without paying our requisite <FONT STYLE="white-space:nowrap">buy-out</FONT> or residual benefit fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may
infringe our issued patents or other intellectual property, which we may not always be able to detect. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims
we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property or alleging that our intellectual property is invalid or unenforceable. Grounds for a
validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an
allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise challenges to the validity of certain of our owned patent
claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, interference
proceedings, derivation proceedings and equivalent proceedings in international jurisdictions (e.g., opposition proceedings). In any such lawsuit or other proceedings, a court or other administrative body may decide that a patent of ours is invalid
or unenforceable, in whole or in part, construe the patent&#146;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outcome following legal assertions of invalidity and unenforceability is unpredictable. If a third-party were to prevail on a legal
assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the protection on products that we may develop. If our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against
the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#146;s competition in the market. An adverse result
in any litigation or other proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Any of these events could materially and adversely affect our business, financial condition and results of operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other proceedings relating to intellectual
property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or
developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Class&nbsp;A common stock. Such litigation or proceedings could substantially increase our
operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of
litigation. Uncertainties resulting from the initiation and continuation of patent and other intellectual property litigation or other proceedings could have a material adverse effect on our business, financial condition and results of operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other
proprietary information that is not patentable or that we elect not to patent. However, trade secrets can be difficult to protect and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade
secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, contractors, Biote-certified practitioners, collaborators and others upon the commencement of their
relationship with us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We may not be able to prevent the unauthorized
disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions. These contracts may not provide meaningful protection for our trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary
information. There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by
competitors. Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to
protect our intellectual property or other proprietary rights will be adequate. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. The
laws of many countries will not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited in the
United States and abroad, which could affect our ability to expand in domestic and international markets or require costly efforts to protect our technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct
competition. A third-party could, without authorization, copy or otherwise obtain and use our Biote-branded dietary supplements, technology, or develop similar technology. Our competitors could purchase our Biote-branded dietary supplements and
attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the
value of our Biote-branded dietary supplements, as well as the value of our brand and business. The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our
Biote-branded dietary supplements and harm our business, the value of our investment in development or business acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary
information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, it is possible that others will independently develop the same or similar
technology or otherwise obtain access to our unpatented technology, and in such cases, we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of
our trade secret rights and related confidentiality and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> provisions. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently
develop technology similar to ours or competing technologies, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets, and agreement terms that
address <FONT STYLE="white-space:nowrap">non-competition</FONT> are difficult to enforce in many jurisdictions and might not be enforceable in certain cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of
our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or
misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able
to obtain adequate remedies for any breach. Any of the foregoing could materially and adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we or our employees, consultants or contractors have wrongfully used, disclosed or otherwise misappropriated the
intellectual property of a third-party, including trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements with our competitors or claims asserting an ownership interest in intellectual property we regard as our own. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, consultants and contractors were previously employed at or engaged by other medical device, biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors may have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property, proprietary information, <FONT
STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, used, disclosed or otherwise misappropriated intellectual
property, including trade secrets or other proprietary information, of their former employers or our competitors or potential competitors. Additionally, we may be subject to claims from third parties challenging our ownership interest in
intellectual property we regard as our own, based on claims that our employees, consultants or contractors have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to defend against such claims, and it may be necessary or we may desire to enter into a license to settle any such
claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. For example, a court could prohibit us from using technologies or features that are essential to the Biote Method or our Biote-branded dietary supplements, if such technologies or features are found to incorporate or be derived
from the trade secrets or other proprietary information of the former employer. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An inability to incorporate technologies or features that are important or essential to the Biote Method and our Biote-branded dietary
supplements could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from providing our training and selling our Biote-branded dietary supplements. Any litigation or the threat thereof
may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize the products that we recommend as part of our
training and our Biote-branded dietary supplements, which could have an adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging our intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former consultants, contractors or other third parties have an interest in our trade secrets
or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> While it is our policy to require our employees, consultants and contractors who may be involved in the conception or development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of
intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we
regard as our intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual
property that is important to our Biote-branded dietary supplements. Any such events could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build brand recognition in our markets and our business may
be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trademarks, service marks, trade names and brand names to distinguish our training and
Biote-branded dietary supplements from our competitors and have registered or applied to register these trademarks. Our registered or unregistered trademarks, service marks, trade names and brand names may be challenged, infringed, diluted,
circumvented or declared generic or determined to be infringing on other marks. Additionally, we cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we
are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many international jurisdictions, third parties are given an opportunity
to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In the event that our trademarks
are successfully challenged, we could be forced to rebrand our Biote-branded dietary supplements, which could result in loss of brand recognition and could require us to devote significant resources towards advertising and marketing new brands. At
times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In some cases, we may need to litigate claims to enforce our rights in our marks
to avoid market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based
on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We market dietary
supplements and convenience kits, which are regulated by the FDA, and are subject to certain requirements under the FDCA and the laws enforced by the FTC. Our failure to meet those requirements could cause us to cease certain of our business
activities and may involve the payment of financial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sell dietary supplements and convenience kits, which are
regulated by the FDA. Each of these product categories have differing requirements that must be followed to ensure compliance with the FDCA and regulations promulgated thereunder, and failure to do so may result in the products being misbranded or
adulterated. If we are found to have manufactured, distributed, sold, or labeled any products in violation of the FDCA, we may face significant penalties which may result in a material adverse effect on our business, financial condition, and results
of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC enforces the Federal Trade Commission Act (the &#147;FTCA&#148;) and related
regulations, which governs the advertising associated with the promotion and sale of our Biote-branded dietary supplements to prevent misleading or deceptive claims. For advertisements relating to dietary supplements, the FTC typically requires all
factual claims, both express and implied, to be substantiated by competent and reliable scientific evidence. The FTC has promulgated policies and guidance that apply to advertising for dietary supplements that may be costly to comply with. The FDA
may also determine that a particular dietary supplement or ingredient that we may market presents an unacceptable health risk. If that occurs, we could be required to cease distribution of and/or recall Biote-branded dietary supplements containing
that ingredient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or FTC may also determine that certain labeling, advertising and promotional claims, statements or activities
with respect to a dietary supplement are not in compliance with applicable laws and regulations and may determine that a particular statement is an unapproved health claim, a drug claim, a false or misleading claim, or a deceptive advertising claim.
Any such determination or any other failure to comply with FDA, FTCA or other regulatory requirements could prevent us from marketing our Biote-branded dietary supplements as a dietary supplement and subject us to administrative, civil or criminal
penalties. The FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions
have often resulted in warning letters, consent decrees and the payment of civil penalties and/or restitution by the companies involved. Should the FTC determine that our claims are false or misleading or unsubstantiated, we could be subject to FTC
enforcement action and may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have developed and market a method and training program where the practitioner may prescribe a compounded bioidentical hormone. Compounded drugs are
regulated by the FDA and are subject to certain requirements under the FDCA. Failure of compounding entities to meet those requirements could cause us to cease certain of our business activities and may involve the payment of financial penalties.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we do not sell compounded or prescription drugs, we have developed and market a method and training program where the
practitioner may prescribe a compounded bioidentical hormone that is made by a third-party 503B outsourcing facility and requires compliance with the FDCA, and failure to do so may result in the products being misbranded or adulterated. Amendments
to the FDCA in 2013 created Section&nbsp;503B, which creates a category of compounding pharmacies known as &#147;outsourcing facilities&#148; which are subject to certain FDCA requirements, including the requirement to adhere to cGMP regulations,
though it exempts such facilities from certain of the FDCA requirements that otherwise apply to drug manufacturers. Understanding and complying with these laws and regulations may require substantial time, money, and effort. While we have only
established relationships with 503B outsourcing facilities to support practitioners, if we are found to have manufactured, distributed, marketed, sold, or labeled any products in violation of the FDCA, we may face significant penalties which may
result in a material adverse effect on our business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compounded preparations and the pharmacy
compounding industry are subject to regulatory scrutiny, which may impair our growth and sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Formulations prepared and
dispensed by compounding pharmacies are not approved by the FDA. As we are a medical marketing and training company, we do not manufacture or compound pharmaceutical products. However, we contract with
<FONT STYLE="white-space:nowrap">FDA-registered</FONT> 503B outsourcing facilities to build relationships to support Biote-certified practitioners by offering an option for the compounding of bioidentical hormone pellets that the practitioner may
order to prescribe. These pellets, compounded by 503B outsourcing facilities, are not subject to the FDA new drug approval process. Certain compounding pharmacies have been the subject of widespread negative media coverage in recent years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the outsourcing facilities with which we have relationships must comply with applicable provision of the FDCA and its
implementing regulations. They may only distribute compounded drugs either pursuant to a patient-specific prescription or in response to an order from a healthcare provider, such as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hospital, which is not for an identified individual patient (e.g., for office stock). Further, such outsourcing facilities are inspected by the FDA according to a risk-based schedule, and must
meet certain other conditions, such as reporting adverse events and providing the FDA with certain information about the products they compound. When the FDA finds that a manufacturer has violated FDA regulations, the FDA may notify the manufacturer
of such violations in the form of a warning letter. The FDA also will issue an FDA Form 483 at the conclusion of an inspection if an investigator has observed a violative condition relating to the manufacturing and storage conditions of any drug
product that may result in the product being adulterated, or any other regulatory <FONT STYLE="white-space:nowrap">non-compliance</FONT> such as inadequate reporting or record-keeping. The outsourcing facilities with which we have relationships have
each received warning letters and FDA Form 483s from the FDA. If the FDA takes enforcement action against outsourcing facilities with which we have relationships, it may have a material adverse impact on our business, results of operations and
financial conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, state laws and regulations may differ from the FDCA. We and the 503B outsourcing facilities are
required to comply with state laws and regulations in the states where we and they do business. Efforts to ensure compliance with these laws may require ongoing substantial cost. For example, some of the 503B outsourcing facilities with which we
have relationships have received unfavorable enforcement actions from state regulators for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Failure to comply with applicable state laws and regulations could expose us and these 503B
outsourcing facilities to significant penalties which may harm our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a compounded drug
formulation provided through a compounding pharmacy or an outsourcing facility leads to patient injury or death or results in a product recall, we may be exposed to significant liabilities and reputational harm. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be adversely affected if compounded pellets are subject to negative publicity. We could also be adversely affected if compounded
pellets sold by any compounding outsourcing facilities, prove to be, or are asserted to be, harmful to patients or are otherwise subject to negative publicity. For example, in 2015, the FDA required labeling changes for prescription testosterone
replacement therapy to warn of increased risk of heart attacks and strokes. There are a number of factors that could result in the injury or death of a patient who receives a compounded formulation, including quality issues, manufacturing or
labeling flaws, improper packaging or unanticipated or improper uses of the products, any of which could result from human or other error. Any of these situations could lead to a recall of, or safety alert relating to, one or more of the products we
recommend as part of our training. Similarly, to the extent any of the components of approved drugs or other ingredients used by the outsourcing facilities with whom we have relationships have quality or other problems that adversely affect the
finished compounded preparations, our sales could be adversely affected. For example, some of the contracted outsourcing facilities have been the subject of civil suits alleging patient harm as a result of an improper formulation unrelated to the
products we recommend. If a product which we recommend as part of our training becomes the subject of a civil or criminal suit, we may be subject to significant liability for any damages suffered by the plaintiffs and associated costs and penalties.
Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business
may be impaired. In addition, in the ordinary course of business, a voluntary recall of one of the products we recommend as part of our training or may be instituted in response to a practitioner or clinic complaint. Because of our dependence upon
medical and patient perceptions, any adverse publicity associated with illness or other adverse effects resulting from the use or misuse of the compounded products we recommend as part of our training or any other compounded formulations made or
sold by other companies, could have a material adverse impact on our business, results of operations and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA takes regulatory action to implement any of the NASEM recommendations for compounded
bioidentical hormones, this may have a substantial effect on the ability of the outsourcing facilities to compound the hormone pellets utilized by Biote-certified practitioners, which would have a substantially negative impact on Biote&#146;s
revenue and business operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fall 2018, the FDA commissioned the NASEM to appoint an ad hoc committee to examine the
clinical utility of treating patients with compounded bioidentical hormones. The NASEM committee held a series of open and closed sessions from March 2019 to April 2020, to examine data, research, and stakeholder input in order to form conclusions
and recommendations regarding the clinical utility of these products. On July&nbsp;1, 2020, the NASEM committee published its report, wherein it concluded that there is a lack of high-quality clinical evidence to demonstrate the safety and
effectiveness of these products and, accordingly, that there is insufficient evidence to support the overall clinical utility of these products as treatment for menopause and male hypogonadism symptoms. The NASEM Committee recommended restricted use
of these products, assessments of their difficulty to compound, and additional education, state and federal regulatory oversight, and research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More specifically, NASEM Committee made six recommendations to the FDA: (1)&nbsp;Restrict the use of compounded bioidentical hormone
preparations; (2)&nbsp;Review select bioidentical hormone therapies and dosage forms as candidates for the FDA Difficult to Compound List; (3)&nbsp;Improve education for prescribers and pharmacists who market, prescribe, compound, and dispense these
preparations; (4)&nbsp;Additional federal and state-level oversight should be implemented to better address public health and clinical concerns regarding the safety and effectiveness of these preparations; (5)&nbsp;Collect and disclose conflicts of
interest; and (6)&nbsp;Strengthen and expand the evidence base on the safety, effectiveness, and use of these preparations. NASEM&#146;s report is purely advisory and <FONT STYLE="white-space:nowrap">non-binding</FONT> on the FDA. Biote cannot
predict whether or not the FDA will accept the recommendations made in the NASEM report in whole, in part, or whether the FDA will reject NASEM&#146;s recommendations. If the FDA were to take regulatory action to implement any of NASEM&#146;s
recommendations, in whole or in part, this may have a substantial effect on the ability of the outsourcing facilities to compound the hormone pellets utilized by Biote-certified practitioners as part of the Biote Method, and, in turn, have a
substantially negative impact on Biote&#146;s revenue and business operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with the FDCA and analogous state laws and
regulations can result in administrative, civil, criminal penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, acting under the scope of the FDCA and its
implementing regulations, has broad authority to regulate the manufacture, distribution, and labeling of many products, including medical devices, cosmetics, drugs, and food, including dietary supplements
<FONT STYLE="white-space:nowrap">(FDA-regulated</FONT> products). The FDCA prohibits, among other things, the introduction or delivery for introduction into interstate commerce of any <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> product
that is adulterated or misbranded, as well as the adulteration or misbranding of any <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> product while the product is in interstate commerce. However, the FDCA does not regulate the practice of
medicine. Drugs that are compounded pursuant to a practitioner&#146;s orders are considered to be the result of a compounding pharmacy or practitioner combining, mixing, or altering ingredients to create a medication tailored for the needs of a
particular patient, and are not regulated as new drugs under the FDCA. We have developed relationships with 503B outsourcing facilities who compound bioidentical pellets to support Biote-certified practitioners who prescribe such products. If any of
these compounded bioidentical hormone pellets are determined to be unapproved new drugs or are determined to be adulterated or misbranded under the FDCA, we could be subject to enforcement action by the FDA. If any of our operations are found to
have violated the FDCA or any other federal, state, or local statute or regulation that may apply to us and our business, we could face significant penalties including the seizure of product, civil, criminal, and administrative penalties, damages,
fines, disgorgement, imprisonment, contractual damages, reputational harm, and diminished profits and future earnings. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be significantly impaired. Additionally, the FDA or analogous state agencies could determine that we or the outsourcing
facilities with whom we have relationships are not in compliance with the FDCA or analogous or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related state laws applicable to outsourcing facilities, which could significantly impact our business. Further, the FDA could recommend a voluntary recall, or issue a public health notification
or safety notification about one or more of the products we recommend in training, which could materially harm our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with FDA or state regulations governing our Biote-branded dietary supplements, our business could suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also market Biote-branded dietary supplements that are regulated by the FDA or state regulatory authorities. We may need to develop and
maintain a robust compliance and quality program to ensure that the products that we market comply with all applicable laws and regulations, including the FDCA. If we are found to have manufactured, distributed, sold, or labeled any products in
violation of the FDCA, we may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. For example, in May 2017, we received a warning letter from the FDA concerning
both cGMP violations observed during a 2016 FDA inspection of our facility, and unapproved new drug claims that were made for certain of our dietary supplement products (the &#147;Warning Letter&#148;). Although our response to the Warning Letter
resulted in a closeout by the FDA in May 2018, we cannot assure you that we will not receive warning letters or other regulatory action by the FDA on the same or similar violations in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with FDA regulations governing our medical device products, our business could suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also offer for sale to practitioners two convenience kits for use with hormone optimization therapies, one for male patients and one for
female patients. These kits largely contain commercially available products, including only disposable supplies (e.g., gloves, antiseptic, gauze, disposable trocar, etc.) assembled in a sterile package. The products contained in the kits are
sourced, assembled, and supplied by Medline Industries, LP, with the components, including the Class&nbsp;1 disposable trocars, being manufactured by various other component suppliers. Trocars and convenience kits are medical devices that are
regulated by the FDA. Because we previously manufactured and sold reusable and disposable trocars, we registered with the FDA as a repackager, relabeler and specification developer, and we currently list the trocars we previously manufactured and
the convenience kits we currently sell in compliance with FDA registration and listing requirements. We may need to develop and maintain a robust compliance and quality program to ensure that the convenience kits we sell comply with all applicable
laws and regulation, including the FDCA and other regulatory requirements thereunder including for example cGMPs and Medical Device Reporting (MDR) where applicable. If the FDA determines that the convenience kits we sell require 510(k) clearance,
or are otherwise considered unapproved medical devices, we may be in violation of the FDCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we offer our proprietary
clinical decision support (&#147;CDS&#148;) software to practitioners to provide information from published literature and clinical guidelines to assist practitioners in providing precise, patient-specific treatment options at various intervals
through a patient&#146;s therapy. The FDA has recently issued a <FONT STYLE="white-space:nowrap">non-binding</FONT> final CDS guidance that significantly narrows what the agency considers <FONT STYLE="white-space:nowrap">non-device</FONT> CDS.
Further, since this final guidance, the FDA has begun to issue warnings for CDS products that are not exempt under the 21st Century Cures Act. For example, on September&nbsp;19, 2023, the FDA issued a warning letter to Abiomed Inc., in which it
explained that Abiomed&#146;s software was an adulterated and misbranded medical device because the agency disagreed with Abiomed&#146;s assessment that the software product was <FONT STYLE="white-space:nowrap">non-device</FONT> CDS. If the FDA
determines that our CDS is a medical device under the FDCA, the FDA may determine that our algorithm requires premarket approval or clearance, and may determine that unless and until we obtain such premarket approval or clearance that we are
distributing an unapproved medical device in violation of the FDCA. If we are found to have manufactured, distributed, sold, or labeled any medical devices in violation of the FDCA, we may face significant penalties which may result in a material
adverse effect on our business, financial condition, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the products recommended as part of training in the Biote Method are not covered by third-party and
government payors we could see decreased demand for our training and support services. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Coverage and reimbursement from third party
payors, such as commercial health insurers and governmental health care programs, may not be available for the products recommended as part of our training in the Biote Method. To the extent that these products are not reimbursable by third party
payors, the demand for these products may be diminished. If the products recommended as part of training in the Biote Method do not generate patient demand, we may be unable to attract physicians to take part in our training and support services. If
we are unable to attract physicians to participate in our training and utilize our support services, our business, results of operations and financial condition could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our information technology systems or data is or were compromised, we could experience adverse consequences resulting from such compromise,
including, but not limited to, interruptions to our operations; claims that we breached our data protection obligations; decreased use of the Biote Method; loss of Biote-partnered clinics or Biote-certified practitioners or sales; regulatory
investigations or actions; litigation; fines and penalties; reputational harm; loss of revenue or profits; and other adverse consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating our business (including the Biote Method) involves the collection, storage, transmission, disclosure and other processing of
proprietary, confidential and sensitive information, as well as the personal information of patients that we may receive from clinics. We may rely upon third-party service providers, such as identity verification and payment processing providers,
for our information processing-related activities. We may share or receive sensitive information with or from third parties. We also depend on our information technology systems for the efficient functioning of our business, including to support
Biote Method, our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> platform to enable Biote-certified practitioners to establish, build, and successfully operate a Biote-partnered clinic for optimizing
hormone levels in their specific aging patient population, the distribution and maintenance of our Biote-branded dietary supplements, as well as for accounting, data storage, compliance, purchasing and inventory management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to protect sensitive information, we have implemented security measures designed to protect against security incidents and
protect sensitive information. However, advances in information technology capabilities, increasingly sophisticated tools and methods used by hackers, cyber terrorists and other threat actors, new or other developments, and intentional or accidental
exposures of sensitive information by those with authorized access to our network, may result in our failure or inability to adequately protect sensitive information. We may expend significant resources or modify our business activities in an effort
to protect our information and against security incidents. Certain information privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our
information technology systems and information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to a variety of evolving threats including, but not limited to, hacking,
malware, computer viruses, unauthorized access, phishing or social engineering attacks, malware (including ransomware) attacks, credential stuffing attacks,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, supply-chain attacks, software bugs, information technology malfunction, software or hardware failures, loss of data, theft of data, misuse of
data, telecommunications failures, earthquakes, fire, flood, exploitation of software vulnerabilities, and other real or perceived threats. Any of these incidents could lead to interruptions or shutdowns of our IT systems, loss or corruption of data
or unauthorized access to, or disclosure of personal data or other sensitive information. Ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent
and severe and can lead to significant interruptions, delays, or outages in our operations, loss of data, loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the
financial, operational and reputational impact of a ransomware attack it may be preferable to make extortion payments, but we may be unwilling or unable to do so. Cyberattacks could also result in the theft of our intellectual property, damage to
our IT systems or disruption of our ability to make financial reports, and other public disclosures required of public companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other
similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are
increasingly difficult to detect, and come from a variety of sources, including traditional computer &#147;hackers,&#148; threat actors, &#147;hacktivists,&#148; organized criminal threat actors, personnel (such as through theft or misuse),
sophisticated nation states, and nation-state-supported actors. We have been subject to attempted cyber, phishing, or social engineering attacks in the past and may continue to be subject to such attacks and other cybersecurity incidents in the
future. If we gain greater visibility, we may face a higher risk of being targeted by cyberattacks. Advances in information technology capabilities, new technological discoveries, or other developments are likely to result in cyberattacks becoming
more sophisticated and more difficult to detect. We and third parties upon whom we rely for our information technology systems and information, may experience such cyberattacks and may not have the resources or technical sophistication to anticipate
or prevent all threats. Moreover, techniques used to obtain unauthorized access to systems change frequently and may not be known until launched. Security breaches can also occur as a result of <FONT STYLE="white-space:nowrap">non-technical</FONT>
issues, including intentional or inadvertent actions by our personnel and third-party service providers (including their personnel). Any of the previously identified or similar threats could cause a security incident. A security incident could
result in unauthorized, unlawful or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of or access to information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public
sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of the Company or our
customers could be leaked, disclosed, or revealed as a result of or in connection with our employees&#146;, personnel&#146;s, or vendors&#146; use of generative AI (&#147;AI&#148;) technologies. Our employees and personnel use generative AI
technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating
generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive
disadvantages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable information privacy and security obligations may require us to notify relevant stakeholders of security
incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements, could lead to adverse impacts. If we (or a third-party upon whom we rely) experience a security incident or are perceived to have
experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements
and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations
(including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause Biote-partnered clinics or Biote-certified practitioners to stop using the Biote Method and Biote-branded dietary
supplements and may deter new clinics and practitioners from using the Biote Method and Biote-branded dietary supplements and negatively impact our ability to grow and operate our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we maintain cyber errors and omissions insurance coverage that covers certain aspects of cyber risks, these losses may not be adequately
covered by insurance or other contractual rights available to us. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us
from liabilities, damages, or claims related to our data privacy and security obligations. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies,
including premium increases or the imposition of large deductible or <FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements, could have an adverse effect on our business, financial condition, and results of operations. Further, even in
the absence of claims, we cannot be sure that our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurance coverage will be adequate to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or
at all, or that such coverage will pay future claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we may be required to disclose personal data pursuant to demands from
individuals, privacy advocates, regulators, government agencies, and law enforcement agencies in various jurisdictions with conflicting privacy and security laws. Any disclosure or refusal to disclose personal data may result in a breach of privacy
and data protection policies, notices, laws, rules, court orders, and regulations and could result in proceedings or actions against us in the same or other jurisdictions, damage to our reputation and brand, and inability to provide our trainings
and Biote-branded dietary supplements to clinics and practitioners in certain jurisdictions. Additionally, changes in the laws and regulations that govern our collection, use, and disclosure of certain data could impose additional requirements with
respect to the retention and security of customer data, could limit our marketing activities, and have an adverse effect on our business, reputation, brand, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Following the consummation of the Business Combination, we have incurred, and we expect to continue to incur, significant increased expenses and
administrative burdens as a public company, which could negatively impact our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, we have faced increased legal, accounting, administrative and other costs and expenses
in connection with operation as a public company which Biote did not incur as a private company. Our significantly increased expenses and administrative burdens as a public company could have an adverse effect on our business, financial condition
and results of operation. The Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), including the requirements of Section&nbsp;404, as well as rules and regulations subsequently implemented by the SEC, the Dodd-Frank Wall
Street Reform and Consumer Protection Act of 2010, as amended (the &#147;Dodd-Frank Act&#148;) and the rules and regulations promulgated and to be promulgated thereunder, and the securities exchanges, impose additional reporting and other
obligations on public companies. Compliance with public company requirements has increased, and may continue to increase, costs and make certain activities more time-consuming. A number of those requirements require us to carry out activities that
Biote has not done previously. For example, we have adopted new charters for our board committees and new internal controls and disclosure controls and procedures. In addition, expenses associated with SEC reporting requirements and stock exchange
listing requirements have been, and will continue to be, incurred. Furthermore, if any issues in complying with those requirements are identified (for example, if the auditors identify a material weakness or significant deficiency in the internal
control over financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely affect our reputation or investor perceptions of it. It may also be more expensive to obtain director and
officer liability insurance. Risks associated with our status as a public company may make it more difficult to attract and retain qualified persons to serve on our board of directors or as executive officers. The additional reporting and other
obligations imposed by these rules and regulations may continue to increase legal and financial compliance costs and the costs of related legal, accounting and administrative activities. These increased costs require us to divert a significant
amount of money that could otherwise be used to expand the business and achieve strategic objectives. Additionally, advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which
could further increase costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal controls over financial reporting currently do not meet all of the standards contemplated by
Section&nbsp;404 of the Sarbanes-Oxley Act, and a material weakness resulted in the restatement of previously issued financial statements. Failure to achieve and maintain an effective system of disclosure controls and internal control over financial
reporting could impair our ability to produce timely and accurate financial statements or comply with applicable regulations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management, including our Chief Executive Officer and our Chief Financial Officer, assessed the effectiveness of our internal control over
financial reporting as of December&nbsp;31, 2023, and concluded that we did not maintain effective internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A material weakness is a deficiency, or combination of deficiencies, in internal control
over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. In the course of preparing our financial statements
for the fiscal years ended December&nbsp;31, 2020 and 2019, our management identified a material weakness in the aggregate in our internal control over financial reporting. Specifically, we determined that we did not have appropriate accounting
competence and capabilities to properly record in our financial statements certain complex and <FONT STYLE="white-space:nowrap">non-routine</FONT> accounting issues, particularly related to revenue recognition, financial instruments, and equity.
This resulted in incorrect accounting entries that were identified and corrected through the audit of our fiscal years ended December&nbsp;31, 2020 and 2019. In addition, this material weakness resulted in errors in the financial statements and
related disclosures in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended June&nbsp;30, 2022 and September&nbsp;30, 2022, which we have restated as described in the Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q/A</FONT> for each of the affected quarters, each filed on March&nbsp;29, 2023. This material weakness has not been remediated as of the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to remediate this material weakness in the aggregate, we plan to continue to hire personnel with public company experience and
provide additional training for our personnel on internal controls as our company continues to grow, and engage external consultants to assist in the development and improvement of methodologies, policies and procedures designed to ensure adequate
internal control over financial reporting, including the technical application of U.S. GAAP and evaluating segregation of duties. Although we believe these measures will remediate this material weakness, there can be no assurance that the material
weakness will be remediated on a timely basis or at all, or that additional material weaknesses will not be identified in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
current controls and any new controls that we develop may also become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the
future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a
restatement of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations and annual independent
registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective
disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the market price of our Class&nbsp;A common stock could be negatively affected, and we could become subject to investigations by
the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. In addition, if we are unable to continue to meet these requirements, we may not be
able to <FONT STYLE="white-space:nowrap">re-list</FONT> on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public accounting firm is not required to
formally attest to the effectiveness of our internal control over financial reporting until after we are no longer an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). At
such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our internal control over financial reporting is then documented, designed or operating. Any
failure to maintain effective disclosure controls and internal control over financial reporting could have an adverse effect on our business and results of operations and could cause a decline in the price of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We recently restated our financial statements for certain prior periods, which resulted in unanticipated costs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously announced, we concluded that our previously issued consolidated financial statements as of and for the quarters ended
June&nbsp;30, 2022 and September&nbsp;30, 2022 (the &#147;Affected Periods&#148;) should no longer be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relied upon. As a result, we restated the financial statements for the Affected Periods. The restatements of our financial statements for the Affected Periods were due, in part, to an error in
the calculation of our earnout valuation, resulting in an overstatement of our earnout liability and our gain (loss) from change in fair value of earnout liability. We also determined that we should attribute changes in fair value of our warrant and
earnout liabilities to our operating subsidiary, BioTE Holdings, LLC (&#147;Holdings&#148;), whereas these changes had previously been attributed to the Company due to an error related to the calculation of the fair value of our contingent earnout
liability in each of the Affected Periods. We determined that attributing these changes in fair value to Holdings more appropriately reflects the economics of the net income allocation to equity interests in our condensed consolidated financial
statements in accordance with Accounting Standards Codification 810, given our <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure. As a result, we corrected the error and restated our financial statements for the quarters ended
June&nbsp;30, 2022 and September&nbsp;30, 2022 to reflect a reduction in our basic and diluted income (loss) per common share, as a pro rata portion of gain (loss) from changes in fair value of the warrant and earnout liabilities attributed to
noncontrolling interests of Holdings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we incurred unanticipated costs for accounting and legal fees in connection with the
restatements. The restatements may negatively impact the trading price of our securities and make it more difficult for us to raise capital on acceptable terms, or at all, which could have a material adverse effect on our business, results of
operations and financial condition. See also &#147;Controls and Procedures.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Resales of shares of common stock could depress the market price
of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, 74,661,449 shares (which includes 10,000,000 Earnout Voting Shares and
1,587,500 Sponsor Earnout Shares) of our common stock are outstanding, consisting of 35,842,383 shares of Class&nbsp;A common stock and 38,819,066 shares of Class&nbsp;V voting stock. Following the Business Combination, shares held by HYAC&#146;s
public stockholders have been freely tradeable, and the shares held by the Sponsor and the Members, following their exercise of Exchange Rights, are freely tradeable as of the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the
Closing, subject to applicable securities laws. We have also registered all shares of Class&nbsp;A common stock that we may issue under the Incentive Plan or the ESPP. These shares can be freely sold in the public market upon issuance, subject to
volume limitations applicable to Affiliates. As a result, there may be a large number of shares of Class&nbsp;A common stock sold in the market. These sales of shares of Class&nbsp;A common stock, or the perception of these sales, may depress the
market price of our Class&nbsp;A common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the benefits from the Business Combination do not meet the expectations of investors,
stockholders or financial analysts, the market price of our securities may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the benefits from the Business Combination
do not meet the expectations of investors or securities analysts, the market price of our securities may decline. For example, from the Closing Date through March&nbsp;11, 2024, our stock price fluctuated from a low of $2.00 to a high of $10.51.
Fluctuations in the price of our securities could contribute to the loss of all or part of your investment. Immediately prior to the Business Combination, there was not a public market for Biote&#146;s stock and trading in the shares of our
Class&nbsp;A common stock was not active. Accordingly, the valuation ascribed to Biote and our Class&nbsp;A common stock in the Business Combination may not be indicative of the price that will prevail in the trading market following the Business
Combination. The trading price of our securities could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. Any of the factors listed below could adversely affect your investment in our
securities, and our securities may trade at prices significantly below the price you paid for them. In these circumstances, the trading price of our securities may not recover and may experience a further decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities following the Business Combination may include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of
companies perceived to be similar to us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market&#146;s expectations about our operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public&#146;s reaction to our press releases, our other public announcements and our filings with the SEC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">speculation in the press or investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">success of competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our operating results failing to meet the expectation of securities analysts or investors in a particular period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates and recommendations by securities analysts concerning the Biote or the market in
general; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating and stock price performance of other companies that investors deem comparable to the Biote;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to market new and enhanced products on a timely basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws and regulations affecting our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of, or involvement in, litigation involving Biote, including the Donovitz Litigation (as defined
herein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in Biote&#146;s capital structure, such as future issuances of securities or the incurrence of additional
debt; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volume of shares of our Class&nbsp;A common stock available for public sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our securities on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any major change of officers or directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of substantial amounts of Class&nbsp;A common stock by our directors, officers or significant stockholders
or the perception that such sales could occur; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and political conditions such as recessions, interest rates, fuel prices, international currency
fluctuations and acts of war or terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broad market and industry factors may materially harm the market price of
our securities irrespective of our operating performance. The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected.
The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence in the market for the stocks of other companies that investors perceive to be similar to Biote could depress our stock
price regardless of our business, prospects, financial condition or results of operations. A decline in the market price of our securities also could adversely affect our ability to issue additional securities and our ability to obtain additional
financing in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been initiated against companies following periods of
volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#146;s attention and resources and could also require us to make substantial payments to satisfy judgments or to settle litigation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; and we take advantage of certain exemptions from
disclosure requirements available to emerging growth companies and/or smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; within the meaning of the Securities Act, as modified by the JOBS Act, and we take
advantage of certain exemptions from various reporting requirements that are applicable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor internal controls attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five
years following our initial public offering, although circumstances could cause us to lose that status earlier, including if the market value of our Class&nbsp;A common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700&nbsp;million as of any June&nbsp;30 before that time, in which case we would no longer be an emerging growth company as of the following December 31. We cannot predict whether investors will find our securities less attractive because we may
rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading
market for our securities and the trading prices of our securities may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act
exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a
class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the
requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard
is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make
comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the
potential differences in accounting standards used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#147;smaller reporting company&#148; as defined in Item
10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of the fiscal year in which (1)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as of the prior June 30th,
or (2)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th.
To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain our listing on Nasdaq, it could become more difficult to sell our Class&nbsp;A common stock in the public market.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A common stock is listed on Nasdaq. To maintain our listing on this market, we must meet Nasdaq&#146;s listing
maintenance standards. On July&nbsp;20, 2022, Nasdaq suspended trading of our Class&nbsp;A common stock for failure to meet certain initial listing requirements and indicated it intended to pursue delisting our Class&nbsp;A common stock once all
applicable appeal and review periods expired. On August&nbsp;25, 2022, Nasdaq approved our application to relist our Class&nbsp;A common stock and we began trading on August&nbsp;29, 2022. If we are unable to continue to meet Nasdaq&#146;s listing
maintenance standards for any reason, our Class&nbsp;A common stock could be delisted from Nasdaq. If delisted, we may seek to list our securities on a different stock exchange or, if one or more broker-dealer market makers comply with applicable
requirements, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (OTC) market. Listing on such other market or exchange could reduce the liquidity of our Class&nbsp;A common stock. If our
Class&nbsp;A common stock were to trade in the OTC market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the Class&nbsp;A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A delisting from The Nasdaq Global Market and failure to obtain listing on another market or exchange would subject our Class&nbsp;A common
stock to <FONT STYLE="white-space:nowrap">so-called</FONT> penny stock rules that impose additional sales practice and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
market-making requirements on broker-dealers who sell or make a market in such securities. Consequently, removal from Nasdaq and failure to obtain listing on another market or exchange could
affect the ability or willingness of broker-dealers to sell or make a market in our Class&nbsp;A common stock and the ability of purchasers of our Class&nbsp;A common stock to sell their securities in the secondary market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;8, 2024, the closing price of our Class&nbsp;A common stock was $5.93 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future resales of Class&nbsp;A common stock may cause the market price of our securities to drop significantly, even if our business is doing well.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions agreed to in connection with the A&amp;R IRA have expired, except
with respect to the Member Earnout Units, which <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will expire on such later date the Member Earnout Units are earned in accordance with the Business Combination Agreement. As such, each
Retained Holdings Unit and corresponding share of Class&nbsp;V voting stock held by the Members (other than the Member Earnout Units) may be redeemed at any time, upon the exercise of such Members&#146; Exchange Rights, in exchange for either one
share of Class&nbsp;A common stock or, at the election of Biote in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&nbsp;A common stock, pursuant to the terms and conditions of the Holdings
A&amp;R OA. Assuming the full exercise of the Exchange Rights by all of the Members (including with respect to the Member Earnout Units), the Members would have owned approximately 58.8% of our Class&nbsp;A common stock, with one such member
beneficially owning 30.0% of our Class&nbsp;A common stock as of December&nbsp;31, 2023. Except with respect to the Member Earnout Units, the Members are no longer restricted from selling the shares of Class&nbsp;A common stock held by them
following their exercise of Members&#146; Exchange Rights, other than by applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor is no
longer restricted from transferring, selling, assigning or otherwise disposing of its shares of Class&nbsp;A common stock (other than the Sponsor Earnout Shares, which may not be transferred, sold assigned or otherwise disposed of until the Sponsor
Earnout Shares are earned). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further we and each of our officers, directors and selling stockholders executed <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements in which they agreed not to offer, sell, agree to sell, directly or indirectly, or otherwise dispose of any shares of Class&nbsp;A common stock or any securities convertible into or exchangeable
for shares of Class&nbsp;A common stock without the prior written consent of the underwriters for a period of 90 days after January&nbsp;6, 2023, subject to customary exceptions. We do not, however, expect to receive
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements from any other stockholders, including the Company&#146;s former owner, who beneficially held 29.9% of shares of our common stock outstanding as of March&nbsp;11, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such, sales of a substantial number of shares of Class&nbsp;A common stock in the public market could occur at any time. These sales, or
the perception in the market that the holders of a large number of shares intend to sell shares, could cause the market price of our Class&nbsp;A common stock to decline or increase the volatility in the market price of our Class&nbsp;A common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Our Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because there are no current plans to pay cash dividends on our Class&nbsp;A common stock for the foreseeable future, you may not receive any return on
investment unless you sell our Class&nbsp;A common stock for a price greater than that which you paid for it. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may retain future
earnings, if any, for future operations, expansion and debt repayment and we have no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the
discretion our Board and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our Board may deem relevant. In addition, our ability to pay dividends
may be limited by covenants of any existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return on an investment in our Class&nbsp;A common stock unless you sell your shares of
Class&nbsp;A common stock for a price greater than that which you paid for it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may require additional capital to support business growth, and if
capital is not available to us or is available only by diluting existing stockholders, our business, operating results and financial condition may suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We require significant capital to continue to develop and grow our business, including with respect to the design, development, marketing,
distribution and sale of the Biote Method and Biote-branded dietary supplements. We may need additional capital to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be certain
that additional financing will be available, which could limit our ability to grow and jeopardize our ability to continue our business operations. We fund our capital needs primarily from available working capital; however, the timing of available
working capital and capital funding needs may not always coincide, and the levels of working capital may not fully cover capital funding requirements. From time to time, we may need to supplement our working capital from operations with proceeds
from financing activities. For instance, on July&nbsp;27, 2022, we entered into a standby equity purchase agreement (the &#147;SEPA&#148;) with YA II PN, LTD., a Cayman Islands exempt limited partnership (&#147;Yorkville&#148;), whereby we have the
right, but not the obligation, to sell to Yorkville up to 5,000,000 shares of our Class&nbsp;A common stock at our request, subject to terms and conditions specified in the SEPA. We expect to continue to opportunistically seek access to additional
funds by utilizing the SEPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that current and anticipated future sources of liquidity are insufficient to fund our future
business activities and requirements, we may need to engage in equity or debt financings to secure additional funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could
suffer significant dilution, and any new securities we issue could have rights, preferences and privileges superior to those of holders of our Class&nbsp;A common stock. The amount of dilution due to equity-based compensation of our employees and
other additional issuances could be substantial. Additionally, any debt financing secured by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make
it more difficult for us to obtain additional capital and to pursue business opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there can be no assurance that
further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for any product
candidates we may develop and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the equity and credit markets
deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could impair our ability to achieve our growth
strategy, could harm our financial performance and stock price and could require us to delay or abandon our business plans. In addition, there is a risk that our current or future suppliers, service providers, manufacturers or other partners may not
survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. We cannot anticipate all of the ways in which the current economic climate and financial market conditions could
adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions contained in the Charter and Bylaws, as well as provisions of Delaware law, could impair a
takeover attempt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our Charter and Bylaws, as well as provisions under Delaware law, could make acquiring us more
difficult, may limit attempts by stockholders to replace or remove our management, may limit stockholders&#146; ability to obtain a favorable judicial forum for disputes with the us or our directors, officers, or employees, and may limit the market
price of our Class&nbsp;A common stock. These provisions may make more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales, or the perception of future sales, by the Company or its stockholders in the public market, the issuance of rights to purchase the
Company&#146;s Class&nbsp;A common stock, including pursuant to the Incentive Plan and the ESPP, and future exercises of registration rights could result in the additional dilution of the percentage ownership of the Company&#146;s stockholders and
cause the market price for the Company&#146;s Class&nbsp;A common stock to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;11, 2024, 74,531,558 shares
(which includes 10,000,000 Earnout Voting Shares and 1,587,000 Sponsor Earnout Shares) of our common stock are outstanding, consisting of 35,712,492 shares of Class&nbsp;A common stock and 38,819,066 shares of Class&nbsp;V voting stock. Assuming the
full exercise of the Exchange Rights by all of the Members (including with respect to the Member Earnout Units), and after giving effect to the secondary offering of shares of Class&nbsp;A common stock by certain stockholders pursuant to the
registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> declared effective by the SEC on January&nbsp;4, 2023, the Members would have owned approximately 58.5% of our Class&nbsp;A common stock, with one such Member beneficially
owning approximately 29.9% of our Class&nbsp;A common stock, as of March&nbsp;11, 2024. The Members are not restricted from selling the shares of Class&nbsp;A common stock held by them following their exercise of Members&#146; Exchange Rights, other
than by applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have registered up to 21,947,987 shares of Class&nbsp;A common stock that we may
issue under the Incentive Plan and the ESPP. We have registered 5,000,000 shares of Class&nbsp;A common stock for resale related to the SEPA with Yorkville, including 130,559 shares of Class&nbsp;A common stock issued and outstanding as of
March&nbsp;11, 2024 and 4,869,441 shares of Class&nbsp;A common stock that may be issued pursuant to the SEPA in the future. Once we issue these shares, they can be freely sold in the public market upon issuance, subject to volume limitations
applicable to Affiliates. As a result, there may be a large number of shares of Class&nbsp;A common stock sold in the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of
shares of the Company&#146;s Class&nbsp;A common stock, convertible securities or other securities in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of the Company&#146;s
Class&nbsp;A common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for the Company to sell securities in the future at a time and at a price that it deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the Company sells shares of its Class&nbsp;A common stock, convertible securities or other securities, investors may be
materially diluted by subsequent sales. Such sales may also result in material dilution to the Company&#146;s existing stockholders, and new investors could gain rights, preferences, and privileges senior to the holders of the Company&#146;s
Class&nbsp;A common stock, including the Company&#146;s Class&nbsp;A common stock issued in connection with the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Incentive Plan, the Company is authorized to grant equity awards to its employees, directors and consultants. In addition,
pursuant to the ESPP, the Company is authorized to sell shares to its employees. The Company initially reserved 15% of the shares of Class&nbsp;A common stock outstanding on a fully-diluted basis upon the Closing for future issuance under the
Incentive Plan, plus 3,887,750 shares of Class&nbsp;A common stock necessary to satisfy payments to Phantom Equity Holders under the Phantom Equity Acknowledgments (such 3,887,750 shares of Class&nbsp;A common stock will not again become available
for issuance under the Incentive Plan and will not be subject to the automatic annual increases described below). In addition, the Company initially reserved 1% of the shares of Class&nbsp;A common stock outstanding on a fully-diluted basis upon the
Closing for future issuance under the ESPP. The Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, beginning on January&nbsp;1, 2023. As a result of such annual increases, the Company&#146;s
stockholders may experience additional dilution, which could cause the price of the Company&#146;s Class&nbsp;A common stock to fall. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, the Company may also issue its securities in connection with investments or
acquisitions. The number of shares of the Company&#146;s Class&nbsp;A common stock issued in connection with an investment or acquisition could constitute a material portion of the Company&#146;s then-outstanding shares of Class&nbsp;A common stock.
Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to the Company&#146;s stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to periodic claims and litigation, including the Donovitz Litigation (as defined below), that could result in unexpected expenses and
could ultimately be resolved against us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in litigation and other proceedings, including
matters related to product liability claims, stockholder class action and derivative claims, commercial disputes, copyright infringement, trademark challenges, and other intellectual property claims, as well as trade, regulatory, employment, and
other claims related to our business. Any of these proceedings could result in significant settlement amounts, damages, fines, or other penalties, divert financial and management resources, and result in significant legal fees. An unfavorable
outcome of any particular proceeding could exceed the limits of our insurance policies or the carriers may decline to fund such final settlements and/or judgments and could have an adverse impact on our business, financial condition, and results of
operations. In addition, any proceeding could negatively impact our reputation among our practitioners and clinics and our brand image. The Company is currently involved in the Donovitz Litigation (See Item 3 Legal Proceedings). The outcome of the
Donovitz Litigation, regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the ultimate liability, if any, which may arise therefrom. In addition, litigation and
related matters are costly and may divert the attention of the Company&#146;s management and other resources that would otherwise be engaged in other activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Organizational Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
only material asset is our ownership interest in Holdings, and accordingly we depend on distributions from Holdings to pay distributions, dividends on our Class&nbsp;A common stock, taxes and other expenses, and make any payments required to be made
by us under the Tax Receivable Agreement (the &#147;TRA&#148;). </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a holding company and have no material assets other than
our ownership of the Holdings Units. We are not expected to have independent means of generating revenue or cash flow, and our ability to pay distributions, dividends on our Class&nbsp;A common stock, taxes and other expenses, and make any payments
required to be made by us under the TRA will be dependent upon the financial results and cash flows of Holdings. The earnings from, or other available assets of, Holdings may not be sufficient to pay dividends or make distributions or loans to
enable us to pay any dividends on our Class&nbsp;A common stock or satisfy our other financial obligations. There can be no assurance that Holdings will generate sufficient cash flow to distribute funds to us or that applicable state law and
contractual restrictions, including negative covenants under debt instruments, will permit such distributions. If Holdings does not distribute sufficient funds to us to pay our taxes or other liabilities, we may default on contractual obligations or
have to borrow additional funds. In the event that we are required to borrow additional funds it could adversely affect our liquidity and subject us to additional restrictions imposed by lenders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holdings will continue to be treated as a partnership for U.S. federal income tax purposes and, as such, generally will not be subject to any
entity-level U.S. federal income tax. Instead, taxable income or loss will be allocated, for U.S. federal income tax purposes, to the holders of Holdings Units, including us. Accordingly, we will be required to pay U.S. federal income taxes on our
allocable share of the net taxable income of Holdings. Under the terms of the Holdings A&amp;R OA, Holdings is obligated to make tax distributions to holders of Holdings Units (including us) calculated at certain assumed rates. In addition to tax
expenses, we also will incur expenses related to our operations, some of which expenses will be reimbursed by Holdings. We intend to cause Holdings to make ordinary distributions and tax distributions to the holders of Holdings Units on a pro rata
basis in amounts sufficient to cover all applicable taxes, relevant operating expenses (to the extent not already payable or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursable by Holdings pursuant to the Holdings A&amp;R OA), payments under the TRA and dividends, if any, declared by us. However, as discussed herein, Holdings&#146; ability to make such
distributions may be subject to various limitations and restrictions, including, but not limited to, retention of amounts necessary to satisfy the obligations of the Company and its subsidiaries (the &#147;BioTE Companies&#148;) and restrictions on
distributions that would violate any applicable restrictions contained in Holdings&#146; debt agreements, or any applicable law, or that would have the effect of rendering Holdings insolvent. To the extent we are unable to make payments under the
TRA for any reason, such payments will be deferred and will accrue interest until paid, provided, however, that nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the
TRA and therefore accelerate payments under the TRA, which could be substantial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, although Holdings generally will not be
subject to any entity-level U.S. federal income tax, it may be liable under certain U.S. federal income tax legislation for any adjustments to its tax return, absent an election to the contrary. In the event Holdings&#146; calculations of taxable
income are incorrect, Holdings and/or its Members, including us, in later years may be subject to material liabilities pursuant to this U.S. federal income tax legislation and its related guidance. We anticipate that the distributions we receive
from Holdings may, in certain periods, exceed our actual liabilities and our obligations to make payments under the TRA. Our board of directors, in its sole discretion, will make any determination from time to time with respect to the use of any
such excess cash so accumulated, which may include, among other uses, paying dividends on our Class&nbsp;A common stock. We will have no obligation to distribute such cash (or other available cash other than any declared dividend) to our public
stockholders. We may, if necessary, undertake ameliorative actions, which may include pro rata or <FONT STYLE="white-space:nowrap">non-pro</FONT> rata reclassifications, combinations, subdivisions or adjustments of outstanding Holdings Units, to
maintain <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> parity between Holdings Units held by us and shares of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pursuant to the TRA, we will be required to pay to the Members 85% of the net income tax savings that we realize as a result of increases in tax basis
of the BioTE Companies&#146; assets resulting from the Business Combination and the redemptions of the Retained Holdings Units in exchange for shares of Class&nbsp;A common stock (or cash) pursuant to the Holdings A&amp;R OA and tax benefits related
to the TRA, including tax benefits attributable to payments under the TRA, and those payments may be substantial. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with the Business Combination, a historic Member was deemed for U.S. federal (and applicable state and local) income tax purposes to have sold Holdings Units to the Company for the Cash Consideration and rights under the TRA (the
&#147;Purchase&#148;) and the Members may in the future have their Holdings Units (including the Earnout Units, if any, that have vested in accordance with the Business Combination Agreement), together with the cancelation of an equal number of
shares of Class&nbsp;V voting stock, redeemed in exchange for shares of our Class&nbsp;A common stock (or cash) pursuant to the Holdings A&amp;R OA, subject to certain conditions and transfer restrictions as set forth therein and in the A&amp;R IRA.
These sales and exchanges are expected to result in increases in our allocable share of the tax basis of the tangible and intangible assets of the BioTE Companies. These increases in tax basis may increase (for income tax purposes) depreciation and
amortization deductions allocable to us and therefore reduce the amount of income or franchise tax that we would otherwise be required to pay in the future had such sales and exchanges never occurred, although the U.S. Internal Revenue Service (the
&#147;IRS&#148;) or any applicable foreign, state or local tax authority may challenge all or part of that tax basis increase, and a court could sustain such a challenge. We have entered into the TRA, which generally provides for the payment by us
of 85% of certain net tax benefits, if any, that we realize (or in certain cases are deemed to realize) as a result of these increases in tax basis and tax benefits related to the transactions contemplated under the Business Combination Agreement
and the redemption of Retained Holdings Units in exchange for Class&nbsp;A common stock (or cash) pursuant to the Holdings A&amp;R OA and tax benefits attributable to payments under the TRA. These payments are our obligation and are not an
obligation of the BioTE Companies. The actual increase in our allocable share of tax basis in the BioTE Companies&#146; assets, as well as the amount and timing of any payments under the TRA, will vary depending upon a number of factors, including
the timing of exchanges, the market price of the Class&nbsp;A common stock at the time of the exchange and the amount and timing of the recognition of our income. While many of the factors that will determine the amount of payments that we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will make under the TRA are outside of our control, we expect that the payments we will make under the TRA will be substantial and could have a material adverse effect on our financial condition.
Any payments we make under the TRA generally will reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we are unable to make timely payments under the TRA for any reason, the unpaid amounts will
be deferred and will accrue interest until paid; however, nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the
TRA, as further described below. Furthermore, our future obligation to make payments under the TRA could make us a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits
that may be deemed realized under the TRA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In certain cases, payments under the TRA may exceed the actual tax benefits we realize. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments under the TRA will be based on the tax reporting positions that we determine, and the IRS or another taxing authority may challenge
all or any part of the tax basis increases, as well as other tax positions that we take, and a court may sustain such a challenge. In the event that any tax benefits initially claimed by us are disallowed, the Members will not be required to
reimburse us for any excess payments that may have been made previously under the TRA, for example, due to adjustments resulting from examinations by the IRS or other taxing authorities. Rather, excess payments made to Members will be applied
against and reduce any future cash payments otherwise required to be made to such Members, if any, after the determination of such excess. However, a challenge to any tax benefits initially claimed by us may not arise for a number of years following
the initial time of such payment and, even if challenged earlier, such excess cash payment may be greater than the amount of future cash payments that we might otherwise be required to make under the terms of the TRA and, as a result, there might
not be future cash payments against which such excess can be applied. As a result, in certain circumstances we could make payments under the TRA in excess of our actual income or franchise tax savings, which could materially impair our financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In certain cases, payments under the TRA may be accelerated or significantly exceed the actual benefits we realize in respect of the tax
attributes subject to the TRA. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TRA provides that, in the event that (i)&nbsp;we exercise our early termination rights under
the TRA, (ii)&nbsp;certain changes of control occur (as described in the TRA), (iii) we, in certain circumstances, fail to make a payment required to be made pursuant to the TRA by the applicable final payment date, which <FONT
STYLE="white-space:nowrap">non-payment</FONT> continues for 30 days following such final payment date or (iv)&nbsp;we materially breach any of our material obligations under the TRA, which breach continues without cure for 30 days following receipt
by us of written notice thereof (unless, in the case of clauses (iii)&nbsp;and (iv), certain liquidity exceptions apply) our obligations under the TRA will accelerate and we will be required to make a <FONT STYLE="white-space:nowrap">lump-sum</FONT>
cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment would be based on
certain assumptions, including those relating to our future taxable income. The change of control payment to the Members could be substantial and could exceed the actual tax benefits that we receive as a result of acquiring Holdings Units from the
Members because the amounts of such payments would be calculated assuming that we would be able to use the potential tax benefits each year for the remainder of the amortization periods applicable to the basis increases, and that tax rates
applicable to us would be the same as they were in the year of the termination. Decisions made in the course of running our business, such as with respect to mergers, asset sales, other forms of business combinations or other changes in control, may
influence the timing and amount of payments that are received by the holders of Retained Holdings Units under the TRA. For example, the earlier disposition of assets following an exchange or acquisition transaction will generally accelerate payments
under the TRA and increase the present value of such payments, and the disposition of assets before an exchange or acquisition transaction will increase an existing owner&#146;s tax liability without giving rise to any rights of holders of Retained
Holdings Units to receive payments under the TRA. There may be a material negative effect on our liquidity if the payments under the TRA exceed the actual income or franchise tax savings that we realize in respect of the tax attributes subject to
the TRA or if distributions to us by Holdings are not sufficient to permit us to make payments under the TRA after we have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
paid taxes and other expenses. Furthermore, our obligations to make payments under the TRA could make us a less attractive target for an acquisition, particularly in the case of an acquirer that
cannot use some or all of the tax benefits that are deemed realized under the TRA. We may need to incur additional indebtedness to finance payments under the TRA to the extent our cash resources are insufficient to meet our obligations under the TRA
as a result of timing discrepancies or otherwise which may have a material adverse effect on our financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to realize
all or a portion of the tax benefits that are expected to result from the acquisition of Retained Holdings Units from Biote Members. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the TRA, we will share tax savings resulting from (A)&nbsp;the amortization of the anticipated
<FONT STYLE="white-space:nowrap">step-up</FONT> in tax basis in the BioTE Companies&#146; assets as a result of (i)&nbsp;the deemed sale of Holdings Units in connection with the Business Combination and (ii)&nbsp;the redemption of Retained Holdings
Units in exchange for shares of Class&nbsp;A common stock or cash pursuant to the Holdings A&amp;R OA and (B)&nbsp;certain other related transactions with the Members. The amount of any such tax savings will be paid 85% to the applicable Members and
retained 15% by us. Any such amounts payable will only be due once the relevant tax savings have been realized by us, unless our obligations under the TRA are accelerated. Our ability to realize, and benefit from, these tax savings depend on a
number of assumptions, including that we will earn sufficient taxable income each year during the period over which the deductions arising from any such basis increases and payments are available and that there are no adverse changes in applicable
law or regulations. If our actual taxable income were insufficient to fully utilize such tax benefits or there were adverse changes in applicable law or regulations, we may be unable to realize all or a portion of these expected benefits and our
cash flows and stockholders&#146; equity could be negatively affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, gross receipts, value added or
similar taxes and may successfully impose additional obligations on us, and any such assessments or obligations could adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The application of indirect taxes, such as sales and use tax, value-added tax, goods and services tax, business tax and gross receipts tax, to
platform businesses is a complex and evolving issue. Many of the fundamental statutes and regulations that impose these taxes were established before the adoption and growth of the Internet and <FONT STYLE="white-space:nowrap">e-commerce.</FONT>
Significant judgment is required on an ongoing basis to evaluate applicable tax obligations and, as a result, amounts recorded are estimates and are subject to adjustments. In many cases, the ultimate tax determination is uncertain because it is not
clear how new and existing statutes might apply to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may face various indirect tax audits in various U.S. jurisdictions.
In certain jurisdictions, we collect and remit indirect taxes. However, tax authorities may raise questions about or challenge or disagree with our calculation, reporting or collection of taxes and may require us to collect taxes in jurisdictions in
which we do not currently do so or to remit additional taxes and interest, and could impose associated penalties and fees. For example, after the U.S. Supreme Court decision in South Dakota v. Wayfair Inc., certain states have adopted, or started to
enforce, laws that may require the calculation, collection and remittance of taxes on sales in their jurisdictions, even if we do not have a physical presence in such jurisdictions. A successful assertion by one or more tax authorities requiring us
to collect taxes in jurisdictions in which we do not currently do so or to collect additional taxes in a jurisdiction in which we currently collect taxes, could result in substantial tax liabilities, including taxes on past sales, as well as
penalties and interest, could harm our business, financial condition and results of operations. Although we have reserved for potential payments of possible past tax liabilities in our financial statements, if these liabilities exceed such reserves,
our financial condition will be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these and other factors, the ultimate amount of tax obligations owed may differ
from the amounts recorded in our financial statements and any such difference may adversely impact our results of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operations in future periods in which we change our estimates of our tax obligations or in which the ultimate tax outcome is determined. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect
our financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to income taxes in the United States, and our domestic tax
liabilities are subject to the allocation of expenses in differing jurisdictions. Our future effective tax rates could be subject to volatility or adversely affected by a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the valuation of our deferred tax assets and liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expected timing and amount of the release of any tax valuation allowances; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax effects of stock-based compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to intercompany restructurings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in tax laws, regulations or interpretations thereof; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower than anticipated future earnings in jurisdictions where we have lower statutory tax rates and higher than
anticipated future earnings in jurisdictions where we have higher statutory tax rates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject
to audits of our income, sales and other transaction taxes by U.S. federal and state authorities. Outcomes from these audits could adversely affect our financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Increases in our income tax rates, changes in tax laws or disagreements with tax authorities may adversely affect our business, financial condition or
results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in our income tax rates or other changes in tax laws in the United States or any jurisdiction in
which we operate could reduce our <FONT STYLE="white-space:nowrap">after-tax</FONT> income and adversely affect our business, financial condition or results of operations. Existing tax laws in the United States have been, and in the future could be,
subject to significant change. For example, the Inflation Reduction Act of 2022 was recently enacted, which includes a one percent excise tax on share buybacks imposed on the corporation repurchasing such stock, effective for tax years beginning
after 2022. Also, effective for tax years beginning after December&nbsp;31, 2021, legislation commonly referred to as the Tax Cuts and Jobs Act eliminated the option to currently deduct research and development expenditures and requires taxpayers to
capitalize and amortize U.S.-based and <FONT STYLE="white-space:nowrap">non-U.S.-based</FONT> research and development expenditures over five and fifteen years, respectively. Although there has been proposed legislation that would defer the
capitalization requirement to later years, we have no assurance that the provision will be repealed or otherwise modified. Future regulatory guidance from taxing authorities or other executive or Congressional actions in the United States or other
jurisdictions may be forthcoming. These or other changes in the relevant tax regimes, including changes in how existing tax laws are interpreted or enforced, may adversely affect our business, financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also will be subject to regular reviews, examinations and audits by the IRS and other taxing authorities with respect to income and <FONT
STYLE="white-space:nowrap">non-income-based</FONT> taxes. Economic and political pressures to increase tax revenues in jurisdictions in which we operate, or the adoption of new or reformed tax legislation or regulation, may make resolving tax
disputes more difficult and the final resolution of tax audits and any related litigation can differ from our historical provisions and accruals, resulting in an adverse impact on our business, financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_6"></A>COMMITTED EQUITY FINANCING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;27, 2022, we entered into the Purchase Agreement, with Yorkville. Pursuant to the Purchase Agreement, we have the right to sell to
Yorkville up to 5,000,000 shares of our Class&nbsp;A common stock, subject to certain limitations and conditions set forth in the Purchase Agreement, from time to time during the term of the Purchase Agreement. Sales of Class&nbsp;A common stock to
Yorkville under the Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to Yorkville under the Purchase Agreement. In accordance with our obligations under the Purchase
Agreement, we have filed the registration statement that includes this prospectus with the SEC to register under the Securities Act the resale by Yorkville of up to 5,000,000 shares of Class&nbsp;A common stock, consisting of 25,000 shares of
Class&nbsp;A common stock that we issued to Yorkville in consideration of its commitment to purchase shares of Class&nbsp;A common stock at our election under to the Purchase Agreement, and up to 4,975,000 shares of Class&nbsp;A common stock that we
have issued and sold or may elect, in our sole discretion, to issue and sell to Yorkville, from time to time under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to Yorkville&#146;s purchase obligation set forth in the Purchase Agreement, including that the
registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC, we will have the right, but not the obligation, from time to time at our discretion until the
first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> period after the date of the Purchase Agreement, to direct Yorkville to purchase an Advance by delivering an Advance Notice. While there is no mandatory minimum
amount for any Advance, it may not exceed the greater of (i)&nbsp;an amount equal to thirty percent (30%) of the Daily Volume Traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&nbsp;A common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The per share purchase price for the shares of Class&nbsp;A common stock, if any, that we elect to sell to the Selling Securityholder in
an Advance pursuant to the Purchase Agreement will be determined by reference to the VWAP and calculated in accordance with the Purchase Agreement, less a variable discount of 3%, provided however that the Company may establish a minimum acceptable
price in each Advance Notice below which it shall not be obligated to make any sales to the Selling Securityholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper
limit on the price per share that Yorkville could be obligated to pay for the Class&nbsp;A common stock we may elect to sell to it in any Advance. The purchase price per share of Class&nbsp;A common stock that we may elect to sell to Yorkville in an
Advance under the Purchase Agreement will be equitably adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the timing and amount of any sales of Class&nbsp;A common stock to Yorkville. Actual sales of shares of our Class&nbsp;A
common stock to Yorkville under the Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Class&nbsp;A common stock and
determinations by us as to the appropriate sources of funding for our business and its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not issue or sell any shares of
Class&nbsp;A common stock to Yorkville under the Purchase Agreement which, when aggregated with all other shares of Class&nbsp;A common stock then beneficially owned by Yorkville and its Affiliates (as calculated pursuant to Section&nbsp;13(d) of
the Exchange Act, and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in Yorkville beneficially owning more than the Beneficial Ownership Limitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds under the Purchase Agreement to us will depend on the frequency and prices at which we sell shares of our stock to Yorkville.
We expect that any proceeds received by us from such sales to Yorkville will be used for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has agreed that it and its Affiliates will not engage in any short sales of the Class&nbsp;A common stock nor enter into any
transaction that establishes a net short position in the Class&nbsp;A common stock during the term of the Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement will automatically terminate on the earliest to occur of (i)&nbsp;the
first day of the month next following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date of the Purchase Agreement or (ii)&nbsp;the date on which the Selling Securityholder shall have purchased from us under the Purchase
Agreement 5,000,000 shares of our Class&nbsp;A common stock. We have the right to terminate the Purchase Agreement at no cost or penalty upon five (5)&nbsp;trading days&#146; prior written notice to Yorkville, provided that there are no outstanding
Advance Notices and all outstanding amounts owed to Yorkville are repaid. We and Yorkville may also agree to terminate the Purchase Agreement by mutual written consent. Neither we nor Yorkville may assign or transfer our respective rights and
obligations under the Purchase Agreement, and no provision of the Purchase Agreement may be modified or waived by us or Yorkville other than by an instrument in writing signed by both parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#146;s commitment to purchase shares of Class&nbsp;A common stock at our direction upon the terms and subject
to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, we issued 25,000 shares of Class&nbsp;A common stock to Yorkville. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. The
representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed
upon by the contracting parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advances of Class&nbsp;A common stock Under the Purchase Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advances </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have the right, but not
the obligation, from time to time at our discretion, until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> period after the date of the Purchase Agreement, to direct Yorkville to purchase up to a specified
maximum amount of shares of Class&nbsp;A common stock as set forth in the Purchase Agreement by delivering an Advance Notice an Advance Notice Date, so long as the amount under any single Advance does not exceed the greater of (i)&nbsp;an amount
equal to thirty percent (30%) of the Daily Volume Traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&nbsp;A common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to Each Advance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling
Securityholder&#146;s obligation to accept Advance Notices that are timely delivered by us under the Purchase Agreement and to purchase shares of our Class&nbsp;A common stock in Advances under the Purchase Agreement, are subject to the
satisfaction, at the applicable Advance Notice Date, of the conditions precedent thereto set forth in the Purchase Agreement, all of which are entirely outside of the Selling Securityholder&#146;s control, which conditions include the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy in all material respects of the representations and warranties of the Company included in the
Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company having performed, satisfied and complied in all material respects with all covenants, agreements and
conditions required by the Purchase Agreement to be performed, satisfied or complied with by the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the registration statement that includes this prospectus (and any one or more additional registration statements
filed with the SEC that include shares of Class&nbsp;A common stock that may be issued and sold by the Company to the Selling Securityholder under the Purchase Agreement) having been declared effective under the Securities Act by the SEC, and the
Selling Securityholder being able to utilize this prospectus (and any other prospectus included in any one or more additional registration statements filed with the SEC) to resell all of the shares of Class&nbsp;A common stock issuable pursuant to
such Advance Notice (and included in any such additional prospectuses); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the SEC shall not have issued any stop order suspending the effectiveness of the registration statement that
includes this prospectus (or any one or more additional registration statements filed with the SEC </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
that include shares of Class&nbsp;A common stock that may be issued and sold by the Company to the Selling Securityholder under the Purchase Agreement) or prohibiting or suspending the use of
this prospectus (or any other prospectus included in any one or more additional registration statements filed with the SEC), and the absence of any suspension of qualification or exemption from qualification of the Class&nbsp;A common stock for
offering or sale in any jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all reports, notices and other documents required to have been filed by the Company with the SEC during the
preceding twelve-month period pursuant to the reporting requirements of the Exchange Act shall have been timely filed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading in the Class&nbsp;A common stock shall not have been suspended by the SEC or Nasdaq (or, in the case of
an Advance Notice, the Principal Market, as such term is defined in the Purchase Agreement), the Company shall not have received any final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> notice threatening the continued quotation of the
Class&nbsp;A common stock, except as disclosed in any documents filed with the SEC prior to the date of this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company shall have materially complied with all applicable federal, state and local governmental laws, rules,
regulations and ordinances in connection with the execution, delivery and performance of the Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of the shares of Class&nbsp;A common stock that may be issued pursuant to the Advance Notice shall have been
approved for listing or quotation on Nasdaq (or, in the case of an Advance Notice, the Principal Market), subject only to notice of issuance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no condition, occurrence, state of facts or event constituting a Material Outside Event (as such term is defined
in the Purchase Agreement) shall have occurred and be continuing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the Selling Securityholder of the legal opinion as required under the Purchase Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination of the Purchase Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated as provided in the Purchase Agreement, the Purchase Agreement will terminate automatically on the earliest to occur
of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the first day of the month next following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the
date of the Purchase Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the Selling Securityholder shall have purchased 5,000,000 shares of Class&nbsp;A common stock
under the Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have the right to terminate the Purchase Agreement at any time, at no cost or
penalty, upon five (5)&nbsp;trading days&#146; prior written notice to the Selling Securityholder, provided that there are no outstanding Advance Notices under which we are yet to issue Class&nbsp;A common stock. We and the Selling Securityholder
may also terminate the Purchase Agreement at any time by mutual written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Short-Selling by the Selling Securityholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has agreed that it and its Affiliates will not engage in any short sales during the term of the Purchase Agreement
and will not enter into any transaction that establishes a net short position with respect to the Class&nbsp;A common stock. The Purchase Agreement stipulates that the Selling Securityholder may sell our Class&nbsp;A common stock to be issued
pursuant to an Advance Notice, following receipt of the Advance Notice, but prior to receiving such shares and may sell other Class&nbsp;A common stock acquired pursuant to the Purchase Agreement that the Selling Securityholder has continuously held
from a prior date of acquisition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of Sales of our Class&nbsp;A common stock under the Purchase Agreement on our Stockholders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of Class&nbsp;A common stock that may be issued or sold by us to the Selling Securityholder under the Purchase Agreement
that are being registered under the Securities Act for resale by the Selling Securityholder in this offering are expected to be freely tradable. The shares of Class&nbsp;A common stock being registered for resale in this offering may be issued and
sold by us to the Selling Securityholder from time to time at our discretion over the term of the Purchase Agreement. The resale by the Selling Securityholder of a significant amount of shares registered for resale in this offering at any given
time, or the perception that these sales may occur, could cause the market price of our Class&nbsp;A common stock to decline and to be highly volatile. Sales of our Class&nbsp;A common stock, if any, to the Selling Securityholder under the Purchase
Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some or none of the shares of our Class&nbsp;A common stock that may be available for us to
sell to the Selling Securityholder pursuant to the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do elect to sell shares of our Class&nbsp;A common
stock to the Selling Securityholder pursuant to the Purchase Agreement, the Selling Securityholder may resell all, some or none of such shares in its discretion and at different prices subject to the terms of the Purchase Agreement. As a result,
investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and
different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as a result of future sales made by us to the Selling Securityholder at
prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder under the Purchase Agreement, or if investors expect that we will do so, the
actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of Class&nbsp;A common stock that we may elect to
sell to the Selling Securityholder under the Purchase Agreement, if any, will fluctuate based on the market prices of our Class&nbsp;A common stock during the applicable Pricing Period, as of the date of this prospectus we cannot reliably predict
the number of shares of Class&nbsp;A common stock that we will sell to the Selling Securityholder under the Purchase Agreement, the actual purchase price per share to be paid by the Selling Securityholder for those shares, or the actual gross
proceeds to be raised by us from those sales, if any. As of July&nbsp;28, 2022, there were 67,727,595 shares of common stock outstanding (excluding the Commitment Shares), consisting of 9,161,771 shares of our Class&nbsp;A common stock and
58,565,824 shares of our Class&nbsp;V voting stock, of which 9,515,519 shares of common stock were held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> consisting of 5,301,991 shares of our Class&nbsp;A common stock and 4,213,528 shares
of our Class&nbsp;V voting stock. If all of the 5,000,000 shares offered by Yorkville for resale under the registration statement that includes this prospectus were issued and outstanding as of the date hereof (without taking into account the 4.99%
Beneficial Ownership Limitation), such shares would represent approximately 6.9% of the total number of shares of our Common Stock outstanding and approximately 52.5% of the total number of outstanding shares held by
<FONT STYLE="white-space:nowrap">non-affiliates,</FONT> in each case as of July&nbsp;28, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance, if any, of our Class&nbsp;A
common stock to the Selling Securityholder pursuant to the Purchase Agreement would not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders would be
diluted. Although the number of shares of our Class&nbsp;A common stock that our existing stockholders own would not decrease as a result of sales, if any, under the Purchase Agreement, the shares of our Class&nbsp;A common stock owned by our
existing stockholders would represent a smaller percentage of our total outstanding shares of our Class&nbsp;A common stock after any such issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of our Class&nbsp;A common stock offered by the Selling Securityholder pursuant to this prospectus will be sold by the
Selling Securityholder for their respective accounts. We will not receive any of the direct proceeds from these sales. However, we expect to receive proceeds under the Purchase Agreement from sales of Class&nbsp;A common stock that we may elect to
make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. See the section titled &#147;Plan of Distribution&#148; elsewhere in this registration statement for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use any proceeds that we receive under the Purchase Agreement for working capital and general corporate purposes. As of the date
of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_8"></A>MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing
of our business combination, HYAC common stock, units and warrants were listed on Nasdaq under the symbols &#147;HYAC,&#148; &#147;HYACU&#148; and &#147;HYACW,&#148; respectively. On May&nbsp;27, 2022, our Class&nbsp;A common stock and public
warrants began trading on Nasdaq under the symbols &#147;BTMD&#148; and &#147;BTMDW,&#148; respectively. We no longer have any outstanding units or warrants. As of March&nbsp;11, 2024, there were 35,712,492 shares of Class&nbsp;A common stock issued
and outstanding and 38,819,066 shares of our Class&nbsp;V voting stock (the &#147;Class&nbsp;V voting stock&#148;) issued and outstanding. No market exists for the Class&nbsp;V voting stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;11, 2024, there
were 36 holders of record of our Class&nbsp;A Common Stock and 9 holders of record of our Class&nbsp;V Voting Stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial
owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared
or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on
then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_9"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to &#147;Biote&#148; refer to Biote and its subsidiaries prior to the
consummation of the Business Combination, or the Company from and after the Business Combination in the present tense. Biote&#146;s business and the industry in which Biote operates is subject to a high degree of uncertainty and risk due to a
variety of factors, including those described in the section titled &#147;Risk Factors&#148; and elsewhere in this registration statement. These and other factors could cause results to differ materially from those expressed in the estimates made by
the independent parties and by Biote. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate a high-growth practice-building business within the hormone optimization space. Similar to a franchise model, we provide the
necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a
comprehensive, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> practice building platform that provides Biote-certified practitioners with the following components specifically developed for practitioners
in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (&#147;HRT&#148;) products, as well
as digital and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> marketing support. We also sell a complementary Biote-branded line of dietary supplements. We generate revenues by charging the
Biote-partnered clinics fees associated with the support Biote provides for HRT and from the sale of Biote-branded dietary supplements. By virtue of our historical performance over the 12 years ended December&nbsp;31, 2023, we believe that our
business model has been successful, remains differentiated, and is well positioned for future growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By incorporating the Biote Method
in their practices, we enable practitioners to participate in the large and growing hormone optimization space. Bioidentical hormone therapy, which is offered by Biote-certified practitioners, is one segment of the large HRT market. It is estimated
that, as of 2020, the total U.S. market opportunity for HRT products, available in various forms, exceeds $7&nbsp;billion and is expected to grow 7% annually through 2026. We believe our business opportunity in providing educational and practice
management services is large and will similarly grow. Growth in this field is expected to be fueled by &#147;aging&#148; demographics and expanding consumer demand for medical information and treatment options to address hormonal imbalances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient symptoms associated with menopause in women and andropause in men, such as hot flashes, night sweats, depressed mood, low libido,
weight gain, and issues with concentration and focus, while negatively impacting quality of life, may also be associated with higher risks for chronic diseases attributable to declining hormone levels, including cardiovascular disease, osteoporosis
and breast cancer. Approximately 20&nbsp;million men over age 45 in the United States are affected by hypogonadism and only about 10&nbsp;million (12%) of those affected undergo testosterone treatment. An average of 27&nbsp;million women between the
ages of 45 and 64, or 20% of the American workforce, experience menopause every year. Despite the prevalence of <FONT STYLE="white-space:nowrap">symptoms-84%</FONT> of women report menopausal symptoms that interfere with their lives-only 58% have
discussed menopause with a health provider, and only 28%, or approximately 13&nbsp;million, undergo HRT (and of that 28%, only 31%, or approximately 4&nbsp;million, undergo bioidentical HRT). By 2030, over 1.2&nbsp;billion women, 14% of the global
population, will be in menopause or post-menopause. Yet, despite the growing number of women experiencing menopause, they remain an underserved population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One key driver of this unmet medical need is the lack of knowledge and experience of treating physicians. For many practitioners, the last
time they received meaningful instruction on treating menopause and andropause was during medical school. Based on a 2018 article by Jennifer Wolff, entitled &#147;What Doctors Don&#146;t Know About Menopause,&#148; among newer doctors surveyed in
2015, 80% of medical residents reported feeling &#147;barely comfortable&#148; discussing or treating menopause. While this knowledge gap applies to training, we believe it also applies to the understanding of treatment alternatives, access to new
therapies, methods to drive efficiencies in a hormone optimization practice and finally, how to profitably treat this growing population. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To capitalize on this large and underserved market opportunity, we developed a highly
differentiated practice-building platform to enable practitioners to treat the hormone imbalance symptoms experienced by their patients. The Biote Method has been designed specifically for practitioners who focus on treating perimenopause in women;
post-menopause in women; and andropause/hypogonadism in men. It is constructed to bridge the existing gaps which exist in education and treatment options, while improving the efficiency of practitioners&#146; business operations and the hormone
health of their aging patient base. Over the past 12 years, we have built our platform to provide highly differentiated education and training, practice support resources and inventory management tools that would be difficult for a practice to
otherwise attain on their own. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We empower Biote-certified practitioners by requiring rigorous
<FONT STYLE="white-space:nowrap">in-person</FONT> training, testing and certification for all Biote-certified practitioners and office staff wishing to use the Biote Method in their practice. Our practitioner instructors are among the nation&#146;s
most experienced clinical experts in hormonal therapy, including multiple modalities of HRT such as creams, gels, patches, pills, injections and compounded bioidentical hormone pellets. We teach clinicians how to identify early indicators of
hormone-related aging conditions, and we believe we are the top practitioner educators by virtue of our experience over 12 years, with approximately four million hormone optimization procedures performed by Biote-certified practitioners to date,
including approximately 393,000 active patients. We offer training centrally and regionally to provide consistent and ongoing technical education. On an ongoing basis, we provide access to clinical and technical support for Biote-certified
practitioners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To offer a turnkey platform, we leverage the data Biote-certified practitioners collect using our BioTracker software for
regulatory and record management to seamlessly assess a simple procedure-based revenue model that encompasses fees for the education, training, <FONT STYLE="white-space:nowrap">re-training,</FONT> comprehensive administrative services and support
and pass-through cost of pellets that practitioners may choose to provide as part of the Biote Method. We believe our revenue model represents an objective method to assess fees across the varying size and sophistication of our Biote-certified
practitioners and clinics beginning with the first day of training and continuing throughout the treatment of each practitioner&#146;s patient. Additionally, this revenue model provides our Biote-certified practitioners with consistency and
predictability, notwithstanding the variability in services required to support their practices during any given period. Our revenue model also offers efficiency and transparency for inventory management, as each procedure is electronically recorded
through our technology platform without requiring additional workflow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method&#146;s proprietary clinical decision support
(&#147;CDS&#148;) software assists physicians in establishing individualized dosing for patients. Our BioTracker software and business tools allow practitioners to efficiently manage the record management, product acquisition, inventory logistics
and the business end of a robust hormone optimization practice. We provide Biote-partnered clinics access to <FONT STYLE="white-space:nowrap">FDA-registered</FONT> outsourcing facilities that can supply a wide array of hormone optimization products
for Biote-certified practitioner patients. We provide information to Biote-certified practitioners regarding how to integrate with our BioTracker software. Our BioTracker software allows Biote-certified practitioners to manage orders and maintain
accurate inventory records to keep their regulatory and business systems up to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the breadth and depth of our commercial and
operational platform, the Biote name has achieved strong brand recognition among practitioners and patients in the communities we serve, as illustrated by QY Research&#146;s market research publication entitled &#147;South&nbsp;&amp; North America
Hormone Replacement Therapy Market Insights and Forecast to 2026.&#148; Practitioners undertaking the Biote Method can be confident that our exclusive training and practice building tools will prepare them to provide excellent and differentiated
care to patients. This has led to high practitioner satisfaction and a retention rate of approximately 95% among Biote-certified practitioners. We are contracted with and provide comprehensive support to over 7,100 practitioners that have adopted
the Biote Method in their practices. Leveraging our brand strength, we offer marketing assistance, including office signage and patient education materials, to every Biote-certified practitioner within our network. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe by virtue of their participation in our robust training and practice certification, Biote-certified practitioners are well informed
on all aspects of hormone optimization. We believe our brand advantage with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
both practitioners and patients is a key element of our commercial growth strategy, and an asset that we intend to leverage to expand our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complementing the Biote Method is our expanding line of private-labeled dietary supplements to address hormone, vitamin, and physiological
deficiencies that regularly manifest in an aging population. This business segment appeals to practitioners&#146; patient demographic and enables patients the opportunity to receive practitioner-recommended Biote-branded dietary supplements to
support healthy aging. By leveraging our existing Biote-certified practitioner base to sell and distribute our Biote-branded dietary supplements, we believe we have created an efficient and complementary business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also designed the Biote Method to permit beneficial practice economics for our Biote-partnered clinics. Our educational training and
practice management platform helps enable Biote-partnered clinics to execute this <FONT STYLE="white-space:nowrap">all-cash</FONT> model with minimal reimbursement risk. This contrasts to consistently decreasing reimbursement rates for most other
treatments and therapies offered by physician offices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a track record of consistently achieving accelerated and highly profitable
growth. Our four-year procedure revenue compound annual growth rate (&#147;CAGR&#148;) from 2019-2023 was 11.8%. Our revenue was $185.4&nbsp;million and $165.0&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. Net loss
was $2.8&nbsp;million and net income was $1.3&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chief Financial Officer Transition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2024, the Company appointed Robert C. Peterson as Chief Financial Officer (principal accounting and principal financial
officer) of the Company. In connection with his appointment, the Company entered into an employment agreement with Mr.&nbsp;Peterson, dated as of January&nbsp;8, 2024, which provides for Mr.&nbsp;Peterson&#146;s
<FONT STYLE="white-space:nowrap">at-will</FONT> employment as the Chief Financial Officer for a term commencing on January&nbsp;8, 2024 and continuing until terminated by either the Company or Mr.&nbsp;Peterson. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Samar Kamdar, the Company&#146;s prior Chief Financial Officer, transitioned out of his role, effective immediately. On January&nbsp;11, 2024,
Mr.&nbsp;Kamdar entered into an executive transition agreement with the Company, which provided that Mr.&nbsp;Kamdar would remain employed by the Company through February&nbsp;29, 2024, to assist with the transition and work on special projects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Clinical Need to Treat Hormone Imbalance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners primarily focus their treatments on women experiencing symptoms due to hormonal imbalance before, during, and
after menopause, and men experiencing symptoms of hypogonadism and male sex hormone deficiency. According to a 2015 study entitled &#147;Use of Compounded Hormone Therapy in the United States: Report of The North American Menopause Society
Survey,&#148; by Margery L.S. Gass, Cynthia A. Stuenkel, Wulf H. Utian, Andrea LaCroix, James H. Liu and Jan L. Shifren, it is estimated that as many as 200&nbsp;million Americans are affected by hormonal imbalance and approximately 80% are
untreated, according to a 2014 study entitled &#147;Systematic Literature Review of the Epidemiology of Nongenetic Forms of Hypogonadism in Adult Males&#148; by Victoria Zarotsky, et al. The corresponding treatment market for hormone replacement
therapies is large and diverse, both in terms of the number of products, the number of suppliers, the type of administration and regulatory requirements for producing and distributing these products. Bioidentical optimization, which provides hormone
supplementation that can be administered to patients just two or three times per year, is a highly differentiated segment of this market. Biote-certified practitioners perform about 84% of their hormone optimization procedures on female patients and
approximately 16% of such procedures on male patients. As the U.S. population continues to age, we believe the number of patients seeking relief from the symptoms of hormone imbalance will continue to grow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What We Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biote Business Model/Solution </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have developed a comprehensive platform for Biote-certified practitioners to establish and operate a personalized hormone optimization program in their practices. Biote-certified practitioners seek to optimize imbalances in their patients&#146;
hormone, vitamin, and mineral levels and may prescribe bioidentical hormone therapies and/or recommend dietary supplements to accomplish this end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our competitive advantage lies in the breadth and completeness of our offering, which supports practices in pursuing excellence in
all facets of patient care. We provide partnered clinics with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> scientific education delivered by highly experienced practitioner instructors. Our training
content is based on a scientifically rigorous approach and is continually updated. We further provide Biote-certified practitioners with the clinical mentorship, practice support resources, inventory management tools and marketing capability
necessary to operate an efficient hormone optimization practice. Biote-certified practitioners can access <FONT STYLE="white-space:nowrap">FDA-registered</FONT> outsourcing facilities that can supply hormone optimization therapies should
practitioners determine such treatment is appropriate for their patients. Further, our practice management software allows Biote-certified practitioners to efficiently order, track and manage hormone optimization product inventory, and meet other
administrative requirements. Our BioTracker software is integrated with the outsourcing facilities&#146; own software to facilitate ordering and inventory control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners who are trained in the Biote Method may prescribe bioidentical compounded hormone pellets prepared by
independent third-party compounding pharmacies, known as outsourcing facilities, which are governed by Section&nbsp;503B of the FDCA. Section&nbsp;503B includes requirements regarding registration and reporting, use of bulk drug substances in
compounding, a prohibition on compounding copies of <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs and wholesaling, and certain requirements for labeling, among others. Entities registering as outsourcing facilities are subject to
current good manufacturing practices (&#147;cGMP&#148;) requirements and regular FDA inspections, among other requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs
compounded by outsourcing facilities in compliance with Section&nbsp;503B are exempt from the new drug approval requirements of the FDCA and certain labeling requirements of the FDCA. This means that FDA does not review or verify the safety or
effectiveness of compounded products distributed or dispensed by outsourcing facilities; rather Section&nbsp;503B of the FDCA establishes standards for manufacturing processes and controls applicable to outsourcing facilities as a means to ensure
drug quality. Section&nbsp;503B outsourcing facilities are subject to FDA inspection and are inspected by FDA on a risk-based schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote contracts with operators of certain <FONT STYLE="white-space:nowrap">FDA-registered</FONT> 503B outsourcing facilities, namely
AnazaoHealth Corporation, or AnazaoHealth, Right Value Drug Stores, LLC d/b/a Carie Boyd&#146;s Prescription Shop, or Carie Boyd&#146;s, and F.H. Investments, Inc. d/b/a Asteria Health. While Biote-certified practitioners have the option to use a
variety of different outsourcing facilities, AnazaoHealth, Carie Boyd&#146;s and Asteria Health are the primary outsourcing facilities for the compounded testosterone and estradiol implantable subcutaneous pellets used by Biote-certified
practitioners as part of the Biote Method. It is Biote&#146;s understanding that these 503B outsourcing facilities make these compounded drugs from bulk substances that comport with FDA&#146;s final guidance on its interim policy on bulk substances.
However, we do not control or direct the compounding or manufacturing processes of these 503B outsourcing facilities. While Biote generates revenue by charging the Biote-partnered clinics procedure-based fees associated with the Biote-provided <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> platform for running an efficient practice that includes tracking compounded products ordered from 503B outsourcing facilities, as well as other services, Biote
does not receive compensation for the sale of bioidentical pellets from these 503B outsourcing facilities to Biote-certified practitioners. For more information about compounding facilities, please see the section entitled &#147;Regulation of
Compounded Drug Products.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biote-branded dietary supplements are a natural extension of our practice-building business and
represent approximately 21% of our annual revenues. We sell dietary supplements that may support hormone, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vitamin and physiological balances in an aging population. Our Biote-branded dietary supplements provide Biote-certified practitioners with an opportunity to further balance other important
aspects of a patient&#146;s profile and simultaneously increase practice revenue. Biote-partnered clinics directly purchase Biote-branded dietary supplements from us, and our third-party logistics (&#147;3PL&#148;) suppliers fill and ship directly
to the ordering practice. The Biote-partnered clinic then sets their own pricing in compliance with our applicable policies and sells Biote-branded dietary supplements directly to patients. We have leveraged our existing commercial infrastructure
and relationships with Biote-certified practitioners to build our Biote-branded dietary supplement business. As a result, as of December&nbsp;31, 2023, approximately 89% of Biote-branded dietary supplements were sold through Biote-certified
practitioners. Approximately 77% of our partnered clinics offer Biote-branded dietary supplements, for an average supplement volume per practice of approximately $11,800 as of 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hormone Therapy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method
is purpose built to enable Biote-certified practitioners to treat hormone imbalance using bioidentical estrogen and testosterone products as necessary. The term bioidentical refers to hormone formulations that match the hormones of the human body.
Estradiol (the most active estrogen), progesterone and testosterone can be produced as bioidentical formulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Estradiol </B>is FDA
approved and commercially available under several different brand names. Examples include Vivelle Dot (patch), Estrogel, Elestrin, Evamist, Vagifem, Estring and FemRing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Testosterone </B>can be formulated for use by both women and men. However, <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
testosterone products exist exclusively for males. Testopel is an example. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Progesterone </B>is FDA approved, and available
commercially as a capsule of micronized progesterone in peanut (or olive) oil. Progesterone is also available in patch and cream formulations. Prometrium is an example. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hormones that are not bioidentical are commonly known as synthetic hormone formulations. Examples of synthetic hormones include conjugated
equine estrogens, oral contraceptive pills, medroxyprogesterone (Provera) and methyltestosterone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method is focused on
promoting the use of bioidentical hormones to provide optimized clinical results using bioidentical estrogen, progesterone and testosterone rather than synthetic, chemically-modified versions of the hormone. The Biote Method encourages practitioners
to begin each patient treatment with comprehensive lab testing, which includes checking testosterone, thyroid and vitamin levels. Patients complete symptom questionnaires to enable practitioners to appropriately gauge symptom scores. These
questionnaires and lab results are evaluated by the practitioner, along with patient data such as age, weight, medical history and desired outcomes. The Biote software then can assist Biote-certified practitioners in developing patient-specific
treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners utilize a wide variety of hormone therapies. In addition to bioidentical hormone
pellets, practitioners may also choose to administer hormone therapy to their patients via topical methods (creams, gels, patches), oral methods (sublingual tablets, pills) or injections, depending on the practitioners&#146; medical assessment of
their patients&#146; clinical needs. Creams, lotions and patches are prescribed on a per patient basis and obtained from pharmacies. If the physician chooses to utilize pellets, they generally administer the pellets that they obtain from 503B
outsourcing facilities through &#147;in office&#148; procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a 2014 study published in the Journal of Sexual Medicine, pellet
therapy was chosen by 17% of 382 male patients when presented with the choice of the following methods of hormone therapy: gels, injections and implantable subcutaneous pellets. Further, according to a 2013 study published in the same journal, of
113 men who underwent subcutaneous testosterone pellet therapy, 52.2% had switched to pellet therapy from topical gel therapy and 35.4% had switched from injection therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Biote Difference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Biote training and certification program-</B>For many practitioners, medical school was the last time they received instruction in
menopause, andropause and hormone deficiency. In fact, according to a 2018 article, in a survey of more than 1,000 medical professionals, only 57% reported being
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;up-to-date&#148;</FONT></FONT> on information regarding HRT for menopause symptoms. Effectively managing hormone levels is an involved, complex and highly data-intensive
process. We believe that contemporary medical training is a critical element of our platform and seek to bridge any gap in a practitioner&#146;s experience and clinical education. To become a Biote-certified practitioner, we carefully vet healthcare
providers to ensure they possess the necessary commitment, patient population and office staff needed to build a successful hormone optimization practice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective practitioners and their staff attend a <FONT STYLE="white-space:nowrap">two-day</FONT> Biote Method training program. The training
includes didactic lectures designed to educate practitioners on the latest science of HRT. The training program also includes <FONT STYLE="white-space:nowrap">in-clinic</FONT> training during which practitioners gain experience performing hormone
replacement procedures in a supervised setting. We also understand the importance of staff interaction in any patient experience and require each prospective Biote-partnered clinic&#146;s office staff to attend training regarding the best practices
for maintaining a hormone therapy practice. We believe that this comprehensive training program, as well as continuing education and mentoring, is critical to the successful establishment of new Biote-certified practitioners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to completing training, Biote-certified practitioners must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Be in good standing with their respective state professional licensing board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Successfully pass a post-training certification exam / requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Utilize our BioTracker platform to comply with the U.S. Drug Enforcement Administration&#146;s (the
&#147;DEA&#148;) inventory control regulations for all scheduled drugs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use our proprietary technology, including training materials, therapy instruction and training videos to
facilitate optimal therapy and patient outcomes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Biote training facilities</B><B></B><B>&nbsp;&amp; faculty-</B>We
operate one national and four regional training facilities for Biote-certified practitioners, healthcare providers and medical staff. The <FONT STYLE="white-space:nowrap">10-person</FONT> practitioner clinical faculty and 15 medical advisors provide
<FONT STYLE="white-space:nowrap">on-site</FONT> and virtual educational programs, seminars, training, refresher courses in hormone optimization, vitamin and Biote-branded dietary supplement guidance, and other topics. As of December&nbsp;31, 2023,
over 7,100 providers in more than 4,100 clinics nationwide have successfully completed our rigorous curriculum and clinical training program. Upon completion, each Biote-certified practitioner is teamed with an experienced Biote-certified
practitioner who is committed to providing mentorship and guidance, including with respect to regulatory compliance, education and new research updates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Biote BioTracker system-</B>We require Biote-partnered clinics to keep patient and inventory records, which was accomplished historically
with manually-completed paper copies. To help our practitioners automate this process, we offer as part of our platform the BioTracker system, which provides inventory management services to enable Biote-partnered clinics to comply with federal
(DEA) and applicable state regulations for the hormones that Biote-certified practitioners may order from 503B outsourcing facilities. Our BioTracker software is integrated with the outsourcing facilities&#146; software to facilitate ordering and
inventory control. As each Biote-partnered clinic stores and dispenses these hormones, this software performs the critical function of monitoring and tracking the necessary detail regarding the administration of controlled substances. BioTracker
also provides robust data analytics which allows the practitioner to effectively manage their processes and internal records. We also leverage this data to electronically transmit to us the number of hormone optimization pellet insertion procedures
performed, affording us the most direct way to seamlessly assess a fair, transparent and consistent fee for our Biote Method, including the education, training, <FONT STYLE="white-space:nowrap">re-training</FONT> and comprehensive services and
support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Biote Clinical Decision Support software-</B>The CDS is part of our offerings available to Biote-certified practitioners. The
CDS programs assist practitioners in identifying potential patient-specific treatment options </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and provide these practitioners with access to publications and guidelines that serve as independently verifiable bases for treatment recommendations. The practitioner enters a patient&#146;s
clinical markers into the program, and an algorithm based on the published literature with clinical data and clinical guidelines suggests potential individualized treatment option for the practitioner&#146;s evaluation and consideration. While
Biote-certified practitioners may consider the treatment options identified by the CDS, responsibility for treatment decisions remains solely with the practitioners in the exercise of their independent medical judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Biote-branded Dietary Supplements-</B>Our expanding Biote-branded dietary supplements business sells dietary supplements that may support
hormone, vitamin and physiological balances in an aging population. We introduced our line of Biote-branded dietary supplements in 2013 with two specific dietary supplement products, DIM SGS+ and ADK 5. The line has since grown to include 23 dietary
supplements, priced between $15.00 and $99.00. We offer wholesale sales directly to over 2900 Biote-certified practitioners through our own eCommerce site, efficiently leveraging the core Biote provider platform. Practitioners then <FONT
STYLE="white-space:nowrap">re-sell</FONT> to their patients through online stores or <FONT STYLE="white-space:nowrap">in-clinic.</FONT> As of December&nbsp;31, 2023, 89% of Biote-partnered clinics also offer our Biote-branded dietary supplement
products. Biote-branded dietary supplement sales accounted for approximately 21% of our revenue in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, we launched a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> eCommerce platform whereby practitioners can invite their patients to buy Biote-branded dietary supplement products online via their own online store.
Enhancements to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> platform included a subscription service that launched in early 2022 for added convenience to patients, and to help drive
reoccurring revenue for both us and Biote-partnered clinics. Our team plans to continue researching new formulations, product expansion opportunities and architecting an innovation pipeline that will offer solutions and revenue expansion for our
practitioners and for Biote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that as awareness of our Biote brand name associated with our supplements continues to increase,
so too will the incidence of our Biote-branded dietary supplements being sold in online stores. In the broader global dietary supplement market, by 2025, it is estimated that approximately 26% of sales will be generated through online markets,
mirroring trends across global retail trade. We are preparing for this shift with the introduction of an online <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> store in conjunction with expanding our
digital marketing outreach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are a leader in the practice-building market focused on the hormone optimization space as evidenced by our size as compared to
competitors. We have designed the Biote Method to offer practitioners an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> platform to enable them to successfully establish and grow a profitable hormone
therapy practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Proprietary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> hormone
optimization platform-</B>The Biote Method provides a comprehensive solution that quickly enables new clinics to effectively start and run an efficient bioidentical HRT practice. Our <FONT STYLE="white-space:nowrap">two-day</FONT> mandatory,
practitioner-paid training program educates the practitioner on clinical and back-office aspects of treating patients. Biote&#146;s CDS identifies treatment options while customized practice management and data software enable efficient workflow and
inventory and vendor management. By virtue of the breadth and quality of the systems and services provided by the Biote Method, we believe our platform is differentiated within our industry and represents a competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Accretive practice economics-</B>Our relationship with Biote-certified practitioners delivers positive practice economics. As of July 2021,
Biote-partnered clinics generated average profits of approximately $100,000 per year from the hormone optimization space. In an environment of expanding patient needs due to an aging population and declining reimbursement for patient care related
costs, extending quality of care while providing a profitable revenue stream are compelling contributors to practitioners joining the Biote network. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Size compared to competition and brand awareness among practitioners-</B>With more than 4,100 clinics, 7,100 Biote-certified practitioners
and four million procedures performed to date, and over 393,000 active </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients, we believe we are approximately 5 times larger than our nearest competitor. We believe that our patient education materials reinforce the commitment by our Biote-certified practitioners
to be medically and technically well-prepared to effectively address patients&#146; symptoms by providing individualized treatment to help patients &#147;achieve their best self&#148;. We believe that Biote-certified practitioners identify with the
Biote brand because we provide a reliable education and business platform and enable them to build a profitable practice area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Complementary product lines augment growth-</B>In addition to our practice building business, our growth opportunities are also driven by
our Biote-branded dietary supplement products. These Biote-branded dietary supplements support consumer health with differentiated formulations. Biote-branded dietary supplements are contract manufactured to approved specifications by a select group
of experienced supplement manufacturers. These supplements are primarily sold by Biote-certified practitioners as well as on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> basis, extending their
consumer appeal beyond the HRT patient base. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Proven leadership team with expansive industry experience-</B>We have a highly
experienced leadership team comprised of senior corporate leaders from within global healthcare and consumer markets. Our team has demonstrated skill in scaling our business model <FONT STYLE="white-space:nowrap">to-date.</FONT> We believe we
possess the skills and knowledge to complete our national expansion and capitalize on the growing category awareness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Practitioner Growth, Sales,
Brand and Marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinic and Practitioner Growth </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, we contract with over 7,100 Biote-certified practitioners in approximately 4,100 partnered clinics, and many
Biote-certified practitioners are also patients. In 2023, we contracted with 898 new partnered clinics, bringing the total number of partnered clinics to 4,100. The 898 new partnered clinics account for 43% of our 2023 revenue growth. Since we
started in 2012, our commercial footprint has expanded to 10 core states, which, as of December&nbsp;31, 2023, generated approximately 60% of our revenue: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alabama</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Louisiana</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arkansas</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mississippi</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Colorado</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>New Mexico</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Florida</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Oklahoma</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Georgia</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Texas</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ targeted methodologies that consider practice demographics and practitioner prescribing history to
identify the best potential practitioners within each area of medical specialty and geography. We also utilize these analytics in determining optimal geographies for new sales territories. Although there are approximately 1.2&nbsp;million total
providers in the United States, we target practitioners who are already prescribing alternative HRT patient care-related and having conversations with patients about hormone-related symptoms that impact patient health and wellbeing. This target set
includes practitioners in OB/GYN, family and general practice, urology, and internal medicine. In our experience, patients most often seek out practitioners within these distinct specialties when experiencing menopause or andropause symptoms. In
2019, there were approximately 260,000 practitioners in the United States within our targeted specialties: family and general practice (~108,000); obstetricians and gynecologists (~39,000); internal medicine (~104,000); and urologists (~9,000).
These are the specialties that patients typically contact when experiencing the symptoms associated with menopause and andropause. As a result, these practitioners are actively searching for a therapeutic solution to the health challenges faced by
their existing patients. Of this group, we currently target the top three deciles from the relevant specialties, which represents approximately 78,000 practitioners. Practitioners in these four specialties have appropriate patient demographics and
have proven they can be developed into capable hormone optimization practices. Our own business experience confirms that more than half of our revenue in 2023 was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generated from two provider specialties: family and general practice and OB/GYN. Currently, approximately 60% of our customer base is comprised of OB/GYN, family and general practice, urology and
internal medicine practices. We believe this target mix accurately reflects our potential by specialty. As such, our practitioner-focused marketing efforts are directed accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe medical practitioners choose our company for three primary reasons: 1) our intensive, onsite and virtual education and training,
and ongoing mentorship, is unique and highly valued; 2) our proprietary, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> business platform enables efficient practice
<FONT STYLE="white-space:nowrap">start-up</FONT> and management; and 3) through the Biote cash pay model, the average Biote-partnered clinic generates meaningful incremental, comparatively high margin profit to their legacy profitability. Our <FONT
STYLE="white-space:nowrap">all-cash,</FONT> minimal reimbursement model is cost-effective for patients across income levels while delivering strong profits to our partnered clinics. As of 2019, 50% of Biote-certified practitioners&#146; patients had
an annual household income of less than $100,000. We believe this demonstrates the affordability of the procedures and their accessibility to patients of varying income levels, and the scale of the addressable consumer market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive the majority of our revenue through service fees that encompass the comprehensive platform and wraparound support we provide our
Biote-partnered clinics. These service fees are realized when Biote-certified practitioners perform HRT procedures utilizing pellets dispensed in office. During the year ended December&nbsp;31, 2023, these service fees generated approximately 76% of
our revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This procedure-based revenue model provides our Biote-certified practitioners with consistency and predictability and is not
dependent on the volume of bioidentical hormone pellets ordered by practitioners or the number of patients that may visit a clinic. Although there is a correlation between our revenue model and the hormone optimization procedure involving the use of
bioidentical hormone pellets, the fees that we charge our Biote-partnered clinics are designed to cover the wide array of education, training, <FONT STYLE="white-space:nowrap">re-training,</FONT> comprehensive administrative services and support and
pass-through cost of pellets that practitioners may prescribe as part of the Biote Method. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company began in Texas in 2012 and, since that time, has expanded into the geographically adjacent states. As of December&nbsp;31, 2023, we
had a <FONT STYLE="white-space:nowrap">112-person</FONT> sales force, structured to attract new Biote-certified practitioners while simultaneously supporting the productivity within existing partnered clinics. As of December&nbsp;31, 2023, the
regional sales team consisted of 95 liaisons and practice development managers (&#147;PDMs&#148;) and are led locally by a regional manager. Liaisons are charged with identifying <FONT STYLE="white-space:nowrap">non-Biote-certified</FONT>
practitioners and educating them on value in attending the comprehensive <FONT STYLE="white-space:nowrap">two-day</FONT> training program to become a Biote-certified practitioner. The role of the PDM is to act as a resource and facilitate the
practice management of the Biote Method in both new and existing partnered clinics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout the initial years of our rapid growth,
high practitioner and patient satisfaction made referrals from satisfied practitioners and patients one of our most important marketing tools. Many patients of Biote-certified practitioners or Biote-partnered clinics share their experiences with
friends, family, and other practitioners. Biote-certified practitioners often report the positive clinical results and powerful patient descriptions of their hormone optimization experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brand </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote brand has been
cultivated over 12 years to reinforce a &#147;science-based, patient focused&#148; approach to our practice building model. We believe that the quality of our platform, our size and scale differential, combined with strong brand placement throughout
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> delivery has enabled us to establish Biote as a highly recognized brand in the hormone optimization space. By the end of 2023, more than four million
patient procedures had been performed by Biote-certified practitioners. We believe the patient experiences generated through the Biote Method are both strong and unique in our competitive environment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For practitioners, we believe that those who choose to engage with Biote understand that we
offer them a practice-building platform that is highly refined and delivers the critical elements necessary to build a successful hormone optimization practice. Each facet of the Biote Method&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-to-end</FONT></FONT> platform reinforces our commitment to developing practitioner excellence. Biote-certified practitioners thus understand the value of operating their practice under the Biote brand and are loyal.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patients visiting a Biote-certified practitioner, our brand represents an opportunity for them to be the &#147;best version of
themselves.&#148; Patients can be confident that their Biote-certified practitioner will have a keen, informed focus on their unique symptoms and provide top notch medical care accordingly. Patients see the Biote logo and imagery at every step along
the way, from the practitioner&#146;s website to the decal on the door. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the acceptance and strength of the Biote brand
has enabled us to successfully launch and build our companion Biote-branded dietary supplement line. Practitioners frequently prescribe supplements as adjunct to hormone therapy. As of December&nbsp;31, 2023, approximately 77% of Biote-partnered
clinics also sell Biote-branded dietary supplement products. As patients trust the recommendations of their practitioner, our Biote-branded dietary supplements are likewise trusted and purchased. As a company, we benefit from this continued brand
leverage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinic / Practitioner
Marketing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary objective in marketing to healthcare providers is to inform them of the value in becoming a Biote-certified
practitioner. We accomplish this through referrals from existing Biote-certified practitioners to their healthcare provider relationships, a dedicated sales force, and through digital and traditional marketing channels. We target specific healthcare
providers based on their specialty, prescribing data, demographic information and location match with our existing geographic footprint and targeted new geographic markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lead generation through sales force efforts remains our highest priority channel. To that end, we plan to meaningfully expand the number of
sales representatives calling on practitioners within targeted specialties in both current and new geographies. From a central marketing perspective, we have carefully built comprehensive omnichannel expertise and leverage evidence-based content to
drive differentiated Biote branding. All tactical execution of marketing and promotion is handled internally. We have invested significantly in building our digital marketing capabilities, we are utilizing this extensive capability to generate
practitioner leads and have established media capabilities across all digital channels. We believe the scale and breadth of our marketing capabilities to be a competitive advantage that could be difficult to duplicate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consumer Marketing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consumer
outreach is a growing portion of our marketing. We believe that the Biote brand is highly differentiated and leverageable across key consumer channels. We direct consumers that are actively seeking care to Biote-certified practitioners via the
&#147;Find A Provider&#148; feature on our company website. Through our growing digital outreach capabilities, we connect with consumers seeking general information to Biote-certified practitioners for more information. This not only builds
incremental patient starts, but also extends strong practitioner loyalty to our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Growth Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Geographic Expansion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
our initial founding in Texas, we have demonstrated a strong ability to scale. During the year ended December&nbsp;31, 2023, we conducted approximately 60% of our business in Texas, Oklahoma, New Mexico, Colorado, Arkansas, Louisiana, Mississippi,
Alabama, Georgia and Florida. Informed by both data and our past </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
success, we are confident in our ability to further expand our U.S. geographic footprint. In 2024, we plan to expand our field sales and support staff to add liaisons in critical locations, add
new geographies and expand our training capacity to meet the increased rate of new Biote-partnered clinics. In order to efficiently identify new growth opportunities, we use demographic and practitioner-level data such as identifying prescription
patterns and prescription purchasing data to assist in understanding the needs of new practices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International
<FONT STYLE="white-space:nowrap">Scale-up</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for private-label dietary supplement products, and the training and
support requirements for practitioners outside of the United States is well-established and growing. According to the Mater Data Forecast&#146;s &#147;Global Hormone Replacement Therapy Market Size, Share, Trends,
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Impact&nbsp;&amp; Growth Analysis Report-Segmented By Type, Route of Administration&nbsp;&amp; Region-Industry Forecast (2022 to 2027),&#148; as of April 2021, 57% of the current global market for
hormone products exists outside of North America. We believe there is opportunity to grow our practice building platform in a core group of Latin American countries, in Europe and potentially in Asia, which some market analysts project to be the
fastest growing market globally. However, we recognize the challenges and potential risk associated with simultaneously expanding in multiple geographies and believe that international expansion may require a different access model, such as a
license model, which may require the utilization of one or more local distributors with established practitioner relationships. We evaluate potential international expansion opportunities on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">market-by-market</FONT></FONT> basis with the intention of determining the most appropriate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy and growing our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such, our U.S. growth strategy is the most strategically and financially vital. Ensuring that the U.S. plan is <FONT
STYLE="white-space:nowrap">on-track</FONT> and moving toward success will be our primary focus prior to launching international expansion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current presence outside of the continental United States is in Puerto Rico, Mexico, and the Dominican Republic where we enjoy a fast
growing but still nascent business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Research Support </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical research program supports our education programs through systematic literature reviews and analysis of patient therapy effects in
clinical practice. By leveraging existing literature and existing data, we will strengthen our educational programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, we
published a nine-year retrospective breast cancer study in the European Journal of Breast Health. This study demonstrated testosterone is breast protective. Testosterone and/or testosterone/estradiol delivered subcutaneously significantly reduced
the incidence of breast cancer. Additionally, in 2021, we published a safety review of seven years of adverse events data regarding the use of subcutaneous hormone therapy. This study showed an overall complication rate of less than 1%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022, we made significant strides in understanding hormone replacement therapy for women, specifically testosterone therapy, as highlighted
in a comprehensive literature review published in the Journal of Personalized Medicine titled &#147;A Personal Perspective on Testosterone Therapy in Women-What We Know in 2022.&#148; This review clarified the lack of scientific evidence for the
safety concerns surrounding testosterone therapy in women, paving the way for further research and potential <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a supportive commentary titled &#147;Testosterone Therapy in Women: A Clinical Challenge&#148; published in Obstetrics and
Gynecology in 2022 reinforced the benefits of subcutaneously administered testosterone in appropriately selected women to treat menopausal symptoms. This commentary emphasized the need to overcome the negative narratives and focus on the potential
positive impact of testosterone therapy for women&#146;s health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This and other peer-reviewed medical literature has the strongest
influence on defining the proper suggestions for clinical practice when focused on the data from controlled clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In parallel, we are engaging with clinical practices to define how to access, analyze and
publish their clinical findings. Over the past decade, the FDA and academic communities have targeted real-world evidence as critical to understanding the effects of therapy and process in clinical practice, a trend that we can utilize to teach
Biote-certified practitioners about optimal use of hormone therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Product Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to advancing healthcare through product improvement. We constantly evaluate the potential for advanced education and tools to
support the hormone optimization market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biote-branded dietary supplement business has grown at a 21.1% CAGR between 2019 and 2023.
In addition to generating continued growth through new patients added via our geographic expansion and through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> channels, we believe there is an
important growth opportunity to expand the size of our Biote-branded dietary supplement portfolio through new product launches and increased education of Biote-certified practitioners on these products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Acquisitions and Product Offerings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically reinvested our revenue to fund our geographic expansion. Over the next three years, we plan to accelerate that expansion
to grow our practice-building business in the hormone optimization market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also believe that by becoming a public company, the
resources and access to public markets will provide us with the financial leverage to become strategically acquisitive. We currently evaluate selective business development opportunities as they present themselves, while simultaneously strategizing
on moves that we believe could benefit our model and our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, we had 194 employees, across 11 departments. This includes seven employees on the executive team, 128 in sales
and marketing, and nine in finance and operations. We believe our employee relations are good. None of our employees work under any collective bargaining agreements. All of our employment and consulting agreements include employees&#146; and
consultants&#146; covenants with respect to confidentiality, noncompetition, nonsolicitation and assignment to us of intellectual property rights developed in the course of their employment with us. However, there can be no assurance that these
agreements will be enforceable or that they will provide us with adequate protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to creating, nurturing and
sustaining an inclusive culture where differences drive innovative solutions to meet the needs of our practitioners and partnered clinics, their patients, and our employees. We believe that having varied perspectives helps generate better ideas to
solve the complex healthcare problems of a changing and increasingly diverse-world. A diverse, equitable and inclusive workforce is a critical focus of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Organizationally, we are progressing our diversity recruiting and advancement goals by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Targeting diverse job boards that market to diverse candidate pools </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Targeting networking/user groups that are diverse in nature </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Developing an employer brand that conveys our diversity, equality and inclusion commitment and initiatives
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Creating and continually improving company policies that appeal to diverse candidates </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Offering future talent acquisition recruiters the opportunity to attend and complete a thorough diversity
certification course </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nurturing a respectful and encouraging workplace </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Providing professional development assessments and opportunities to support skill and career growth
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These initiatives represent the next steps in our diversity, equity and inclusion commitments. With time and consistent
focus, we are building a truly inclusive and equitable workplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supply Chain for Dietary Supplements and Pellet Insertion Kits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our supply chain management enables precise planning of near-term and long-term business growth because we have full visibility into the
production and distribution of resources that influence capacity planning. We sell 23 custom-branded dietary supplements, manufactured to exacting specifications by 11 U.S.-based suppliers. Currently, no one supplier manufactures more than seven
products within our portfolio. We have chosen and continually evaluate our dietary supplement suppliers based on multiple factors including: 1) reputation and experience in the dietary supplement space; 2) expertise they bring to a specific product
category; 3) ability to consistently execute all aspects of the manufacturing and packaging process to Biote quality standards; 4) <FONT STYLE="white-space:nowrap">on-time</FONT> order fulfillment; and 5) cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive for supplier consistency within our supply chain. However, we do not hesitate to change or add new suppliers when there is potential
to either improve our dietary supplement product offerings or gain operational leverage through better cost position and/or supplier service levels. We aim to maintain rigid quality control standards, ensuring the products and services of every
dietary supplement and ingredient supplier and vendor meet or exceed our expectations. While all dietary supplement products are currently single source manufactured, we have identified potential <FONT STYLE="white-space:nowrap">back-up</FONT>
suppliers for contingency situations, should they arise. While no single dietary supplement product is sufficiently large enough to justify dual source of supply, we regularly evaluate this decision from a risk management perspective and will add
second source dietary supplement suppliers when appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biote-branded dietary supplement inventory and shipping are executed by
a 3PL partner. Our current structure is with B2B as our 3PL ships Biote-branded dietary supplements directly to Biote-certified practitioners, who in turn, sell directly to patients. As our business scales, we envision that our dietary supplement
distribution mix will also evolve. We expect to add more Biote-certified practitioners and that a growing percentage of our dietary supplement sales will be
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer.</FONT></FONT> We anticipate this will result in fulfillment shifting to a much greater volume of more frequent, smaller orders-directly to patients. While these
shifts will occur over time, we are currently planning for the necessary changes to our 3PL structure, including adding one or more shipping locations, to successfully manage this expansion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also offer for sale to practitioners two sterile pellet insertion kits for use with hormone optimization therapies, one for male patients
and one for female patients. These kits largely contain commercially available products, including disposable supplies (gloves, antiseptic, gauze, disposable trocar, etc.) assembled in a sterile package. The products contained in the kits are
sourced, assembled, and supplied by a third-party with whom we have an agreement. Sales of these products are modest as most clinics currently choose to assemble these parts <FONT STYLE="white-space:nowrap">in-house.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Administering hormone therapy via subcutaneous placement of hormone pellets is a procedure performed by health care providers in the office.
Once the patient&#146;s individualized dose is established, a local anesthetic is applied to the upper buttock or flank. A small incision (about <FONT STYLE="white-space:nowrap">3-4mm</FONT> in length) is made and the pellets (about the size of a
grain of rice) are inserted into the subcutaneous fat using <FONT STYLE="white-space:nowrap">a-trocar</FONT> insertion device. Upon placement of the pellets and removal of the trocar insertion device, wound closure tape is placed over the incision.
A protective dressing is then placed over the wound closure tape. Experienced practitioners typically complete the pellet insertion process in four to seven minutes, depending on the number of pellets inserted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners utilize a wide variety of hormone therapies. In addition to
bioidentical hormone pellets, practitioners may also choose to administer hormone therapy to their patients via topical methods (creams, gels, patches), oral methods (sublingual tablets, pills), or injections depending on the practitioners&#146;
medical assessment of their patients&#146; clinical needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We manage and monitor our supply chain, in part, via a Sales and Operations
Planning Process (&#147;S&amp;OP&#148;). This has a goal of continually iterating a capital-efficient supply chain that underpins practitioners&#146; confidence in providing care for their patients. This process collects inputs from the following as
part of our direct responsibility for planning and sourcing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Feedback from dietary supplement suppliers we talk to regularly regarding inventory availability and fulfillment
performance </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sales and finance teams that monitor sales volumes, and develop product pricing structures </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marketing teams that monitor sales and inventory metrics, developing promotional events to optimize revenue and
inventory investment </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New dietary supplement product development teams that create new offerings to bring to market, based on industry
trends and customer needs </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other inputs are reconciled monthly as part of the S&amp;OP process to ensure that
expected market demand, product forecasts, orders and dietary supplement production delivery are tightly aligned across all involved functions, including sales, marketing, finance and operations. This process helps ensure that product inventories
are managed to appropriate levels, simultaneously enabling targeted customer service levels and optimized inventory costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Biote-branded dietary supplement supply chain has remained highly stable over the past two years. As a preventative measure due to global supply chain disruptions, we increased our safety stock (minimum required inventory on hand) from three weeks
to four weeks. For the foreseeable future, we will continue to monitor the marketplace and assess potential dietary supplement supply chain changes and alter our strategy accordingly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop and
continue to refine our CDS and proprietary formulations for our Biote-branded dietary supplements. We believe the completeness of our offerings represents a sustainable competitive advantage and is but one contributing factor to our high rate of
practice retention. While their existence is not a trade secret, their details, as well as the investment and practice experience required by a competitor to reproduce them represents a barrier of entry in that respect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2023, we owned three issued U.S. design patents related to trocars. The first filed of these three patents, D773,664, is subject to a <FONT STYLE="white-space:nowrap">14-year</FONT> term and will expire on December&nbsp;6, 2030. The remaining two
patents, D791,322 and D800,307, are subject to a <FONT STYLE="white-space:nowrap">15-year</FONT> term and will expire on July&nbsp;4, 2032, and October&nbsp;17, 2032, respectively. We pursued these patents to protect the unique design qualities of
the trocars recommended for use in our education and training. However, we are no longer using our design patents as specifications for trocar manufacturing, opting instead to purchase and market trocar convenience kits that include commercially
available and sourced disposable trocars. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, our trademark portfolio comprises 25 trademark registrations or active trademark applications worldwide. Such
portfolio includes 10 U.S. trademark registrations, 14 <FONT STYLE="white-space:nowrap">non-U.S.</FONT> trademark registrations and one pending U.S. trademark applications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade Secrets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our reliance on trademark protection for our brand and tradename, we also rely on trade secrets,
<FONT STYLE="white-space:nowrap">know-how,</FONT> confidentiality agreements and continuing technological innovation to develop and maintain our competitive position. New employee hires, as well as vendors and consultants, are required to sign
contractual agreements to protect our confidential information from disclosure. We take various physical security and cybersecurity measures, including having policies in place to prevent data breaches to help prevent our confidential information
from being transferred to unsecured systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have competitors, we believe that no current competitor has the strength and size of our practice-building business within the
hormone optimization space. We believe our company is significantly larger than our next competitors in a highly fragmented space. The below chart details our principal competitors&#146; offerings compared to Biote (based on publicly available
information): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Company Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Biote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Evexipel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Sottopelle</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Pellecome</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">HTCA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">Pro-pell</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Number of Practice&#146;s Locations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">4,100</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">859</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">213</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">100</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">127</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">150</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Geographic Area</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">North America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">U.S.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">U.S.&nbsp;South<BR>America</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Most&nbsp;U.S.&nbsp;States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Most<BR>U.S.&nbsp;States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">29 States</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Services Provided</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">BHRT&nbsp;Education,<BR>Training, and<BR>Inventory<BR>Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Pellet Therapy<BR>Education</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Pellet<BR>Therapy<BR>Education</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Pellet Training,<BR>Pellet Insertion<BR>Devices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Pellet<BR>Therapy<BR>Education</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Pellet&nbsp;Training,<BR>Compounding<BR>Pharmacy<BR>Items</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Products Sold</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Training Classes,<BR>Dietary<BR>Supplements&nbsp;&amp;<BR>Convenience</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Training&nbsp;Classes,<BR>Dietary<BR>Supplements&nbsp;&amp;<BR>Convenience&nbsp;Kits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Training<BR>Classes&nbsp;&amp;<BR>Pellets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Training&nbsp;Classes,<BR>Dietary<BR>Supplements&nbsp;&amp;<BR>Convenience&nbsp;Kits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Training<BR>Classes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">Training,<BR>Pellets,<BR>Supplements</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dietary supplement space is a large, fragmented and highly competitive industry, with few barriers to
entry for both branded dietary supplements sold through practitioners as well as direct to consumer online and through conventional retailers and department stores. For instance, of our competitors listed above, Evexipel, Pellecome, and <FONT
STYLE="white-space:nowrap">Pro-Pell</FONT> maintain their own branded dietary supplements that they sell through affiliated practitioners and Sottopelle and HTCA sell their branded dietary supplements direct to consumers online. Further, an internet
search for providers of DIM, a popular dietary supplement, illustrates more than 20 other accessible brands, including Nature&#146;s Way and The Vitamin Shoppe, available online and sold through conventional retailers and department stores such as
The Vitamin Shoppe, Walmart, and Target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the significant availability of dietary supplements, the contents of different brands
vary substantially leaving to the consumers to ensure that their purchase matches their physiologic needs. In contrast to other competitors, our Biote-branded dietary supplements are primarily sold and recommended by Biote-certified practitioners.
As of December&nbsp;31, 2023, approximately 77% of Biote-partnered clinics also sell Biote-branded dietary supplement products. We believe consumers primarily choose our Biote-branded dietary supplements as they are recommended by their
practitioner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulations/Healthcare Laws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business
is the development and instruction in the Biote Method to practitioners who then become certified in the Biote Method. We offer training courses in our Biote Method and access to a network of other providers who have been trained in the Biote
Method. The Biote Method involves educating and training medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
providers in the analysis of patient hormone wellness. The Biote-certified practitioner will use both our proprietary user platform and his or her own independent medical judgment to assess
patient wellness and make recommendations to improve wellness. This assessment may result in the Biote-certified practitioner&#146;s prescription for drugs, including compounded bioidentical hormones and/or recommendation of dietary supplements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare industry in the United States is subject to extensive regulation by a number of governmental entities at the federal,
state and local level. The healthcare regulatory landscape is also subject to frequent change. Laws and regulations in the healthcare industry are extremely complex and, in many instances, the industry does not have the benefit of significant
regulatory or judicial interpretation. Moreover, our business is impacted not only by those laws and regulations that are directly applicable to us but also by certain laws and regulations that are applicable to vendors, medical providers,
outsourcing facilities and traditional compounding pharmacies. While our management believes that we are in substantial compliance with all of the existing laws and regulations applicable to us as stated below, such laws and regulations are subject
to rapid change and often are uncertain and inconsistent in their application. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area may increase, the impact of which
cannot be predicted. There can be no assurance that we will not be subject to scrutiny or challenge under one or more of these laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a
material adverse effect upon our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the various federal and state laws and regulations which may
govern or impact our current and planned operations are the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Dietary Supplements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners who are trained in the Biote Method may recommend dietary supplements. We are a private-labeler of dietary
supplements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, &#147;dietary supplements&#148; are defined as vitamins, minerals, herbs, other botanicals, amino acids and
other dietary substances that are used to supplement the diet, as well as concentrates, constituents, extracts, metabolites, or combinations of such dietary ingredients. The FDCA and its amendments, such as the Food Safety Modernization Act and the
Dietary Supplement Health and Education Act of 1994 (the &#147;DSHEA&#148;), provide the FDA with the authority to regulate dietary supplements and the dietary ingredients in the supplement products and ensure that they comply with the requirements
for identity, purity, quality, strength, and composition. The FDA has the authority to regulate the entire lifecycle of a dietary supplement product, and regulates the formulation, development, manufacture, packaging, labeling, holding, promotion,
sale, and distribution of dietary supplements. Under the FDCA, introduction into interstate commerce of misbranded, adulterated, or otherwise unlawful <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products is prohibited. Violations such as <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with the FDA labeling requirements, false or misleading statements on a product&#146;s labeling, or <FONT STYLE="white-space:nowrap">non-compliant</FONT> nutrient declarations can render a product
misbranded. In addition, violations such as inclusion of prohibited or dangerous ingredients, production in facilities that do not comply with the cGMP requirements, or production under insanitary conditions can render a product adulterated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a dietary supplement product can become adulterated if it includes a new dietary ingredient and the product does not comply with
the requirements for new dietary ingredients. A new dietary ingredient is a dietary ingredient that was not marketed in the United States before October&nbsp;15, 1994. Under the DSHEA, manufacturers and distributors of dietary supplements containing
new dietary ingredients must submit a new dietary ingredient notification, unless the ingredient has been present in the food supply as an article used for food in a form in which the food has not been chemically altered. A new dietary ingredient
notification must provide the FDA with evidence of a &#147;history of use or other evidence of safety&#148; that establishes that use of the dietary ingredient &#147;will reasonably be expected to be safe.&#148; A new dietary ingredient notification
must be submitted to the FDA at least 75 days before the new dietary ingredient can be marketed. There can be no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assurance that the FDA will accept evidence purporting to establish the safety of any new dietary ingredients that we may want to market, and the FDA&#146;s refusal to accept such evidence could
prevent the marketing of such dietary ingredients. In addition, there is no definitive list of dietary ingredients that are exempt from the new dietary ingredient notification requirement. There is no guarantee that the FDA will agree with us that
all of our dietary ingredients comply with this requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining whether a product should be regulated as a dietary
supplement, the FDA reviews the objective intent of a product&#146;s manufacturer and/or distributor, as evidenced by the manufacturer and/or distributor&#146;s expressed or implied labeling claims, advertising matter, and oral and written
statements, to determine the product&#146;s classification. The FDA may classify a product as a drug, food, or supplement depending on the objective intent. For example, claims to cure diseases can render a product a drug that is subject to
FDA&#146;s drug requirements, such as the requirement to submit to the FDA a new drug application prior to marketing the product. However, certain &#147;health claims,&#148; which are claims that have been reviewed and approved by the FDA
associating a nutrient with risk-reduction, but not treatment, of a disease or health-related condition may be included on dietary supplement product&#146;s labeling. In addition, &#147;statements of nutritional support,&#148; including <FONT
STYLE="white-space:nowrap">so-called</FONT> &#147;structure/function claims,&#148; can be included in labeling without the FDA&#146;s review of the statement. Such statements may describe how a particular dietary ingredient affects the structure,
function or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect the structure, function or well-being of the body, but such statements may not claim that a dietary supplement will reduce the risk or
incidence of a disease unless such claim has been reviewed and approved by the FDA. A company that uses a statement of nutritional support in labeling must possess <FONT STYLE="white-space:nowrap">evidence-at</FONT> the time that the statement is
made-substantiating that the statement is truthful and not misleading. Such statements must be submitted to the FDA no later than thirty days after first marketing the product with the certification that the company possesses the necessary evidence
and must be accompanied by an <FONT STYLE="white-space:nowrap">FDA-mandated</FONT> label disclaimer tied to the statement, indicating that &#147;This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure
or prevent any disease.&#148; There is no assurance, however, that the FDA will agree with our positions on these matters, and it may interpret a claim as an unauthorized health claim, in which case we may not be able to use the claim for our
products, and we may be subject to enforcement actions stemming from the claims that render a dietary supplement misbranded or cause a product to become an unapproved new drug under the FDCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As authorized by the FDCA, the FDA has adopted and implemented cGMPs, specifically for dietary supplements. These cGMPs impose extensive
process controls on the manufacture, holding, labeling, packaging, and distribution of dietary supplements and the components of dietary supplements. They require that every dietary supplement be made in accordance with a master manufacturing record
with all dietary ingredients verified by identity testing before use; that each step in manufacture, holding, labeling, packaging, and distribution be defined with written standard operating procedures, monitored, and documented; and that any
deviation in manufacture, holding, labeling, packaging, or distribution be contemporaneously documented, assessed by a quality-control expert, and corrected through documented corrective action steps (whether through an intervention that restores
the product to the specifications in the master manufacturing record or to document destruction of the <FONT STYLE="white-space:nowrap">non-conforming</FONT> product). The cGMPs are designed to ensure documentation, including testing results that
confirm the identity, purity, quality, strength, and composition of finished dietary supplements. In addition, cGMPs require a company to make and keep written records of every product complaint that is related to cGMPs. The regulations directly
affect all who manufacture the dietary supplements that we sell and our distribution of dietary supplements. The FDA may deem any dietary supplement adulterated, whether presenting a risk of illness or injury or not, based on a failure to comply
with any one or more process controls in the cGMP regulations. If deemed adulterated, a dietary supplement may not be lawfully distributed and may have to be recalled from the market. It is possible that the FDA will find one or more of the process
controls for our products to be inadequate and may require corrective action, may render any one or more of the dietary supplements we sell unlawful for sale, or may result in a judicial order that may impair our ability to market and sell dietary
supplements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also requires product labels to include phone numbers or addresses for reporting of
adverse events, and requires serious adverse event reporting for all supplements. An &#147;adverse event&#148; is defined by statute to include &#147;any health-related event associated with the use of a dietary supplement that is adverse.&#148;
While all adverse event complaints received must be recorded in accordance with the cGMPs discussed above, only serious adverse events must be reported to the FDA. A &#147;serious adverse event&#148; is an adverse event that: results in death, a
life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect; or requires, based on reasonable medical judgment, a medical or surgical intervention to prevent
an outcome described above. When a manufacturer, packer, or distributor whose name appears on the product label of a dietary supplement receives any report of a serious adverse event associated with the use of the dietary supplement in the United
States, the company must submit a &#147;serious adverse event report&#148; on MedWatch Form 3500A. The report must be filed within 15 business days of receipt of information regarding the adverse event. All adverse event reports, whether serious or
not, must be recorded and kept in company records under the cGMP rules. A company must maintain records of each report of any adverse event (both serious and <FONT STYLE="white-space:nowrap">non-serious)</FONT> for a minimum of six years. These
records should include any documents related to the report, including: the company&#146;s serious adverse event report to the FDA with attachments; any new medical information about the serious adverse event received; all reports to the FDA of new
medical information related to the serious adverse event; and any communications between the company and any other person(s) who provided information related to the adverse event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, the FDA also has the authority to inspect facilities that manufacture, process, pack, hold, or otherwise further the
introduction of dietary supplement products into interstate commerce. The FDA typically reviews the facilities and the products that are manufactured, processed, packed, or held in those facilities for compliance with the requirements under the FDCA
and its implementing regulations. If the FDA finds <FONT STYLE="white-space:nowrap">non-compliance</FONT> during the inspection, the FDA may issue a Form 483 Notice of Inspectional Observations that lists and explains the deficiencies that the FDA
identified during the inspection. Facilities then must implement corrective actions and provide responses to the FDA; if the FDA finds the corrective actions and responses to be satisfactory, the FDA will close out the inspection. <FONT
STYLE="white-space:nowrap">Non-compliance</FONT> with any of the FDA requirements under the FDCA can result in enforcement actions, including civil and criminal penalties. The FDA may send warning letters, untitled letters, or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">it-has-come-to-our-attention</FONT></FONT></FONT></FONT></FONT> letters, make public
announcements about illegal products, require mandatory or recommend voluntary recalls, or it may place the violative company and its products on the Import Alert, thereby stopping all applicable incoming shipments. For more serious or repeat
violations, the FDA may seek more drastic remedies such as seizures, disgorgement, or injunctions. Criminal violations can result in fines or incarceration. Enforcement actions from the FDA can severely interfere with a company&#146;s ability to
conduct its business and can also negatively impact the company&#146;s ability to operate in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC requires advertising for
any product, including dietary supplements, to be truthful, not misleading, and properly substantiated. For advertisements relating to dietary supplements, the FDA typically requires a substantiation standard of competent and reliable scientific
evidence for all express and implied claims. The FTC has promulgated policies and guidance that apply to advertising for food and dietary supplements. Advertisers must possess adequate substantiation for the product claims before disseminating
advertisements. The FTC also regulates other aspects of consumer purchases including, but not limited to, promotional offers, telemarketing, continuity plans, and &#147;free&#148; offers. The FTC has instituted numerous enforcement actions against
dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in warning letters, consent decrees and the payment
of civil penalties and/or restitution by the companies involved. Should the FTC determine that our claims are false or misleading or unsubstantiated, we could be subject to FTC enforcement action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is also subject to regulation under various state and local laws that include provisions governing, among other things, the
formulation, manufacturing, packaging, labeling, advertising and distribution of dietary supplements. For example, under Proposition 65 in the State of California, there is a list of substances that are deemed to pose a risk of carcinogenicity or
birth defects at or above certain levels. If any such ingredient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in California only if accompanied by a prominent warning label alerting consumers that
the product contains an ingredient linked to cancer or birth-defect risk. Private actions as well as California attorney general actions may be brought against <FONT STYLE="white-space:nowrap">non-compliant</FONT> parties and can result in
substantial costs and fines. In addition, there are state consumer protection statutes that allow consumers to bring lawsuits against marketers of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products. For example, California has a law
called the &#147;Consumers Legal Remedies Act&#148; (Cal. Civ. Code &#167; 1750 et seq.) that allows private parties to assert a class action claim for false or deceptive advertising. It is typically asserted in combination with claims for false
advertising and unfair competition under the California Business and Professions Code. California law firms specializing in this type of consumer class action claims have recently been targeting dietary supplement and OTC homeopathic drug makers and
sellers of products sold in California, claiming injury based on the products&#146; failure to deliver results as claimed in product labeling and promotion. Many other states, such as New York and Illinois, have similar laws and we may become the
subject of lawsuits filed under such laws, which tend to be plaintiff-friendly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress continues to enact new laws or amend the
existing laws that are applicable to some of our business. From time to time in the future, we may become subject to additional laws or regulations administered by the FDA; the FTC; or by other federal, state, or local regulatory authorities; to the
repeal of laws or regulations, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals or interpretations, and we cannot predict what effect additional
governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be
reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel or other new requirements. Any such
developments could have a material adverse effect on our business. There can be no assurance that, if more stringent statutes are enacted for dietary supplements, or if more stringent regulations are promulgated, we will be able to comply with such
statutes or regulations or that compliance won&#146;t first require us to incur substantial expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Compounded Drug Products
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;503B Outsourcing Facilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners who are trained in the Biote Method may prescribe bioidentical compounded hormone pellets prepared by independent
third-party compounding pharmacies, known as outsourcing facilities. Outsourcing facilities must be registered with the FDA under Section&nbsp;503B of the FDCA. Outsourcing facilities are primarily regulated by Section&nbsp;503B, however,
outsourcing facilities may also be subject to state statutes and regulations governing the practice of pharmacy, and the Controlled Substances Act (the &#147;CSA&#148;) and corresponding state-controlled substance regulations, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Food, Drug</I><I></I><I>&nbsp;&amp; Cosmetic Act</I>. Under Section&nbsp;503B of the FDCA, outsourcing facilities are permitted to compound
large quantities of drug formulations pursuant to a practitioner&#146;s order, and to distribute drug formulations without a patient-specific prescription for office administration or for the purpose of dispensing. Section&nbsp;503B includes
requirements regarding registration and reporting, use of bulk drug substances, a prohibition on wholesaling and compounding copies of <FONT STYLE="white-space:nowrap">FDA-approved</FONT><I> </I>drugs, and certain requirements for labeling, among
others. Entities registering as outsourcing facilities are subject to cGMP requirements and regular FDA inspections, among other requirements. FDA has issued a series of draft and final guidance which further explain FDA&#146;s positions on the
requirements of certain portions of Section&nbsp;503B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs compounded by outsourcing facilities in compliance with Section&nbsp;503B
are exempt from the new drug approval requirements of the FDCA and certain labeling requirements. This means that FDA does not verify the safety or effectiveness of compounded products distributed by outsourcing facilities; rather Section&nbsp;503B
of the FDCA establishes standards for manufacturing processes and controls to ensure drug quality applicable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outsourcing facilities. Drugs compounded by outsourcing facilities also lack an FDA finding of manufacturing quality before such drugs are marketed. Section&nbsp;503B outsourcing facilities are
subject to FDA inspection and are inspected by FDA on a risk-based schedule. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> with FDA requirements can result in FDA enforcement actions. FDA may send warning letters or untitled letters; make
public announcements about illegal products; request recalls; or it may place the violative company and its products on Import Alert, thereby stopping all applicable incoming shipments. For more serious or repeat violations, FDA may seek more
drastic remedies such as seizures, disgorgement, injunctions, or prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>State Regulation</I>. Outsourcing facilities are
primarily regulated by the FDCA, however, certain states impose state licensing requirements on outsourcing facilities and may, where applicable, require that such<I> </I>facilities comply with applicable state statutes and regulations governing the
preparation of drug products. Depending on the state, outsourcing facilities may be subject to further inspection by state regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Controlled Substance Act</I>. The CSA regulates the manufacture, importation, possession, use, and distribution of certain substances.
These controlled substances are categorized into one of five schedules, and their placement is based upon the substance&#146;s medical use, potential for abuse, and safety or dependence liability. Controlled substances are subject to extensive
regulation by the DEA, as well as state and local regulatory agencies, regarding procurement, manufacture, storage, shipment, sale, and use. These regulations add additional complications and costs to the storage, use, sale and distribution of such
products. All pharmacies, including outsourcing facilities, that handle controlled substances must register with DEA and ensure compliance with the CSA as it relates to the controlled substances in the pharmacy&#146;s possession. All pharmacies,
including outsourcing facilities, that are registered with DEA are subject to inspection by DEA. Failure to comply with the CSA may result in civil and criminal liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Medical Devices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, FDA defines a medical device as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or
other similar or related article, including any component part or accessory, which is (i)&nbsp;intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other
animals, or (ii)&nbsp;intended to affect the structure or any function of the body of man or other animals and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and
which is not dependent upon being metabolized for the achievement of any of its primary intended purposes. Medical devices are subject to extensive regulation by the FDA under the FDCA and its implementing regulations, and other federal and state
statutes and regulations. The laws and regulations govern, among other things, medical device design and development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, <FONT STYLE="white-space:nowrap">pre-market</FONT>
clearance, authorization or approval, establishment registration and product listing, product manufacturing, product packaging and labeling, product storage, advertising and promotion, product distribution, recalls and field actions, servicing and
post-market clinical surveillance. A number of U.S. states also impose licensing and compliance regimes on companies that manufacture or distribute prescription devices into or within the state. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Trocar Convenience Kits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA classifies medical devices into three classes based on risk. The level of regulatory control increases from Class&nbsp;I (lowest risk),
to Class&nbsp;II (moderate risk), to Class&nbsp;III (highest risk). Marketing of most Class&nbsp;II and III medical devices within the United States must be preceded either by <FONT STYLE="white-space:nowrap">(a)&nbsp;pre-market</FONT> notification
and FDA clearance pursuant to Section&nbsp;510(k) of the FDCA or (b)&nbsp;the granting of <FONT STYLE="white-space:nowrap">pre-market</FONT> approval (&#147;PMA&#148;). Both 510(k) notifications and PMA applications must be submitted to the FDA with
significant user fees, although reduced fees for small businesses are available. Class&nbsp;I devices are generally exempt from <FONT STYLE="white-space:nowrap">pre-market</FONT> review and notification, as are some moderate-risk Class&nbsp;II
devices. Most Class&nbsp;II devices are subject to the requirement to submit a 510(k) notification and receive a clearance for marketing. Manufacturers of all classes of devices must comply with the FDA&#146;s Quality System Regulation
(&#147;QSR&#148;), establishment registration, medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
device listing, labeling requirements, and medical device reporting (&#147;MDR&#148;) regulations, which are collectively referred to as medical device general controls. Class&nbsp;II devices may
also be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling. Some Class&nbsp;I and Class&nbsp;II devices can be exempted by regulation from the requirement of compliance
with substantially all of the QSR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations for medical devices include requirements to (a)&nbsp;register medical devices
establishments and (b)&nbsp;list marketed medical devices in the FDA medical device database. We are registered with FDA for our facility as a repackager/relabeler and a specification developer and our Class&nbsp;I disposable and reusable trocars
which are included in convenience kits for sale to our customers are listed on FDA&#146;s device database. We currently market only disposable trocar convenience kits. The convenience kits include commercially available and sourced disposable trocar
with obdurator and tip protector; a sterile tray; sterile, latex free, CSR wrap; a medicine cup; latex free gloves, a Syringe and needles; alcohol prep pad; chlorhexidine gluconate and isopropyl alcohol skin antiseptic swab stick; compound benzoin
tincture vial; a fenestrated drape; gauze dressings; a plastic forceps; a scalpel, tape strips, and transparent dressing. These convenience kits are assembled by Medline Industries, LP, with the components, including the trocars, being manufactured
by various other component suppliers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;convenience kit&#148; is defined in 21 CFR 801.3 as &#147;two or more different medical
devices packaged together for the convenience of the user.&#148; FDA interprets this to mean a convenience kit is a device that contains two or more different medical devices packaged together and intended to remain packaged together and not to be
replaced, substituted, repackaged, sterilized, or otherwise processed or modified before being used by an end user. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most medical devices,
including the devices within a convenience kit, must undergo <FONT STYLE="white-space:nowrap">pre-market</FONT> review by and receive clearance, authorization, or approval from the FDA prior to commercialization, unless the device is of a type
exempted from such review by statute, regulation, or an FDA exercise of enforcement discretion. However, if a convenience kit falls under enforcement discretion such that it is not required to obtain a premarket clearance, the convenience kit must
not modify the intended use(s) of the individual kit components. If the labeling of the kit suggests an intended use for components that differs from the approved uses, the FDA may require premarket review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under FDA&#146;s Convenience Kits Interim Regulatory Guidance, FDA exercises enforcement discretion and thereby does not require premarket
clearance for convenience kits, as it is FDA&#146;s current thinking that such clearance may not be necessary to ensure protection of the public health. Accordingly, unless and until there is formal rulemaking on this issue, FDA intends to exercise
its enforcement discretion, i.e. not require 510(k) clearance, for convenience kits if they are consistent with the &#147;Types of Convenience Kits&#148; list. To qualify for the enforcement discretion guidance and not be required to obtain
premarket clearance, these kits must consist of components that do not alter the intended use of the individual kit components; only contain components that are legally marketed preamendments devices, exempt from premarket notification, or have been
found to be substantially equivalent through premarket notification process; and where the assembler/manufacturer is able to reasonably conclude that any further processing of the kit and its components does not significantly affect the safety or
effectiveness of any of its components. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>State Oversight of Convenience Kits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of convenience kits is also regulated by certain states, some of which impose state licensure requirements as a resident or
nonresident distributor. That is, even if a facility does not handle the physical distribution of the convenience kit, the facility could still be required to obtain a state distributor license if the facility causes the convenience kit to be
distributed or furthers the marketing of the convenience kit. We cause the convenience kits to be distributed and further the marketing of the same, therefore, we hold a resident device distributor license with the Texas Department of State Health
Services. We also cause the distribution of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convenience kits into several other states, some of which require Biote, as a nonresident facility, to hold a nonresident device distributor license. Accordingly, we also hold all applicable and
required nonresident distributor licenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Decision Support Software </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As stated above, our proprietary CDS provides Biote-certified practitioners with information from published literature and clinical guidelines
to assist practitioners in evaluating patient-specific treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA has become increasingly active in addressing the regulation
of computer software functions intended for use in healthcare settings. FDA has the authority to regulate a software function as a medical device if it falls within the definition of a &#147;device&#148; under the FDCA. However, FDA has exercised
enforcement discretion for software said to be &#147;low risk.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 21st Century Cures Act clarified FDA&#146;s authority to
regulate software functions as medical devices by amending the definition of &#147;device&#148; in the FDCA to exclude certain software functions, including clinical decision support software that meet certain criteria. In December 2017, FDA issued
a draft guidance document describing FDA&#146;s proposed interpretation of the exemption under the 21st Century Cures Act for CDS software. FDA issued a revised draft of this CDS software guidance document in September 2019. Under the 21st Century
Cures Act and FDA CDS guidance, certain software functions are excluded from FDA&#146;s definition of &#147;device&#148; when they meet all the following criteria: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not intended to acquire, process, or analyze a medical image or a signal from an in vitro diagnostic device or
a pattern or signal from a signal acquisition system; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">intended for the purpose of displaying, analyzing, or printing medical information about a patient or other
medical information (such as peer-reviewed clinical studies and clinical practice guidelines); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">intended for the purpose of supporting or providing recommendations to a healthcare professional about
prevention, diagnosis, or treatment of a disease or condition; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">intended for the purpose of enabling such healthcare professional to independently review the basis for such
recommendations that such software presents so that it is not the intent that such healthcare professional rely primarily on any of such recommendations to make a clinical diagnosis or treatment decision regarding an individual patient.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe that our technologies and software are not subject to active FDA regulation, there is a risk that
the FDA could disagree. There is also a risk that FDA could finalize its guidance for CDS software in such a way that it excludes our software and technologies from the scope of the CDS software exclusion under the 21st Century Cures Act.
Additionally, on September&nbsp;28, 2022, the FDA published a final guidance, Clinical Decision Support Software, Guidance for Industry and Food and Drug Administration Staff, that significantly narrows the CDS exception set forth under the 21st
Century Cures Act. Further, since this final guidance, the FDA has begun to issue warnings for CDS products that are not exempt under the 21st Century Cures Act. For example, on September&nbsp;19, 2023, the FDA issued a warning letter to Abiomed
Inc., in which it explained that Abiomed&#146;s software was an adulterated and misbranded medical device because the agency disagreed with Abiomed&#146;s assessment that the software product was <FONT STYLE="white-space:nowrap">non-device</FONT>
CDS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines that any of our current or future services, technologies or software applications, including our CDS software,
are regulated by the FDA as medical devices, we would become subject to various statutes, regulations and policies enforced by the FDA and other governmental authorities, including both <FONT STYLE="white-space:nowrap">pre-market</FONT> and
post-market requirements, and we would need to bring the affected services, technologies, and/or software into compliance with such requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Advertising </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC regulates advertising pursuant to its authority to prevent &#147;unfair or deceptive acts or practices in or affecting commerce&#148;
under the Federal Trade Commission Act (the &#147;FTCA&#148;). The FTC will find an advertisement to be deceptive if it contains a representation or omission of fact that is likely to mislead consumers acting reasonably under the circumstances, and
the representation or omission is material and if the advertiser does not possess and rely upon a reasonable basis, such as competent and reliable evidence, substantiating the claim. The FTC may attack unfair or deceptive advertising practices
through either an administrative adjudication or judicial enforcement action, including preliminary or permanent injunction. The FTC may also seek consumer redress from the advertiser in instances of dishonest or fraudulent conduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA regulates the advertising of prescription drugs. Promotional materials for prescription compounded drugs may not be false
or misleading. Failure to comply with FDA requirements can result in a prescription drug being deemed misbranded under the FDCA. This can result in administrative or judicial penalties, including civil penalties, injunctions, or in extreme
instances, criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, states have similar unfair and deceptive acts and practices statutes (sometimes called
&#147;little FTC Acts&#148; or &#147;UDAP&#148; statutes). They vary, but often the state regulator can seek monetary relief along with an order of discontinuance. Under certain state UDAP laws, consumers can bring private claims against companies
who disseminate false or deceptive advertising claims. Although those UDAP statutes often provide for statutory damages in the case of individual consumers, more often such cases take the form of class actions, which can lead to damages awards and
awards of attorney&#146;s fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, federal and state laws also give causes of action to competitors to seek injunctive and monetary
relief for false and misleading advertising statements. Any person who is or may be likely to be damaged by false or misleading advertising statements may bring an action in federal court pursuant to the Lanham Act, &#167; 43(a). Proven damages may
be trebled and attorney&#146;s fees and costs may be awarded in appropriate cases. There are state analogs of this sort of unfair competition statute as well. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Practice of Medicine Laws; Fee Splitting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We contract with Biote-certified practitioners to provide them with access to our services. These contractual relationships are subject to
various state laws that prohibit fee splitting or the practice of a healthcare profession by lay entities or persons that are intended to prevent unlicensed persons from interfering with or influencing a practitioner&#146;s professional judgment,
known as the corporate practice of medicine. Activities other than those directly related to the delivery of healthcare may be considered an element of the practice of medicine in many states. Under the corporate practice of medicine prohibition of
certain states, decisions and activities that may be performed by unlicensed individuals or entities and perceived as impacting the clinical decision-making of licensed professionals such as policy and procedure development, contracting, setting
rates and the hiring and management of clinical personnel may implicate the restrictions on the corporate practice of medicine. Similarly, certain compensation arrangements between licensed professionals and unlicensed individuals and entities can
implicate state <FONT STYLE="white-space:nowrap">fee-splitting</FONT> prohibitions, which prohibit providers from sharing a portion of their professional fees collected with third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">State corporate practice of medicine and <FONT STYLE="white-space:nowrap">fee-splitting</FONT> laws and rules vary from state to state and are
not always consistent across various healthcare professions within the same state. In addition, these requirements are subject to broad interpretation and enforcement by state regulators. Some of these requirements may apply to our business even if
we do not have a physical presence in the state, based solely on our relationship with a practitioner licensed in the state. Thus, regulatory authorities or other parties, including Biote-certified practitioners, may assert that we are engaged in
the corporate practice of medicine or that our contractual arrangements with Biote-certified practitioners or their practice groups constitute unlawful fee splitting. In such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
event, failure to comply could lead to adverse judicial or administrative action against us and/or Biote-certified practitioners, civil, criminal or administrative penalties, receipt of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cease-and-desist</FONT></FONT> orders from state regulators, loss of provider licenses, the need to make changes to the terms of engagement of our Biote-certified practitioners that
interfere with our business, and other materially adverse consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Licenses and Accreditations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, as well as the Biote-certified practitioners, may be subject to professional and private licensing, certification and accreditation
requirements. These include, but are not limited to, requirements imposed by Medicare, Medicaid, state licensing authorities, voluntary accrediting organizations and third-party private payors. Receipt and renewal of such licenses, certifications
and accreditations are often based on inspections, surveys, audits, investigations or other reviews, some of which may require affirmative compliance actions by us to ensure we are accurately representing our services that could be burdensome and
expensive. The applicable standards may change in the future. There can be no assurance that we will be able to maintain all necessary licenses or certifications in good standing or that they will not be required to incur substantial costs in doing
so. The failure to maintain all necessary licenses, certifications and accreditations in good standing, or the expenditure of substantial funds to maintain them, could have an adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. State Healthcare Fraud and Abuse Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many states, including certain states in which we conduct our business, prohibit any person from offering, paying, soliciting or receiving any
remuneration, directly or indirectly, in cash or in kind, for the referral of patients or other items or services to or with licensed healthcare providers, subject to limited exceptions. The scope of these laws and the interpretations of them vary
by jurisdiction and are enforced by local courts and regulatory authorities, each with broad discretion. Some state fraud and abuse laws apply to items or services reimbursed by any third-party payor, including commercial insurers, some apply only
to state healthcare program payors, while other state laws apply regardless of payor, including funds paid out of pocket by a patient. A determination of liability under such state fraud and abuse laws could result in fines and penalties and
restrictions on our ability to operate in these jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits the knowing and willful offer,
payment, solicitation or receipt of any form of remuneration to induce the referral of a patient or the purchase, lease or order (or the arranging for or recommending of the purchase, lease or order) of healthcare items or services paid for by
federal healthcare programs, including Medicare or Medicaid. A violation does not require proof that a person had actual knowledge of the statute or specific intent to violate the statute, and court decisions under the Anti-Kickback Statute have
consistently held that the law is violated where one purpose of a payment is to induce or reward referrals. Violation of the federal Anti-Kickback Statute could result in felony conviction, administrative penalties, liability (including penalties)
under the False Claims Act, 31 U.S.C. &#167; 3729 (the &#147;False Claims Act&#148;) and/or exclusion from federal healthcare programs. A number of states have enacted anti-kickback laws that sometimes apply not only to state-sponsored healthcare
programs, but also to items or services that are paid for by private insurance and <FONT STYLE="white-space:nowrap">self-pay</FONT> patients. State anti-kickback laws can vary considerably in their applicability and scope and sometimes have fewer
statutory and regulatory exceptions than does the federal law. We consider the importance of anti-kickback laws when structuring company operations and relationships. That said, we cannot ensure that the applicable regulatory authorities will not
determine that some of our arrangements with physicians violate the Anti-Kickback Statute or other applicable laws. An adverse determination could subject us to different liabilities, including criminal penalties, civil monetary penalties and
exclusion from participation in Medicare, Medicaid or other healthcare programs, any of which could have a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Civil Monetary Penalties Law, a person (including an organization) is prohibited from knowingly presenting or causing to be
presented to any United States officer, employee, agent, or department, or any state agency, a claim for payment for medical or other items or services where the person knows or should know </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(a)&nbsp;the items or services were not provided as described in the coding of the claim, (b)&nbsp;the claim is a false or fraudulent claim, (c)&nbsp;the claim is for a service furnished by an
unlicensed physician, (d)&nbsp;the claim is for medical or other items or service furnished by a person or an entity that is in a period of exclusion from the program, or (e)&nbsp;the items or services are medically unnecessary items or services.
Penalties range from $20,000 to $100,000 per violation up to $20,000 per claim, treble damages, and exclusion from federal healthcare programs. The Civil Monetary Penalties Law also prohibits a person from transferring any remuneration to a Medicare
or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#146;s selection of a particular provider of Medicare or Medicaid payable items or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act imposes civil penalties for knowingly submitting or causing the submission of a false or fraudulent claim for
payment to a government-sponsored program, such as Medicare and Medicaid. Violations of the False Claims Act present civil liability of treble damages plus a penalty of at least $21,563 per false claim. The False Claims Act has
&#147;whistleblower&#148; or &#147;qui tam&#148; provisions that allow individuals to commence a civil action in the name of the government, and the whistleblower is entitled to share in any subsequent recovery (plus attorney&#146;s fees). Many
states also have enacted civil statutes that largely mirror the federal False Claims Act but allow states to impose penalties in a state court. The existence of the False Claims Act, under which <FONT STYLE="white-space:nowrap">so-called</FONT> qui
tam plaintiffs can allege liability for a wide range of regulatory noncompliance, increases the potential for such actions to be brought and has increased the potential financial exposure for such actions. These actions are costly and time-consuming
to defend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in the United States and some foreign jurisdictions there have been, and continue to be, several legislative and
regulatory changes and proposed reforms of the healthcare system in an effort to contain costs, improve quality, and expand access to care. These reform initiatives may, among other things, result in modifications to the aforementioned laws and/or
the implementation of new laws affecting the healthcare industry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. State and Federal Health Information Privacy and Security
Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal identifiable
information (&#147;PII&#148;), including health information. HIPAA is a federal law that required the creation of national standards to protect sensitive patient health information from being disclosed without the patient&#146;s consent or
knowledge. In particular, HIPAA establishes privacy and security standards that limit the use and disclosure of PHI, and require the implementation of administrative, physical, and technical safeguards to ensure the confidentiality, integrity and
availability of PHI in electronic form. Biote-certified practitioners and their clinics may be regulated as covered entities under HIPAA. We may be a business associate of our covered entity clients when we are working on behalf of our covered
entity clients and providing services to those clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent we qualify as a business associate, we will also be regulated by
HIPAA and may be required to provide satisfactory written assurances to our covered entity clients through written business associate agreements that we will provide our services in accordance with HIPAA. Failure to comply with these contractual
agreements could lead to loss of clients, contractual liability to our clients, and direct action by the U.S. Department of Health and Human Services (&#147;HHS&#148;) Office for Civil Rights, including monetary penalties. Violations of HIPAA may
result in significant civil and criminal penalties. Under the breach notification rule, covered entities must notify affected individuals without unreasonable delay in the case of a breach of unsecured PHI, which may compromise the privacy, security
or integrity of the PHI. In addition, notification must be provided to HHS and the local media in cases where a breach affects more than 500 individuals. Breaches affecting fewer than 500 individuals must be reported to HHS on an annual basis. HIPAA
also requires a business associate to notify its covered entity clients of breaches by the business associate without unreasonable delay and no later than 60 days from the discovery of the breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states. While HIPAA does not
create a private right of action that would allow individuals to sue in civil </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
court for a HIPAA violation, its standards have been used as the basis for the duty of care in state civil suits, such as those for negligence or recklessness in misusing personal information. It
also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. In light of the HIPAA Omnibus Final Rule,
recent enforcement activity, and statements from HHS, we expect increased federal and state HIPAA privacy and security enforcement efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many states where we operate and where patients treated by Biote-certified practitioners reside also have laws that protect the privacy and
security of sensitive and personal information, including health information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws may be similar to or even more protective than
HIPAA and other federal privacy laws. For example, the laws of the State of California that govern personal information and medical information such as the California Consumer Protection Act or the California Confidentiality of Medical Information
Act, in which we operate, are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to, in addition to HIPAA. In certain cases, it may be necessary to modify our planned
operations and procedures to comply with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but, unlike HIPAA, some may afford private rights of action to individuals who believe their
personal information has been misused. In addition, state laws are changing rapidly, and there have been proposals for a new federal privacy law or federal breach notification law, to which we may be subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to HIPAA and state health information privacy laws, we may be subject to other state and federal privacy laws, including laws that
prohibit unfair privacy and security acts or practices and deceptive statements about privacy and security and laws that place specific requirements on certain types of activities, such as data security and texting. The FTC and states&#146;
attorneys general have brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act and similar state laws. FTC jurisdiction in data privacy and security cases is concurrent with
the HHS Office for Civil Rights&#146; jurisdiction with respect to HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, there have been a number of well-publicized
data breaches involving the improper use and disclosure of PII and PHI. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data
breach, such as providing prompt notification of the breach to affected individuals and state officials and provide credit monitoring services and/or other relevant services to impacted individuals. In addition, under HIPAA and pursuant to the
related contracts that we may enter into with Biote-certified practitioners or Biote-partnered clinics who are covered entities, we must report breaches of unsecured PHI to them following discovery of the breach within a set timeframe. Notification
must also be made in certain circumstances to affected individuals, federal and state authorities, media, and other relevant parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course
of business. Although the results of litigation and claims are inherently unpredictable and uncertain, we are not currently a party to any legal proceedings the outcome of which, if determined adversely to us, are believed to, either individually or
taken together, have a material adverse effect on our business, operating results, cash flows or financial condition. Regardless of the outcome, litigation has the potential to have an adverse impact on us due to defense costs and possible
settlement expenses, diversion of management resources and other factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Donovitz Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is currently involved in litigation described below with one of the Company&#146;s stockholders, Dr.&nbsp;Gary&nbsp;S. Donovitz
(&#147;Donovitz&#148;) (the &#147;Donovitz Litigation&#148;). The outcome of the Donovitz Litigation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the ultimate liability, if any, which may arise
therefrom. In addition, litigation and related matters are costly and may divert the attention of the Company&#146;s management and other resources that would otherwise be engaged in other activities. However, the Donovitz Litigation is not expected
to have a material adverse effect on the consolidated results of operations or financial position of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2022,
Donovitz sued Haymaker Sponsor, LLC, the Company&#146;s outside legal counsel, and certain Company executive officers and directors in the District Court of Dallas County, Texas (the &#147;Donovitz Dallas Action&#148;), generally alleging fraud,
fraudulent inducement, negligent misrepresentation, a breach of the covenant of good faith and fair dealing, breaches of fiduciary duties, and/or aiding and abetting those alleged breaches against the defendants (the &#147;Donovitz Claims&#148;).
Donovitz subsequently dismissed without prejudice the Donovitz Claims brought in the Donovitz Dallas Action, and the Court entered an order of dismissal without prejudice on March&nbsp;28, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;11, 2022, the Company sued Donovitz in the Delaware Court of Chancery, pursuing injunctive relief to prevent Donovitz from
proceeding with the litigation in the Donovitz Dallas Action in Texas (the &#147;First Delaware Action&#148;). The Company seeks to enforce (a)&nbsp;the Company&#146;s certificate of incorporation, which mandates that stockholders must bring certain
actions, including some or all of the Donovitz Claims, exclusively in Delaware, and (b)&nbsp;the Business Combination Agreement, by which Donovitz consented to the exclusive jurisdiction of the Delaware Court of Chancery and agreed that Delaware law
governs any related claims, including some or all of the Donovitz Claims. Pending a ruling from the Delaware Court of Chancery, Donovitz agreed to stay all answer dates in the Donovitz Dallas Action. Then, on March&nbsp;23, 2023, Donovitz filed an
amended answer and counterclaims in the First Delaware Action generally reasserting the Donovitz Claims he had previously brought in the Donovitz Dallas Action. On August&nbsp;24, 2023, Donovitz filed amended counterclaims in the First Delaware
Action, again generally reasserting the Donovitz Claims previously brought in the Donovitz Dallas Action but also asserting derivative claims against the Company&#146;s directors. On October&nbsp;23, 2023, the Company filed its response to
Donovitz&#146;s amended counterclaims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;24, 2022, Donovitz sued the Company, including certain executive officers and
directors of the Company, in the Delaware Court of Chancery, seeking (a)&nbsp;a status quo order preventing the defendants from diluting any stockholder&#146;s equity or voting power, (b)&nbsp;an injunction requiring the defendants to convene a
special meeting of the stockholders, and (c)&nbsp;a request to either void a portion of the Company&#146;s Certificate of Incorporation or allow stockholders to elect directors to a vacancy on the board in accordance with Delaware General Corporate
Law (the &#147;Second Delaware Action&#148;). On September&nbsp;8, 2022, the Delaware Court of Chancery denied Donovitz&#146;s request for injunctive relief, determining that expedited proceedings and a status quo order were both unwarranted and
rejecting a mandated meeting of the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;2, 2022, the Company sued Donovitz, Lani Hammonds Donovitz, and Lani D.
Consulting in the District Court of Dallas County, Texas, seeking injunctive relief to enforce <FONT STYLE="white-space:nowrap">non-disparagement</FONT> obligations of that certain founder advisory agreement with Donovitz and the independent
contractor agreement with Lani Hammonds Donovitz, both of which were entered into by the subject parties in connection with the Business Combination (the &#147;Biote Dallas Action&#148;). The Company successfully obtained a temporary restraining
order to enforce the <FONT STYLE="white-space:nowrap">non-disparagement</FONT> obligations of Donovitz and Lani Hammonds Donovitz. The parties subsequently entered into an agreed order that the temporary restraining order will stay in effect until
the entry of a final judgment. On August&nbsp;23, 2022, the defendants filed an answer in the Biote Dallas Action, which included affirmative defenses to the Company&#146;s claims and certain counterclaims and third-party claims against certain
executive officers of the Company. On April&nbsp;12, 2023, Lani Hammonds Donovitz, individually and on behalf of Lani D Consulting, dismissed with prejudice all of her counterclaims and third-party claims in the Biote Dallas Action, and subsequently
agreed to a permanent injunction in favor of the Company, which was entered by the Court on April&nbsp;17, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the filing of the
Biote Dallas Action, the Company amended its claim in the Delaware Court of Chancery to also seek an injunction to prevent Donovitz from proceeding with certain of the affirmative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defenses, counterclaims, and third-party claims filed by the defendants on August&nbsp;23, 2022. On November&nbsp;4, 2022, the Delaware Court of Chancery denied that request for injunctive
relief, permitting the Biote Dallas Action and all defenses and claims asserted therein to proceed in Texas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A jury trial in the Biote
Dallas Action was to commence on September&nbsp;11, 2023, to address the Company&#146;s affirmative claim for breach of contract, request for a permanent injunction, as well as the counterclaims and third-party claims asserted by Donovitz. On
August&nbsp;17, 2023, Donovitz nonsuited without prejudice all of his counterclaims and third-party claims in the Biote Dallas Action, leaving only the Company&#146;s affirmative claim against Donovitz to be tried on September&nbsp;11, 2023. On
September&nbsp;8, 2023, three days before the scheduled trial in the Biote Dallas Action, Donovitz agreed to stipulate that he breached his contract, and Donovitz agreed to a partial judgment and the entry of a permanent injunction against him,
which was signed by the Court on September&nbsp;9, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sought recovery of its attorneys&#146; fees against Donovitz in a
jury trial that began on October&nbsp;30, 2023. On November&nbsp;2, 2023, the jury returned a verdict awarding the Company $4.7&nbsp;million plus the potential for an additional $0.2&nbsp;million for future fees, which constituted all of the
attorneys&#146; fees that the Company had sought against Donovitz in the Biote Dallas Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;16, 2023, Donovitz, as
trustee for the Gary S. Donovitz 2012 Irrevocable Trust, together with Biote Management, LLC, sued Biote Holdings, LLC and BioTE Medical, LLC in the Delaware Court of Chancery. Donovitz sought inspection of the books and records of Biote Holdings,
LLC. The parties stipulated to dismissal of BioTE Medical, LLC and agreed to stay the case pending completion of the parties&#146; scheduled mediation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2024, the Company and Donovitz, through mediation, executed a binding settlement term sheet to resolve all remaining
outstanding litigation with Donovitz. Pursuant to the settlement term sheet, the Company and other parties thereto have agreed to prepare and enter into a definitive settlement agreement, which will supersede the settlement term sheet and
substantially incorporate the terms thereof. Pursuant to the settlement term sheet, the Company will repurchase all of the Class&nbsp;A common units of Biote Holdings, LLC, the Class&nbsp;V common stock of Biote and the Class&nbsp;A common stock of
the Company, currently beneficially owned by Donovitz for approximately $76.9&nbsp;million in the aggregate. The Company will repurchase the shares over a three-year period commencing on the date the definitive settlement agreement is signed. In
addition, the Company and Donovitz have agreed to, among other things, (i)&nbsp;a customary mutual release of all claims arising out of or relating to the Donovitz Litigation, (ii)&nbsp;the termination of the founder advisory agreement, dated as of
May&nbsp;18, 2022, by and between Donovitz and BioTE Medical, LLC, (iii)&nbsp;two year <FONT STYLE="white-space:nowrap">non-compete</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements for Donovitz and (iv)&nbsp;the
negotiation of and entry into a voting agreement with customary terms acceptable to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to the &#147;Company,&#148; &#147;Biote,&#148; &#147;we,&#148;
&#147;us&#148;, or &#147;our&#148; refer to the business of the &#147;BioTE Companies&#148; prior to the business combination and to biote Corp. and its subsidiaries from and following the Business Combination in the present tense. Throughout this
section, unless otherwise noted, &#147;Holdings&#148; refers to BioTE Holdings, LLC and its consolidated subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The
following discussion and analysis provides information that management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. You should read this discussion and analysis in
conjunction with the accompanying consolidated financial statements and notes thereto included elsewhere in this registration statement. Certain amounts may not foot due to rounding. This discussion and analysis contains forward-looking statements
and involves numerous risks and uncertainties, including, but not limited to, those described under the sections entitled &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking Statements&#148; included elsewhere in this
registration statement. We assume no obligation to update any of these forward-looking statements except as required by law. Actual results may differ materially from those contained in any forward-looking statements. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate a high growth
practice-building business within the hormone optimization space. Similar to a franchise model, we provide the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to
optimize hormone levels using personalized solutions for their aging patient populations. The Biote Method is a comprehensive, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> practice building platform that
provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software,
and information regarding available HRT products, as well as digital and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> marketing support. We also sell a complementary Biote-branded line of dietary
supplements. By virtue of our historical performance over the past 12 years, we believe that our business model has been successful, remains differentiated, and is well positioned for future growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategy focuses on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Increase the number of Biote-certified practitioners</B>. Our primary objective in marketing to healthcare
providers is to inform them of the value in joining the Biote network. We accomplish this through provider referrals, a dedicated sales force, and through digital and traditional marketing channels. We target specific physicians based on their
specialty, prescribing data, demographic information and location match with our existing geographic footprint. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Grow the practice of our Biote-certified practitioners and Biote-partnered clinics</B>. When the practices of
our Biote-certified practitioners and Biote-partnered clinics grow, we grow. We help our Biote-certified practitioners and Biote-partnered clinics grow by, among other things: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing mentorship, practice management and marketing capability necessary to operate an efficient hormone
optimization practice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing high-quality Biote-branded dietary supplement products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing Biote-certified practitioners and Biote-partnered clinics a full array of wellness education and
marketing materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directing consumers that are actively seeking care to Biote-certified practitioners via the &#147;Find A
Provider&#148; feature on our company website; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">utilizing our growing digital outreach capabilities to connect with consumers seeking general information.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Increasing sales of Biote-branded dietary supplements</B>. Our Biote-branded dietary supplement line currently
includes 19 dietary supplements that we offer to our Biote-certified practitioners through our eCommerce site, efficiently leveraging our core Biote provider platform. Practitioners then <FONT STYLE="white-space:nowrap">re-sell</FONT> Biote-branded
dietary supplements to their patients, enabling patients to receive physician-guided therapies to manage the related effects of aging. In August 2021, we launched a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> eCommerce platform whereby practitioners can invite their patients to buy Biote-branded dietary supplements online via our online store.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The hormone pellet products used by Biote-certified practitioners are manufactured by third-party compounding
pharmacies and shipped directly to Biote-certified practitioners. Custody of the pellets is with Biote-certified practitioners. However, the pellets are recorded as inventory on our financial statements from the date of shipment until such time as
they are administered in a patient treatment as monitored and recorded in our BioTracker system as an additional service for administrative convenience of Biote-certified practitioners and Biote-partnered clinics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These products have a finite life ranging from six to twelve months. We assume the risk of loss due to expiration, damage or otherwise.
Additionally, the products offered in our Biote-branded dietary supplement portfolio are produced by third-party manufacturers located in the United States. Biote contracts with a third-party to provide warehousing,
<FONT STYLE="white-space:nowrap">co-packing</FONT> and logistics services for our Biote-branded dietary supplements. As such our consolidated balance sheets as of December&nbsp;31, 2023 and December&nbsp;31, 2022 reflect inventories relating to
these items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue was $185.4&nbsp;million and $165.0&nbsp;million, our net loss was $2.8&nbsp;million and our net income was
$1.3&nbsp;million, and our Adjusted EBITDA was $55.3&nbsp;million and $50.1&nbsp;million, for the years ended December&nbsp;31, 2023 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impact of Global Economic
Trends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global economic conditions have been challenging, with disruptions to, and volatility in, the credit and financial markets
in the U.S. and worldwide resulting from the effects of public health crises and otherwise. If these conditions persist and deepen, we could experience an inability to access additional capital or our liquidity could otherwise be impacted. If we are
unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs and/or other efforts. A recession or additional market corrections resulting from the impact of the
effects of global health crises, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, could materially affect our business and the value of our securities. The impact of global health crises and the related disruptions caused to
the global economy did not have a material impact on our business during the years ended December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally,
the recent trends of rising inflation may also materially adversely affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of our clinical trial materials and supplies, interest
rates and overhead costs may adversely affect our operating results. Rising interest and inflation rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable
terms, if at all, in the future. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates continue
to rise) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with global health crises and ongoing international conflicts such as the conflict between Russia
and Ukraine and the Israel-Hamas war, and employee availability and wage increases, which may result in additional stress on our working capital resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chief Financial Officer Transition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2024, the Company appointed Robert C. Peterson as Chief Financial Officer (principal accounting and principal financial
officer) of the Company. In connection with his appointment, the Company entered into an employment agreement with Mr. Peterson, dated as of January&nbsp;8, 2024, which provides for Mr. Peterson&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT>
employment as the Chief Financial Officer for a term commencing on January&nbsp;8, 2024 and continuing until terminated by either the Company or Mr. Peterson. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Samar Kamdar, the Company&#146;s prior Chief Financial Officer, transitioned out of his role, effective immediately. On January&nbsp;11, 2024,
Mr.&nbsp;Kamdar entered into an executive transition agreement with the Company, which provided that Mr.&nbsp;Kamdar would remain employed by the Company through February&nbsp;29, 2024, to assist with the transition and work on special projects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;26, 2022 (the &#147;Closing Date&#148;), BioTE Holdings, LLC (&#147;Holdings,&#148; inclusive of its direct and indirect subsidiaries, the &#147;BioTE Companies,&#148; and as to its members, the &#147;Members&#148;) completed a series of
transactions (the &#147;Business Combination&#148;) with Haymaker Acquisition Corp. III (&#147;Haymaker&#148;), Haymaker Sponsor III LLC (the &#147;Sponsor&#148;), BioTE Management, LLC, Dr.&nbsp;Gary&nbsp;S. Donovitz, in his individual capacity,
and Teresa S. Weber, in her capacity as the Members&#146; representative (in such capacity, the &#147;Members&#146; Representative&#148;) pursuant to the business combination agreement (the &#147;Business Combination Agreement&#148;) dated
December&nbsp;13, 2021. The Business Combination was accounted for as a common control transaction, in accordance with U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;). Under this method of accounting, Haymaker&#146;s
acquisition of the BioTE Companies was accounted for at their historical carrying values, and the BioTE Companies were deemed the predecessor entity. This method of accounting is similar to a reverse recapitalization whereby the Business Combination
was treated as the equivalent of the BioTE Companies issuing stock for the net assets of Haymaker, accompanied by a recapitalization. The net assets of Haymaker are stated at historical cost, with no goodwill or other intangible assets recorded.
Operations prior to the Business Combination are those of the BioTE Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, the
Company was organized in an umbrella <FONT STYLE="white-space:nowrap">partnership-C</FONT> corporation <FONT STYLE="white-space:nowrap">(&#147;Up-C&#148;)</FONT> structure in which the business of the Company is operated by Holdings and its
subsidiaries, and Biote&#146;s only material direct asset consists of membership interests in Holdings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business
Combination, on the Closing Date, BioTE Medical entered into a credit agreement with Truist Bank and Truist Securities, Inc. providing for (i)&nbsp;the Revolving Loans, a $50.0&nbsp;million senior secured revolving credit facility in favor of BioTE
Medical and (ii)&nbsp;the Term Loan, a $125.0&nbsp;million senior secured term loan facility in favor of BioTE Medical, which was borrowed in full at the Closing Date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generate revenue by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of
Biote-branded dietary supplements. Revenue generated from individual Biote-partnered clinics varies significantly due to many factors. including but not limited to, the tenure of practitioners as Biote-certified practitioners; the number of
certified practitioners in an individual clinic; the number of patients served by a clinic; the clinic&#146;s patient demographics; and the clinic&#146;s geographic location and population density. The master services agreements (&#147;MSAs&#148;)
we enter into with Biote-partnered clinics contain tiered pricing provisions for the management fees. These provisions provide for decreasing management fees owed to us based on the number of new patients treated. This can result in declines in
revenue we realize from management fees from existing Biote-partnered clinics unless these are offset by revenue generated from newly acquired Biote-partnered clinics which begin at higher fee levels under the MSA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue fluctuates in response to a combination of factors, including the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales volumes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the mix of male and female patients treated by Biote-certified practitioners, as treatment for males generates
more revenue per patient than treatment for females; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our overall product mix of dietary supplements sold; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of competition on market share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new Biote-partnered clinics acquired as customers, less any existing clinics lost as customers (&#147;net new
clinics&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">number of procedures performed by practitioners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical industry acceptance of hormone optimization generally as a solution to unmet medical needs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of business days in a particular reporting period, including as a result of holidays;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">weather disruptions impacting medical offices&#146; ability to maintain regular operating schedules;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of competition and competitive pricing strategies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">governmental regulations influencing our markets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">global and regional economic cycles. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, our MSAs require us to provide (1)&nbsp;initial training to practitioners on the Biote Method, (2)&nbsp;inventory management
services and (3)&nbsp;other contract-term marketing and practice development services (including recurring training and licenses of Biote IP). Historically, we have provided the optional free lease of reusable trocars by Biote-certified
practitioners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of our revenue originates from sales to clinic locations in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product revenue includes
both pellets, in connection with the service described above, and the related inventory management services provided to clinics. Product revenue is recognized at the point in time when the clinic obtains ownership of the pellet, which we determined
to be when the Biote-certified practitioner performs the procedure to implant the pellet into their patient. The consideration allocated to this performance obligation is a procedure-based service fee which we refer to as procedure revenue. Our
product revenue also includes revenue earned from sales of pellet insertion kits and Biote-branded dietary supplements. Revenue from the sale of pellet insertion kits and Biote-branded dietary supplements is recognized when the clinic or
clinic&#146;s patient (supplements only) obtains control of the product and is generally at the time of shipment from our distribution facility. Any shipping or handling fees paid by clinics are also recorded within product revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Service revenue is
revenue earned from fees paid by Biote-partnered clinics for training services and other contract term services pursuant to our MSAs. While the option to receive and right to use the reusable trocars through the term of the contract represents an
embedded lease, we have adopted the practical expedient within ASC 842 to combine the lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components and account for the combined component under ASC 606. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Biote Method arrangements, we recognize revenue for training and for management services over time. For initial training, progress is
measured by the number of training sessions completed, and for contract-term services, progress is measured on a time-elapsed basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The training completion and time-elapsed bases represent the most reliable measure of
transfer of control to the clinic for trainings and contract-term services, respectively. Revenue is deferred for amounts billed or received prior to delivery of the services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of service
revenue consists primarily of costs incurred to deliver training to Biote-partnered clinics. Cost of product revenues include the pass-through cost of pellets purchased from outsourcing facilities, the cost of pellet insertion kits and Biote-branded
dietary supplements purchased from manufacturing facilities, and the shipping and handling costs incurred to deliver these products to Biote-partnered clinics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in
corporate functions, such as finance and accounting, information technology, human resources, legal, and executive management. Also included are rent occupancy costs, office expenses, recruiting expenses, marketing and advertising expenses,
entertainment allocations, depreciation and amortization, share-based compensation, transaction related expenses, other general overhead costs, insurance premiums, professional service fees, research and development and costs related to regulatory
and legal matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, net consists primarily of cash and <FONT STYLE="white-space:nowrap">non-cash</FONT> interest under our Term Loan, commitment
fees for our unused Revolving Loans and interest income earned on our money market account and now matured short-term investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain (Loss) from
Change in Fair Value of Warrant Liability </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain (loss) from change in fair value of warrant liability consists of the change in
fair value of the warrant liability during the period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain (Loss) from Change in Fair Value of Earnout Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain (loss) from change in fair value of earnout liability consists of the change in fair value of the Member and Sponsor earnouts during the
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss from extinguishment of debt </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt consists of the remaining unamortized portion of the debt issuance costs related to the Bank of America Credit
Agreement (as defined below) written off upon repayment in connection with the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income / Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income and other expense consist of the foreign currency exchange gains and losses for sales denominated in foreign currencies and other
income or payments not appropriately classified as operating expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to federal and state income taxes in the United States and taxes in foreign jurisdictions in which we operate. We recognize
deferred tax assets and liabilities based on temporary differences between the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial reporting and income tax bases of assets and liabilities using statutory rates. We regularly assess the need to record a valuation allowance against net deferred tax assets if, based
upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the years ended December&nbsp;31, 2023 and 2022 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table and discussion below present our results for the years ended December&nbsp;31, 2023 and 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) from change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) from change in fair value of earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue for the year ended December&nbsp;31, 2023 increased $20.4&nbsp;million to $185.4&nbsp;million, or 12.4% compared to the year ended
December&nbsp;31, 2022. The increase was primarily driven by a $17.7&nbsp;million increase of procedure and Biote-branded dietary supplement revenue. Procedures performed increased 9.3% versus the prior year resulting in a $12.0&nbsp;million
increase in procedure revenue. During the year ended December&nbsp;31, 2023, the number of active clinics billed increased 14.1% over the year ended December&nbsp;31, 2022. Biote-branded dietary supplement sales increased 17.5% or $5.7&nbsp;million
over the same period in the prior year. Service revenue increased 52.8% over the same period in the prior year resulting from an increase in the number of training sessions during the year ended December&nbsp;31, 2023 compared to the year ended
December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost of revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the year ended December&nbsp;31, 2023 increased $3.3&nbsp;million, to $57.9&nbsp;million, or 6.1% compared to the year
ended December&nbsp;31, 2022. The increase was primarily due to the net impact of higher </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
volumes at sustained unit costs. Cost of procedures increased $1.3&nbsp;million for the period, consisting of $1.4&nbsp;million attributable to volume increases in pellets dispensed which was
offset by a reduction of $0.1&nbsp;million related to broken, damaged, or expired pellets. Biote branded dietary supplement costs increased $0.4&nbsp;million or 3%, due to higher sales volume. Additionally, there was an increase in both trocar and
shipping and freight costs of $0.7&nbsp;million and $0.2&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense for the year ended December&nbsp;31, 2023 decreased $72.3&nbsp;million to $98.8&nbsp;million, or
(42.2%), compared to the year ended December&nbsp;31, 2022. This decrease was primarily driven by a $73.1&nbsp;million decline in stock compensation expense compared to the year ended December&nbsp;31, 2022, as the Closing of the Business
Combination triggered the accelerated vesting of incentive units and phantom equity rights and resulted in the recognition of $78.0&nbsp;million of stock compensation expense. Additionally, during the year ended December&nbsp;31, 2022, the Company
incurred transaction-related expenses of $21.6&nbsp;million related to the Business Combination and other associated capital structure transactions that did not recur during the year ended December&nbsp;31, 2023. The transaction-related expenses
consisted of the excess closing costs of the Business Combination over the Business Combination proceeds received, costs associated with sponsor share transfers and certain compensation paid resulting from the transaction. These decreases were
partially offset by a $5.3&nbsp;million increase in employee-related expenses due to an overall increase in headcount, an increase in sales incentives consistent with sales growth for the year and an increase in severance expense. Additionally,
outsourced professional services fees increased $6.0&nbsp;million, primarily due to an increase in legal expenses related to litigation costs incurred to defend the Company against claims asserted by the Company&#146;s former owner (see
&#147;Business&#151;Legal Proceedings&#151;Donovitz Litigation&#148; in this prospectus and Note 18 to our consolidated financial statements for additional information). Furthermore, during the year ended December&nbsp;31, 2023, the Company entered
into a $1.2&nbsp;million legal settlement with a former employee. Marketing expenses increased $1.9&nbsp;million due to an increase in <FONT STYLE="white-space:nowrap">web-based</FONT> marketing and the production of informational materials in an
ongoing effort to increase awareness of the products and services offered by Biote-certified practitioners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, net for the year ended December&nbsp;31, 2023 increased $2.3&nbsp;million to $6.4&nbsp;million, or 57.2%, compared to the
year ended December&nbsp;31, 2022. The increase was primarily a result of higher interest rates incurred during the period, partially offset by interest income earned on our money market account and no matured short-term investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gain (Loss) from Change in Fair Value of Warrant Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in the gain (loss) from change in fair value of warrant liability was primarily due to the Company&#146;s offer to exchange its
outstanding warrants for common stock. On May&nbsp;9, 2023, the Company announced the commencement of its offer to each holder of its outstanding warrants, the opportunity to receive shares of common stock in exchange for each warrant tendered by
the holder. During the year ended December&nbsp;31, 2023, the Company issued common stock valued at $17.5&nbsp;million in exchange for all outstanding warrants. The warrants were remeasured to fair value prior to each exchange, and in doing so, we
recognized a net loss from the change in fair value of our warrant liability of $13.4&nbsp;million for the year ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gain
(Loss) from Change in Fair Value of Earnout Liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in the gain (loss) from change in fair value of the earnout liability
was primarily due to the change in the closing price of our Class&nbsp;A common stock during the years ended December&nbsp;31, 2023 and 2022. For the year ended December&nbsp;31, 2023, the closing price of the Company&#146;s class A common stock
increased 32.4%, compared with a decrease of 58.6% in the corresponding period of 2022. The increase in the closing price </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our Class&nbsp;A common stock increased the fair value of the earnout liability; therefore, the Company recognized a corresponding loss of $9.0&nbsp;million for the year ended
December&nbsp;31, 2023. In comparison, the decrease in the closing price of our Class&nbsp;A common stock decreased the fair value of the earnout liability, resulting in a gain of $61.8&nbsp;million for the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company entered into a new loan agreement with Truist Bank and used a portion of the proceeds
to refinance and replace its existing credit facility with Bank of America, N.A. As a result of this refinancing, the Company recorded a $0.5&nbsp;million charge to loss from extinguishment of debt during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in
other income (expense) for the year ended December&nbsp;31, 2023 compared to the year ended December&nbsp;31, 2022. primarily resulted from currency fluctuations during the period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Tax Expense (Benefit) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax
expense for the year ended December&nbsp;31, 2023 increased $2.3&nbsp;million compared to the year ended December&nbsp;31, 2022. This increase reflects the taxability of the income attributable to Biote that prior to the Business Combination was
taxable to the Company&#146;s Members offset by a tax benefit from certain <FONT STYLE="white-space:nowrap">one-time</FONT> expenses related to the Business Combination that will be attributed to Biote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the years ended December&nbsp;31, 2022 and 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table and discussion below present our results for the years ended December&nbsp;31, 2022 and 2021: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B><I>(U.S. dollars, in thousands)</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">163,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">137,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (excluding depreciation and amortization included in selling, general and
administrative, below)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52.6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(275.7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(94.8</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95.9</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Not a meaningful change </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue for the year ended
December&nbsp;31, 2022 increased by $25.6&nbsp;million to $165.0&nbsp;million, or 18.3% as compared to the year ended December&nbsp;31, 2021. The increase was primarily driven by a $24.7&nbsp;million increase of procedure and Biote-branded dietary
supplement revenue. Procedures performed increased by 17.8% versus the prior year resulting in a $19.5&nbsp;million increase in procedure revenue. During the year ended December&nbsp;31, 2022, the number of active clinics billed increased by 13%
over the year ended December&nbsp;31, 2021. Biote-branded dietary supplement sales increased by 19.0% or $5.2&nbsp;million over the same period in the prior year. Service revenue increased by 1.4% over the same period in the prior year resulting
from an increase in the number of training sessions during the year ended December&nbsp;31, 2022 compared to the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost of revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the
year ended December&nbsp;31, 2022 increased by $5.8&nbsp;million, to $54.6&nbsp;million, or 11.8% as compared to the year ended December&nbsp;31, 2021. The increase was primarily due to the net impact of higher volumes at sustained unit costs. Cost
of procedures increased by $4.6&nbsp;million for the period, consisting of $4.8&nbsp;million attributable to volume increases in pellets dispensed which was offset by a reduction of $0.2&nbsp;million
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related to broken, damaged, or expired pellets. Biote branded dietary supplement costs increased $0.5&nbsp;million or 3.5%, due to higher sales volume. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commissions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commissions expense for the
year ended December&nbsp;31, 2022 decreased by $1.1&nbsp;million to $1.0&nbsp;million, or 52.6%, as compared to the year ended December&nbsp;31, 2021. The decrease is primarily driven by our shift to an internal sales force to generate product
demand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing expense
for the year ended December&nbsp;31, 2022 decreased by $0.3&nbsp;million to $4.6&nbsp;million, or 5.7%, as compared to the year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense for the year ended December&nbsp;31, 2022 increased by $116.4&nbsp;million to $165.5&nbsp;million,
or 237.4%, as compared to the year ended December&nbsp;31, 2021. This increase was primarily driven by stock compensation expense of $82.2&nbsp;million. This expense represented the cumulative impact of unrecognized compensation expense for
stockholders upon completion of the Business Combination as well as subsequent vesting of certain shares awarded. An additional component of the increase was $21.6&nbsp;million of transaction-related expenses related to the Business Combination and
other associated capital structure transactions recognized during the period. These consisted of the excess closing costs of the Business Combination over the Business Combination proceeds received; costs associated with sponsor share transfers and
certain compensation paid resulting from the transaction. The increase also included a $7.2&nbsp;million increase in payroll and related expenses due to increases in sales incentives consistent with sales growth for the period and additional sales
and management hiring; $0.7&nbsp;million of travel and entertainment expenses due to increases in sales force headcount. Depreciation and amortization expenses increased by $0.8&nbsp;million attributable to assets placed in service at the beginning
of the year. Additionally, professional fees and insurance costs increased during the period by $6.2&nbsp;million mainly attributable to increases in costs associated with being a public company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for
the year ended December&nbsp;31, 2022 increased by $3.4&nbsp;million to $5.1&nbsp;million, or 204.3%, as compared to the year ended December&nbsp;31, 2021. The increase is primarily a result of the higher debt balance outstanding from the new debt
issued as part of closing the Business Combination as well as higher interest rates incurred during the period. Interest expense relates primarily to interest on an outstanding note payable and amortization of origination fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gain from Change in Fair Value of Warrant Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The gain from the change in fair value of our warrant liability of $5.1&nbsp;million was primarily a result of the decrease in the trading
price of our Public Warrants listed on Nasdaq to $0.30 per share on December&nbsp;31, 2022 from $0.68 per share on the closing of the Business Combination, May&nbsp;26, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Gain from Change in Fair Value of Earnout Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination on the Closing Date, we recognized an earnout liability of $93.9&nbsp;million and subsequently
remeasured the earnout liability to its fair value of $32.1&nbsp;million as of December&nbsp;31, 2022. The gain from the change in fair value of our earnout liability of $61.8&nbsp;million was primarily a result of the decrease in the closing price
of our Class&nbsp;A Common Stock listed on Nasdaq to $3.73 per share on December&nbsp;31, 2022 from $9.02 per share on the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income for the year ended December&nbsp;31, 2022 increased by $1.1&nbsp;million to $1.1&nbsp;million as compared to the year ended
December&nbsp;31, 2021. The increase was primarily due to interest income earned on higher on hand cash balances and currency fluctuations during the period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Tax Expense (Benefit) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax
expense for the year ended December&nbsp;31, 2022 decreased by $0.1&nbsp;million as compared to the year ended December&nbsp;31, 2021. This increase reflects the taxability of the income attributable to Biote that prior to the Business Combination
was taxable to the Company&#146;s Members offset by a tax benefit from certain <FONT STYLE="white-space:nowrap">one-time</FONT> expenses related to the Business Combination that will be attributed to Biote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> performance measure that provides supplemental information that we
believe is useful to analysts and investors to evaluate the Company&#146;s ongoing results of operations when considered alongside net income (the most directly comparable U.S. GAAP measure). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use Adjusted EBITDA as alternative measures to evaluate our operational performance. We calculate Adjusted EBITDA by excluding from net
income: interest expense; depreciation and amortization expenses; and income taxes. Additionally, we exclude certain expenses we believe are not indicative of our ongoing operations or operational performance. We present Adjusted EBITDA because it
is a key measure used by our management to evaluate our operating performance, generate future operating plans and determining payments under compensation programs. Accordingly, we believe that Adjusted EBITDA provides useful information to
investors and others in understanding and evaluating our operating results in the same manner as our management. However, <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial information is presented for supplemental informational purposes
only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. Some of these limitations are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">although depreciation and amortization are <FONT STYLE="white-space:nowrap">non-cash</FONT> charges, the assets
being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjusted EBITDA does not reflect tax payments that may represent a reduction in cash available to us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgment by Biote&#146;s
management about which expenses are excluded or included. Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled <FONT STYLE="white-space:nowrap">non-GAAP</FONT> measures differently or may use other
measures to evaluate their performance, all of which could reduce the usefulness of our Adjusted EBITDA as a tool for comparison. Investors are encouraged to review the reconciliation, and not to rely on any single financial measure to evaluate our
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a reconciliation of net income (loss) to Adjusted EBITDA: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation expenses-former owner(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation-other(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlement (gain) loss(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction-related expenses(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merger and acquisition expenses(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss from change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss from change in fair value of earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents unamortized debt issuance costs of $0.4&nbsp;million charged to extinguishment of debt upon full
repayment of the Company&#146;s credit agreement with Bank of America. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents employee compensation expense associated with equity-based stock awards. This includes expense
associated with equity incentive instruments including phantom stock awards, stock options and restricted stock units. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents legal expenses to defend the Company against claims asserted by the Company&#146;s former owner. See
&#147;Business&#151;Legal Proceedings&#151;Donovitz Litigation&#148; in this prospectus and Note 18 to our consolidated financial statements for additional information. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents litigation expenses other than those incurred in connection with claims asserted by the
Company&#146;s former owner that are not related to the Company&#146;s ongoing business. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents settlements of legal matters. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents transaction costs including legal fees of $0.9&nbsp;million, filing fees of $0.2&nbsp;million and
professional services fees of $1.0&nbsp;million, each of which were incurred in connection with the filing of, and transactions contemplated by, the Company&#146;s securities offerings. For the year ended December&nbsp;31, 2022, this amount
represents transaction costs including professional services fees of $4.0&nbsp;million, legal fees of $4.8&nbsp;million, consulting fees of $0.2&nbsp;million, filing fees of $0.4&nbsp;million, share redemption costs of $7.2&nbsp;million and
transaction bonuses of $4.2&nbsp;million, each of which were incurred in connection with the Business Combination that occurred during the year ended December&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents executive severance costs of $0.8&nbsp;million, costs related to recruiting executive level
management, including the Chief Commercial Officer of $0.2&nbsp;million, legal fees of $0.1&nbsp;million and professional services fees of $0.1&nbsp;million associated with the restatement of the Company&#146;s financial statements for the quarters
ended June&nbsp;30, 2022 and September&nbsp;30, 2022 and a realized foreign currency loss of less than $0.02&nbsp;million. For the year ended December&nbsp;31, 2022, this amount represents executive severance costs of $0.4&nbsp;million, private air
transportation expense incurred by the Company&#146;s previous controlling stockholder of $0.2&nbsp;million, expenses related to the transition of the CEO and CFO of $0.07&nbsp;million and a realized foreign currency gain of $0.03&nbsp;million.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents professional fees of $0.6&nbsp;million, consulting fees of $0.4&nbsp;million and legal fees of
$1.8&nbsp;million all of which were associated with strategic opportunities to expand the business. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our liquidity is derived primarily from available cash and cash equivalents, cash generated from operations, capacity under our revolving loans
and, when necessary, debt and equity financing activities. We believe that for at least the next 12 months, our current cash position, coupled with anticipated cash generated from operations and the capacity under our revolving loans, is sufficient
to fund our operations and our debt service obligations. As of December&nbsp;31, 2023 and 2022, we had cash and cash equivalents of $89.0&nbsp;million and $79.2&nbsp;million, respectively. Additionally, as of both December&nbsp;31, 2023 and 2022, we
had $50.0&nbsp;million of revolving loans available under our Truist credit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have financed our
operations and capital expenditures primarily through capital investment from our founder and other members, debt financing in the form of short-term lines of credit and long-term notes payable, and net cash inflows from operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating and capital expenditures to increase as we increase headcount, expand our operations and grow our clinic base. If
additional funds are required to support our working capital requirements, acquisitions or other purposes, we may seek to raise funds through additional debt or equity financings or from other sources. If we raise additional funds through the
issuance of equity or convertible debt securities, the percentage ownership of our equity holders could be significantly diluted, and these newly issued securities may have rights, preferences or privileges senior to those of existing equity
holders. If we raise additional funds by obtaining loans from third parties, the terms of those financing arrangements may include negative covenants or other restrictions on our business that could impair our operating flexibility and also require
us to incur additional interest expense. We can provide no assurance that additional financing will be available at all or, if available, that we would be able to obtain additional financing on terms favorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to raise additional capital through the sale of equity or convertible debt securities could be significantly impacted by the
resale of shares of Class&nbsp;A common stock by selling securityholders pursuant to the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed with the SEC on June&nbsp;17, 2022, which could result in a significant decline
in the trading price of our Class&nbsp;A common stock and potentially hinder our ability to raise capital at terms that are acceptable to us or at all. In addition, debt financing and equity financing, if available, may involve agreements that
include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, or substantially reduce our operations. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in the section titled &#147;Risk
Factors&#148; included in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our consolidated cash flows for the years ended December&nbsp;31, 2023 and 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Cash Flows Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our consolidated cash flows for the years ended
December&nbsp;31, 2022 and 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Cash Flows Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127.2</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the years ended December&nbsp;31, 2023 and 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities result primarily from fees associated with the Biote Method and from the sale of Biote-branded dietary
supplements. Cash flows from operating activities are affected by earnings levels and changes in working capital related to our business. Working capital varies from period to period and can be affected by changes in our inventory levels due to
varying demand for our products. Net cash provided by operating activities increased $36.0&nbsp;million to $26.9&nbsp;million for the year ended December&nbsp;31, 2023 compared to cash used by operating activities of $9.2&nbsp;million for the year
ended December&nbsp;31, 2022. Our cash flow from working capital for the year ended December&nbsp;31, 2023 was positively impacted by the cash settlement of liabilities incurred related to the Business Combination during the year ended
December&nbsp;31, 2022 and negatively impacted by increases in inventory levels and advances and prepayments made to certain vendors during the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the years ended December&nbsp;31, 2022 and 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities for the year ended December&nbsp;31, 2022 decreased $42.9&nbsp;million as compared to the year ended
December&nbsp;31, 2021. Net income, adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses such as depreciation and amortization, provisions for bad debts, stock compensation, change in fair value of warrants and earnout liabilities,
and provisions for obsolete inventories, among others, resulted in a net decrease of $15.9&nbsp;million as compared to the prior period. Additionally, our working capital investment in our Biote-branded supplement inventory increased by
$4.1&nbsp;million as compared to the prior period. This resulted from the initial investment in our third-party fulfillment centers during the year ended December&nbsp;31, 2021. These net changes were offset by a $2.3&nbsp;million increase in
working capital from advances and prepayments made to certain vendors and increases in accounts receivable of $0.8&nbsp;million. Additionally, $31.1&nbsp;million of transaction closing costs were assumed as accrued expenses and subsequently paid
upon completion of the reverse-merger with Haymaker which reduced cash flow from operating activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the years ended December&nbsp;31, 2023 and 2022 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities increased $0.9&nbsp;million to $2.7&nbsp;million for the year ended December&nbsp;31, 2023 compared to
$1.8&nbsp;million for the year ended December&nbsp;31, 2022, principally related to expenditures for capitalized software development costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the years ended December&nbsp;31, 2022 and 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&nbsp;31, 2022 decreased by $2.0&nbsp;million as compared to the year ended
December&nbsp;31, 2021. This decrease was primarily driven by a reduction in purchases </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of property and equipment of $1.1&nbsp;million, primarily reusable trocars. Additionally capitalized software development costs decreased by $0.9&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the years
ended December&nbsp;31, 2023 and 2022 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in financing activities during the year ended December&nbsp;31, 2023 consisted of
quarterly interest payments on our term loan with Truist and $8.7&nbsp;million in distributions to our partners, which decreased $4.2&nbsp;million from the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2022, the Company received proceeds of $12.3&nbsp;million in relation to the Business Combination with Haymaker and executed a Term
Loan with Truist Bank that included borrowings of $125.0&nbsp;million as of the Closing Date. Additionally, during the year ended December&nbsp;31, 2022, we incurred debt issuance costs of $4.0&nbsp;million, recorded a $36.3&nbsp;million charge
related to the extinguishment of our term loan with Bank of America, incurred capitalized transaction costs of $8.3&nbsp;million and settled an aggregate of $7.3&nbsp;million in phantom equity rights, each of which were incurred in relation to the
Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Comparison of the years ended December&nbsp;31, 2022 and 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&nbsp;31, 2022 increased $83.8&nbsp;million as compared to the year ended
December&nbsp;31, 2021. The increase is primarily due to the completion of the Business Combination with Haymaker. This included $12.3&nbsp;million of cash proceeds from the Business Combination and $125.0&nbsp;million of debt issue proceeds. These
were offset by payments to retire existing debt of $37.5&nbsp;million, principal payment of $3.1&nbsp;million on the Truist debt, and $12.4&nbsp;million of transaction and debt issuance costs. Other items included a decrease in distributions to
Members of $1.5&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires our management to make judgments,
assumptions and estimates that affect the amounts reported in our accompanying consolidated financial statements and the accompanying notes included elsewhere in this registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management bases its estimates and judgments on historical experience, current economic and industry conditions and on various other
factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that we report
in our consolidated financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most critical accounting estimates include revenue recognition, the valuation of inventory, the valuation of stock compensation and the
valuation of earnout liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are described in Note 2 to our consolidated financial statements. We
believe that the accounting policies described reflect our most critical accounting policies and estimates, which represent those that involve a significant degree of judgment and complexity. Accordingly, we believe these policies are critical in
fully understanding and evaluating our reported financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements within the scope of Financial Accounting Standards Board (&#147;FASB&#148;) Accounting
Standard Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-09,</FONT> Revenue from Contracts with Customers, and subsequent amendments (collectively, &#147;ASC 606&#148;), we perform the following five steps: (1)&nbsp;identify the
contract(s) with a clinic; (2)&nbsp;identify the performance obligations in the contract; (3)&nbsp;determine the transaction price; (4)&nbsp;allocate the transaction price to the performance obligations in the contract; and (5)&nbsp;recognize
revenue when (or as) we satisfy performance obligations. We recognize revenue when the control of the promised goods or services is transferred to Biote-partnered clinics in an amount that reflects the consideration we expect to receive in exchange
for such goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our revenue is derived from our long-term service agreements for Biote-partnered clinics of
the Biote Method. In determining the transaction price, we evaluate whether the price is subject to discounts or adjustments to determine the net consideration to which we expect to be entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is recognized when control of the product or service is transferred to the clinic (i.e., when our performance obligation is
satisfied), which varies between the different performance obligations within the contract. In determining whether control has transferred for a product, we consider if there is a present right to payment and legal title, and whether risks and
rewards of ownership have transferred to the clinic. For services, we consider whether we have an enforceable right to payment and when the clinic receives the benefits of our performance. Refer to Note 2 to our consolidated financial statements for
additional discussion of our revenue recognition policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventories </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inventories consist of physician-prescribed pellets used by Biote-certified practitioners in partnered clinics and Biote-branded dietary
supplements which are sold and distributed to the Biote-partnered clinics and their patients. Custody of the pellets remains with Biote-certified practitioners. The pellets are presented as inventory on our financial statements from the date of
shipment until such time as they are administered in a treatment by a Biote-certified practitioner on their patient for the convenience of Biote-certified practitioners and Biote-partnered clinics. Biote-partnered clinics directly purchase
Biote-branded dietary supplements from us, and our 3PL suppliers fill and ship directly to the ordering practice. The Biote-partnered clinic then sets their own pricing in compliance with our applicable policies and sells Biote-branded dietary
supplements directly to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories are valued at the lower of cost or net realizable value. We regularly review our
inventories and write down our inventories for estimated losses due to obsolescence or expiration. The allowance for pellets is determined based on the age of the specific manufacturing lots of the product and its remaining life until expiration.
Dietary supplements are evaluated at the product level based on sales of our products in the recent past and/or expected future demand. Future demand is affected by market conditions, new products and strategic plans, each of which is subject to
change with little or no forewarning. In estimating obsolescence, we utilize information that includes projecting future demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The need
for strategic inventory levels to ensure competitive delivery performance to our Biote-partnered clinics are balanced against the risk of inventory obsolescence due to clinic requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based compensation awards previously granted by Holdings were valued using a Monte-Carlo simulation as of the grant date because the
value of the awards was dependent on future distributions to be received from a change in control or qualifying liquidity event. The significant assumptions used in the valuation include the constant risk-free rate, constant volatility factor and
the Geometric Brownian Motion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Earnout Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our earnout liability was valued using a Monte-Carlo simulation in order to simulate the future path of our stock price over the earnout
period. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the liability&#146;s estimate value. The significant assumptions used in the valuation include the Company&#146;s stock
price, volatility and the drift rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Commitments and Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, we did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined in Item
303(a)(4)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal contractual obligations and commitments consist of obligations to pay loan principal and interest under our long-term debt
agreement and obligations under our operating lease agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note 8 and Note 10 to our consolidated financial statements for a
discussion of the nature and timing of our obligations under these agreements. The future amount and timing of interest payments under our long-term debt agreement are expected to vary with the amount and then-prevailing contractual interest rates
of our debt, which are discussed in Note 8 to our consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 to our consolidated financial statements for a discussion of accounting pronouncements recently adopted and recently issued
accounting pronouncements not yet adopted and their potential impact to our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;),
as modified by the JOBS Act. Section&nbsp;107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised
accounting standards applicable to public companies, allowing them to delay the adoption of those standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act.
As a result, following the Business Combination, our consolidated financial statements may not be comparable to the financial statements of companies that are required to comply with the effective dates for new or revised accounting standards that
are applicable to public companies, which may make our common stock less attractive to investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth
company under the JOBS Act until the earliest of (i)&nbsp;March&nbsp;4, 2026, (ii) the last date of our fiscal year in which we have total annual gross revenue of at least $1.235&nbsp;billion, (iii)&nbsp;the date on which we are deemed to be a
&#147;large accelerated filer&#148; under the rules of the SEC with at least $700.0&nbsp;million of outstanding securities held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> or (iv)&nbsp;the date on which we have issued more than
$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the previous three years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and
Qualitative Disclosures about Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business, including the effects
of interest rate changes and inflation. Information relating to quantitative and qualitative disclosures about these market risks is set forth below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Fluctuation Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of our investment activities is to maintain cash reserves to meet the capital requirements of our operations and our
contractual obligations. In future periods, we will continue to evaluate our investment policy in order to ensure that we continue to meet our overall objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to interest rate risk in relation to our long-term debt outstanding. As is more fully described in Note 8 to the consolidated
financial statements elsewhere in this registration statement, our outstanding long-term debt has a variable rate of interest, which is primarily based on the Standard Overnight Financing Rate. We estimate that an increase of 100 basis points in the
interest rates related to our long-term debt would increase our annualized interest expense by approximately $1.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
engage in any strategies to limit our exposure to this interest rate risk. In addition to the interest rate risk related to our current borrowings, changes in interest rates could affect the interest we pay under any future borrowings on the line of
credit available to us under our long-term debt agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variable interest rate on our long-term debt has increased since our last
fiscal year, to a rate of 8.0% as of December&nbsp;31, 2023 from a rate of 6.9% as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that inflation has had a material effect on our business, financial condition, or results of operations. We continue to
monitor the impact of inflation in order to minimize its effects through pricing strategies, productivity improvements and cost reductions. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset
such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management and Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth certain information, including ages as of March 11, 2024, of our executive officers and members of the Board. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc D. Beer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Chairman (Class&nbsp;III Director)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana Jacoby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;I Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Cone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;II Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven J. Heyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;II Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew R. Heyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;I Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra L. Morris</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;II Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, Class&nbsp;III Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Business Development&nbsp;&amp; General Counsel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary J. Puncochar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Head of Strategic Sales &amp; Business Analytics</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief biography of each of Biote&#146;s executive officers and key employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Teresa S. Weber</I></B>, <I>Chief Executive Officer, Director</I>. Ms.&nbsp;Teresa&nbsp;S. Weber has served as the Chief Executive
Officer of Biote since March 2019, on the Board since May 2022 and on the board of managers of Holdings since June 2018. Prior to joining Biote, Ms.&nbsp;Weber served as the chief executive officer of Amen Clinics, Inc., an outpatient healthcare
clinic company, from January 2015 to March 2019. Ms.&nbsp;Weber has also been partner and consultant at Mattioli Weber Consulting, a marketing, service and retain consulting firm, since June 2013. She holds an M.S. in Management from Purdue
University and a B.S. in Economics from New College Florida. Ms.&nbsp;Weber is qualified to serve as a director due to her significant leadership experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Robert C. Peterson,</I></B> <I>Chief Financial Officer</I>. Mr.&nbsp;Robert&nbsp;C.&nbsp;Peterson has served as the Chief Financial
Officer of Biote since January 2024. Prior to joining Biote, Mr.&nbsp;Peterson served as the executive vice president and chief financial officer at Virbac Corp., a subsidiary of Virbac S.A., a global veterinary pharmaceutical and wellness company,
from September 2017 to January 2024. Mr.&nbsp;Peterson is a Certified Public Accountant and holds a B.B.A and an M.B.A. from the Texas Christian University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mary Elizabeth Conlon</I></B><I>, Vice President, Business Development</I><I></I><I>&nbsp;&amp; General Counsel</I>. Ms.&nbsp;Mary
Elizabeth Conlon has served as the Vice President, Business Development and General Counsel of Biote since June 2021. Prior to joining Biote, Ms.&nbsp;Conlon founded The Conlon Law Firm, P.C., where she practiced law from January 2012 to June 2021.
Prior to that, Ms.&nbsp;Conlon was named partner at Travis, Calhoun&nbsp;&amp; Conlon, P.C., where she practiced law from September 2004. Ms.&nbsp;Conlon holds a J.D. from Baylor Law School and a B.A. in Communications from Baylor University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mary J. Puncochar</I></B>, <I></I><I>Head of Strategic Sales and Business Analytics</I>. Ms.&nbsp;Mary&nbsp;J. Puncochar has served as
the Head of Strategic Sales &amp; Business Analytics of Biote since March 2024 and was previously Biote&#146;s Chief Commercial Officer from May 2023 to March 2024, bringing more than 30 years of experience in sales, tech-enabled marketing and
management roles at leading healthcare, pharmaceutical and medical device companies. Prior to joining Biote, from April 2019 to April 2022, Ms.&nbsp;Puncochar served as Head of the U.S. Region at Ascensia Diabetes Care, a global diabetes care
company, and as the U.S. Commercial Head from January 2018 to April 2019, where she achieved commercial success through the development and launch of innovative solutions and precision tools aimed at helping consumers more effectively manage their
health. Ms.&nbsp;Puncochar holds a B.S. in Nursing from the University of Minnesota and an A.A. from the North Dakota State University, and is a member of the Women Business Leaders of the U.S. Health Care Industry Foundation (WBL). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Marc D. Beer</I></B>, <I>Executive Chairman</I>. Mr.&nbsp;Marc&nbsp;D. Beer has served as the Chairman of the Board since May 2022 and as
chairman of the board of managers of Holdings since January 2021. Mr.&nbsp;Beer has also served as the chairman of the board of Papyrus Therapeutics Inc. since August 2021, chairman of the board of Origami Surgical LLC since April 2020 and as the
chairman of the board of LumeNXT LLC since August 2018. Prior to that, Mr.&nbsp;Beer <FONT STYLE="white-space:nowrap">co-founded</FONT> Renovia Inc. in August 2016, where he previously held the positions of chairman of the board and chief executive
officer and continues to serve as a strategic advisor. Before starting Renovia Inc., Mr.&nbsp;Beer was the chairman of the board of Minerva Neurosciences, Inc. (Nasdaq: NERV) from December 2013 to January 2018. Mr.&nbsp;Beer holds a BS from Miami
University. Mr.&nbsp;Beer is qualified to serve as a director due to his significant leadership background and industry experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dana Jacoby</I></B>, <I>Director</I>. Ms.&nbsp;Dana Jacoby has served as a member of the Board since May 2022 and as a member of the
board of managers of Holdings since August 2021. Prior to Biote, Ms.&nbsp;Jacoby served as the chief executive officer of Specialty Networks Consulting from November 2015 to December 2020. In October 2017, Ms.&nbsp;Jacoby founded Vector Medical
Group, where she continues to serve as chief executive officer. Ms.&nbsp;Jacoby holds an M.S. in Business and Healthcare, Master of Health Systems from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey
and a B.S. in Political Science and Public Relations from Louisiana State University. Ms.&nbsp;Jacoby is qualified to serve as a director due to her extensive leadership experience and background in the industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>S. Mark Cone</I></B>, <I>Director</I>. Dr.&nbsp;Mark Cone has served as a member of the Board since May 2022 and as a member of the
board of managers of Holdings since August 2021. Dr.&nbsp;Cone has also served as the market president of Privia Health&#146;s South Texas market (Nasdaq: PRVA) since October 2015 and as the president of Privia Medical Group Gulf Coast since October
2015. Additionally, since December 2013, Dr.&nbsp;Cone has served as vice president of the board of directors of the U.S. Women&#146;s Health Alliance and as chairman of the board of Global Women&#146;s Health Providers, a Cedar Gate Technologies
company, since October 2020. Dr.&nbsp;Cone currently serves as chairman of the advisory board for Fannin Surgicare, an outpatient ASC. Prior to these positions, Dr.&nbsp;Cone was the chief executive officer of Complete MD Solutions, a physician
management company from December 2014 to October 2015. He holds an M.D. from Baylor College of Medicine and a Bachelor of Science in Biology and Medicine from Texas A&amp;M University. Dr.&nbsp;Cone is qualified to serve as a director due to his
extensive industry and leadership experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Andrew R. Heyer,</I></B> <I>Director.</I> Mr.&nbsp;Andrew&nbsp;R. Heyer has served as
a member of the Board since May 2022. Mr.&nbsp;Heyer previously served as the president and director of HYAC from July 2020 until HYAC completed its business combination in May 2022, and is a finance professional with over 40 years of experience
investing in the consumer and consumer-related products and services industries, as well as a senior banker in leveraged finance during which time his clients included many large private equity firms. Mr.&nbsp;Heyer served as president and director
of Haymaker Acquisition Corp. II (&#147;<B><I>Haymaker II</I></B>&#148;) until it completed its business combination in December 2020 with GPM and ARKO Holdings Ltd. (&#147;<B><I>ARKO Holdings</I></B>&#148;), which together merged under a new
holding company, ARKO Corp. (Nasdaq: ARKO) as part of the business combination, and has remained on the board since such time. Mr.&nbsp;Heyer was president and director of Haymaker Acquisition Corp. I (&#147;<B><I>Haymaker I</I></B>&#148;) until it
completed its business combination with OneSpaWorld Holdings in March 2019, and has since remained on its board since such time. Currently, Mr.&nbsp;Heyer is the Chief Executive Officer and founder of Mistral Equity Partners
(&#147;<B><I>Mistral</I></B>&#148;), a private equity fund manager founded in 2007 that invests in the consumer industry. Prior to founding Mistral in 2007, from 2000 to 2007, Mr.&nbsp;Heyer served as a Founding Managing Partner of Trimaran Capital
Partners, a $1.3&nbsp;billion private equity fund. Mr.&nbsp;Heyer was formerly a vice chairman of CIBC World Markets Corp. and a <FONT STYLE="white-space:nowrap">co-head</FONT> of the CIBC Argosy Merchant Banking Funds from 1995 to 2001. Prior to
joining CIBC World Markets Corp. in 1995, Mr.&nbsp;Heyer was a founder and Managing Director of The Argosy Group L.P. from 1985 to 1995. Before Argosy, from 1984 to 1985, Mr.&nbsp;Heyer was a Managing Director at Drexel Burnham Lambert Incorporated
and, previous to that, he worked at Shearson/American Express. Mr.&nbsp;Heyer also currently serves as president and a director of Haymaker Acquisition Corp. IV, a SPAC that has not yet completed its
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initial public offering. From 1993 through 2009, Mr.&nbsp;Heyer also served on the board of The Hain Celestial Group, Inc. (Nasdaq: HAIN), a natural and organic food and products company,
rejoining the board from 2012 to April 2019. Mr.&nbsp;Heyer also serves on the board of several private companies owned in whole or in part by Mistral, including Worldwise, Inc., a pet accessories business from 2011 to the present, and The Lovesac
Company, Inc. (Nasdaq: LOVE), a branded omni-channel retailer of technology-forward furniture, from 2010 to the present. Mr.&nbsp;Heyer has also served on the board of Insomnia Cookies, a retailer of desserts open primarily in the evening and
nighttime, and on the investment committee of AF Ventures, an investor in high-growth consumer product companies. In the past, Mr.&nbsp;Heyer has served as a director of XpresSpa Group, Inc. from 2016 to 2019, Las Vegas Sands Corp., a casino
company, from 2006 to 2008, El Pollo Loco Holdings, Inc., a casual Mexican restaurant, from 2005 to 2008, and Reddy Ice Holdings, Inc., a manufacturer of packaged ice products, from 2003 to 2006. Mr.&nbsp;Heyer received his B.Sc. and M.B.A. from the
Wharton School of the University of Pennsylvania, graduating magna cum laude. Mr.&nbsp;Heyer is the brother of Mr.&nbsp;Steven Heyer, our Chief Executive Officer. Mr.&nbsp;Heyer is qualified to serve as a director due to his extensive finance,
investment and operations experience, particularly in the consumer and consumer-related products and services industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Steven J.
Heyer,</I></B> <I>Director.</I> Mr.&nbsp;Steven&nbsp;J. Heyer has served as a member of the Board since May 2022. Mr.&nbsp;Heyer previously served as HYAC&#146;s chief executive officer and executive chairman from July 2020 until HYAC completed its
business combination in May 2022, and has over 40 years of experience in the consumer and consumer-related products and services industries, leading a range of companies and brands. Mr.&nbsp;Heyer has applied his experience and analytical skills in
a variety of leadership positions across diverse industry groups, including broadcast media, consumer products, and hotel and leisure companies. Over the past ten years, he has been acting as an advisor and director to, and investor in, several
private companies across the consumer subsectors of health and wellness, restaurants, technology, marketing services and technology and furniture. Mr.&nbsp;Heyer currently serves as Chief Executive Officer and a Director of Haymaker Acquisition
Corp. IV, a SPAC that has not yet completed its initial public offering. Mr.&nbsp;Heyer served as the Chief Executive Officer and Chairman of Haymaker II until it completed its business combination in December 2020 with GPM Investments, LLC
(&#147;<B><I>GPM</I></B>&#148;) and ARKO Holdings, which together merged under a new holding company, ARKO Corp. (Nasdaq: ARKO) as part of the business combination, and has remained on its board since such time as a director. Mr.&nbsp;Heyer was
Chief Executive Officer and Chairman of Haymaker I from its formation until it completed its business combination with OneSpaWorld Holdings (Nasdaq: OSW) in March 2019. Since its business combination, he has served as Vice Chairman on the board of
directors of OneSpaWorld Holdings. Mr.&nbsp;Heyer&#146;s operating experiences include: leading the turnaround of Outback Steakhouse as an advisor (from 2010 to 2012); as Chief Executive Officer of Starwood Hotels&nbsp;&amp; Resorts Worldwide (from
2004 until 2007); as President and Chief Operating Officer of The Coca-Cola Company (from 2001 to 2004); as a member of the boards of Coca-Cola FEMSA, and Coca-Cola Enterprises (all from 2001 to 2004); as President and Chief Operating Officer of
Turner Broadcasting System, Inc., and a member of AOL Time Warner&#146;s Operating Committee (from 1994 to 2001); as President and Chief Operating Officer of Young&nbsp;&amp; Rubicam Advertising Worldwide (from 1992 to 1994); and before that
spending 15 years at Booz Allen&nbsp;&amp; Hamilton, ultimately becoming Senior Vice President and Managing Partner. For the last five years, Mr.&nbsp;Heyer has served on the boards of Lazard Ltd, Lazard Group, and Atkins Nutritionals Inc. (each as
further described below) as well as investing in a private capacity in early stage and venture consumer and consumer media companies. Mr.&nbsp;Heyer has extensive board experience, including: the board of Atkins Nutritionals Inc. until 2017, when it
was acquired by Conyers Park Acquisition Corp, a publicly traded special purpose acquisition company; Lazard Ltd and Lazard Group (2005 to present); the board of WPP Group, a publicly traded digital, internet, and traditional advertising company
(2000 to 2004); the board of Equifax, the publicly traded consumer credit reporting and insights company (2002 through 2003); the board of Omnicare, Inc., a supplier of pharmaceutical care to the elderly (2008 through 2015); the board of Vitrue,
Inc., a provider of social marketing publishing technologies (2007 through 2012); and the board of Internet Security Systems, Inc. a provider of internet security software, appliance, and services (2004 through 2005). In March 2011, Harry&nbsp;&amp;
David Holdings, Inc. (&#147;<B><I>Harry</I></B><B><I></I></B><B><I>&nbsp;&amp; David</I></B>&#148;), a company where Mr.&nbsp;Heyer had been Chief Executive Officer from 2010 until February 2011, filed a prearranged Chapter 11 plan under the U.S.
Bankruptcy Code. Subsequently, Harry&nbsp;&amp; David filed a reorganization plan in bankruptcy court in May 2011 and emerged from bankruptcy in September 2011. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&nbsp;Heyer received his B.S. from Cornell University and an M.B.A. from New York University. Mr.&nbsp;Heyer is the brother of Mr.&nbsp;Andrew Heyer, our President. Mr.&nbsp;Heyer is qualified
to serve as a director due to his extensive operations, management and business background, particularly in the consumer and consumer-related products and services industries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debra L. Morris</I></B>,<B><I> </I></B><I>Director</I>. Ms.&nbsp;Debra&nbsp;L. Morris has served as a member of the Board since November
2022. Ms.&nbsp;Morris served as the executive vice president and chief financial officer of Apria, Inc. (Nasdaq: APR) from March 2013 through October 2022. Prior to that, Ms.&nbsp;Morris served as Chief Financial Officer of Americas for Sitel
Worldwide Corporation from February 2010 to February 2013. Prior to that she served as a Partner of Tatum LLC from 2004 to 2010 and as a Director from 2008 to 2010 and provided interim and permanent Chief Financial Officer services for companies
contracted with Tatum LLC including LifeMasters Supported SelfCare and RelaDyne. Effective May&nbsp;15, 2020, Ms.&nbsp;Morris serves as a Director for Alternative Logistics Technologies, Holdco, LLC (a.k.a EverDriven) where she serves as the chair
of the audit committee. Effective December&nbsp;31, 2020, Ms.&nbsp;Morris serves as a director of Rexford Industrial (NYSE: REXR) and serves on the audit, compensation and nomination and governance committees. Ms.&nbsp;Morris holds a B.S. in
Business Administration from Colby Sawyer College in New London, New Hampshire. Ms.&nbsp;Morris is qualified to serve as a director due to her extensive experience serving on public company boards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family
relationships among any of our executive officers or directors with the exception of Mr.&nbsp;Steven Heyer and Mr.&nbsp;Andrew Heyer, who are brothers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Classified Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business affairs are managed under the direction of the Board. The Board consists of six directors and is divided into three staggered classes of directors. At each annual meeting of its stockholders, a class of directors will be elected for a
three-year term to succeed the same class whose term is then expiring, as follows, or in each case until their respective successors are elected and qualified, or until their earlier resignation, removal or death, or in each case until their
respective successors are elected and qualified, or until their earlier resignation, removal or death: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors, whose terms will expire in 2024, are Steven J. Heyer, S. Mark Cone, and Debra L.
Morris; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors, whose terms will expire in 2025, are, Marc Beer and Terry Weber; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors, whose terms will expire in 2026, are Andrew R. Heyer and Dana Jacoby.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Corporate Governance Guidelines require a majority of Board members to be independent. Our Board has determined that all Board members,
other than Mr.&nbsp;Beer and Ms.&nbsp;Weber, are independent under applicable rules of The Nasdaq Stock Market LLC (&#147;Nasdaq&#148;). Mr.&nbsp;Beer is not deemed to be independent under Nasdaq rules by virtue of his role as our Executive
Chairman. Ms.&nbsp;Weber is not deemed to be independent under Nasdaq rules by virtue of her role as our Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the
Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The standing committees of our Board currently include an audit committee, a compensation committee and nominating
and corporate governance committee. Each of the committees report to the Board as they deem appropriate and as the Board may request. The composition, duties and responsibilities of these committees are set forth below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee consists of Messrs. Andrew Heyer and Steven Heyer and Mses. Jacoby and Morris, with Mr.&nbsp;Andrew Heyer serving as
chairperson. Our Board has determined that Mr.&nbsp;Andrew Heyer qualifies as our &#147;audit committee financial expert,&#148; as that term is defined in Item 407(d)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The principal
functions of the Audit Committee include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting Board oversight of (1)&nbsp;the integrity of our financial statements, (2)&nbsp;our compliance with
legal and regulatory requirements, (3)&nbsp;our independent registered public accounting firm&#146;s qualifications and independence, and (4)&nbsp;the performance of our internal audit function and independent registered public accounting firm; the
appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit and
<FONT STYLE="white-space:nowrap">non-audit</FONT> services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing <FONT STYLE="white-space:nowrap">pre-approval</FONT> policies and
procedures; reviewing and discussing with the independent registered public accounting firm all relationships the auditors have with us in order to evaluate their continued independence; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">setting clear policies for audit partner rotation in compliance with applicable laws and regulations; obtaining
and reviewing a report, at least annually, from the independent registered public accounting firm describing (1)&nbsp;the independent registered public accounting firm&#146;s internal quality-control procedures and (2)&nbsp;any material issues
raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits
carried out by the firm and any steps taken to deal with such issues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting to review and discuss our annual audited financial statements and quarterly financial statements with
management and the independent auditor, including reviewing our specific disclosures under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;; reviewing and approving any related party transaction
required to be disclosed pursuant to Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> prior to us entering into such transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management, the independent auditor, and our legal advisors, as appropriate, any legal, regulatory
or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant
changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Compensation Committee consists of Ms.&nbsp;Jacoby and Messrs. Cone and Andrew Heyer, with Ms.&nbsp;Jacoby serving as the chairperson. The principal functions of the Compensation Committee include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive
Officer&#146;s compensation evaluating our Chief Executive Officer&#146;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to our Board with respect to the compensation, and any incentive
compensation and equity-based plans that are subject to Board approval of all of our other officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our executive compensation policies and plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementing and administering our incentive compensation equity-based remuneration plans; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting management in complying with our proxy statement and annual report disclosure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements
for our officers and employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing a report on executive compensation to be included in our annual proxy statement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee consists of Messrs. Steven Heyer and Beer and Dr.&nbsp;Cone, with Mr.&nbsp;Steven Heyer
serving as the chairperson. The principal functions of the Nominating and Corporate Governance Committee include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by our
Board, and recommending to our Board of Director candidates for nomination for election at annual meetings of stockholders or to fill vacancies on our Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our Board and overseeing implementation of our Corporate Governance Guidelines;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating and overseeing the annual self-evaluation of the Board of Directors, its committees, individual
directors and management in the governance of the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing on a regular basis our overall corporate governance and recommending improvements as and when
necessary. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws provide our Board with the flexibility to combine or separate the positions of chairperson of the Board and Chief Executive Officer
to reflect our evolving needs and strategy, changes in our Board&#146;s composition and leadership needs, as well as other factors, including the views of our stockholders and other stakeholders. Our Corporate Governance Guidelines specify that our
Board will select our Chief Executive Officer and chairperson of our Board in the manner that it determines to be in the best interests of our stockholders. We do not believe there should be a fixed rule regarding the positions of Chief Executive
Officer and chairperson being held by different individuals, or whether the chairperson should be an employee of the Company or should be elected from among the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The needs of the Company
and the individuals available to assume these roles may require different outcomes at different times, and our Board believes that retaining flexibility in these decisions is in the best interests of the Company and its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to its charter, the Nominating and Corporate Governance Committee periodically reviews this matter and make recommendations to our
Board. The Nominating and Corporate Governance Committee has recommended, and our Board of directors has determined, that the roles of Chief Executive Officer and chairperson of our Board of directors should be separate. The role of chairperson is
currently held by Mr.&nbsp;Beer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key function of our Board is informed oversight of our risk management process. In particular, our Board is responsible for monitoring and
assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. Our Board does not have a standing risk management committee, but rather administers this oversight function directly through
our Board as a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. Our Board and its committees consider specific risk topics, including risks associated with our
strategic plan, business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operations, capital structure, information technology, data privacy and cyber security. It is the responsibility of the committee chairpersons to report findings regarding material risk exposures
to our Board as quickly as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee has the responsibility to consider and discuss with management and the auditors,
as appropriate, our guidelines and policies with respect to financial risk management and financial risk assessment, including our major financial risk exposures and the steps taken by management to monitor and control these exposures. Areas of
focus for our Audit Committee include our policies and other matters relating to our investments, cash management and foreign exchange management, major financial risk exposures, the adequacy and effectiveness of our information security policies
and practices and the internal controls regarding information security, and the steps taken by management to monitor and mitigate or otherwise control these exposures and to identify future risks. Our Compensation Committee assesses and monitors
whether any of our compensation policies and programs has the potential to encourage excessive risk-taking, including risks related to executive compensation and overall compensation and benefit strategies, plans, arrangements, practices and
policies. Our Nominating and Corporate Governance Committee monitors the effectiveness of our Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. The Nominating and
Corporate Governance Committee also oversees and reviews with management our major legal compliance risk exposures and the steps management has taken to monitor or mitigate such exposures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its reviews of our business operations and corporate functions, our Board addresses the primary risks associated with those
operations and corporate functions. In addition, our Board reviews the risks associated with our business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies. While our Board and its
committees oversee risk management strategy, management is responsible for implementing and supervising <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> risk management processes and reporting to our Board
and its committees on such matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a code of ethics (the &#147;Code of Ethics&#148;) applicable to our directors, executive officers and employees that complies
with the rules and regulations of Nasdaq, which is available on the Governance section of our investor relations website at <I>ir.biote.com</I>. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq
listing standards concerning any amendments to, or waivers from, any provision of the Code of Ethics. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our
website, and you should not consider it to be a part of this registration statement. We also intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> You may review these documents by accessing public filings at the SEC&#146;s web site at www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our named executive officers who are identified in the
2023 Summary Compensation Table below, who are also the named executive officers of Biote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have opted to comply with the executive compensation disclosure rules applicable to emerging growth companies, as the Company is an emerging
growth company. The scaled down disclosure rules require compensation disclosure for our principal executive officer and its two most highly compensated executive officers other than the principal executive officer whose total compensation for 2023
exceeded $100,000 and who were serving as executive officers as of December&nbsp;31, 2023. We refer to these individuals as &#147;named executive officers.&#148; For 2023, our named executive officers were: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Teresa S. Weber, Biote&#146;s Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mary Elizabeth Conlon, Vice President, Business Development&nbsp;&amp; General Counsel; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mary Puncochar, Chief Commercial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2023 Compensation of Named Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary
Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for each of the last two completed fiscal years regarding compensation
awarded to or earned by our Chief Executive Officer and the two other most highly compensated executive officers, or collectively, the named executive officers, during the fiscal years indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP><SUP STYLE="font-size:75%; vertical-align:top"><BR></SUP>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP><SUP STYLE="font-size:75%; vertical-align:top"><BR></SUP>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP><SUP
STYLE="font-size:75%; vertical-align:top"><BR></SUP>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP><SUP STYLE="font-size:75%; vertical-align:top"><BR></SUP>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teresa S. Weber</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,758,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,816,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">541,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">340,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,689,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,823,435</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,729,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Mary Puncochar<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">773,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,094,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Commercial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Mary Elizabeth Conlon</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">493,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,045,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Vice President, Business Development&nbsp;&amp; General Counsel</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">766,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Salary amounts represent actual amounts earned during the applicable year. See &#147;&#151;Narrative to the
Summary Compensation Table&#151;Annual Base Salary&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Amounts represent the aggregate grant date fair value of stock and option awards granted to our named executive
officers during 2023, computed in accordance with ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 14 to our financial statements included in our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023. These amounts do not necessarily correspond to the actual value recognized or that may be recognized by the named executive officers. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The amounts in this column represent Biote&#146;s matching contributions to the named executive officer&#146;s
401(k) plan as well as the following in 2023: (i) a <FONT STYLE="white-space:nowrap">gross-up</FONT> of taxable gift of $340 and $267 for Ms.&nbsp;Puncochar and Ms.&nbsp;Conlon, respectively, and (ii)&nbsp;cell phone expenses and housing allowances
of $42,775 for Ms.&nbsp;Puncochar. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Amount reflects performance-based cash bonuses awarded to Ms.&nbsp;Weber during the fiscal year ended
December&nbsp;31, 2022 in connection with the Closing of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect target performance-based cash bonuses awarded to our named executive officers. See &#147;
--Employment and Other Arrangements&#148; below for a description of the material terms of the program pursuant to which this compensation will be awarded. The 2023 performance-based cash bonus for Ms. Weber is $457,125, reflecting a 75% achievement
of the Company&#146;s 2023 Corporate Goals, and for Ms. Puncochar and Ms. Conlon is $72,479 and $145,298, respectively, reflecting an 85% achievement of the Company&#146;s 2023 Corporate Goals. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Puncochar was appointed as the Company&#146;s Chief Commercial Officer in May 2023. Amounts in the
table reflect actual compensation awarded to Ms.&nbsp;Puncochar and are not annualized. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Narrative to the Summary Compensation Table </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Base Salary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive
officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience,
role and responsibilities. None of our named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. See &#147;&#151;Employment
Arrangements&#148; for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the annual base salaries for our named executive officers
for 2022 and 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022&nbsp;Base<BR>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023&nbsp;Base<BR>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">575,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">610,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Puncochar<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">395,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Puncochar was appointed as the Company&#146;s Chief Commercial Officer in May 2023. Amounts in the
table reflect actual compensation awarded to Ms.&nbsp;Puncochar and are not annualized. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to motivate and reward our executives for achievements relative to our corporate goals and expectations for each fiscal year. In
accordance with the terms of their respective employment agreements, our named executive officers are eligible to receive discretionary annual bonuses of up to a percentage of each executive&#146;s gross base salary based on individual performance,
company performance or as otherwise determined appropriate, as determined by the Compensation Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board
previously approved specified company and individual performance metrics for annual bonuses for our executives for fiscal 2023 as well as target bonuses for certain executives of the Company. The Compensation Committee has reviewed the
Company&#146;s fiscal year 2023 corporate performance, reflecting an 85% achievement of the 2023 Corporate Goals, and deemed it advisable to approve a bonus pool in the amount of $1,131,945 for <FONT STYLE="white-space:nowrap">non-executive</FONT>
employees, based on the 2023 Corporate Goals Achievement, for the payment of 2023 cash performance bonuses to <FONT STYLE="white-space:nowrap">non-executive</FONT> employees of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the bonus amounts for our named executive officers for 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023&nbsp;Bonus<BR>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Puncochar<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Puncochar was appointed as the Company&#146;s Chief Commercial Officer in May 2023. Amounts in the
table reflect actual compensation awarded to Ms.&nbsp;Puncochar and are not annualized. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity-Based Incentive Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards granted to our named executive officers are designed to align our interests and those of our stockholders
with those of our employees and consultants, including our executive officers. As of the date of this prospectus, stock awards and stock option awards were the only form of equity awards we have granted to any of our executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use stock options as an incentive for long-term compensation to our executive officers
because the stock options allow our executive officers to profit from this form of equity compensation only if our stock price increases relative to the stock option&#146;s exercise price, which exercise price is set at the fair market value of our
Common Stock on the date of grant. Vesting of equity awards is generally tied to each officer&#146;s continuous service with us and serves as an additional retention measure. We may grant equity awards at such times as the Board or Compensation
Committee determines appropriate. Our executives generally are awarded an initial grant in the form of a stock option award in connection with their commencement of employment with us. Additional grants may occur periodically in order to
specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we have granted all stock options pursuant to our 2022 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All options are granted with an exercise price per share that is no less than the fair market value of our Common Stock on the date of grant
of such award. Our stock option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. See &#147;&#151; Outstanding Equity Awards at
Fiscal <FONT STYLE="white-space:nowrap">Year-End.&#148;</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding outstanding equity awards held by our named executive officers as of
December&nbsp;31, 2023. All awards were granted pursuant to the Incentive Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares or<BR>Units of<BR>Stock that<BR>Have Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<BR>of Shares<BR>or Units of<BR>Stock that<BR>Have Not<BR>Vested<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP> ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,137,430</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/14/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">755,150</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/2/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Puncochar<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/31/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,161</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/14/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/2/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the option awards listed in the table were granted with an exercise price per share that is no less than
the fair market value of our Class&nbsp;A Common Stock on the date of grant of such award, as determined in good faith by the Board. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The market value of unvested shares is calculated by multiplying the number of unvested shares by the closing
market price of our Class&nbsp;A Common Stock on Nasdaq on December&nbsp;31, 2023, the last trading day of the year, which was $4.94 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50% of the shares vest on the second-year anniversary of the vesting commencement date, with the remainder of
the shares vesting in 24 equal monthly installments thereafter, subject to the recipient&#146;s continuous service through each applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% of the shares vest on the first-year anniversary of the vesting commencement date, with the remainder of
the shares vesting in 36 equal monthly installments thereafter, subject to the recipient&#146;s continuous service through each applicable vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Puncochar was appointed as the Company&#146;s Chief Commercial Officer in May 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to a change in employment status, Ms.&nbsp;Puncochar&#146;s option awards were modified to allow for
immediate vesting of twenty five percent (25%) of the unvested total, a quantity of 55,375 options. The remaining balance of 166,125 options will vest in 36 equal monthly increments, approximately two point seven eight percent (2.78%) per month,
thereafter subject to continuous service and all other terms within the Award Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;&#151;Potential Payments and Benefits upon Termination or Change of Control&#148;
for a description of vesting acceleration applicable to stock options held by our named executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future, on an
annual basis or otherwise, grant additional equity awards to our executive officers pursuant to our Incentive Plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Benefits and Perquisites </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide benefits to our named executive officers on the same basis as provided to all of our employees, including health, dental and vision
insurance; life insurance; accidental death and dismemberment insurance; employee assistance program; life planning, financial and legal resources; and worldwide emergency travel assistance. We do not maintain any executive-specific benefit or
executive perquisite programs other than as provided in the agreements described in the section immediately below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the
director and officer insurance coverage we maintain for our directors and officers, we do not maintain any executive-specific health and welfare benefit or perquisites. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Health and Welfare Benefits and Perquisites </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide benefits to our named executive officers on the same basis as provided to all of our employees, including: health, dental and vision
insurance; life insurance; accidental death and dismemberment insurance; life planning financial and legal resources; and worldwide emergency travel assistance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>401(k) Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote&#146;s named executive
officers are eligible to participate in a defined contribution retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees may contribute a portion of their annual
compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor, <FONT STYLE="white-space:nowrap">non-elective</FONT> contribution to the 401(k) Plan equal to 3% of each
participant&#146;s eligible employee compensation. Safe harbor contributions vest immediately for each participant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below are descriptions of our employment agreements and arrangements with our named executive officers. The agreements generally provide for <FONT
STYLE="white-space:nowrap">at-will</FONT> employment without any specific term and set forth the named executive officer&#146;s initial base salary and annual target bonus. Each named executive officer is also eligible to participate in all employee
benefit plans that are generally available to our employees. Furthermore, each of our named executive officers has executed our standard employee confidential information and invention assignment agreement, which includes, among other things, <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teresa S. Weber </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote Medical entered into a services agreement with Ms.&nbsp;Weber effective as of May&nbsp;26, 2022. Ms.&nbsp;Weber&#146;s services agreement
provides that she will serve as the Chief Executive Officer of Biote and BioTE Management, LLC, and as a member of the Board, receive an annual base salary of $575,000 and be eligible for a discretionary annual cash bonus, with a target of 100% of
base salary based on annual performance standards to be established and determined by Biote in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
Ms.&nbsp;Weber&#146;s services agreement provides for severance benefits upon an involuntary termination. Ms.&nbsp;Weber&#146;s amended and restated employment agreement provides that if Ms.&nbsp;Weber&#146;s employment is terminated without cause
or with good reason she shall receive (a)&nbsp;continuation of her then-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
current base salary plus (b)&nbsp;payment of monthly COBRA premiums for continuation coverage under her medical, dental and life insurance plans coverage (if any) as in effect on the day prior to
the effective date of her termination, for a period of 18 months if such termination is in connection with a change in control event, or 12 months if such termination is not in connection with a change in control event. In addition, in the event
such termination is in connection with a change in control event, Ms.&nbsp;Weber shall also receive a monthly payment in an amount equal to 1/12<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of her then-current target bonus for a period of
18 months. Such payments are contingent on Ms.&nbsp;Weber&#146;s execution and nonrevocation of an effective written release of claims and the COBRA premium payments shall cease in the event Ms.&nbsp;Weber (i)&nbsp;becomes eligible for substantially
equivalent health insurance coverage in connection with new employment or self-employment or (ii)&nbsp;ceases to be eligible for COBRA continuation coverage. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mary Puncochar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2023,
Biote Medical entered into an employment agreement with Mary Puncochar, effective as of May&nbsp;30, 2023. Ms.&nbsp;Puncochar&#146;s employment agreement provides that she will serve as Biote&#146;s Chief Commercial Officer, receive an annual base
salary of $350,000 and be eligible for a discretionary annual cash bonus, with a target of 40% of base salary based on annual performance standards to be established and determined by Biote in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Ms.&nbsp;Puncochar&#146;s employment agreement provides that if Ms.&nbsp;Puncochar&#146;s employment is terminated without cause
or with good reason she shall receive (a)&nbsp;continuation of her then-current base salary plus (b)&nbsp;payment of monthly COBRA premiums for continuation coverage under her medical, dental and life insurance plans coverage (if any) as in effect
on the day prior to the effective date of her termination, for a period of 12 months if such termination is in connection with a change in control event, or 9 months if such termination is not in connection with a change in control event. In
addition, in the event such termination is in connection with a change in control event, Ms.&nbsp;Puncochar shall also receive a monthly payment an amount equal to 1/12<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of her then-current
target bonus for a period of 12 months. Such payments are contingent on Ms.&nbsp;Puncochar&#146;s execution and nonrevocation of an effective written release of claims and the COBRA premium payments shall cease in the event Ms.&nbsp;Puncochar
(i)&nbsp;becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment or (ii)&nbsp;ceases to be eligible for COBRA continuation coverage. Biote has also entered into an indemnification
agreement with Ms.&nbsp;Puncochar on the same terms as it has with its other directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2024,
Biote Medical entered into a change in employment status agreement with Ms.&nbsp;Puncochar, effective as of March&nbsp;10, 2024. Ms.&nbsp;Puncochar&#146;s change in employment status provides that she will serve as the Company&#146;s Head of
Strategic Sales&nbsp;&amp; Business Analytics, receive an annual base salary of $270,375 and be eligible for a discretionary annual cash bonus, with a target of 40% of the adjusted base salary based on annual performance standards. Further,
Ms.&nbsp;Puncochar&#146;s outstanding option awards will be modified to allow for immediate vesting of twenty five percent (25%) of the unvested total, a quantity of 55,375 options. The remaining balance of 166,125 options will vest in 36 equal
monthly increments, approximately two point seven eight percent (2.78%) per month, thereafter subject to continuous service and all other terms within the applicable award agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mary Elizabeth Conlon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;31,
2022, Biote Medical entered into an employment agreement with Mary Elizabeth Conlon, effective as of May&nbsp;26, 2022. Ms.&nbsp;Conlon&#146;s employment agreement provides that she will serve as Biote&#146;s Vice President, Business
Development&nbsp;&amp; General Counsel, receive an annual base salary of $395,400 and be eligible for a discretionary annual cash bonus, with a target of 40% of base salary based on annual performance standards to be established and determined by
Biote in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Ms.&nbsp;Conlon&#146;s employment agreement provides that if Ms.&nbsp;Conlon&#146;s employment
is terminated without cause or with good reason she shall receive (a)&nbsp;continuation of her then-current base salary plus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(b)&nbsp;payment of monthly COBRA premiums for continuation coverage under her medical, dental and life insurance plans coverage (if any) as in effect on the day prior to the effective date of
her termination, for a period of 12 months if such termination is in connection with a change in control event, or 9 months if such termination is not in connection with a change in control event. In addition, in the event such termination is in
connection with a change in control event, Ms.&nbsp;Conlon shall also receive a monthly payment an amount equal to 1/12<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of her then-current target bonus for a period of 12 months. Such payments
are contingent on Ms.&nbsp;Conlon&#146;s execution and nonrevocation of an effective written release of claims and the COBRA premium payments shall cease in the event Ms.&nbsp;Conlon (i)&nbsp;becomes eligible for substantially equivalent health
insurance coverage in connection with new employment or self-employment or (ii)&nbsp;ceases to be eligible for COBRA continuation coverage. Biote has also entered into an indemnification agreement with Ms.&nbsp;Conlon on the same terms as it has
with its other directors and executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments Upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreements for our named executive officers provide for severance and change in control benefits as described above under
&#147;&#151;Employment Arrangements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Benefit Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity-based compensation has been and will continue to be an important foundation in executive compensation packages as Biote believes it is
important to maintain a strong link between executive incentives and the creation of stockholder value. Biote believes that performance and equity-based compensation can be an important component of the total executive compensation package for
maximizing stockholder value while, at the same time, attracting, motivating and retaining high-quality executives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Equity Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s amended non-employee director compensation policy, effective as of March&nbsp;29, 2024, is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as
directors and to align our directors&#146; interests with those of our stockholders. Under this policy, we pay each of our non-employee directors a cash retainer for service on the Board and for service on each committee on which the director is a
member. Any non-executive chair and any lead director of the Board will each receive a higher retainer for such services. The chairperson of each committee will also receive a higher retainer for such service. These retainers are payable in arrears
in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on the Board or the applicable committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The retainers to be paid to non-employee directors for service on the Board and for service on each committee of the Board on which the
director is a member is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual</B><br><B>Service</B><br><B>Retainer</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Chairperson</B><br><B>Additional</B><br><B>Retainer&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The lead director will receive a retainer of $20,000, in addition to the annual service retainer.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An increase of $5,000. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Instead of receiving the foregoing retainers as a cash&nbsp;fee,&nbsp;non-employee&nbsp;directors&nbsp;may elect to receive an award of fully
vested deferred settlement RSUs in lieu of all, but no less than all, of such fees. Such RSUs will be granted on the same day as the annual grants (described below) are made and will be fully vested upon grant, but settlement of such RSUs will be
deferred until the earlier of (i)&nbsp;the date such director ceases to continue to serve as a director and (ii)&nbsp;such date as specified by the director in the election for such grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on the date of each annual meeting of stockholders, each non-employee director that continues to serve as a non-employee director
will receive an option to purchase shares of our Class A common stock with a grant value of $216,000. The shares subject to each annual option grant will vest in full on the earlier of the first anniversary of the grant date or the day prior to the
date of our next annual stockholder meeting, subject to the director&#146;s continued service as a director. The exercise price per share of these options will equal the fair market value of our Class&nbsp;A common stock on the date of grant. All
options granted under this policy will vest in full upon the occurrence of a change in control prior to the termination of the director&#146;s continuous service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each non-employee director may elect to convert his or her cash compensation into an award of restricted stock units, which we refer to as the
retainer grant. If a non-employee director timely makes this election, each such retainer grant will be automatically granted on the first business day following the date the corresponding cash compensation otherwise would be paid under the policy
and will cover a number of shares of our Common Stock equal to (A) the aggregate amount of the corresponding cash compensation otherwise payable to the non-employee director divided by (B) the closing sales price per share of our Common Stock on the
date the corresponding cash compensation otherwise would be paid (or, if such date is not a business day, on the first business day thereafter), rounded down to the nearest whole share. In addition, each retainer grant will be fully vested on the
grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, any member of the Board that is entitled to the above
compensation may elect to forego all or a portion of such compensation from time to time by giving notice to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation for
2023 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the compensation earned for service on the Board <FONT
STYLE="white-space:nowrap">by&nbsp;our&nbsp;non-employee&nbsp;directors&nbsp;during</FONT> the year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees</B><br><B>Earned</B><br><B>or</B><br><B>Paid&nbsp;in</B><br><B>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock</B><br><B>Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Awards<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(1)</SUP>&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive&nbsp;Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc D. Beer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,181,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217,600</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,651,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana Jacoby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Mark Cone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven J. Heyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew R. Heyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra L. Morris</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this column reflect the aggregate grant date fair value of the stock and option awards
granted to our directors as computed in accordance with ASC Topic 718. Note that the amounts reported in this column reflect the accounting cost for these awards and do not reflect the actual economic value that may be realized by the directors.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects performance-based cash bonus awarded to Mr.&nbsp;Beer. See &#147;&#151;Employment and Other
Arrangements&#151;Marc Beer&#148; above for a description of the material terms of the program pursuant to which this compensation will be awarded. The 2023 performance-based cash bonus for Mr.&nbsp;Beer is $217,600, reflecting an 85% achievement of
the Company&#146;s 2023 Corporate Goals. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The table below
<FONT STYLE="white-space:nowrap">shows&nbsp;each&nbsp;non-employee&nbsp;director&nbsp;who</FONT> was serving, and held outstanding equity awards, as of December&nbsp;31, 2023: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Underlying</B><br><B>Options</B><br><B>Outstanding</B><br><B>(Vested)&nbsp;at</B><br><B>Fiscal</B><br><B>Year&nbsp;End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Underlying</B><br><B>Options</B><br><B>Outstanding</B><br><B>(Unvested)</B><br><B>at&nbsp;Fiscal</B><br><B>Year&nbsp;End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vested</B><br><B>Stock</B><br><B>Awards</B><br><B>at</B><br><B>Fiscal</B><br><B>Year</B><br><B>End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested</B><br><B>Stock</B><br><B>Awards</B><br><B>at&nbsp;Fiscal</B><br><B>Year</B><br><B>End</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc D. Beer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana Jacoby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Mark Cone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven J. Heyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew R. Heyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra L. Morris</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY COMPENSATION PLAN INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate information of our equity compensation plans in effect as of December&nbsp;31, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan&nbsp;Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;securities</B><br><B>to&nbsp;be&nbsp;issued&nbsp;upon</B><br><B>exercise&nbsp;of</B><br><B>outstanding</B><br><B>options<SUP
STYLE="font-size:75%; vertical-align:top">1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-average</B><br><B>exercise&nbsp;price&nbsp;of</B><br><B>outstanding&nbsp;
options,</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number
of&nbsp;securities</B><br><B>remaining&nbsp;available</B><br><B>for</B><br><B>future&nbsp;issuance&nbsp;under</B><br><B>equity&nbsp;compensation</B><br><B>plans&nbsp;(excluding</B><br><B>securities&nbsp;reflected&nbsp;in</B><br><B>column&nbsp;(a))<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,556,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,090,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 Employee Stock Purchase Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,561,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,556,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,652,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes shares subject to outstanding awards under our 2022 Equity Incentive Plan as of December&nbsp;31,
2023, of which 8,141,716 shares are subject to outstanding options and 414,566 shares are subject to outstanding RSUs. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The weighted average exercise price is calculated based solely on the exercise prices of the outstanding
options and does not reflect the shares that will be issued upon the vesting of outstanding RSUs, which have no exercise price. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 8,090,746 shares available for future issuance under our 2022 Equity Incentive Plan and
1,561,744&nbsp;shares available for future issuance under our 2022 Employee Stock Purchase Plan. The number of shares available for future issuance under our 2022 Equity Incentive Plan will automatically increase on January&nbsp;1 of each year for a
period of ten years, from January&nbsp;1, 2023 through January&nbsp;1, 2032, in an amount equal to five percent (5%) of the total number of shares of the Company&#146;s capital stock outstanding on a fully diluted basis and securities convertible
into or exchangeable for the Company&#146;s capital stock on December&nbsp;31 of the preceding year; provided, however that the Board may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of
shares of Common Stock. The number of shares available for future issuance under our 2022 Employee Stock Purchase Plan will automatically increase on January&nbsp;1 of each year, from January&nbsp;1, 2023 through January&nbsp;1, 2032, in an amount
equal to the lesser of (i)&nbsp;1% of the total number of shares of capital stock outstanding and securities convertible into or exchangeable for the Company&#146;s capital stock on December 31st of the preceding calendar year, and (ii)&nbsp;797,724
shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first&nbsp;day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the
share reserve for such calendar year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than compensation and indemnification arrangements for our directors and executive officers, which are described elsewhere in this
registration statement, the following is a description of each transaction since January&nbsp;1, 2021 and each currently proposed transaction in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HYAC or Biote has been or is to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or exceeds the lesser of (i) $120,000 or (ii)&nbsp;one percent of the average of
our total assets on a consolidated basis at year end for the past two fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or holders of more than five percent of our outstanding capital stock,
or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biote&#146;s Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment
Relationships </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mandy Cotten, the daughter of Dr.&nbsp;Gary&nbsp;S. Donovitz, Biote&#146;s founder, former chairman and one of our
five percent or greater stockholders, was employed by BioTE Medical as a Clinic Director from September&nbsp;1, 2015 to June&nbsp;14, 2022. Mandy Cotten also provided services as a proctor and, from January&nbsp;1, 2021 to June&nbsp;14, 2022, Mandy
Cotten also managed Biote&#146;s therapy hotline. Mandy Cotten&#146;s compensation included an annual salary of $137,000 in addition to a potential bonus based on services performed for Biote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BioTE Medical granted Mandy Cotten phantom equity for her contributions as key personnel pursuant to that certain Phantom Equity Rights Grant
Notice and Award Agreement, dated January&nbsp;1, 2021, by and between BioTE Medical and Mandy Cotten (the &#147;Cotten Phantom Equity Award&#148;), which were forfeited as a result of her departure on June&nbsp;9, 2022. Pursuant to the Cotten
Phantom Equity Award, Mandy Cotten was entitled to receive a stated percentage of the net sales proceeds of a change in control paid or payable to Biote or Biote&#146;s Members. BioTE Medical&#146;s board of managers determined that the net sale
proceeds from the Business Combination was $555,000,000, and that such amount would be satisfied through the issuance of, in the aggregate, approximately 138,750 shares of the Company&#146;s Class&nbsp;A Common Stock to Mandy Cotten, to be issued in
eight equal quarterly installments following the Closing of the Business Combination; however, the Cotten Phantom Equity Award was forfeited as a result of her departure on June&nbsp;9, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lani Hammonds-Donovitz, the wife of Dr.&nbsp;Gary&nbsp;S. Donovitz, Biote&#146;s founder, former chairman and one of our five percent or
greater stockholders, was employed by BioTE Medical from January&nbsp;1, 2021 through April&nbsp;30, 2021 as Director, Business Development &#150; Research. Effective May&nbsp;1, 2021, Ms.&nbsp;Donovitz became an independent contractor of BioTE
Medical pursuant to that certain Independent Contractor Agreement with Lani D. Consulting, a company affiliated with Ms.&nbsp;Hammonds-Donovitz, which was terminated immediately prior to the Closing. Total compensation received by Ms.&nbsp;Donovitz
and Lani D. Consulting was $157,639 and $265,936 for the years ended December&nbsp;31, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Founder Advisory Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2022, BioTE Medical and Dr.&nbsp;Gary&nbsp;S. Donovitz, MD, the founder of BioTE Medical (the &#147;Founder Advisor&#148;),
entered into a Founder Advisory Agreement, effective as of the Closing (the &#147;Founder Advisory Agreement&#148;). Pursuant to the Founder Advisory Agreement, the Founder Advisor transitioned from an officer and manager of BioTE Medical into the
role of Founder Advisor and Senior Advisor (as defined in the Founder Advisory Agreement) as of the Closing. Pursuant to the Founder Advisory Agreement, Founder Advisor provides strategic advisory services to BioTE Medical for a period of four
years, unless terminated earlier pursuant to the terms of the Founder Advisory Agreement, and receives an annual fee equal to $300,000 per year, continued coverage under BioTE Medical&#146;s employee benefits and reimbursement for reasonable
business expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Independent Contractor Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2022, BioTE Medical entered into an Independent Contractor Agreement with Lani D. Consulting, a company affiliated with Lani
Hammonds Donovitz, the wife of Dr.&nbsp;Gary&nbsp;S. Donovitz, MD, Biote&#146;s founder and one of our five percent or greater stockholders (the &#147;<B><I>New Independent Contractor Agreement</I></B>&#148;). Immediately upon the Closing, the New
Independent Contractor Agreement replaced the Independent Contractor Agreement, dated as of May&nbsp;3, 2021, between Lani D. Consulting and BioTE Medical. Pursuant to the New Independent Contractor Agreement, Lani D. Consulting will provide certain
services to BioTE Medical for a period of four years, unless terminated earlier pursuant to the terms of the New Independent Contractor Agreement, and will receive an annual fee equal to $250,000 per year and reimbursement for reasonable business
expenses. The New Independent Contractor Agreement was terminated effective September&nbsp;9, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transactions in Connection with the
Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Receivable Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the Closing, Biote entered into a tax receivable agreement (the &#147;TRA&#148;) with Holdings, the Members and the
Members&#146; Representative. Pursuant to the TRA, Biote generally will be required to pay to the Members 85% of certain net tax benefits, if any, that we realize (or in certain cases are deemed to realize) as a result of the increases in tax basis
and tax benefits related to the transactions contemplated under the Business Combination Agreement and the redemption of Retained Holdings Units in exchange for Class&nbsp;A Common Stock (or cash) pursuant to the Holdings A&amp;R OA, and tax
benefits attributable to payments under the TRA. The term of the TRA will continue until all such tax benefits have been utilized or expired unless Biote exercises its right to terminate the TRA for an amount representing the present value of
anticipated future tax benefits under the TRA (calculated under certain assumptions) or certain other acceleration events occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsor Letter
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, certain of HYAC&#146;s then current officers and
directors, the Sponsor, Biote, Holdings and the Members&#146; Representative entered into the &#147;Sponsor Letter&#148;, pursuant to which, among other things, the Sponsor agreed to (i)&nbsp;vote, at any duly called meeting of stockholders of the
Company, in favor of the Business Combination Agreement and the transactions contemplated thereby, (ii)&nbsp;subject to certain exceptions, not to effect any sale or distribution of any of its shares of Class&nbsp;B common stock and (iii)&nbsp;waive
any and all anti-dilution rights described in the current charter or otherwise with respect to the shares of Class&nbsp;B common stock held by the Sponsor that may be implicated by the Business Combination such that the Class&nbsp;B common stock
Conversion will occur as discussed herein (and as more fully described in the Sponsor Letter). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A&amp;R Investor Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, Biote, the Members, the Sponsor, the Members&#146; Representative and certain other parties entered into an investor rights
agreement, which was amended and restated on July&nbsp;19, 2022, and which we refer to as the A&amp;R IRA. Pursuant to the terms of the A&amp;R IRA, among other things, (i)&nbsp;that certain Registration Rights Agreement, by and between HYAC and
certain security holders, dated March&nbsp;1, 2021, entered into in connection with HYAC&#146;s IPO, was terminated, (ii)&nbsp;the Company provided certain registration rights for the shares of Class&nbsp;A Common Stock held (or underlying certain
securities held) by the Members, the Sponsor, and certain other parties, (iii)&nbsp;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&nbsp;A Common Stock, Class&nbsp;V Voting
Stock and the Holdings Units held by such Members, as applicable, for six months following the Closing, and the Member Earnout Units until the date such securities have been earned in accordance with the Business Combination Agreement and
(iv)&nbsp;the Sponsor agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of its (a)&nbsp;shares of Class&nbsp;A Common Stock (other than the Sponsor Earnout Shares, as defined therein) for six months following
the Closing and (b)&nbsp;Sponsor Earnout Shares until the date such securities have been earned in accordance with the Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination Agreement, for 30 days following the Closing Date (such <FONT STYLE="white-space:nowrap">lock-up</FONT> period superseding the <FONT STYLE="white-space:nowrap">lock-up</FONT> period
set forth in the Insider Letter (as defined in the A&amp;R IRA)), in each case, as more fully described in the A&amp;R IRA). All <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions, other than those related to the Member Earnout Units and
the Sponsor Earnout Shares, have now expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the A&amp;R IRA does not purport to be complete and is
qualified in its entirety by the full text of the A&amp;R IRA, a copy of which is attached as Exhibit 10.3 hereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Second Amended and Restated
Operating Agreement of Biote </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, Biote, Holdings and the Members entered into the Holdings A&amp;R OA, which, among
other things, permitted the issuance and ownership of Holdings Units as contemplated to be issued and owned upon the consummation of the Business Combination, designated Biote as the sole manager of Holdings, provided for the Exchange Rights, set
forth the rights and preferences of the Class&nbsp;A common units of Holdings (&#147;Holdings Units&#148;), and established the ownership of the Holdings Units by the persons or entities indicated in the Holdings A&amp;R OA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Holdings A&amp;R OA does not purport to be complete and is qualified in its entirety by the full text of the
Holdings A&amp;R OA, a copy of which is attached as Exhibit 10.5 hereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director and Officer Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter contains provisions limiting the liability of directors and provides that the Biote will indemnify each of its directors and
officers to the fullest extent permitted under Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors
and executive officers. The indemnification agreements provide that Biote will indemnify each of its directors and executive officers against any and all expenses incurred by that director, executive officer, or other key employee because of his or
her status as one of the Biote&#146;s directors or executive officers to the fullest extent permitted by Delaware law, our Charter and our Bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware
law, the Biote will advance all expenses incurred by its directors and executive officers in connection with a legal proceeding involving his or her status as a director, executive officer, or key employee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Policies and Procedures for Related Person Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board adopted a written related person transaction policy that sets forth the policies and procedures for the review and approval or
ratification of related person transactions (the &#147;RPT Policy&#148;). The RPT policy requires that a &#147;related person&#148; (as defined in paragraph (a)&nbsp;of Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K)</FONT> must
promptly disclose to the our general counsel any &#147;related person transaction&#148; (defined as any transaction that is reportable under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> in which we are or will be a
participant and the amount involved exceeds $120,000 and in which any related person has or will have a direct or indirect material interest) and all material facts with respect thereto. The general counsel will promptly communicate such information
to the Audit Committee or another independent body of our Board. No related person transaction will be entered into without the approval or ratification of our Audit Committee or another independent body of our Board. Directors interested in a
related person transaction will be required to recuse themselves from any such vote. The RPT Policy does not specify the standards to be applied by its Audit Committee or another independent body of the Board in determining whether or not to approve
or ratify a related person transaction, although such determinations are made in accordance with Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_14"></A>PRINCIPAL SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our shares as of March&nbsp;11,&nbsp;2024 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known by us to be the beneficial owner of more than 5% of our Common Stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules and regulations of the SEC and the information is not necessarily
indicative of beneficial ownership for any other purpose. This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13G or 13D filed with the SEC. Except as indicated by the footnotes below, we
believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership is based on 74,531,558 shares of Common Stock outstanding as of March&nbsp;11, 2024, which includes
10,000,000 Earnout Voting Shares and 1,587,400 Sponsor Earnout Shares. In computing the number of shares beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by
the person that are currently exercisable, or exercisable or would vest based on service-based vesting conditions within 60 days of March&nbsp;11, 2024. However, except as described above, we did not deem such shares outstanding for the purpose of
computing the percentage ownership of any other person. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial
Owner<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven J. Heyer<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,101,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew R. Heyer<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,568,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana Jacoby<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc D. Beer<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,967,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Mark Cone<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra L. Morris<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,171,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary J. Puncochar<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All directors and executive officers as a group (10 individuals)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,367,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Greater than Five Percent Holders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Gary&nbsp;S.
Donovitz<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,418,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donovitz Family Irrevocable
Trust<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,279,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">325 Capital Entities<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,766,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bandera Partners LLC<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,832,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston Partners<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">831,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roystone Entities<SUP STYLE="font-size:75%; vertical-align:top">(17)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,188,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*Less than 1%. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise stated, the business address of each of these entities or individuals is 1875 W Walnut Hill Ln
#100, Irving, TX 75038, United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,101,725 shares of Class&nbsp;A common stock (which includes 126,132 Sponsor Earnout Shares),
and (ii) 40,500 shares of Class&nbsp;A common stock issuable upon the exercise of options within 60&nbsp;days of March&nbsp;10, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) (a) 1,746,262 shares of Class&nbsp;A common stock (which includes 237,369 Sponsor Earnout
Shares) and (b) 52,509 shares of Class&nbsp;A common stock issuable upon the exercise of options within 60&nbsp;days of March&nbsp;10, 2024 held by Mr.&nbsp;Andrew Heyer, (ii) 392,185 shares of Class&nbsp;A common stock (which includes 42,375
Sponsor Earnout Shares) held by Heyer Investment Management, LLC, (iii) 73,044 shares of Class&nbsp;A common stock (which includes 10,593 Sponsor Earnout Shares) held by Harris Reid Heyer Trust, (iv) 73,044 shares of Class&nbsp;A common stock (which
includes 10,593 Sponsor Earnout Shares) held by James Heyer Trust, (v) 73,044 shares of Class&nbsp;A common stock (which includes 10,593 Sponsor Earnout Shares) held by Peter Justin Heyer Trust, (vi) 73,044 shares of Class&nbsp;A common stock (which
includes 10,593 Sponsor Earnout Shares) held by William Heyer Trust, and (vii) 137,559 shares of Class&nbsp;A common stock (which includes 26,484 Sponsor Earnout Shares) held by the Mindy B. Heyer 2021 Grantor Retained Annuity Trust. Mr.&nbsp;Andrew
Heyer is (i)&nbsp;a trustee of each of Harris Reid Heyer Trust, James Heyer Trust, Peter Justin Heyer Trust, and William Heyer Trust; and (ii)&nbsp;the managing member of Heyer Investment Management, LLC, and has voting and dispositive power of the
securities held by such entities. Accordingly, Mr.&nbsp;Andrew Heyer may be deemed to have or share beneficial ownership of such securities. In addition, Mr.&nbsp;Andrew Heyer&#146;s spouse is the sole trustee, grantor and recipient of annuity
payments of the Mindy B. Heyer 2021 Grantor Retained Annuity Trust. Mr.&nbsp;Andrew Heyer disclaims beneficial ownership of the securities held by the Mindy B. Heyer 2021 Grantor Retained Annuity Trust, and the filing of this report should not be
deemed an admission that Mr.&nbsp;Andrew Heyer is the beneficial owner of such securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 82,666 shares of Class&nbsp;A common stock, (ii) 11,595 deferred restricted stock units
(&#147;DRSUs&#148;) and (iii) 31,696 shares of Class&nbsp;A common stock issuable upon the exercise of options within 60&nbsp;days of March&nbsp;11, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,967,092 shares of Class&nbsp;A common stock underlying Class&nbsp;V voting stock (which includes
654,387 Earnout Voting Shares). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 163,945 shares of Class&nbsp;A common stock; (ii) 11,595 DRSUs and (iii) 9,524 shares of
Class&nbsp;A common stock issuable upon the exercise of options within 60 days of March&nbsp;11, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 70,806 shares of Class&nbsp;A common stock; (ii) 9,110 DRSUs and (iii) 31,696 shares of
Class&nbsp;A common stock issuable upon the exercise of options within 60 days of March&nbsp;11, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 2,967,092 shares of Class&nbsp;A common stock underlying Class&nbsp;V voting stock (which
includes 654,387 Earnout Voting Shares) and (ii) 204,519 shares of Class&nbsp;A common stock issuable upon the exercise of options within 60 days of March&nbsp;11, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 176,955 shares of Class&nbsp;A common stock and (ii) 36,562 shares of Class&nbsp;A common stock
issuable upon the exercise of options within 60 days of March&nbsp;11, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 64,604 shares of Class&nbsp;A common stock issuable upon the exercise of options within 60 days
of March&nbsp;11, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 5,075,090 shares of Class&nbsp;A common stock held by the Gary S. Donovitz 2012 Irrevocable
Trust (formerly Marci M. Donovitz Trust) (ii) 848,726 shares of Class&nbsp;A common stock underlying Class&nbsp;V common stock (which includes 144,918 Earnout Voting Shares) held by BioTE Management, LLC, of which Dr.&nbsp;Donovitz is the sole
member; and (iii) 16,494,946 shares of Class&nbsp;A common stock underlying Class&nbsp;V common stock (which includes 3,840,969 Earnout Voting Shares) held by the Gary S. Donovitz 2012 Irrevocable Trust (formerly Marci M. Donovitz Trust).
Dr.&nbsp;Donovitz is the trustee of the Gary S. Donovitz 2012 Irrevocable Trust (formerly Marci M. Donovitz Trust) and exercises sole voting and dispositive power over the shares held by the trust. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 12,279,107 shares of Class&nbsp;A common stock underlying Class&nbsp;V common stock (which includes
3,985,887 Earnout Voting Shares) held by the Donovitz Family Irrevocable Trust, of which Marci Donovitz is the trustee and beneficial owner. The business address of the Donovitz Family Irrevocable Trust is Synergy Wealth Partners, 600 N Shepherd
Drive, Suite 200, Houston, TX 77007. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information based on Form 3 filed with the SEC on June&nbsp;15, 2023, which report beneficial ownership of each
of: (i) 325 Capital Master Fund LP (&#147;325 Master Fund&#148;); (ii) 325 Capital GP LLC (&#147;325 Capital GP&#148;), the general partner of 325 Master Fund; (iii) 325 Capital LLC (&#147;325&#148;), the investment manager to 325
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Master Fund; (iv)&nbsp;Michael D. Braner; (v)&nbsp;Daniel M. Friedberg and (vi)&nbsp;Anil K Shrivastava (collectively the &#147;325 Capital Entities&#148;). This filing indicates that (i) 325
Capital LLC holds 3,108,618 shares of Class&nbsp;A common stock; (ii) 325 Capital Master Fund LP holds 658,048 shares of Class&nbsp;A common stock; (iii)&nbsp;Mr.&nbsp;Braner, Mr.&nbsp;Friedberg and Mr.&nbsp;Shrivastava (collectively, the
&#147;Managing Members&#148; of 325). As a result, the Managing Members may be deemed to beneficially own the securities directly owned by 325 Master Fund. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information based on the Schedule 13G filed with the SEC on February&nbsp;13, 2024, which reports beneficial
ownership for each of (i)&nbsp;Bandera Partners LLC; (ii)&nbsp;Gregory Bylinsky and (iii)&nbsp;Jefferson Gramm. Bandera Partners is the investment manager of Bandera Master Fund and may be deemed to have beneficial ownership over the Shares held by
Bandera Master Fund by virtue of the sole and exclusive authority granted to Bandera Partners by Bandera Master Fund to vote and dispose of such Shares. Messrs. Bylinsky and Gramm are Managing Members of Bandera Partners and may be deemed to
beneficially own the Shares held by Bandera Master Fund. Bandera Master Fund specifically disclaims beneficial ownership of the Shares held by it by virtue of its inability to vote or dispose of such Shares. The shares of Class&nbsp;A common stock
beneficially owned by Bandera Partners LLC represent approximately 5.4% of the outstanding shares of Class&nbsp;A common stock. The business address for Bandera Partners LLC is 50 Broad Street, Suite 1820, New York, New York 10004.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information based on the Schedule 13G filed with the SEC on February&nbsp;13, 2024. The shares of Class&nbsp;A
common stock beneficially owned by Boston Partners, represent approximately 2.45% of the outstanding shares of Class&nbsp;A common stock. The business address of Boston Partners is One Beacon Street, 30th Floor, Boston, MA 02108.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information based on the Schedule 13G, Form 3 and Form 4 filed with the SEC on February&nbsp;14, 2024, which
report beneficial ownership for each of: (i)&nbsp;Roystone Capital Management LP (&#147;Roystone Management&#148;); (ii) Roystone Capital Holdings LLC (&#147;Roystone Capital&#148;); (iii) Guines LLC and (iv)&nbsp;Richard Barrerra (together with
Roystone Management, Roystone Capital and Guines LLC, the &#147;Roystone Entities&#148;). These filings indicate that (i)&nbsp;Guines LLC holds 3,188,268 shares of Class&nbsp;A common stock (which includes 117,330 Sponsor Earnout Shares), (ii) each
of the entities or individuals listed above has shared power to vote and dispose of such shares of Class&nbsp;A common stock and (iii)&nbsp;none of the entities or individuals listed above has sole power to vote or dispose of such shares of
Class&nbsp;A common stock. The shares of Class&nbsp;A common stock beneficially owned by the Roystone Entities, in the aggregate, represent approximately 9% of the outstanding shares of Class&nbsp;A common stock. The business address of the Roystone
Entities is 767 Third Avenue, 29th Floor, New York, NY 10017. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_15"></A>SELLING SECURITYHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale by Yorkville of up to 5,000,000 shares of Class&nbsp;A common stock that have been and may be
issued by us to Yorkville under the Purchase Agreement. For additional information regarding the shares of Class&nbsp;A common stock included in this prospectus, see the section entitled &#147;Committed Equity Financing&#148; above. We are
registering the shares of Common Stock included in this prospectus pursuant to the provisions of the Purchase Agreement we entered into with Yorkville on July&nbsp;27, 2022 in order to permit the Selling Securityholder to offer the shares included
in this prospectus for resale from time to time. Except for the transactions contemplated by the Purchase Agreement, and as set forth in the section entitled &#147;Plan of Distribution&#148; in this prospectus, Yorkville has not had any material
relationship with us within the past three years. As used in this prospectus, the term &#147;Selling Securityholder&#148; and &#147;Yorkville&#148; mean YA II PN, LTD., a Cayman Islands exempt limited partnership. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the Selling Securityholder and the shares of Common Stock that may be resold by the Selling
Securityholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholder, and reflects holdings as of July&nbsp;28, 2022. The number of shares in the column &#147;Maximum Number
of Shares of Common Stock to be Offered Pursuant to this Prospectus&#148; represents all of the shares of Common Stock being offered for resale by the Selling Securityholder under this prospectus. The Selling Securityholder may sell some, all or
none of the shares being offered for resale in this offering. We do not know how long the Selling Securityholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling Securityholder and any
other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our Common Stock being offered for resale by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> promulgated by the SEC under the
Exchange Act, and includes shares of Common Stock with respect to which the Selling Securityholder has sole or shared voting and investment power. The percentage of shares of Common Stock beneficially owned by the Selling Securityholder prior to the
offering shown in the table below is based on an aggregate of 74,531,558 shares of our Common Stock outstanding on March&nbsp;11, 2024. Because the purchase price to be paid by the Selling Securityholder for shares of Common Stock, if any, that we
may elect to sell to the Selling Securityholder in one or more Advances from time to time under the Purchase Agreement will be determined on the applicable Advance Dates for such Advances, the actual number of shares of Class&nbsp;A common stock
that we may sell to the Selling Securityholder under the Purchase Agreement may be fewer than the number of shares being offered for resale under this prospectus. The fourth column assumes the resale by the Selling Securityholder of all of the
shares of Class&nbsp;A common stock being offered for resale pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in
accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the Selling Securityholder has sole voting and investment power with respect to all shares of Class&nbsp;A
common stock that they beneficially own, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the Selling Securityholder, the Selling Securityholder is not a broker-dealer or
an affiliate of a broker-dealer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares&nbsp;of&nbsp;Common<BR>Stock Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum&nbsp;Number<BR>of<BR>Shares&nbsp;of&nbsp;Common<BR>Stock&nbsp;Being&nbsp;Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock<BR>Beneficially<BR>Owned&nbsp;After&nbsp;the&nbsp;Offered&nbsp;Shares<BR>of<BR>Common Stock are Sold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Name of Selling<BR>Securityholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">YA II PN, LTD.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (i) 25,000 shares of Common Stock we issued to Yorkville on July&nbsp;27, 2022 as Commitment Shares
in consideration for entering into the Purchase Agreement with us, (ii) 40,000 shares of Common Stock we issued to Yorkville on September&nbsp;16, 2022 and (iii) 65,559 shares of Common Stock we issued to Yorkville October&nbsp;20, 2022. In
accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that Yorkville may be required to purchase under the
Purchase Agreement, because the issuance of such shares is at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of Yorkville&#146;s control, including the registration
statement that includes this prospectus becoming and remaining effective. Furthermore, the Advances of Common Stock under the Purchase Agreement are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also,
the Purchase Agreement prohibits us from issuing and selling any shares of our Common Stock to Yorkville to the extent such shares, when aggregated with all other shares of our Common Stock then beneficially owned by Yorkville, would cause
Yorkville&#146;s beneficial ownership of our Common Stock to exceed the 4.99% Beneficial Ownership Limitation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Applicable percentage ownership is based on 74,531,558 shares of our Common Stock outstanding as of
March&nbsp;11, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes the sale of all shares being offered pursuant to this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yorkville is a fund managed by Yorkville Advisors Global, LP (&#147;Yorkville LP&#148;). Yorkville Advisors
Global II, LLC (&#147;Yorkville LLC&#148;) is the General Partner of Yorkville LP. All investment decisions for YA II PN, LTD are made by Yorkville LLC&#146;s President and Managing Member, Mr.&nbsp;Mark Angelo. The business address of YA is 1012
Springfield Avenue, Mountainside, NJ 07092. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_16"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and
preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you, and is qualified by reference to our Charter, the Bylaws and the Investor Rights Agreement, which are exhibits to
the registration statement of which this prospectus is a part. We urge you to read each of the Charter, the Bylaws and the Investor Rights Agreement, which are filed as exhibits to this registration statement, in their entirety for a complete
description of the rights and preferences of our securities. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized and Outstanding Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter authorizes the issuance of 718,000,000 shares, consisting of 708,000,000 shares of common stock, including (i) 600,000,000 shares
of Class&nbsp;A common stock, (ii) 8,000,000 shares of Class&nbsp;B common stock, and (iii) 100,000,000 shares of Class&nbsp;V voting stock, and 10,000,000 shares of preferred stock. The outstanding shares of our common stock are, and the shares of
Common Stock issuable pursuant to the Exchange Rights will be, duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> These numbers of holders do not include DTC participants or beneficial owners
holding shares through nominee names. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of Holdings Units equal to the number of Sponsor Earnout Shares (the Sponsor Earnout
Units together with the Sponsor Earnout Shares, the Earnout Voting Shares and the Member Earnout Units, the &#147;Earnout Securities&#148;), are subject to certain restrictions and potential forfeiture pending the achievement (if any) of certain
earnout targets pursuant to the terms of the Business Combination Agreement or the occurrence of a Change of Control. The Earnout Securities have voting rights but no right to dividends or distributions (except for certain tax distributions from
Biote in accordance with the Holdings A&amp;R OA) until such restrictions and potential forfeiture have lapsed. One third of each of the Member Earnout Units, Earnout Voting Shares, Sponsor Earnout Shares and Sponsor Earnout Units will vest upon the
occurrence of each of the following events: (i)&nbsp;the first time, prior to the Earnout Deadline, the VWAP equals or exceeds $12.50 per share for 20 consecutive trading days of any 30 consecutive trading day period following the Closing Date,
(ii)&nbsp;the first time, prior to the Earnout Deadline, the VWAP equals or exceeds $15.00 per share for 20 trading days of any 30 consecutive trading day period following the Closing, and (iii)&nbsp;the first time, prior to the Earnout Deadline,
the VWAP equals or exceeds $17.50 per share for 20 trading days of any 30 consecutive trading day period following the Closing. If a definitive agreement with respect to a Change of Control is entered into on or prior to the Earnout Deadline, then
effective as of immediately prior to closing of such Change of Control, unless previously vested pursuant to clauses (i)&nbsp;through (iii) of the preceding sentence, each of the Member Earnout Units, Earnout Voting Shares, Sponsor Earnout Shares
and Sponsor Earnout Units will vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on the six month anniversary of the Closing Date, each Retained Holdings Unit held by the
Members may be redeemed, together with one share of Class&nbsp;V voting stock and subject to certain conditions, in exchange for either one share of Class&nbsp;A common stock or in certain circumstances, at the election of the Company in its
capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&nbsp;A common stock, pursuant to the terms and conditions of the Holdings A&amp;R OA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock consists
of shares of Class&nbsp;A common stock, Class&nbsp;B common stock and Class&nbsp;V voting stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Power </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or the Charter (including any preferred stock designation), the holders of common stock exclusively possess
all voting power with respect to the Company. Except as otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required by law or the Charter (including any preferred stock designation), the holders of shares of common stock are entitled to one vote per share on each matter properly submitted to the
stockholders on which the holders of the common stock are entitled to vote. Except as otherwise required by law or the Charter (including any preferred stock designation), at any annual or special meeting of the stockholders of the Company, holders
of the Class&nbsp;A common stock and holders of the Class&nbsp;V voting stock, voting together as a single class, have the exclusive right to vote for the election of directors and on all other matters properly submitted to a vote of the
stockholders. Notwithstanding the foregoing, except as otherwise required by law or the Charter (including any preferred stock designation), holders of shares of any series of common stock are not entitled to vote on any amendment to the Charter
(including any amendment to any preferred stock designation) that relates solely to the terms of one or more outstanding series of preferred stock or other series of common stock if the holders of such affected series of preferred stock or common
stock, as applicable, are entitled exclusively, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Charter (including any preferred stock designation) or the Delaware General Corporate
Law (the &#147;DGCL&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class&nbsp;B Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or the Charter (including any preferred stock designation), for so long as any shares of Class&nbsp;B
common stock shall remain outstanding, the Company shall not, without the prior vote or written consent of the holders of a majority of the shares of Class&nbsp;B common stock then outstanding, voting separately as a single class, amend, alter or
repeal any provision of the Charter, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or change the powers, preferences or relative, participating, optional or other or special rights of the
Class&nbsp;B common stock. Any action required or permitted to be taken at any meeting of the holders of Class&nbsp;B common stock may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting
forth the action so taken, shall be signed by the holders of the outstanding Class&nbsp;B common stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of
Class&nbsp;B common stock were present and voted and shall be delivered to the Company by delivery to its registered office in the State of Delaware, its principal place of business, or to the Secretary of the Company or another officer or agent of
the Company having custody of the book in which minutes of proceedings of stockholders are recorded. Delivery made to the Company&#146;s registered office shall be by hand or by certified or registered mail, return receipt requested. Prompt written
notice of the taking of corporate action without a meeting by less than unanimous written consent of the holders of Class&nbsp;B common stock shall, to the extent required by law, be given to those holders of Class&nbsp;B common stock who have not
consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by a sufficient number of holders
of Class&nbsp;B common stock to take the action were delivered to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our &#147;Economic Common Stock&#148; means Class&nbsp;A common stock together with Class&nbsp;B common stock. Subject to applicable law, the
rights, if any, of the holders of any outstanding series of preferred stock and the provisions of the Charter, holders of shares of Economic Common Stock will be entitled to receive dividends and other distributions (payable in cash, property or
capital stock of the Company), when, as and if declared thereon by our Board from time to time out of any assets or funds of the Company legally available therefor and shall share equally on a per share basis in such dividends and distributions.
Dividends or distributions of cash, property or shares of capital stock of the Company may not be declared or paid on the Class&nbsp;V voting stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation, Dissolution and Winding Up </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law, the rights, if any, of the holders of any outstanding series of preferred stock and the provisions of the Charter,
in the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, after payment or provision for payment of the debts and other liabilities of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company, the holders of shares of Economic Common Stock shall be entitled to receive all the remaining assets of the Company available for distribution to its stockholders, ratably in
proportion to the number of shares of Economic Common Stock held by them. The holders of shares of Class&nbsp;V voting stock will not be entitled to receive, with respect of such shares, any assets of the Company in excess of the par value thereof,
in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive or Other Rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable
to our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Election of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is divided into three classes, with only one class of directors being elected in each year and each class (except for those directors
appointed prior to the first annual meeting of stockholders of Biote) generally serving a term of three years. As described in our Charter, our initial Class&nbsp;I directors serve until the next annual meeting of stockholders following the Closing,
initial Class&nbsp;II directors serve until the second annual meeting of stockholders following the Closing and initial Class&nbsp;III directors serve until the third annual meeting of stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter provides
that shares of preferred stock may be issued from time to time in one or more series. Our Board is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any
qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board is able, without stockholder approval, to issue preferred stock with voting and other rights that could adversely affect the voting power and
other rights of the holders of the common stock and could have anti-takeover effects. The ability of our Board to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of us
or the removal of existing management. We have no preferred stock outstanding at the date hereof. Although we do not currently intend to issue any shares of preferred stock, we cannot assure you that we will not do so in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid any cash
dividends on our common stock to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends is within the
discretion of our Board. Our Board is not currently contemplating and does not anticipate declaring any stock dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive
covenants we may agree to in connection therewith. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent for our common stock is Continental Stock Transfer&nbsp;&amp; Trust Company. We have agreed to indemnify Continental Stock
Transfer&nbsp;&amp; Trust Company in its roles as transfer agent, its agents and each of its stockholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that
capacity, except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity. Continental Stock Transfer&nbsp;&amp; Trust Company has agreed that it has no right of <FONT
STYLE="white-space:nowrap">set-off</FONT> or any right, title, interest or claim of any kind to, or to any monies in, the trust account, and has irrevocably waived any right, title, interest or claim of any kind to, or to any monies in, the trust
account that it may have now or in the future. Accordingly, any indemnification provided will only be able to be satisfied, or a claim will only be able to be pursued, solely against us and our assets outside the trust account and not against the
any monies in the trust account or interest earned thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Anti-Takeover Provisions of Delaware Law and the Company&#146;s Charter and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time when we have a class of voting stock that is either listed on a national securities exchange or held of record by more than 2,000
stockholders, we will be subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date
that such stockholder became an interested stockholder, subject to certain exceptions. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &#147;business combination&#148; with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#147;interested
stockholder&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Affiliate of an interested stockholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an associate of an interested stockholder, for three years following the date that the stockholder became an
interested stockholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;business combination&#148; includes a merger or sale of more than 10% of our assets.
However, the above provisions of Section&nbsp;203 do not apply if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Board approves the transaction that made the stockholder an &#147;interested stockholder,&#148; prior to the
date of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that
stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to the date of the transaction, the business combination is approved by our Board and authorized
at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter opts out of Section&nbsp;203 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter contains certain limitations on convening special stockholder meetings. In addition, the prior charter and the Charter do not
provide for cumulative voting in the election of directors. Our Board is empowered to elect a director to fill a vacancy created by the expansion of the Board or the resignation, death, or removal of a director in certain circumstances; and our
advance notice provisions require that stockholders must comply with certain procedures in order to nominate candidates to our Board or to propose matters to be acted upon at a stockholders&#146; meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be
utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more
difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forum Selection Clause
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State
of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring: (i)&nbsp;any derivative action or proceeding brought on behalf of the Company; (ii)&nbsp;any action asserting a claim of breach of
fiduciary duty owed by any of the Company&#146;s directors, officers or other employees of the Company to the Company or its stockholders; (iii)&nbsp;any action asserting a claim against the Company, its directors, officers or employees arising
pursuant to any provision of the DGCL or the Charter or Bylaws; or (iv)&nbsp;any action asserting a claim against the Company, its directors, officers or employees governed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the internal affairs doctrine and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#146;s counsel
except any action (A)&nbsp;as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the
Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C)&nbsp;for which the Court of Chancery does not have subject matter
jurisdiction. Unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act. Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and stockholders cannot waive compliance
with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act.
Notwithstanding the foregoing, the forum selection clause will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America shall be
the sole and exclusive forum. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144 promulgated by the SEC under the Securities Act, as may be amended from time to time (&#147;Rule 144&#148;), a person who
has beneficially owned restricted shares of our common stock for at least six months would be entitled to sell their securities provided that, (i)&nbsp;such person is not deemed to have been one of our Affiliates at the time of, or at any time
during the three months preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&nbsp;13 or 15(d) of the Exchange
Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially
owned restricted shares of our common stock for at least six months but who are our Affiliates at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be
entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the total number of shares of Class&nbsp;A common stock then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly reported trading volume of the Class&nbsp;A common stock during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales by our Affiliates under Rule 144 are also
limited by manner of sale provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the Members, the Sponsor, the Members&#146; Representative and certain other parties are party to an investor rights agreement,
which was amended on July&nbsp;19, 2022, or the A&amp;R IRA, pursuant to which, (i)&nbsp;the Company provided certain registration rights for the shares of Class&nbsp;A common stock held by the Members, the Sponsor, and certain other parties,
(ii)&nbsp;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&nbsp;A common stock, shares of Class&nbsp;V voting stock and Holdings Units held by such Members for six months
following the Closing, and the Member Earnout Units until the date such securities have been earned in accordance with the Business Combination Agreement and (v)&nbsp;the Sponsor agreed not to, subject to certain exceptions, transfer, sell, assign
or otherwise dispose of its (a)&nbsp;shares of Class&nbsp;A common stock (other than the Sponsor Earnout Shares) for six months following the Closing and (b)&nbsp;Sponsor Earnout Shares until the date such securities have been earned in accordance
with the Business Combination Agreement (in each case, as more fully described in the A&amp;R IRA). All <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions, other than those related to the Member Earnout Units and the Sponsor Earnout
Shares, have expired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing of Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&nbsp;A Common Stock are listed on the Nasdaq Stock Market LLC under the symbol &#147;BTMD&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_17"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of certain U.S. federal income tax considerations generally applicable to the ownership and disposition
of our Class&nbsp;A common stock. This summary is based upon U.S. federal income tax law as of the date of this prospectus, which is subject to change or differing interpretations, possibly with retroactive effect. This summary does not discuss all
aspects of U.S. federal income taxation that may be important to particular investors in light of their individual circumstances, including investors subject to special tax rules (e.g., financial institutions, insurance companies, broker-dealers,
dealers or traders in securities, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations (including private foundations), qualified retirement plans, taxpayers that have elected <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> accounting, S corporations, partnerships and pass-through entities for U.S. federal income tax purposes (and investors in such entities), regulated investment companies, real estate investment
trusts, passive foreign investment companies, controlled foreign corporations, U.S. Holders (as defined below) that hold Class&nbsp;A common stock as part of a straddle, hedge, conversion, or other integrated transaction for U.S. federal income tax
purposes or that received our Class&nbsp;A common stock as compensation, holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), former citizens or long-term residents of the
United States, or U.S. Holders that have a functional currency other than the U.S. dollar), all of whom may be subject to tax rules that differ materially from those summarized below. This summary does not discuss U.S. federal <FONT
STYLE="white-space:nowrap">non-income</FONT> tax consequences (e.g., estate or gift tax), any state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations, the Medicare contribution tax, the alternative minimum tax, or the
special tax accounting rules under Section&nbsp;451(b) of the Code. In addition, this summary is limited to investors that will hold our Class&nbsp;A common stock as a &#147;<I>capital asset</I>&#148; (generally, property held for investment) under
the Code, and that acquire our Class&nbsp;A common stock for cash pursuant to this prospectus. No ruling from the IRS or opinion of counsel has been or will be sought regarding any matter discussed herein. No assurance can be given that the IRS
would not assert, or that a court would not sustain, a position contrary to any of the tax aspects set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this
summary, a &#147;<I>U.S. Holder</I>&#148; is a beneficial holder of our Class&nbsp;A common stock that, for U.S. federal income tax purposes is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a U.S. citizen or resident of the United States, as determined for U.S. federal income tax
purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity treated as a corporation for United States federal income tax purposes created in,
or organized under the law of, the United States or any state or political subdivision thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of
its source; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (A)&nbsp;the administration of which is subject to the primary supervision of a United States court and
which has one or more United States persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) who have the authority to control all substantial decisions of the trust or (B)&nbsp;that has in effect a valid election under applicable U.S.
Department of Treasury regulations (the &#147;Treasury Regulations&#148;) to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our Class&nbsp;A
common stock, the tax treatment of a partner, member or other beneficial owner in such partnership generally will depend upon the status of the partner, member or other beneficial owner, the activities of the partnership and certain determinations
made at the partner, member or other beneficial owner level. If you are a partner, member or other beneficial owner of a partnership holding our Class&nbsp;A common stock, you are urged to consult your tax advisor regarding the tax consequences of
the ownership and disposition of our Class&nbsp;A common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL
INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE HOLDERS SHOULD CONSULT THEIR TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CONSEQUENCES TO THEM OF OWNING AND DISPOSING OF OUR CLASS A COMMON STOCK, AS WELL AS THE APPLICATION OF ANY, STATE, LOCAL AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> INCOME, ESTATE AND
OTHER TAX CONSIDERATIONS AND THE EFFECT OF ANY TAX TREATIES. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Considerations For U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
make distributions to U.S. Holders in respect of shares of our Class&nbsp;A common stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S.
Holder&#146;s adjusted tax basis in our Class&nbsp;A common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Class&nbsp;A common stock and will be treated as described under &#147;<I>U.S. Federal
Income Tax Considerations For U.S. Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Class</I><I></I><I>&nbsp;A Common Stock</I>&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation generally will qualify for the dividends received deduction if the requisite
holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder generally will constitute &#147;<I>qualified dividends</I>&#148; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. If the applicable holding period
requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders
may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain
or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Class&nbsp;A Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize
gain or loss on the sale, taxable exchange or other taxable disposition of our Class&nbsp;A common stock. Any such gain or loss generally will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#146;s holding
period for the Class&nbsp;A common stock so disposed of exceeds one year. The amount of gain or loss recognized generally will be equal to the difference between (1)&nbsp;the sum of the amount of cash and the fair market value of any property
received by the U.S. Holder in such disposition and (2)&nbsp;the U.S. Holder&#146;s adjusted tax basis in its Class&nbsp;A common stock so disposed of. A U.S. Holder&#146;s adjusted tax basis in its Class&nbsp;A common stock generally will equal the
U.S. Holder&#146;s acquisition cost for such Class&nbsp;A common stock, less any prior distributions treated as a return of capital. If a U.S. Holder received Class&nbsp;A common stock in a taxable exchange for property other than cash, the U.S.
Holder&#146;s acquisition cost generally will be the fair market value of the Class&nbsp;A common stock received in the exchange. Long-term capital gains recognized by <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders generally are
eligible for reduced rates of U.S. federal income tax. If the U.S. Holder&#146;s holding period for the Class&nbsp;A common stock so disposed of is one year or less, any gain on such sale or other taxable disposition would be subject to short-term
capital gain treatment and generally would be subject to U.S. federal income tax at ordinary income tax rates. The deductibility of capital losses is subject to limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other
disposition of shares of Class&nbsp;A common stock, unless the U.S. Holder is an exempt recipient. Backup withholding (currently at a rate of 24%) may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number, a
certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup
withholding rules will be allowed as a credit against a U.S. Holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Income Tax Considerations For <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the term &#147;<I><FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder</I>&#148; means a beneficial owner of Class&nbsp;A
common stock, who or that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign corporation or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate or trust that is not a U.S. Holder; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of disposition
(except to the extent specifically set forth below). If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our Class&nbsp;A
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, any distributions we make to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder in respect of our Class&nbsp;A common stock,
to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes. Subject to the withholding requirements under
Sections 1471 through 1474 of the Code and the U.S. Treasury regulations and administrative guidance issued thereunder, collectively &#147;<I>FATCA</I>,&#148; and, provided such dividends are not effectively connected with the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable). Any distribution not constituting a dividend will be treated first as reducing (but not below zero)
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s adjusted tax basis in its shares of our Class&nbsp;A common stock and, to the extent such distribution exceeds the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s
adjusted tax basis, as gain realized from the sale or other disposition of the Class&nbsp;A common stock, which will be treated as described under &#147;<I>U.S. Federal Income Tax Considerations For <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of Class</I><I></I><I>&nbsp;A Common Stock</I>&#148; below. In addition, if we determine that we are likely to be classified as a &#147;<I>United States real property holding
corporation</I>&#148; (see &#147;<I>U.S. Federal Income Tax Considerations For <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders-Gain on Sale, Exchange or Other Taxable Disposition of Class</I><I></I><I>&nbsp;A Common Stock</I>&#148; below),
we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder that are effectively connected with such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (or if a tax treaty applies are
attributable to a U.S. permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder) generally will not be subject to the U.S. withholding tax described above, provided such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI).</FONT> Instead, such dividends generally will be subject
to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder is a corporation, dividends that are effectively
connected income may also be subject to a &#147;<I>branch profits tax</I>&#148; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain on Sale, Exchange or Other Taxable Disposition of Class&nbsp;A Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax in respect of
gain recognized on a sale, taxable exchange or other taxable disposition of our Class&nbsp;A common stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the conduct of a trade or business by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder is an individual who is present in the United States
for 183 days or more in the taxable year of disposition and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are or have been a &#147;<I>United States real property holding corporation</I>&#148; for U.S. federal income
tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder held our Class&nbsp;A common stock and, in the case where shares of
our Class&nbsp;A common stock are regularly traded on an established securities market, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder has owned, directly or constructively, more than 5% of our Class&nbsp;A common stock at any time
within the shorter of the five-year period preceding the disposition or such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holder&#146;s holding period for the shares of our Class&nbsp;A common stock. There can be no assurance that our
Class&nbsp;A common stock will be treated as regularly traded on an established securities market for this purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder were a U.S. resident for U.S. federal income tax purposes. Any gain described in the first bullet point above of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder that is a foreign
corporation may also be subject to an additional &#147;<I>branch profits tax</I>&#148; at a 30% rate (or lower applicable income tax treaty rate). Gain described in the second bullet point above generally will be subject to a flat 30% U.S. federal
income tax. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder and applicable exceptions are not
available, gain recognized by such holder on the sale, exchange or other disposition of our Class&nbsp;A common stock will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Class&nbsp;A common stock
from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. We will be classified as a United States real property holding corporation if the fair market value of our &#147;<I>United
States real property interests</I>&#148; equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax
purposes. We do not believe we currently are or will become a United States real property holding corporation, however there can be no assurance in this regard. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax
advisors regarding the application of these rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Account Tax Compliance Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FATCA imposes withholding tax at a rate of 30% in certain circumstances on dividends in respect of our Class&nbsp;A common stock that is held
by or through certain foreign financial institutions (which is defined broadly for this purpose and includes investment funds), unless any such institution (1)&nbsp;enters into, and complies with, an agreement with the IRS to report, on an annual
basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities that are wholly or partially owned by U.S.
persons and to withhold on certain payments, or (2)&nbsp;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such
information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Accordingly, the entity through which our Class&nbsp;A common stock is held will affect
the determination of whether such withholding is required. Similarly, FATCA imposes withholding tax at a rate of 30% in certain circumstances on dividends in respect of our Class&nbsp;A common stock that is held by or through certain <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entities unless any such entity either (1)&nbsp;certifies to us or the applicable withholding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent that such entity does not have any &#147;<I>substantial United States owners</I>&#148; or (2)&nbsp;provides certain information regarding the entity&#146;s &#147;<I>substantial United
States owners,</I>&#148; which in turn will be provided to the U.S. Department of Treasury. Withholding under FATCA was scheduled to apply to payments of gross proceeds from the sale or other disposition of property that produces U.S.-source
interest or dividends, however, the IRS has issued proposed regulations (the preamble to which states that taxpayers may rely upon the proposed regulations until final regulations are issued) eliminating FATCA withholding requirements with respect
to gross proceeds from sales or other disposition proceeds from our Class&nbsp;A common stock. Prospective investors should consult their tax advisors regarding the possible implications of FATCA on their investment in our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of distributions and the proceeds from a sale or other disposition
of shares of Class&nbsp;A common stock to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder may have to comply with certification procedures to establish that it is not a United
States person in order to avoid backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup
withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder will be allowed as a credit against such holder&#146;s U.S. federal
income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_18"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Class&nbsp;A common stock offered by this prospectus are being offered by the Selling Securityholder, Yorkville. The shares may
be sold or distributed from time to time by the Selling Securityholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to
the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. We will not receive any of the proceeds from the sale of the securities by the Selling Securityholder. However, we expect to receive proceeds from sales of
Class&nbsp;A common stock that we may elect to make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. The net proceeds from sales, if any, under the Purchase Agreement, will depend on the
frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. See &#147;Committed Equity Financing&#148; for a description of how the price we may sell shares of Class&nbsp;A common
stock to the Selling Securityholder is calculated pursuant to the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of the shares of our Common Stock offered
by this prospectus could be effected in one or more of the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokers&#146; transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions involving cross or block trades; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers, dealers, or underwriters who may act solely as agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; into an existing market for our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in other ways not involving market makers or established business markets, including direct sales to purchasers
or sales effected through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in privately negotiated transactions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed
brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#146;s registration or qualification requirement is available and
complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Common Stock
that it may acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Such registered broker-dealer may, in some circumstances (for
instance if such registered broker-dealer&#146;s involvement is not limited to receiving commission not in excess of the usual and customary distributors&#146; or sellers&#146; commissions), be considered to be an underwriter within the meaning of
Section&nbsp;2(a)(11) of the Securities Act. Yorkville has informed us that each such broker-dealer may receive commissions from Yorkville for executing such sales for Yorkville and, if so, such commissions will not exceed customary brokerage
commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokers, dealers, underwriters or agents participating in the distribution of the shares of our Common Stock offered by this
prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Securityholder through this prospectus. The compensation
paid to any such particular broker-dealer by any such purchasers of shares of our Common Stock sold by the Selling Securityholder may be less than or in excess of customary commissions. Neither we nor the Selling Securityholder can presently
estimate the amount of compensation that any agent will receive from any purchasers of shares of our Common Stock sold by the Selling Securityholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between the Selling Securityholder or any other
stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our Common Stock offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which
this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this
prospectus by the Selling Securityholder, including with respect to any compensation paid or payable by the Selling Securityholder to any brokers, dealers, underwriters or agents that participate in the distribution of such shares by the Selling
Securityholder, and any other related information required to be disclosed under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to
the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered by this prospectus by the Selling Securityholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for its irrevocable commitment to purchase our Common Stock under the Purchase Agreement, we have agreed to issue to
Yorkville 25,000 shares of our Common Stock as Commitment Shares upon execution of the Purchase Agreement. In addition, we have paid Yorkville a structuring fee of $15,000 in connection with the structuring and due diligence of the transactions by
Yorkville under the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have agreed to indemnify Yorkville and certain other persons against certain liabilities
in connection with the offering of shares of our Common Stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.
Yorkville has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Yorkville specifically for use in this prospectus or, if such indemnity is unavailable, to
contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the
opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
estimate that the total expenses for the offering will be approximately $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has represented to us that at no
time prior to the date of the Purchase Agreement has Yorkville or any entity managed or controlled by Yorkville, engaged in or effected, in any manner whatsoever, directly or indirectly, for its own account or for the account of any of its
affiliates, any short sale or any transaction, which establishes a net short position with respect to our Common Stock. Yorkville has agreed that during the term of the Purchase Agreement, none of Yorkville, its officers, its sole member, or any
entity managed or controlled by Yorkville, will enter into or effect, directly or indirectly, any of the foregoing transactions for its own account or for the account of any other such person or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain
exceptions, Regulation M precludes the Selling Securityholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or
purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of
that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will
terminate on the date that all shares of our Common Stock offered by this prospectus have been sold by the Selling Securityholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Common Stock is currently listed on Nasdaq under the symbol &#147;BTMD&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of any securities offered by this prospectus will be passed upon for us by Cooley LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of biote Corp. and subsidiaries as of December&nbsp;31, 2023 and 2022, and for the years then ended,
included in this Prospectus, have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given
their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc822744_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. We have also filed a registration
statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including exhibits, under the Securities Act of 1933, as amended, with respect to the Class&nbsp;A common stock offered by this prospectus. This prospectus is part of the registration
statement, but does not contain all of the information included in the registration statement or the exhibits. Our SEC filings are available to the public on the internet at a website maintained by the SEC located at http://www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain an Internet website at www.biote.com. Through our website, we make available, free of charge, the following documents as soon
as reasonably practicable after they are electronically filed with, or furnished to, the SEC: our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> our proxy statements for our annual and special shareholder meetings; our
Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q;</FONT> our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K;</FONT> Forms 3, 4 and 5 and Schedules 13D; and amendments to those documents. The information contained on, or
that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin822744_1">Report of Independent Registered Public Accounting Firm (PCAOB ID No.&nbsp;
34)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin822744_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin822744_3">Consolidated Statements of Income (Loss) And Comprehensive Income
(Loss)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin822744_4">Consolidated Statements of Stockholders&#146; Equity (Deficit)</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin822744_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin822744_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin822744_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders and the Board of Directors of biote Corp. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of biote Corp. and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31, 2023 and 2022, the related consolidated statements of income (loss) and comprehensive income (loss), stockholders&#146; equity
(deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company as of December&nbsp;31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting.
Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dallas, Texas </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;15, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s
auditor since 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin822744_2"></A>biote Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized software, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TRA liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (See Note 18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; Deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding
as of December&nbsp;31, 2023 and December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common stock, $0.0001 par value, 600,000,000 shares authorized; 35,842,383 and
11,242,887 shares issued, 34,254,883 and 9,655,387 shares outstanding as of December&nbsp;31, 2023 and December&nbsp;31, 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;V voting stock, $0.0001 par value, 100,000,000 shares authorized; 38,819,066 and
58,565,824 shares issued, 28,819,066 and 48,565,824 shares outstanding as of December&nbsp;31, 2023 and December&nbsp;31, 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">biote Corp.&#146;s stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin822744_3"></A>biote Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of products</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) from change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) from change in fair value of earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(445</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Net income (loss) attributable to noncontrolling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to biote Corp. stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,797</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,709,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,059,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,709,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,059,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin822744_4"></A>biote Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retained<BR>Earnings /</B><br><B>(Accumulated</B><br><B>Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other</B><br><B>Comprehensive</B><br><B>Income (Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity<BR>(Deficit)</B><br><B>Attributable<BR>to</B><br><B>biote Corp.</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-</B><br><B>controlling</B><br><B>Interest</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Equity</B><br><B>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Members&#146; Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B><br><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;V</B><br><B>Voting Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">982,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Distributions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net income through May&nbsp;26, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other comprehensive income through May&nbsp;26, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business Combination: Reverse recapitalization on May&nbsp;26, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(982,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,574,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,565,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business Combination: Noncontrolling interest on May&nbsp;26, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Business Combination: Capitalized transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss after May&nbsp;26, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other comprehensive loss after May&nbsp;26, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Settlement of phantom equity rights</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,950,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of shares under SEPA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,655,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,565,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>biote Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other</B><br><B>Comprehensive</B><br><B>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B><br><B>Attributable&nbsp;to</B><br><B>biote Corp.</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Non-</B><br><B>controlling</B><br><B>Interest</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;V Voting Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,655,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,565,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of stock under purchase plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,088,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchanges of Class&nbsp;V voting stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,746,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,746,758</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TRA liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,254,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,819,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin822744_5"></A>biote Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bad debt expense (recoveries)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Write-off</FONT> of capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Benefit from) provision for obsolete inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in settlement of litigation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> sponsor share transfers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> fees under SEPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss from change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss from change in fair value of earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,098</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,505</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing Activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the business combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal repayments on term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings on term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extinguishment of Bank of America term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of phantom equity rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of stock under purchase plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Distributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares under SEPA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEPA transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(702</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental Disclosure of Cash Flow Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital expenditures and capitalized software included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> SEPA transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin822744_6"></A>biote Corp. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Business</B>&#151;biote Corp. (inclusive of its consolidated subsidiaries, the &#147;Company&#148; or &#147;Biote&#148;) is a Delaware
incorporated company headquartered in Irving, Texas. The Company was founded in 2012 and trains physicians and nurse practitioners in hormone optimization using <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone replacement pellet therapy
in men and women experiencing hormonal imbalance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation</B>&#151;The consolidated financial statements have been prepared in
accordance with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;). The consolidated financial statements include the accounts of Biote and its subsidiaries. All intercompany balances and transactions have been
eliminated in consolidation. The Company recognizes noncontrolling interest related to its less-than-wholly-owned subsidiary as equity in the consolidated financial statements separate from the parent entity&#146;s equity. The net income
attributable to noncontrolling interest is included in net income in the consolidated statements of income (loss) and comprehensive income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination</B>&#151;On May&nbsp;26, 2022 (the &#147;Closing Date&#148;), BioTE Holdings, LLC (&#147;Holdings,&#148; inclusive of its direct and
indirect subsidiaries, the &#147;BioTE Companies,&#148; and as to its members, the &#147;Members&#148;) completed a series of transactions (the &#147;Business Combination&#148;) with Haymaker Acquisition Corp. III (&#147;Haymaker&#148;), Haymaker
Sponsor III LLC (the &#147;Sponsor&#148;), BioTE Management, LLC, Dr.&nbsp;Gary&nbsp;S. Donovitz, in his individual capacity, and Teresa S. Weber, in her capacity as the Members&#146; representative (in such capacity, the &#147;Members&#146;
Representative&#148;) pursuant to the business combination agreement (the &#147;Business Combination Agreement&#148;) dated December&nbsp;13, 2021 (the &#147;Closing&#148;), which is discussed in more detail in Note 3. As a result of the Business
Combination, Haymaker was renamed &#147;biote Corp.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a common control transaction, in accordance with
U.S. GAAP. Under this method of accounting, Haymaker&#146;s acquisition of the BioTE Companies was accounted for at their historical carrying values, and the BioTE Companies were deemed the predecessor entity. This method of accounting is similar to
a reverse recapitalization whereby the Business Combination was treated as the equivalent of the BioTE Companies issuing stock for the net assets of Haymaker, accompanied by a recapitalization. The net assets of Haymaker are stated at historical
cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of the BioTE Companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the
Closing of the Business Combination, the Company was organized in an umbrella partnership - C corporation <FONT STYLE="white-space:nowrap">(&#147;Up-C&#148;)</FONT> structure in which the business of the Company is operated by Holdings and its
subsidiaries, and Biote&#146;s only material direct asset consists of equity interests in Holdings. The consolidated financial statements of Holdings and its subsidiaries have been determined to be the predecessor for accounting and reporting
purposes for the period prior to the Business Combination. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates&#151;</B>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research
and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of the Company, the accompanying consolidated financial statements contain all adjustments,
consisting of only normal recurring adjustments, necessary for a fair presentation of its financial position and its results of operations, changes in stockholders&#146; equity (deficit) and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reclassification</B>&#151;The Company reclassified interest income from other income (expense) to interest expense, net in its consolidated statement of
income (loss) and comprehensive income (loss) for the year ended December&nbsp;31, 2022 to conform with the current year presentation. This reclassification had no impact on net income for the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value Measurements</B>&#151;The guidance in FASB ASC 820, <I>Fair Value Measurements and Disclosures </I>(&#147;ASC 820&#148;), defines fair value and
establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1
measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;1</I> &#150; Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the
reporting entity has the ability to access at the measurement date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level 2</I> - Valuations based on quoted prices in markets that are
not active or for which all significant inputs are observable, either directly or indirectly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;3 </I>- Prices
or valuations that require inputs that are both significant to the fair value measurement and unobservable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 12 for further detail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment Information</B>&#151;Operating segments are defined as components of an enterprise about which separate financial information is available that is
evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company&#146;s chief operating decision maker is the chief executive officer. The Company has one business activity and
there are no segment managers who are held accountable for operations, operating results, and plans for levels or components below the consolidated unit level. Accordingly, the Company has one operating segment and, therefore, one reportable
segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash</B>&#151;As of December&nbsp;31, 2023 and 2022, cash consisted primarily of checking and savings deposits. The Company maintains
deposits primarily with two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (&#147;FDIC&#148;). The Company has not experienced any losses related to amounts
in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounts Receivable and Allowance for Doubtful Accounts</B>&#151;Accounts receivable is recorded net of allowances for doubtful accounts. Accounts
receivable consist primarily of invoiced amounts to clinics that are not yet paid. The Company maintains an allowance for doubtful accounts and uses the roll-rate method to estimate current expected credit losses for its accounts receivable
population. Balances still outstanding after management has exhausted all reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bad debt expense is classified in selling, general, and administrative expense within the consolidated
statements of income (loss) and comprehensive income (loss). The Company generally does not require any security or collateral to support its receivables. The following table presents a rollforward of the allowance for doubtful accounts: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions charged to operating results</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Account <FONT STYLE="white-space:nowrap">write-off</FONT> and recoveries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions charged to operating results</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Account <FONT STYLE="white-space:nowrap">write-off</FONT> and recoveries</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inventory</B>&#151;Inventory is carried at the lower of cost or net realizable value using the <FONT
STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> (FIFO) method. Inventory consists of bioidentical hormone pellets and dietary supplements. Bioidentical hormone pellets contain bioidentical testosterone
or estrogen used to achieve hormone balance. Dietary supplements are high-grade vitamins used to enhance pellet therapy. The Company reviews its inventory balances and writes down its inventory for estimated obsolescence or excess inventory equal to
the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. Inventory write-downs are recorded within cost of products. Management recorded a reserve for
obsolescence of inventory related to inventory which has expired. See Note 5 for further details. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Current Assets</B>&#151;Total other current
assets consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include software and technology licensing agreements, insurance premiums and other advance payments for
services to be received over the next 12 months. Advances are comprised of deposit payments to vendors for inventory purchase orders to be received in the next 12 months. Other assets consist of interest earned on the Company&#146;s money market
account and its now matured short-term investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment, Net</B>&#151;Property and equipment are stated at cost less accumulated
depreciation. Depreciation is calculated using the straight-line method and is recorded in selling, general, and administrative expense over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trocars</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful<BR>life of the improvement</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3-5</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">5-7</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">3-5</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 6 for further details. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capitalized Software, Net</B>&#151;Capitalization of costs related to internally developed software
begins when the preliminary project stage is completed and it is probable that the project will be completed and used for its intended function. Once an application has reached the development stage, internal and external costs, if direct and
incremental, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and
enhancements when it is probable the expenditures will result in additional features and functionality. Maintenance costs are expensed as incurred. Internal use software is amortized on a straight-line basis over its estimated useful life, generally
three to five years. Capitalized software is included within capitalized software, net on the consolidated balance sheet. See Note 7 for further details. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impairment of Long-Lived Assets</B>&#151;Long-lived assets, such as property and equipment and capitalized software, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted future cash flows expected to result
from the use and eventual disposition of the asset. The amount of impairment loss, if any, is measured as the difference between the carrying value of the asset and its estimated fair value. Fair value is determined through various valuation
techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment charges were recorded during the years ended December&nbsp;31, 2023 and 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leases</B>&#151;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and
circumstances present in the arrangement including the use of an identified asset(s) and the Company&#146;s control over the use of that identified asset. The Company elected, as allowed under Financial Accounting Standards Board (&#147;FASB&#148;)
Accounting Standard Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases </I>(&#147;ASC 842&#148;), to not recognize leases with a lease term of one year or less on its balance sheet. Leases with a term greater than
one year are recognized on the balance sheet as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets and current and <FONT STYLE="white-space:nowrap">non-current</FONT> lease
liabilities, as applicable. As of December&nbsp;31, 2023 and 2022, the Company did not have any financing leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities and their
corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives, prepaid lease payments, or
initial direct costs. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change. Lease cost for
operating leases is recognized on a straight-line basis over the lease term as an operating expense. Variable lease costs are expensed as incurred as an operating expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the rates implicit in the Company&#146;s leases have not historically been readily determinable, the Company utilizes the appropriate incremental borrowing
rate, which is the rate the Company would incur to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment over the lease term. To estimate the incremental borrowing rate, a
credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842, contracts containing a lease should be split into three categories: lease components,
<FONT STYLE="white-space:nowrap">non-lease</FONT> components, and activities or costs that do not transfer a distinct good or service <FONT STYLE="white-space:nowrap">(&#147;non-components&#148;).</FONT> The fixed and
<FONT STYLE="white-space:nowrap">in-substance</FONT> fixed contract consideration (including any consideration related to <FONT STYLE="white-space:nowrap">non-components)</FONT> must be allocated, based on the respective relative fair values, to the
lease components and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entities may elect not to separate lease and <FONT
STYLE="white-space:nowrap">non-lease</FONT> components. Accordingly, entities making this election would account for each lease component and related <FONT STYLE="white-space:nowrap">non-lease</FONT> component together as a single lease component.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The Company has elected to account for lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components together as a single lease component for all underlying assets and allocate all of
the contract consideration to the lease component only. See Note 15 for further details. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes</B>&#151;The Company accounts for income taxes
under the asset and liability method pursuant to ASC&nbsp;740, <I>Income Taxes</I>. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a
determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT>
strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset
valuation allowance, which would reduce the provision for income taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records uncertain tax positions in accordance with ASC 740 on the
basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process in which (1)&nbsp;the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and
(2)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon
ultimate settlement with the related tax authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest and penalties related to unrecognized tax benefits are included in income tax expense on the
consolidated statements of income (loss) and comprehensive income (loss). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, no accrued interest or penalties are
included in the consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt Issuance Costs</B>&#151;The Company accounts for costs incurred in connection with the issuance of
long-term debt as a direct reduction of the debt. These costs are amortized over the life of the associated debt, using the effective interest method, and are included as a component of interest expense, net on the Company&#146;s consolidated
statements of income (loss) and comprehensive income (loss). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Liabilities</B>&#151;The Company accounts for warrants as either
equity-classified or liability-classified instruments based on an assessment of the warrant&#146;s specific terms and applicable authoritative guidance in ASC&nbsp;480, <I>Distinguishing Liabilities from Equity</I> (&#147;ASC 480&#148;) and ASC 815,
<I>Derivatives and Hedging</I> (&#147;ASC 815&#148;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all
of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#146;s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For issued
or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital at the time of issuance. For issued or
modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their initial fair value on the date of issuance, and remeasured each balance sheet date thereafter. The
Company&#146;s warrants did not meet the criteria for equity classification and are recorded as liabilities. Changes in the estimated fair value of the warrants are recognized as a <FONT STYLE="white-space:nowrap">non-cash</FONT> gain or loss in the
statements of income and comprehensive income. See Note 10 for further detail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earnout Liability</B>&#151;The Company&#146;s earnout liability is valued using a Monte-Carlo simulation
in order to simulate the future path of its stock price over the earnout period. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the liability&#146;s estimate value. The
significant assumptions used in the valuation include the Company&#146;s stock price, volatility and the drift rate. See Note 11 for further detail. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Standby Equity Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
July&nbsp;27, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#147;SEPA&#148;) with YA II PN, Ltd. (&#147;Yorkville&#148;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New
Jersey. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the right, but not the obligation, from time to time at the Company&#146;s discretion until the first day of the month following
the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date of the SEPA (unless earlier terminated), to direct Yorkville to purchase a specified amount of shares of Class&nbsp;A common stock (each such sale, an &#147;Advance&#148;)
by delivering written notice to Yorkville (each, an &#147;Advance Notice&#148;). The shares of Class&nbsp;A common stock purchased pursuant to an Advance will be purchased at a price equal to 97.0% of the lowest daily VWAP of the Class&nbsp;A common
stock during the three consecutive trading days commencing on the date of delivery of a given Advance Notice. &#147;VWAP&#148; means, for any trading day, the daily volume weighted average price of the Company&#146;s common stock for such date as
reported by Bloomberg L.P. during regular trading hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any individual Advance, it may not exceed the
greater of (i)&nbsp;an amount equal to thirty percent (30%) of the daily volume traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&nbsp;A common stock. No more than 5,000,000 shares of Class&nbsp;A
common stock, including the Commitment Shares (as defined below) may be sold pursuant to the SEPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yorkville&#146;s obligation to continue to purchase
shares of Class&nbsp;A common stock pursuant to the SEPA is subject to a number of conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#146;s commitment to
purchase Class&nbsp;A common stock at the Company&#146;s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, the Company issued 25,000 shares of Class&nbsp;A common stock to Yorkville (the
&#147;Commitment Shares&#148;). During the year ended December&nbsp;31, 2023, no Class&nbsp;A common stock was purchased under the SEPA. During the year ended December&nbsp;31, 2022, the Company sold 105,559 shares to Yorkville under the SEPA for
cash proceeds of $0.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Noncontrolling Interest</B>&#151;Pursuant to the Business Combination, as described in Note 3, the Company is
organized in an <FONT STYLE="white-space:nowrap">Up-C</FONT> structure with the Company owning only a portion of its consolidated subsidiaries. The portion of the consolidated subsidiaries not owned by the Company and any related activity is
presented as noncontrolling interest in the consolidated financial statements. The noncontrolling interests, together with their corresponding shares of Class&nbsp;V voting stock, can be exchanged for Class&nbsp;A common stock in Biote or, at the
election of the Company, cash. Because redemptions for cash are solely within the control of the Company, noncontrolling interest is presented in permanent equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition</B>&#151;The Company accounts for revenue in accordance with FASB, ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT>
<I>Revenue from Contracts with Customers</I>, as amended, (Topic 606). Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring
control of a product or service to a customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific
revenue-producing transaction, which are collected by the Company from a customer, are excluded from revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs associated with outbound freight after control of a product has transferred to a
customer are accounted for as fulfillment costs and are included in cost of products in the statements of income and comprehensive income. Shipping and handling costs billed to customers are considered part of the transaction price and are
recognized as revenue with the underlying product sales for dietary supplements and trocars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the principal contract
activities, disaggregated by the contract type, from which the Company generates its revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Biote Method </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generates revenues through standard service agreements with customers who participate in the Biote Method. The Biote Method is a bioidentical
hormone replacement therapy which has been developed as a treatment designed to alleviate hormone imbalances. Under this agreement, the Company provides a bundle of goods and services to customers, including initial training to medical
practitioners, bioidentical hormone pellets and software tools used for inventory management and dosing, and ongoing practice development and marketing support services, which includes a license to use the Company&#146;s trademarks and trade names
in the customer&#146;s marketing materials. The initial contract term is three years, and customers have the option to renew for additional <FONT STYLE="white-space:nowrap">one-year</FONT> periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the bundled goods and services, the Company accounts for individual products and services separately if they are distinct, i.e., if a product or service
is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company has identified three distinct obligations in its
standard service agreement: initial training, pellet procedures (including sales of bioidentical hormone pellets, use of inventory management software to monitor pellet inventory, and use of the Company&#146;s blood dosing website to determine the
appropriate pellets to use in each procedure), contract-term services (including ongoing practice development and marketing support, options to receive reusable trocars, and the right to use the reusable trocars through the term of the contract, if
the option is exercised). The third obligation includes a combined lease/nonlease component for which the Company has adopted the practical expedient within ASC 842 which allows lessors to combine lease and
<FONT STYLE="white-space:nowrap">non-lease</FONT> components that have the same pattern of transfer to the customer-lessee and account for the combined component under the guidance relevant to the predominant portion of the component. By applying
this expedient, the Company applies Topic 606 to the combined component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consideration in the contract is allocated between separate products and
services in the bundle based on the stand-alone selling prices of each good and service. The stand-alone selling prices are determined based on the prices at which the Company separately sells the initial training and the pellet procedures. Judgment
is required to determine the standalone selling price for each distinct performance obligation. For items that are not sold separately and for which the Company has not established a standalone selling price, the Company allocates consideration
based on the residual approach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for initial training over time as the customer completes the training. Training sessions
generally occur over the course of <FONT STYLE="white-space:nowrap">2-3</FONT> consecutive days at or near the time of contract inception. The customer is charged an initial fixed-rate fee for this training. Customers pay in full for the initial
training at the time of contract inception. The standalone selling price of these services is based on the lowest price offered by the Company for the services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for pellet procedures at the point in time the procedures are performed by the practitioner, which is when control of the
pellets transfers to the customer. Consideration for these services is in the form of a management fee assessed for each procedure performed, which includes a volume-based tiered pricing schedule. The standalone selling price for these services
requires judgment and is estimated based on the Company&#146;s historical experience with prices offered to similar customers throughout the initial term of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract. Billings in excess of the standalone selling price constitute a premium charged to customers early in a relationship and are deferred and recognized when or as the remaining goods and
services are transferred to the customer. Fees are billed and paid on a semimonthly basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for contract-term services on a
straight-line basis over the initial term of the contract, which aligns with the Company&#146;s satisfaction of the performance obligation. The Company allocates the residual consideration to this performance obligation, which is consistent with the
allocation objective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dietary Supplements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dietary
supplements are supplements that customer practitioners resell to patients that aid the patients with maintaining hormone balances. The Company recognizes revenue for these, net of any discounts given, when control transfers to the customer, which
is generally the point of shipment from the Company&#146;s distributor. Products are billed at standalone selling price for the dietary supplements and invoiced at shipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disposable Trocars </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disposable Trocars are surgical
instruments intended for use by Biote-certified practitioners. These instruments are used to implant the bioidentical hormone pellets into the customers&#146; patients. The Company recognizes revenue at the time control transfers, which is generally
the point of shipment from the distributor. Products are billed at the standalone selling price for the trocars and invoiced at shipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue
disaggregated by the nature of the product or service and by geography is included within Note 4: Revenue Recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the years ended
December&nbsp;31, 2023 and 2022, the Company allocated $0.2&nbsp;million and $0.1&nbsp;million respectively, of consideration to the unsatisfied initial training obligations, and $2.5&nbsp;million and $1.7&nbsp;million, respectively, of
consideration to the unsatisfied contract-term service obligations provided to the Biote Method customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to initial training
due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year, as the training is complete. Consideration allocated to contract-term services is
presented within deferred revenue and deferred revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&nbsp;31, 2023 and 2022 the amount of consideration
allocated to contract-term services presented within deferred revenue was $1.6&nbsp;million and $1.0&nbsp;million, respectively, and the amount presented within deferred revenue, net of current portion was $0.9&nbsp;million and $0.6&nbsp;million,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current
and deferred revenue, net of current portion for amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&nbsp;31, 2023 and 2022 the amount of these premiums within deferred revenue was
$0.9&nbsp;million and $0.8&nbsp;million, respectively, and the amount within deferred revenue, net of current portion was $0.4&nbsp;million and $0.3&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also elected the practical expedient in ASC 606 to not disclose consideration allocated to contracts with an original term of one year or
less, which includes contracts for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-in-time</FONT></FONT> sales of dietary supplements, disposable trocars, and pellet procedures. Pellet procedures are included in the
Company&#146;s Biote Method service agreement, which has a three-year stated term, but as revenues are recognized at a point in time, there are no minimum purchase volumes, and the contract allows for cancellation with ninety days&#146; notice from
the customer, there are no pellet procedure obligations that are satisfied over a period greater than one year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contract Assets and Liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Customer receivables are made up of consideration to which the Company has an unconditional right to payment, regardless of whether the Company has satisfied
the performance obligations in the contract. All customer receivables are presented within accounts receivable, net in the consolidated balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract assets are the Company&#146;s right to consideration for goods or services that the entity has transferred to the customer when that right is
conditioned on something other than the passage of time. As of December&nbsp;31, 2023 and 2022 the Company did not have any contract assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract
liabilities are the Company&#146;s obligation to transfer goods or services to a customer for which the Company has received consideration or has an unconditional right to receive consideration. The Company&#146;s contract liabilities include
deposits for initial training and contract-term services paid in advance which have not been recognized as revenue during the period. Contract liabilities are presented within deferred revenue and deferred revenue, net of current portion in the
consolidated balance sheets. Contract liabilities are classified as current liabilities for the amount of revenue that the Company expects to recognize within one year of the reporting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in contract liabilities between each period are attributable to fees paid by new customers, revenue recognized for completed training, and revenue
recognized for the Company&#146;s over-time satisfaction of contract-term services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have a history of material returns or refunds,
and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue. For the year ended December&nbsp;31, 2023, the Company had returns of $0.2&nbsp;million. For the
year ended December&nbsp;31, 2022, returns were not material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending contract liabilities is included within Note
4: Revenue Recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cost of Revenue</B>&#151;Cost of services primarily consist of the costs incurred to deliver training to Biote Method
customers. Cost of products includes the cost of pellets purchased from compounding pharmacies and sold to customers of the Biote Method, the cost of trocars and dietary supplements purchased from manufacturing facilities or third-party <FONT
STYLE="white-space:nowrap">co-packers,</FONT> and the shipping and handling costs incurred to deliver these products to the customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advertising</B>&#151;Advertising expenses include costs incurred to market the Company&#146;s products through digital and traditional marketing channels,
such as on third-party websites, television and print media. Advertising expenses also include costs related to certain marketing events and public relations and marketing agency fees. Advertising costs are expensed as incurred and included in
selling, general and administrative expense in the consolidated statements of income (loss) and comprehensive income (loss). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling, General, and
Administrative</B>&#151;Selling, general, and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in corporate functions, such as finance and accounting, information technology, human
resources, legal, and executive management. Selling, general, and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and amortization, other general overhead
costs, insurance premiums, professional service fees, research and development, and costs related to regulatory and litigation matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defined
Contribution Retirement Plan&#151;</B>Effective January&nbsp;1, 2021, the Company offers participation in the BioTE Medical, LLC 401(k) Plan (the &#147;401(k) Plan&#148;), a defined contribution plan providing retirement benefits to eligible
employees. Eligible employees may contribute a portion of their annual compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor,
<FONT STYLE="white-space:nowrap">non-elective</FONT> contribution to the 401(k) Plan equal to 3% of each participant&#146;s eligible compensation. Safe harbor contributions vest immediately for each participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made safe harbor contributions under the 401(k) Plan of $0.8&nbsp;million and $0.9&nbsp;million
for the years ended December&nbsp;31, 2023 and 2022, respectively. Safe harbor contributions are presented within selling, general and administrative expense in the consolidated statements of income (loss) and comprehensive income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share-Based Compensation</B>&#151;Holdings previously granted Class&nbsp;AAAA units (&#147;incentive units&#148;) and phantom equity rights (collectively,
the &#147;equity awards&#148;) to certain key members of management. The equity awards were entitled to share in the distributions of Holdings from a change in control or qualifying liquidity event. The equity awards are accounted for under ASC 718,
<I>Compensation &#150; Stock Compensation</I>, and classified in equity. The Company has elected to recognize forfeitures at the time they occur. The fair value of the equity awards was determined using a Monte-Carlo simulation as of the grant date.
The awards begin to vest on the date of a change in control or qualifying event. The Business Combination constituted such a qualifying event triggering the performance condition in the awards. No compensation cost was recognized historically until
the Closing of the Business Combination as a qualifying event was not previously deemed probable to occur. See Note 14 for further details. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions</B>&#151;Commissions consist primarily of fees paid to a third-party sales force, internal sales force, and partner clinics which participate
in the Company&#146;s new clinic mentor program. Commissions paid to the Company&#146;s internal and third-party sales forces relate to market support and development activities undertaken to drive channel sales through existing customers and are
not considered incremental costs to obtain a customer contract. For the years ended December&nbsp;31, 2023 and 2022 expenses incurred for these commission programs were $6.0&nbsp;million and $0.1&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commissions paid to clinics under the Company&#146;s mentorship program represent amounts paid to existing clinics which provide services to help new
customers complete onboarding and other startup activities and are only incurred after contract initiation. These costs are expensed as incurred, consistent with other contract fulfillment costs. For the years ended December&nbsp;31, 2023 and 2022
commissions paid under this program were $0.4&nbsp;million and $1.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentrations</B>&#151;Financial instruments that
potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, credit agreements, and inventory purchases. The Company&#146;s cash balances exceed those that are federally insured. To date, the
Company has not recognized any losses caused by uninsured balances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, 100% of the Company&#146;s outstanding debt
and available line of credit was from one lender. A failure of the counterparty to perform could result in the loss of access to the available borrowing capacity under the line of credit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory purchases from four vendors totaled 77.8% for the year ended December&nbsp;31, 2023. Inventory purchases from three vendors totaled 87% for the year
ended December&nbsp;31, 2022. Due to the nature of the markets and availability of alternative suppliers, the Company does not believe the loss of any one vendor would have a material adverse impact on the Company&#146;s financial position, results
of operations or cash flows for any significant period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#146;s total
revenue or gross accounts receivable balance. The Company did not have any customers that accounted for 10% or more of total revenues for the years ended December&nbsp;31, 2023 and 2022. The Company did not have any customers that accounted for more
than 10% of its outstanding gross accounts receivable as of December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements</B>&#151;In
December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Income Taxes (Topic 740)&#151;Simplifying the Accounting for Income Taxes</I>, which simplifies the accounting for income taxes by removing certain exceptions to
the general principles of ASC 740, <I>Income Taxes</I>. The amendments also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> is effective
for fiscal years beginning after December&nbsp;15, 2021, and for interim periods beginning after December&nbsp;15, 2022. The Company adopted this standard as of January&nbsp;1, 2022, and there was no material impact to the financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Measurement of Credit Losses on Financial Instruments</I> (&#147;ASU <FONT
STYLE="white-space:nowrap">2016-13&#148;).</FONT> The main objective of the update is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to
extend credit held by companies at each reporting date. For trade and other receivables, held to maturity debt securities, and other instruments, companies will be required to use a new forward-looking &#147;expected losses&#148; model that
generally will result in the recognition of allowances for losses earlier than under previous accounting guidance. Further, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-04,</FONT> ASU <FONT STYLE="white-space:nowrap">2019-05</FONT> and
ASU <FONT STYLE="white-space:nowrap">2019-11</FONT> to provide additional guidance on the credit losses standard. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> was effective for annual and interim periods beginning after December&nbsp;15,
2022, with early adoption permitted. The Company adopted this standard on January&nbsp;1, 2023 using the modified retrospective approach and it elected to apply the roll-rate method to estimate current expected credit losses for its accounts
receivable population. The adoption of this standard did not have a material impact to the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements Not
Yet Adopted</B>&#151;In August 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-06,</FONT><I> Debt&#151;Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and
Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT> Accounting for Convertible Instruments and Contracts in an Entity&#146;s Own Equity</I> (&#147;ASU
<FONT STYLE="white-space:nowrap">2020-06&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> changes how entities account for convertible instruments and contracts in an entity&#146;s own equity and simplifies the accounting for
convertible instruments by removing certain separation models for convertible instruments. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> also modifies the guidance on diluted earnings per share calculations. The amendments are effective for
fiscal years beginning after December&nbsp;15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>BUSINESS COMBINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, (i)&nbsp;Holdings transferred to the Company 9,161,771 Class&nbsp;A common units of Holdings (&#147;Holdings Units&#148;), which was equal to
the number of shares of Haymaker&#146;s Class&nbsp;A common stock, par value $0.0001 per share (&#147;Class&nbsp;A common stock&#148;), issued and outstanding as of immediately prior to the Closing (after giving effect to redemptions by
Haymaker&#146;s public stockholders of 30,525,729 shares of Class&nbsp;A common stock prior to the Closing and the conversion of Haymaker&#146;s Class&nbsp;B common stock, par value $0.0001 per share (&#147;Class&nbsp;B common stock&#148;) into
shares of Class&nbsp;A common stock and (ii)&nbsp;Haymaker issued 58,565,824 shares of newly authorized Class&nbsp;V voting stock, par value $0.0001 per share (&#147;Class&nbsp;V voting stock&#148;), which number of shares of Class&nbsp;V voting
stock was equal to the number of Holdings Units retained by the Members immediately following the Closing (the &#147;Retained Holdings Units&#148;), and which shares of Class&nbsp;V voting stock were distributed to the Members, resulting in the
Company being organized in an <FONT STYLE="white-space:nowrap">&#147;Up-C&#148;</FONT> structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also at Closing, (x)&nbsp;in exchange for the Holdings
Units, Haymaker transferred cash in an amount equal to (i)&nbsp;the cash in the trust account and any cash held by Haymaker outside of the trust account, less (ii)&nbsp;the amounts required by the redemptions of Class&nbsp;A common stock by the
public stockholders, which was equal to $305.5&nbsp;million and (y)&nbsp;the BioTE Companies received aggregate proceeds of $125.0&nbsp;million from the Debt Financing (as defined below) (the aggregate amounts described in (x)&nbsp;and (y) of
$137.3&nbsp;million, the &#147;Closing Date Cash&#148;) in accordance with and in the priority set forth in the Business Combination Agreement and as described further in the Proxy Statement. There was no cash consideration paid to Members at
Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recapitalization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to consummation of
the Business Combination, the Company&#146;s capital structure included voting units (Class A), <FONT STYLE="white-space:nowrap">non-voting</FONT> units (Class AA and AAA), and <FONT STYLE="white-space:nowrap">non-voting</FONT> incentive units
(Class AAAA), with no limit to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the number of units that may be issued. Class&nbsp;A units had 100% of the voting rights, and there was no par value assigned to any of the classes of units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the Closing, Holdings (i)&nbsp;effectuated a recapitalization, pursuant to which all its Class&nbsp;A units, Class&nbsp;AA units,
Class&nbsp;AAA units and Class&nbsp;AAAA units held by the Members were converted or exchanged (whether by direct exchange, merger or otherwise) into a number of equity interests in the Company designated as &#147;Class&nbsp;A Common Units&#148; in
the amounts determined in accordance with Holdings&#146; Second Amended and Restated Operating Agreement (the &#147;Holdings A&amp;R OA&#148;), which was entered into prior to the Closing, the result of which was that the Members hold a single class
of Holdings Units as of immediately prior to the Closing and (ii)&nbsp;converted into a Delaware limited liability company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing and in consideration for the acquisition of Holdings Units, Haymaker and the BioTE Companies, pursuant to the Business Combination Agreement and
the Trust Agreement (as defined in the Business Combination Agreement), disbursed the Closing Date Cash to Holdings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earnout </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date (a)&nbsp;the Members on a pro rata basis subjected (i) 10,000,000 Retained Holdings Units held by them (the &#147;Member Earnout
Units&#148;) and (ii) 10,000,000 shares of Class&nbsp;V voting stock distributed to them by the BioTE Companies (the &#147;Earnout Voting Shares&#148;), (b) the Sponsor subjected 1,587,500 shares of Class&nbsp;A common stock held by it after giving
effect to the Class&nbsp;B common stock Conversion (the &#147;Sponsor Earnout Shares&#148;), and (c)&nbsp;Haymaker subjected a number of Holdings Units equal to the number of Sponsor Earnout Shares (the &#147;Sponsor Earnout Units,&#148; and,
together with the Sponsor Earnout Shares, the Earnout Voting Shares and the Member Earnout Units, the &#147;Earnout Securities&#148;), to certain restrictions and potential forfeiture pending the achievement (if any) of certain earnout targets or
milestones pursuant to the terms of the Business Combination Agreement or the occurrence of a Change of Control (as defined in the Business Combination Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the Closing, each Retained Biote Unit held by the Members may be redeemed,
together with one share of Class&nbsp;V voting stock and subject to certain conditions, in exchange for either one share of Class&nbsp;A common stock or in certain circumstances, at the election of the Company in its capacity as the sole manager of
Holdings, the cash equivalent of the market value of one share of Class&nbsp;A common stock, pursuant to the terms and conditions of the Holdings A&amp;R OA (such exchange rights, as further described in the Holdings A&amp;R OA, the &#147;Exchange
Rights&#148;). See Note 11 for further detail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Agreements&#151;Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contemplated the execution of various additional agreements and instruments, including, among others, the following: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Receivable Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Closing, Biote
entered into a tax receivable agreement (the &#147;TRA&#148;) with Holdings, the Members and the Members&#146; Representative, which provides for, among other things, payment by the Company to the Members of 85% of the U.S. federal, state and local
income tax savings realized by the Company as a result of the increases in tax basis and certain other tax benefits related to any transactions contemplated under the Business Combination Agreement and any redemption of Retained Holdings Units in
exchange for Class&nbsp;A common stock or cash (as more fully described in the TRA). These payments are an obligation of Biote and not of the BioTE Companies. Biote&#146;s only material asset following the Business Combination is its ownership
interest in Holdings and, accordingly, the Company will depend on distributions from Holdings to make any payments required to be made by the Company under the TRA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the TRA will continue until all such tax benefits have been utilized or expired unless the
Company exercises its right to terminate the TRA for an amount representing the present value of anticipated future tax benefits under the TRA or certain other acceleration events occur. The actual increase in the Company&#146;s allocable share of
tax basis in the BioTE Companies&#146; assets, as well as the amount and timing of any payments under the TRA, will vary depending upon a number of factors, including the timing of redemptions of shares of Retained Holdings Units, the market price
of shares of the Class&nbsp;A common stock at the time of the exchange, the extent to which such exchanges are taxable and the amount and timing of the Company&#146;s income. Any payments the Company makes under the TRA will generally reduce the
amount of overall cash flow that might have otherwise been available to the Company. To the extent that the Company is unable to make timely payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until
paid; however, nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The TRA provides that, in the event that (i)&nbsp;the Company exercises its early termination rights under the TRA, (ii)&nbsp;certain changes of control occur
(as described in the TRA), (iii) the Company, in certain circumstances, fails to make a payment required to be made pursuant to the TRA by the applicable final payment date, which <FONT STYLE="white-space:nowrap">non-payment</FONT> continues for 30
days following such final payment date or (iv)&nbsp;the Company materially breaches any of its material obligations under the TRA, which breach continues without cure for 30 days following receipt by the Company of written notice thereof (unless, in
the case of clauses (iii)&nbsp;and (iv), certain liquidity exceptions apply) the Company&#146;s obligations under the TRA will accelerate and the Company will be required to make a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment to the
applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment would be based on certain assumptions,
including those relating to the Company&#146;s future taxable income. As of December&nbsp;31, 2023 units exchanged under the TRA generated a deferred tax asset of $23.8&nbsp;million and a liability under the TRA of $18.9&nbsp;million. As of
December&nbsp;31, 2022, no units were exchanged under the TRA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Second Amended and Restated Operating Agreement of Holdings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, the Company, Holdings and the Members entered into the Holdings A&amp;R OA, which, among other things, (i)&nbsp;provided for a recapitalization
of the ownership structure of Holdings, whereby following the execution of the Holdings A&amp;R OA, the ownership structure of Holdings consists solely of the Holdings Units, (ii)&nbsp;designated the Company as the sole manager of Holdings
(iii)&nbsp;provides that on the Exchange Date (as defined in the Holdings A&amp;R OA) (unless otherwise waived by the Company, or, with respect to the Initial Shares (as defined therein), following the registration under the Securities Act of 1933,
as amended (the &#147;Securities Act&#148;), of such shares), each Retained Biote Unit held by the Members may be redeemed in exchange, subject to certain conditions, for either one share of Class&nbsp;A common stock or, at the election of the
Company in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&nbsp;A common stock (the &#147;Exchange Rights&#148;), and (iv)&nbsp;otherwise amended and restated the rights and preferences of
the Holdings Units, in each case, as more fully described in the Holdings A&amp;R OA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination
Agreement, certain of Haymaker&#146;s officers and directors, Haymaker, the Sponsor, Holdings and the Members&#146; Representative entered into a letter agreement (the &#147;Sponsor Letter&#148;), pursuant to which, among other things, the Sponsor
agreed to (i)&nbsp;vote, at any duly called meeting of stockholders of the Company, in favor of the Business Combination Agreement and the transactions contemplated thereby, (ii)&nbsp;subject to certain exceptions, not to effect any sale or
distribution of any of its shares of Class&nbsp;B common stock or private placement warrants and (iii)&nbsp;waive any and all anti-dilution rights described in Haymaker&#146;s amended and restated certificate of incorporation or otherwise with
respect to the shares of Class&nbsp;B common stock held by the Sponsor that may be implicated by the Business Combination such that the Class&nbsp;B common stock Conversion will occur as discussed therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investor Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, the Company, the Members, the Sponsor, the Members&#146; Representative and certain other parties entered into an Investor Rights Agreement
(the &#147;IRA&#148;). Pursuant to the terms of the IRA, among other things, (i)&nbsp;that certain Registration Rights Agreement, by and between Haymaker and certain security holders, dated March&nbsp;1, 2021, entered into in connection with
Haymaker&#146;s initial public offering, was terminated, (ii)&nbsp;the Company provided certain registration rights for the shares of Class&nbsp;A common stock held (or underlying certain securities held) by the Members, the Sponsor, and certain
other parties, (iii)&nbsp;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&nbsp;A common stock, Class&nbsp;V voting stock and the Holdings Units held by such Members, as
applicable, for six months following the Closing, and the Member Earnout Units (as defined therein) until the date such securities have been earned in accordance with the Business Combination Agreement and (iv)&nbsp;the Sponsor agreed not to,
subject to certain exceptions, transfer, sell, assign or otherwise dispose of its (a)&nbsp;shares of Class&nbsp;A common stock (other than the Sponsor Earnout Shares, as defined therein) for six months following the Closing, (b)&nbsp;Sponsor Earnout
Shares until the date such securities have been earned in accordance with the Business Combination Agreement and (c)&nbsp;warrants issued to the Sponsor pursuant to that certain Private Placement Warrants Purchase Agreement, dated March&nbsp;1,
2021, by and between the Company and the Sponsor, and the underlying shares of Class&nbsp;A common stock, for 30 days following the Closing Date (such <FONT STYLE="white-space:nowrap">lock-up</FONT> period superseding the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period set forth in the Insider Letter (as defined in the IRA)), in each case, as more fully described in the IRA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
Closing, the Company entered into indemnification agreements (each, an &#147;Indemnification Agreement&#148;) with its directors and executive officers. Each Indemnification Agreement provides for indemnification and advancements by the Company of
certain expenses and costs if the basis of the indemnitee&#146;s involvement in a matter was by reason of the fact that the indemnitee is or was a director, officer, employee, or agent of the Company or any of its subsidiaries or was serving at the
Company&#146;s request in an official capacity for another entity, in each case to the fullest extent permitted by the laws of the State of Delaware. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Credit Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, certain
direct and indirect subsidiaries of Biote entered into that certain Credit Agreement, dated as of May&nbsp;26, 2022 (the &#147;Credit Agreement&#148;; any capitalized terms used but not defined herein have the meanings assigned to such terms in the
Credit Agreement), by and among, inter alios, Holdings, BioTE Medical, LLC, (&#147;BioTE Medical&#148;), BioTe IP, LLC, (&#147;BioTe IP&#148; and, together with Holdings and BioTE Medical, collectively, the &#147;Loan Parties&#148;), certain lenders
party thereto from time to time (the &#147;Lenders&#148;), and Truist Bank, as administrative agent for the Lenders (&#147;Administrative Agent&#148;). The Credit Agreement provides for (i)&nbsp;a $50.0&nbsp;million senior secured revolving credit
facility (the &#147;Revolving Loans&#148;) and (ii)&nbsp;a $125.0&nbsp;million senior secured term loan A credit facility, which was borrowed in full on the Closing Date (the &#147;Term Loan&#148; and, together with the Revolving Loans,
collectively, the &#147;Loans&#148;, such transactions together the &#147;Debt Financing&#148;). BioTE Medical used the proceeds of the Debt Financing to refinance and replace an existing credit facility pursuant to a credit agreement, dated as of
May&nbsp;17, 2019, with Bank of America, N.A and for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loans are also subject to customary events of default. Events of
default under the Credit Agreement include (subject to grace periods in certain instances): (i) the failure by any Loan Party to timely make payments due under the Credit Agreement; (ii)&nbsp;material misrepresentations or misstatements in any
representation or warranty by any Loan Party when made; (iii)&nbsp;failure by any Loan Party to comply with the covenants under the Credit Agreement and other related agreements; (iv)&nbsp;certain defaults under a specified amount of other
indebtedness of Holdings or its subsidiaries; (v)&nbsp;insolvency or bankruptcy-related events with respect to Holdings or any of its subsidiaries; (vi)&nbsp;certain undischarged, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgments
above a specified threshold against Holdings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any of its subsidiaries; (vii)&nbsp;certain ERISA-related events reasonably expected to result in liability above a specified threshold to Holdings and its subsidiaries taken as a whole;
(viii)&nbsp;any loan documents or a material part of the liens under the loan documents ceasing to be, or being asserted by Holdings or its subsidiaries not to be, in full force and effect; (ix)&nbsp;any loan party or subsidiary denying that it has
further obligations under any Loan Document; (x)&nbsp;any obligations under the loan documents ceasing to constitute senior indebtedness; and (x)&nbsp;the occurrence of a change of control. If an event of default has occurred and continues beyond
any applicable cure period, Administrative Agent may (i)&nbsp;accelerate all outstanding obligations under the Credit Agreement or (ii)&nbsp;terminate the commitments, amongst other remedies. Additionally, BioTE Medical may not borrow under the
Loans while an event of default is continuing. See Note 9 for further detail. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REVENUE RECOGNITION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized for each revenue stream was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pellet procedures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dietary supplements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposable trocars</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shipping fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Training</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract-term services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized by geographic region was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant changes in contract liability balances were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description of change <BR>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferred<BR>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferred<BR>Revenue,<BR><FONT STYLE="white-space:nowrap">Long-term</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferred<BR>Revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deferred<BR>Revenue,<BR><FONT STYLE="white-space:nowrap">Long-term</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue recognized that was included in the contract liability balance at the beginning of the
period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases due to cash received, excluding amounts recognized as revenue during the period</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfers between current and <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities due
to the expected revenue recognition period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total increase in contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the
consolidated balance sheets and is expected to be recognized as revenue within one year as the training is performed. Consideration allocated to contract-term services is presented within deferred revenue and deferred revenue, long-term for the
amounts expected to be recognized within one year and longer than one year, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to the premiums within the management
fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to performance obligations are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unsatisfied training obligations&#151;Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unsatisfied contract-term services&#151;Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unsatisfied contract-term services&#151;Long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total allocated to unsatisfied contract-term services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unsatisfied pellet procedures&#151;Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unsatisfied pellet procedures&#151;Long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total allocated to unsatisfied pellet procedures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unsatisfied dietary supplements&#151;Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred revenue&#151;Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred revenue&#151;Long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INVENTORY, NET </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of inventory, net were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product inventory&#151;Pellets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Obsolete and expired pellet allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,272</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pellet inventory, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product inventory&#151;Dietary supplements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Obsolete and expired dietary supplement allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dietary supplement inventory, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PROPERTY AND EQUIPMENT, NET </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trocars</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,810</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total depreciation expense related to property and equipment was $0.8&nbsp;million and $1.2&nbsp;million for the years ended
December&nbsp;31, 2023 and 2022, respectively. Total depreciation expense was included in Selling, general and administrative expense in the consolidated statements of income (loss) and comprehensive income (loss). The Company has not acquired any
property and equipment under finance leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s property and equipment are all held within the United States. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CAPITALIZED SOFTWARE, NET </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized software, net consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Website costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,536</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized software, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total amortization expense for capitalized software was $2.2&nbsp;million and $1.0&nbsp;million for the
years ended December&nbsp;31, 2023 and 2022, respectively. Total amortization expense was included in Selling, general and administrative expense in the consolidated statements of income (loss)and comprehensive income (loss). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ACCRUED EXPENSES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LONG-TERM DEBT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bank of America Term Loan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Company
entered into a credit arrangement (the &#147;Bank of America Credit Agreement&#148;) for a term loan of $50.0&nbsp;million (the &#147;Bank of America Term Loan&#148;), which bore an interest rate quoted as LIBOR + 300 Basis Points. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bank of America Credit Agreement also included a line of credit arrangement, under which the Company could borrow up to $10.0&nbsp;million. The line was
set to expire in May of 2024 and was secured by all assets of the Company. The Company did not draw on the line of credit during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with obtaining the Bank of America Credit Agreement in May of 2019, the Company incurred lender&#146;s fees and related attorney&#146;s fees of
$1.1&nbsp;million. The Company capitalized these costs and was amortizing these to interest expense over the maturity of the Bank of America Term Loan. Amortization expense related to the debt issuance costs on the Bank of America Credit Agreement
was $0.09&nbsp;million for the year ended December&nbsp;31, 2022. At the Closing Date, the remaining unamortized Bank of America debt issuance costs of $0.4&nbsp;million were written off as a loss from extinguishment of debt in the Company&#146;s
consolidated statements of income (loss) and comprehensive income (loss) upon extinguishment of the Bank of America Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
the Business Combination, the Company entered into a new loan agreement as described below. A portion of the funds obtained from the new agreement were used to repay the Bank of America Term Loan in full. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Truist Term Loan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, the Company
entered into a new loan agreement with Truist Bank (the &#147;Credit Agreement&#148; and with respect to the term loan within, the &#147;Term Loan&#148;) for $125.0&nbsp;million. Interest on borrowings under the Credit Agreement is based on either,
at the Company&#146;s election, the Standard Overnight Financing Rate plus an applicable margin of 2.5% or 2.75% or the Base Rate plus an applicable margin of 1.5% or 1.75%. At December&nbsp;31, 2023, the interest rate charged to the Company was
approximately 8.00%. The Term Loam requires principal payments of approximately $1.6&nbsp;million in quarterly installments on the last day of each calendar quarter, commencing on September&nbsp;30, 2022, with repayment of the outstanding amount of
the note due on maturity, which occurs on May&nbsp;26, 2027. As of December&nbsp;31, 2023, the outstanding principal on the Term Loan was $115.6&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Credit Agreement, BioTE Medical may borrow under the &#147;Revolving Loans&#148; from time
to time up to the total commitment of $50.0&nbsp;million. The Company did not draw on the Revolving Loans during the year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Credit Agreement is secured by substantially all of the assets of the Company and is subject to, among other provisions, customary covenants regarding
indebtedness, liens, negative pledges, restricted payments, certain prepayments of indebtedness, investments, fundamental changes, disposition of assets, sale and lease-back transactions, transactions with affiliates, amendments of or waivers with
respect to restricted debt and permitted activities of the Company. In addition, the Credit Agreement is subject to (i)&nbsp;a maximum total net leverage ratio and (ii)&nbsp;a minimum fixed charge coverage ratio. The Company must maintain a total
net leverage ratio of less than or equal to (i) 4.25:1.00, with respect to the fiscal quarter ending September&nbsp;30, 2022 through and including the fiscal quarter ending March&nbsp;31, 2023, (ii) 4.00:1.00, with respect to the fiscal quarter
ending June&nbsp;30, 2023 through and including March&nbsp;31, 2024, and (iii) 3.75:1.00 thereafter. Beginning with the third fiscal quarter of 2022, the Company must not permit the Consolidated Fixed Charge Coverage Ratio to be less than 1.25:1.00.
Both financial covenants are tested quarterly. In addition to the financial covenants, the Company is required to deliver financial statements and other information including, but not limited to, a budget for the fiscal year in progress. Although
the Company was in compliance with all required financial covenants associated with the Credit Agreement, it failed to timely deliver a budget for the fiscal year ending December&nbsp;31, 2023, resulting in an event of default as of June&nbsp;30,
2023. On July&nbsp;27, 2023, the lender waived the event of default and also agreed that the Company will not be required to deliver a budget for the fiscal year ending December&nbsp;31, 2023. As of December&nbsp;31, 2023, the Company was in
compliance with all required covenants associated with the Credit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with obtaining the Credit Agreement in May of 2022, the
Company incurred lender&#146;s fees and related attorney&#146;s fees of approximately $4.0&nbsp;million. The Company capitalized these costs and is amortizing these to interest expense over the term of the Term Loan. The balance on the Term Loan is
presented in the consolidated balance sheet net of the related debt issuance costs. Amortization expense related to the debt issuance costs on the Credit Agreement was $0.8&nbsp;million and $0.5&nbsp;million for the years ended December&nbsp;31,
2023 and 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amortization of debt issuance costs, inclusive of those related to both the Bank of America Credit Agreement and
the Credit Agreement, was $0.8&nbsp;million and $0.6&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-term debt was
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Unamortized debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future maturities of long-term debt, excluding debt issuance costs, are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WARRANT LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its initial public offering, Haymaker issued Public Warrants as part of the units sold through the offering (&#147;Public Warrant&#148;) as
well as private placement warrants (&#147;Private Placement Warrant&#148;) to its Sponsor, the terms of which are further described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant
Tender Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2023, the Company commenced (i)&nbsp;its offer to each holder of its outstanding warrants, each whole warrant exercisable
for one share of Class&nbsp;A common stock of the Company, at an exercise price of $11.50 per share (the &#147;Warrants&#148;), the opportunity to receive 0.23 shares of Class&nbsp;A common stock in exchange for each Warrant tendered by the holder
and exchanged pursuant to the offer (the &#147;Offer&#148;), and (ii)&nbsp;the solicitation of consents (the &#147;Consent Solicitation&#148;) from holders of the Warrants (the &#147;Consent Warrants&#148;) to amend the Warrant Agreement (the
&#147;Warrant Agreement&#148;), dated as of March&nbsp;1, 2021, by and between Haymaker Acquisition Corp. III, a Delaware corporation, and Continental Stock Transfer&nbsp;&amp; Trust Company, a New York corporation, as warrant agent (the
&#147;Warrant Amendment&#148;), which governs all of the Warrants. Pursuant to the terms of the Warrant Agreement, all except certain specified modifications or amendments required the vote or written consent of holders of at least 50% of the Public
Warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants, at least 50% of the Private Placement Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Warrant Amendment permitted the Company to require that each Warrant that is outstanding upon the closing of the Offer be converted into 0.207 shares of Class&nbsp;A common stock, which is a ratio 10% less than the exchange ratio applicable to the
Offer. The Offer and Consent Solicitation expired one minute after 11:59 p.m., Eastern Standard Time, on June&nbsp;7, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public Warrants of 8,191,336,
or approximately 97.5% of the outstanding Public Warrants and Private Placement Warrants of 4,464,900, or approximately 87.4% of the outstanding Private Placement Warrants, were validly tendered and not validly withdrawn prior to the expiration of
the Offer and Consent Solicitation. In addition, pursuant to the Consent Solicitation, the Company received the approval of the Warrant Amendment from approximately (i) 97.5% of the outstanding Public Warrants and (ii) 87.4% of the outstanding
Private Placement Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;8, 2023, the Company and the Warrant Agent entered into the Warrant Amendment, which permitted the Company to
require that each Warrant that is outstanding upon the closing of the Offer be converted into 0.207 shares of Class&nbsp;A common stock, which is a ratio 10% less than the exchange ratio applicable to the Offer. The Company exercised its right to
exchange all remaining outstanding Warrants for shares of Class&nbsp;A common stock in accordance with the terms of the Warrant Amendment. As a result of the warrant tender offer, the Company exchanged all of its outstanding Warrants for 3,088,473
shares of Class&nbsp;A Common Stock valued at $17.5&nbsp;million. No Warrants remain outstanding following such exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Public Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant is exercisable to purchase one share of Class&nbsp;A common stock, and only whole warrants were exercisable. The Public Warrants
became exercisable on June&nbsp;25, 2022, 30 days after the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completion of the Business Combination. Each whole Public Warrant entitled the holder to purchase one share of Class&nbsp;A common stock at an exercise price of $11.50. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Class&nbsp;A common stock. This means that
only a whole warrant may be exercised at any given time by a warrant holder. No fractional warrants were issued upon separation of the units and only whole warrants were traded, requiring a purchase of at least four units to receive or trade a whole
warrant. The warrants will expire on May&nbsp;26, 2027, five years after the completion of the Business Combination, or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the shares issuable upon exercise of the warrants were not registered under the Securities Act within 60 business days following the Business Combination,
the Company would have been required to permit holders to exercise their warrants on a cashless basis. However, no warrant was exercisable for cash or on a cashless basis, and the Company was not obligated to issue any shares to holders seeking to
exercise their warrants, unless the issuance of the shares upon such exercise was registered or qualified under the securities laws of the state of the exercising holder, unless an exemption was available. In the event that the conditions in the
immediately preceding sentence were not satisfied with respect to a warrant, the holder of such warrant would not be entitled to exercise such warrant and such warrant would have no value and expire worthless. In no event was the Company be required
to net cash settle any warrant. In the event that a registration statement was not effective for the exercised warrants, the purchaser of a unit containing such warrant would have paid the full purchase price for the unit solely for the share of
Class&nbsp;A common stock underlying such unit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company agreed that as soon as practicable, but in no event later than 15 business days, after the
closing of the Business Combination, the Company would use its reasonable best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of Class&nbsp;A common stock issuable upon exercise of
the warrants. The Company would use its reasonable best efforts to cause the same to become effective within 60 business days following the Business Combination and to maintain the effectiveness of such registration statement, and a current
prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if the Company&#146;s Class&nbsp;A common stock was at the time of any exercise of a warrant not
listed on a national securities exchange such that it satisfied the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, the Company would, at its option, require holders of Public Warrants who exercise
their warrants to do so on a cashless basis in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in the event the Company so elected, the Company would not be required to file or maintain in effect a registration statement, but the
Company would be required to use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of warrants when the price per Class&nbsp;A share equals or exceeds $18.00 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may call the warrants for redemption: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30 days&#146; prior written notice of redemption (which the Company refers to as the <FONT
STYLE="white-space:nowrap">30-day</FONT> redemption period) to each warrant holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price of the Class&nbsp;A common stock equals or exceeds $18.00 per share
(as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date
on which the Company sends the notice of redemption to the warrant holders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of warrants when the price per
Class&nbsp;A share equals or exceeds $10.00 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may call the warrants for redemption: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at $0.10 per warrant upon a minimum of 30 days&#146; prior written notice of redemption provided that holders
will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares of the Company&#146;s Class&nbsp;A common stock to be determined based on the redemption date and the &#147;fair market value&#148; of
shares of the Company&#146;s Class&nbsp;A common stock except as otherwise described below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of shares of the Company&#146;s Class&nbsp;A common stock equals or exceeds
$10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within the <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior
to the date on which the Company sends the notice of redemption to the warrant holders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the closing price of the Company&#146;s Class&nbsp;A common stock for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for stock splits, stock
dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if (x)&nbsp;the Company issues additional shares of Class&nbsp;A common stock or equity-linked securities for capital raising purposes in
connection with the Closing of the Business Combination at an issue price or effective issue price of less than $9.20 per share of Class&nbsp;A common stock (with such issue price or effective issue price to be determined in good faith by the
Company&#146;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#147;Newly
Issued Price&#148;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, inclusive of interest earned on equity held in trust, available for the funding of the Business Combination on the date
of the consummation of the Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of the Company&#146;s common stock during the 20 trading day period starting on the trading day prior to the day on which
the Business Combination is consummated (such price, the &#147;Market Value&#148;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the
Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Public Warrants were treated as liabilities and recorded at fair value in the Warrant liability line of the consolidated balance sheet. Any
changes in fair value were recorded in the changes in fair value of warrants line of the consolidated statements of income (loss) and comprehensive income (loss). Please see Note 12 for further detail.&nbsp;No Public Warrants were redeemed as of
December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor purchased an aggregate of 5,333,333 Private Placement Warrants at a price of $1.50 per whole warrant in a private placement that occurred
simultaneously with the closing of Haymaker&#146;s initial public offering. Subsequently, the Sponsor purchased an additional 233,333 Private Placement Warrants for an aggregate purchase price of $350.0&nbsp;million in conjunction with the partial
exercise of the underwriters&#146; overallotment option. Each whole Private Placement Warrant was exercisable for one share of the Company&#146;s Class&nbsp;A common stock at a price of $11.50 per share. The Private Placement Warrants were <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> and exercisable on a cashless basis so long as they were held by the Sponsor or its permitted transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants (including the Class&nbsp;A common stock issuable upon exercise of the Private Placement Warrants) were not transferable,
assignable or saleable until 30 days after the completion of the Business Combination and they were not redeemable so long as they are held by the Sponsor or its permitted transferees. Otherwise, the Private Placement Warrants had terms and
provisions that were identical to those of the Public Warrants, including as to exercise price, exercisability and exercise period. If the Private Placement Warrants were held by holders other than the Sponsor or its permitted transferees, the
Private Placement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants would be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If holders of the Private Placement Warrants elected to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants
for that number of shares of Class&nbsp;A common stock equal to the quotient obtained by dividing (x)&nbsp;the product of the number of shares of Class&nbsp;A common stock underlying the warrants, multiplied by the difference between the exercise
price of the warrants and the &#147;fair market value&#148; (defined below) by (y)&nbsp;the fair market value. The &#147;fair market value&#148; shall mean the average reported last sale price of the Class&nbsp;A common stock for the 10 trading days
ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounted for the
Public Warrants and Private Placement Warrants in accordance with the guidance contained in ASC <FONT STYLE="white-space:nowrap">815-40.</FONT> Such guidance provides that because the warrants did not meet the criteria for equity treatment
thereunder, each warrant was recorded as a liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant liabilities were subject to <FONT STYLE="white-space:nowrap">re-measurement</FONT> at
each balance sheet date. With each such <FONT STYLE="white-space:nowrap">re-measurement,</FONT> the warrant liabilities were adjusted to current fair value, with the change in fair value recognized in the Company&#146;s consolidated statements of
income (loss) and comprehensive income (loss). The Company reassessed the classification at each balance sheet date. If the classification changed as a result of events during the period, the warrants would have been reclassified as of the date of
the event that caused the reclassification. No such events requiring a change in classification of the warrants had occurred through December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Private Placement Warrants were treated as liabilities and recorded at fair value in the Warrant liability line of the balance sheets. Any
changes in fair value were recorded in the changes in fair value of warrants line of the consolidated statements of income (loss) and comprehensive income (loss). Please see Note 12 for further detail. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EARNOUT LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the Company&#146;s equity holders are entitled to vest in up to&nbsp;11,587,500 Earnout Securities if certain share price targets (the
&#147;Triggering Events&#148;) are achieved by May&nbsp;26, 2027 (the &#147;Earnout Deadline&#148;). The Triggering Events each entitle the eligible equity holders to a certain number of shares per Triggering Event. The Triggering Events are as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the first time, prior to the Earnout Deadline, that the volume-weighted average share price of Biote&#146;s
Class&nbsp;A common stock (&#147;VWAP&#148;) equals or exceeds $12.50 per share (the &#147;Price Target 1&#148;) for twenty (20)&nbsp;trading days of any thirty (30)&nbsp;consecutive trading day period following the Closing, <FONT
STYLE="white-space:nowrap">one-third</FONT> (1/3) of the Earnout Securities shall be vested and no longer subject to forfeiture and other transfer restrictions (the &#147;Earnout Restrictions&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $15.00 per share (the
&#147;Price Target 2&#148;) for twenty (20)&nbsp;trading days of any thirty (30)&nbsp;consecutive trading day period following the Closing, <FONT STYLE="white-space:nowrap">one-third</FONT> (1/3) of the Earnout Securities shall be vested and no
longer subject to the Earnout Restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $17.50 per share (the
&#147;Price Target 3&#148;) for twenty (20)&nbsp;trading days of any thirty (30)&nbsp;consecutive trading day period following the Closing, <FONT STYLE="white-space:nowrap">one-third</FONT> (1/3) of the Earnout Securities shall be vested and no
longer subject to the Earnout Restrictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company completes a change of control prior to the Earnout Deadline, then all remaining unvested Earnout
Securities shall vest and no longer be subject to the Earnout Restrictions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classified the earnout shares as a liability in its consolidated balance sheets because they do
not qualify as being indexed to the Company&#146;s own stock. The earnout liability was initially measured at fair value at the Closing Date and subsequently remeasured at the end of each reporting period. The change in fair value of the earnout
liability is recorded in the consolidated statements of income (loss) and comprehensive income (loss). See Note 12 for further detail. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FAIR VALUE MEASUREMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more
judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on the lowest
level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is a market-based measure considered from the perspective of a market
participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#146;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability
at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many
instruments. This condition could cause an instrument to be reclassified from Level&nbsp;1 to Level&nbsp;2 or Level&nbsp;2 to Level&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s financial instruments consist of accounts receivable, accounts payable, accrued expenses, and short- and long-term debt. The carrying value of accounts receivable, accounts payable, accrued expenses and short-term debt are considered
a reasonable estimate of their fair value, due to the short-term maturity of these instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s debt instruments are carried at
amortized cost in its consolidated balance sheets, which may differ from their respective fair values. The fair values of the Company&#146;s term loan and revolving line of credit generally approximate their carrying values. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the Company&#146;s financial liabilities that were measured at fair value on a recurring basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnout liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no movements between levels during the years ended December&nbsp;31, 2023 and 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Level&nbsp;3 Disclosures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 10, the
Company&#146;s Private Placement Warrants were initially issued by Haymaker and were thus acquired by the Company through the consummation of the Business Combination. Accordingly, the initial measurement date of the Private Placement Warrants for
the Company was the Closing Date. The Private Placement Warrants were valued using a Monte Carlo simulation. Calculating the fair value of the Private Placement Warrants requires the input of subjective assumptions. Other reasonable assumptions
could provide differing results. The carrying amount of the liability may fluctuate significantly, and actual amounts at settlement may be materially different from the liability&#146;s estimated value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs used to measure the fair value of the level 3 Private Placement Warrants: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Earnout Liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Earnout liability was valued using a Monte Carlo simulation in order to project the future path of the Company&#146;s stock price over the earnout period. The carrying amount of the liability may fluctuate significantly, and actual amounts paid may
be materially different from the liability&#146;s estimated value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs used to measure the fair value of
the level 3 earnout liability: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in fair value of the Company&#146;s Level&nbsp;3 financial instruments were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Private</B><br><B>Placement<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Earnout&nbsp;Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,586</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NONCONTROLLING INTEREST </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Closing of the Business Combination on the Closing Date, certain Members of Holdings (the &#147;Minority Interest Holders&#148;)
retained an approximately 86.5% membership interest in Holdings and Biote received an approximately 13.5% ownership interest in Holdings. As a result of share issuances subsequent to the Closing of the Business Combination, Biote&#146;s ownership of
Holdings, was 54.31% as of December&nbsp;31, 2023. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Minority Interest Holders may from time to time, after the Closing Date, exchange with Biote, such holders&#146; units in Holdings for an equal number of shares of Biote&#146;s Class&nbsp;A
common stock. As a result, Biote&#146;s ownership interest in Holdings will continue to increase. The Minority Interest Holders&#146; ownership interests are accounted for as noncontrolling interests in the Company&#146;s consolidated financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the Business Combination was accounted for similar to a reverse recapitalization, the noncontrolling interest was initially recorded
based on the Minority Interest Holders&#146; ownership interest in the <FONT STYLE="white-space:nowrap">pre-combination</FONT> carrying value of Holdings&#146; equity, including net income (loss) for the periods prior to the Closing Date included in
accumulated deficit as of the Closing Date. Subsequent to the Business Combination, the Minority Interest Holders&#146; interest in the net income (loss) of Holdings after the Closing Date is allocated to noncontrolling interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, Biote issued the Minority Interest Holders an aggregate of 48,565,824 shares of Class&nbsp;V voting stock. The
Class&nbsp;V voting stock provides no economic rights in Biote to the holder thereof; however, each holder of Class&nbsp;V voting stock is entitled to vote with the holders of Class&nbsp;A common stock of Biote, with each share of Class&nbsp;V
voting stock entitling the holder to one vote per share of Class&nbsp;V voting stock at the time of such vote (subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SHARE-BASED COMPENSATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#146; share-based compensation awards (as such terms are defined below) were converted into equity in
Biote. Share information below has been converted from historical disclosure based on the equivalent shares received in the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Incentive Units </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holdings previously issued incentive
units, which entitled the holder to participate in the net transaction proceeds from a change in control or qualifying liquidity event. Incentive units equivalent to 987,275&nbsp;shares of Class&nbsp;V voting stock were vested as of
December&nbsp;31, 2021, and the Closing of the Business Combination in 2022 triggered the vesting of the remaining incentive units equivalent to 6,356,178&nbsp;shares of Class&nbsp;V voting stock. No compensation cost was recognized historically
until the Closing of the Business Combination, and $50.0&nbsp;million of share-based compensation expense was recognized at Closing related to the incentive units. As of December&nbsp;31, 2023, there are no incentive units outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units (Including Phantom Equity Rights) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holdings also previously authorized the grant of phantom equity rights, which entitled the holder to participate in the net transaction proceeds from a change
in control or qualifying liquidity event. For current employees as of the Closing Date, these awards vest quarterly over a period of one or two years after a change in control or qualifying liquidity event, and each holder is entitled to receive a
stated percentage of the net transaction proceeds in excess of certain thresholds in accordance with the terms of their respective award agreement. Awards related to former employees vest at the time of a change in control or qualifying liquidity
event, and each holder is entitled to receive a stated percentage of the net transaction proceeds in excess of certain thresholds or a maximum amount in accordance with the terms of their respective award agreement. The Closing of the Business
Combination met the performance condition in the phantom equity rights. No compensation cost was recognized historically until the Closing of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phantom equity rights are equity-classified awards. The grant date fair value of the phantom equity rights was determined using a Monte-Carlo simulation.
The significant assumptions used in valuation include the constant risk-free rate, constant volatility factor and the Geometric Brownian Motion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#146; phantom equity rights related to former employees
vested, and the Company recognized share-based compensation expense of $4.3&nbsp;million related to these awards with an offsetting increase to equity based on the awards&#146; grant-date fair value. At Closing, the Company exercised its option to
settle the awards for cash in the amount of $7.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#146; phantom equity rights related
to current employees were replaced with 3,887,750&nbsp;restricted stock units (&#147;RSUs&#148;) of Biote. The RSUs will continue to vest according to their original terms, quarterly over a period of one or two years after the Closing of the
Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Closing of the Business Combination, the Company continues to grant RSUs to certain employees under the <I>2022 Equity
Incentive Plan</I> adopted on May&nbsp;26, 2022. New RSUs issued are valued at the Company&#146;s stock price on the date of grant. The following table summarizes RSU activity during the year ended December&nbsp;31, 2023: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Grant-Date<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs outstanding at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,887,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(296,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,053,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs outstanding at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,622,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,250,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs outstanding at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">414,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized share-based compensation expense of $3.6&nbsp;million and $26.6&nbsp;million during the years ended
December&nbsp;31, 2023 and 2022, respectively, related to RSUs. As of December&nbsp;31, 2023, there was $0.4&nbsp;million of unrecognized share-based compensation expense related to unvested RSUs. This expense is expected to be recognized over a
weighted-average remaining vesting period of 0.39 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Closing of the Business Combination, the Company began to grant stock options to certain employees, directors, and consultants under the
<I>2022 Equity Incentive Plan</I> adopted on May&nbsp;26, 2022. The following table summarizes stock option activity during the year ended December&nbsp;31, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Remaining<BR>Contractual&nbsp;Term<BR>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,165,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,042,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,286,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(105,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,081,868</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,141,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">285,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized share-based compensation expense of $5.4&nbsp;million and $1.2&nbsp;million during the years ended
December&nbsp;31, 2023 and 2022, respectively, related to stock options. As of December&nbsp;31, 2023, there was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$16.7&nbsp;million of unrecognized share-based compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average remaining vesting period
of 2.97 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average assumptions used to estimate the fair value of stock options granted during the year ended December&nbsp;31, 2023
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Purchase Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;26, 2022, the Company&#146;s Board of Directors approved the 2022 Employee Stock Purchase Plan (the &#147;ESPP&#148;). The Company&#146;s ESPP has a <FONT STYLE="white-space:nowrap">six-month</FONT> offering period and a 15% purchase
discount based on market prices on specified dates for 2023. The maximum number of shares of the Company&#146;s common stock that may be issued under the ESPP shall not exceed 797,724 shares of the Company&#146;s common stock (the &#147;Initial
Share Reserve&#148;), plus the number of shares of the Company&#146;s common stock that may be added to the ESPP annually each year for a period of up to 10 years. Additional shares added to the ESPP on an annual basis is equal to the lesser of 1%
of the total number of shares of the Company&#146;s capital stock on December 31st of the preceding calendar year and the Initial Share Reserve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During
an offering period, employees make contributions to the ESPP through payroll deductions. At the end of each offering period, the accumulated contributions are used by the participating employees to purchase shares of the Company&#146;s common stock.
The issue price of those shares is equal to the lesser of (i) 85% of the Company&#146;s stock price on the first day of the offering period, or (ii) 85% of the Company&#146;s stock price on the purchase date. No participant may purchase more than
$25,000 of common stock in any calendar year, and the maximum number of shares a participant may purchase during a single offering period is 2,000&nbsp;shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Full time employees who had been employed by the Company for at least one year were eligible to begin participating in the ESPP on May&nbsp;15, 2023. The
Company recognized share-based compensation expense of $0.08&nbsp;million for the year ended December&nbsp;31, 2023 related to the ESPP. As of December&nbsp;31, 2023, 33,704 shares had been purchased under the ESPP. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEASES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2014, BioTE Medical entered into a contract to lease office space in the Las Colinas Business Center in Irving, TX. Subsequent to execution of
the contract, the Company revised the lease to include additional space and extend the lease term through June&nbsp;30, 2023. On November&nbsp;1, 2022, the Company executed an extension of lease office space to extend through November&nbsp;30, 2028.
This extension included an additional 3,700 square feet of space that would be available for use in December of 2023, which would be included in monthly rent payments at this date accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes operating lease costs on a straight-line basis over the lease term within Selling,
general and administrative expense in the consolidated statements of income (loss) and comprehensive income (loss). The following table contains a summary of the operating lease costs recognized under ASC 842 and supplemental cash flow information
for leases: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other information:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets obtained in exchange for new operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the balance sheet classification of the Company&#146;s operating leases, amounts of ROU assets
and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company&#146;s operating leases: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term&#151;operating leases (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.48</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the payments by date for the Company&#146;s operating lease, which is then reconciled to the
Company&#146;s total lease obligation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>As of December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(438</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INCOME TAXES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax provision consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current income tax provision (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State and Local</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax provision (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State and Local</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax provision (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal income tax rate to the Company&#146;s effective tax rate was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statutory federal income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nontaxable partnership income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return to provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s significant rate reconciliation items are driven primarily by state taxes, permanent differences associated
with Holdings&#146; flowthrough income and the recognition of a valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s net deferred tax assets (liabilities) were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outside basis difference in partnership</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(528</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net of allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company had a foreign net operating loss of $1.8&nbsp;million, which begins to expire in
2032. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the
deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become
deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management has recorded a
valuation allowance against the foreign net operating losses and the portion of outside basis difference related to Holdings&#146; permanent book/tax differences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of the Company&#146;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both
federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon
examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records uncertain
tax positions as liabilities in accordance with ASC 740 and adjusts these liabilities when the Company&#146;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these
uncertainties, the ultimate resolution may result in a payment that is materially different from the Company&#146;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income
tax expense in the period in which new information is available. As of December&nbsp;31, 2023 and 2022, the Company had not recorded any uncertain tax positions in its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is
subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#146;s tax years are still open under statute from December&nbsp;31, 2020, to the present. The resolution of
tax matters is not expected to have a material effect on the Company&#146;s consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NET LOSS PER COMMON SHARE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The computation of basic and diluted net loss per common share is based on net loss attributable to Biote stockholders divided by the basic and diluted
weighted average number of shares of Class&nbsp;A common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding, each for the period subsequent to the consummation of the Business Combination. The following table sets forth the computation of net loss per common share: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands, except share and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to biote Corp. stockholders (basic and diluted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,709,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,059,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,709,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,059,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, the Company completed the Business Combination which materially impacted the number of shares
outstanding, and the Company was organized in an <FONT STYLE="white-space:nowrap">Up-C</FONT> structure. Net loss per common share information for the year ended December&nbsp;31, 2022 has been presented on a prospective basis and reflects only the
net loss attributable to holders of Biote&#146;s Class&nbsp;A common stock, as well as both basic and diluted weighted average Class&nbsp;A common stock outstanding, for the period from the Closing Date through December&nbsp;31, 2022. Net loss per
common share information prior to the Closing Date is not presented since the ownership structure of Holdings is not a common unit of ownership of the Company, and the resulting values would not be meaningful to the users of the consolidated
financial statements. Net loss per common share is not separately presented for Class&nbsp;V voting stock since it has no economic rights to the income or loss of the Company. Class&nbsp;V voting stock is considered in the calculation of dilutive
net loss per common share on an <FONT STYLE="white-space:nowrap">if-converted</FONT> basis as these shares, together with the related Holdings Units, have Exchange Rights into Class&nbsp;A common stock that could result in additional Class&nbsp;A
common stock being issued. All other potentially dilutive securities are determined based on the treasury stock method. See Note 1 for more information regarding the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted weighted
average shares outstanding for the periods indicated because including them would have had an antidilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">414,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,622,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,141,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,042,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;V Voting Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,819,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,565,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,937,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private Placement Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,566,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnout Voting Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor Earnout Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,587,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,587,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,962,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,322,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMITMENTS AND CONTINGENCIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Litigation Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become
involved in various legal actions arising in the ordinary course of business. Management is of the opinion that the ultimate liability, if any, from these actions will not have a material effect on its financial condition or results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently involved in litigation described below with one of the Company&#146;s stockholders, Dr.&nbsp;Gary&nbsp;S. Donovitz
(&#147;Donovitz&#148;) (the &#147;Donovitz Litigation&#148;). The outcome of the Donovitz Litigation, regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the
ultimate liability, if any, which may arise therefrom. In addition, litigation and related matters are costly and may divert the attention of the Company&#146;s management and other resources that would otherwise be engaged in other activities.
However, the Donovitz Litigation is not expected to have a material adverse effect on the consolidated results of operations or financial position of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2022, Donovitz sued Haymaker Sponsor, LLC, the Company&#146;s outside legal counsel, and certain Company executive officers and directors in
the District Court of Dallas County, Texas (the &#147;Donovitz Dallas Action&#148;),generally alleging fraud, fraudulent inducement, negligent misrepresentation, a breach of the covenant of good faith and fair dealing, breaches of fiduciary duties,
and/or aiding and abetting those alleged breaches against the defendants (the &#147;Donovitz Claims&#148;). Donovitz subsequently dismissed without prejudice the Donovitz Claims brought in the Donovitz Dallas Action, and the Court entered an order
of dismissal without prejudice on March&nbsp;28, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;11, 2022, the Company sued Donovitz in the Delaware Court of Chancery, pursuing
injunctive relief to prevent Donovitz from proceeding with the litigation in the Donovitz Dallas Action in Texas (the &#147;First Delaware Action&#148;). The Company seeks to enforce (a)&nbsp;the Company&#146;s certificate of incorporation, which
mandates that stockholders must bring certain actions, including some or all of the Donovitz Claims, exclusively in Delaware, and (b)&nbsp;the Business Combination Agreement, by which Donovitz consented to the exclusive jurisdiction of the Delaware
Court of Chancery and agreed that Delaware law governs any related claims, including some or all of the Donovitz Claims. Pending a ruling from the Delaware Court of Chancery, Donovitz agreed to stay all answer dates in the Donovitz Dallas Action.
Then, on March&nbsp;23, 2023, Donovitz filed an amended answer and counterclaims in the First Delaware Action generally reasserting the Donovitz Claims he had previously brought in the Donovitz Dallas Action. On August&nbsp;24, 2023, Donovitz filed
amended counterclaims in the First Delaware Action, again generally reasserting the Donovitz Claims previously brought in the Donovitz Dallas Action but also asserting derivative claims against the Company&#146;s directors. On October&nbsp;23, 2023,
the Company filed its response to Donovitz&#146;s amended counterclaims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;24, 2022, Donovitz sued the Company, including certain executive
officers and directors of the Company, in the Delaware Court of Chancery, seeking (a)&nbsp;a status quo order preventing the defendants from diluting any stockholder&#146;s equity or voting power, (b)&nbsp;an injunction requiring the defendants to
convene a special meeting of the stockholders, and (c)&nbsp;a request to either void a portion of the Company&#146;s Certificate of Incorporation or allow stockholders to elect directors to a vacancy on the board in accordance with Delaware General
Corporate Law (the &#147;Second Delaware Action&#148;). On September&nbsp;8, 2022, the Delaware Court of Chancery denied Donovitz&#146;s request for injunctive relief, determining that expedited proceedings and a status quo order were both
unwarranted and rejecting a mandated meeting of the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;2, 2022, the Company sued Donovitz, Lani Hammonds Donovitz, and Lani D.
Consulting in the District Court of Dallas County, Texas, seeking injunctive relief to enforce <FONT STYLE="white-space:nowrap">non-disparagement</FONT> obligations of that certain founder advisory agreement with Donovitz and the independent
contractor agreement with Lani Hammonds Donovitz, both of which were entered into by the subject parties in connection with the Business Combination (the &#147;Biote Dallas Action&#148;). The Company successfully obtained a temporary restraining
order to enforce the <FONT STYLE="white-space:nowrap">non-disparagement</FONT> obligations of Donovitz and Lani Hammonds Donovitz. The parties subsequently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entered into an agreed order that the temporary restraining order will stay in effect until the entry of a final judgment. On August&nbsp;23, 2022, the defendants filed an answer in the Biote
Dallas Action, which included affirmative defenses to the Company&#146;s claims and certain counterclaims and third-party claims against certain executive officers of the Company. On April&nbsp;12, 2023, Lani Hammonds Donovitz, individually and on
behalf of Lani D Consulting, dismissed with prejudice all of her counterclaims and third-party claims in the Biote Dallas Action, and subsequently agreed to a permanent injunction in favor of the Company, which was entered by the Court on
April&nbsp;17, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the filing of the Biote Dallas Action, the Company amended its claim in the First Delaware Action to also seek an injunction
to prevent Donovitz from proceeding with certain of the affirmative defenses, counterclaims, and third-party claims filed by the defendants on August&nbsp;23, 2022. On November&nbsp;4, 2022, the Delaware Court of Chancery denied that request for
injunctive relief, permitting the Biote Dallas Action and all defenses and claims asserted therein to proceed in Texas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A jury trial in the Biote Dallas
Action was to commence on September&nbsp;11, 2023, to address the Company&#146;s affirmative claim for breach of contract, request for a permanent injunction, as well as the counterclaims and third-party claims asserted by Donovitz. On
August&nbsp;17, 2023, Donovitz nonsuited without prejudice all of his counterclaims and third-party claims in the Biote Dallas Action, leaving only the Company&#146;s affirmative claim against Donovitz to be tried on September&nbsp;11, 2023. On
September&nbsp;8, 2023, three days before the scheduled trial in the Biote Dallas Action, Donovitz agreed to stipulate that he breached his contract, and Donovitz agreed to a partial judgment and the entry of a permanent injunction against him,
which was signed by the Court on September&nbsp;9, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sought recovery of its attorneys&#146; fees against Donovitz in a jury trial that
began on October&nbsp;30, 2023. On November&nbsp;2, 2023, the jury returned a verdict awarding the Company $4.7&nbsp;million plus the potential for an additional $0.2&nbsp;million for future fees, which constituted all of the attorneys&#146; fees
that the Company had sought against Donovitz in the Biote Dallas Action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;16, 2023, Donovitz, as trustee for the Gary S. Donovitz 2012
Irrevocable Trust, together with Biote Management, LLC, sued Biote Holdings, LLC and BioTE Medical, LLC in the Delaware Court of Chancery. Donovitz sought inspection of the books and records of Biote Holdings, LLC. The parties stipulated to
dismissal of BioTE Medical, LLC and agreed to stay the case pending completion of the parties&#146; scheduled mediation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2024, the
Company and Donovitz, through mediation, executed a binding settlement term sheet to resolve all remaining outstanding litigation with Donovitz. Pursuant to the settlement term sheet, the Company and other parties thereto have agreed to prepare and
enter into a definitive settlement agreement, which will supersede the settlement term sheet and substantially incorporate the terms thereof. Pursuant to the settlement term sheet, the Company will repurchase all of the Class&nbsp;A common units of
Biote Holdings, LLC, the Class&nbsp;V common stock of Biote and the Class&nbsp;A common stock of the Company, currently beneficially owned by Donovitz for approximately $76.9&nbsp;million in the aggregate. The Company will repurchase the shares over
a three-year period commencing on the date the definitive settlement agreement is signed. In addition, the Company and Donovitz have agreed to, among other things, (i)&nbsp;a customary mutual release of all claims arising out of or relating to the
Donovitz Litigation, (ii)&nbsp;the termination of the founder advisory agreement, dated as of May&nbsp;18, 2022, by and between Donovitz and BioTE Medical, LLC, (iii)&nbsp;two year <FONT STYLE="white-space:nowrap">non-compete</FONT> and <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> agreements for Donovitz and (iv)&nbsp;the negotiation of and entry into a voting agreement with customary terms acceptable to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Distributions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company has funds
legally available, the board of directors will approve distributions to each stockholder on a quarterly basis, in an amount per share that, when added to all other distributions made to such stockholder with respect to the previous calendar year,
equals the estimated federal and state income tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities applicable to such stockholder as the result of its, his or her ownership of the units and the associated net taxable income allocated with respect to such units for the previous
calendar year. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RELATED-PARTY TRANSACTIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilized a professional services firm to perform accounting and tax services for the Company until June&nbsp;30, 2022. Trusts whose beneficiaries
are the children of a partner of the firm hold shares of the Company&#146;s Class&nbsp;V voting stock. The Company did not pay any fees to the firm during the year ended December&nbsp;31, 2023. Fees paid to the firm were $0.03&nbsp;million during
the year ended December&nbsp;31, 2022. Additionally, there were no amounts due to the firm as of December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A former employee of
the Company is the beneficiary of a trust which holds shares of the Company&#146;s Class&nbsp;V voting stock, as well as being the child of the Company&#146;s founder who beneficially owns shares of the Company&#146;s Class&nbsp;V voting stock. The
employment relationship with this employee was terminated in June 2022. The Company did not pay any compensation to this former employee during the year ended December&nbsp;31, 2023. Compensation paid to this former employee was $0.1&nbsp;million
for the year ended December&nbsp;31, 2022. Additionally, there were&nbsp;no amounts due to this former employee as of December&nbsp;31, 2023 and 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
addition to their previous employment by the Company, the above referenced former employee also owns a clinic which was a customer of the Company until June 2022. The Company did not recognize any revenue from this customer during the year ended
December&nbsp;31, 2023. Revenues recognized from sales to this customer were $0.5&nbsp;million for the year ended December&nbsp;31, 2022. Additionally, there were no amounts due from this customer as of December&nbsp;31, 2023 and 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company purchases dietary supplements inventories from a vendor in which the Company&#146;s founder holds a minority interest. Inventory purchases from
this vendor were $1.4&nbsp;million and $1.3&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. Amounts due to the vendor were $0.1&nbsp;million and $0.2&nbsp;million as of December&nbsp;31, 2023 and 2022, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2022, BioTE Medical and Dr.&nbsp;Gary&nbsp;S. Donovitz entered into a founder advisory agreement, effective as of, and contingent upon,
the Closing. Pursuant to the founder advisory agreement, Dr.&nbsp;Gary&nbsp;S. Donovitz transitioned from an officer and manager of BioTE Medical into the role of Founder Advisor and Senior Advisor (as defined in the founder advisory agreement) as
of the Closing. Pursuant to the founder advisory agreement, Dr.&nbsp;Gary&nbsp;S. Donovitz provides strategic advisory services to BioTE Medical for a period of four years from the Closing, unless terminated earlier pursuant to the terms of the
founder advisory agreement, and will receive an annual fee equal to $0.3&nbsp;million per year, continued coverage under BioTE Medical&#146;s employee benefits and reimbursement for reasonable and <FONT STYLE="white-space:nowrap">pre-approved</FONT>
business expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2022, BioTE Medical entered into an independent contractor agreement with Lani D. Consulting, a company affiliated
with Lani Hammonds Donovitz (the &#147;New Independent Contractor Agreement&#148;), the then current wife of the Company&#146;s founder who beneficially owns shares of the Company&#146;s Class&nbsp;V voting stock. Immediately upon the Closing, the
New Independent Contractor Agreement replaced the independent contractor agreement dated as of May&nbsp;3, 2021, between Lani D. Consulting and BioTE Medical. Pursuant to the New Independent Contractor Agreement, Lani D. Consulting provides certain
services to BioTE Medical for a period of four years from the Closing, unless terminated earlier pursuant to the terms of the New Independent Contractor Agreement, and will receive an annual fee equal to $0.3&nbsp;million per year and reimbursement
for reasonable and <FONT STYLE="white-space:nowrap">pre-approved</FONT> business expenses. BioTE Medical terminated the New Independent Contractor Agreement, effective September&nbsp;9, 2022; therefore, no compensation was paid during the year ended
December&nbsp;31, 2023. During the year ended December&nbsp;31, 2022, total compensation paid under both the independent contractor agreement dated May&nbsp;3, 2021 and the New Independent Contractor Agreement was $0.2&nbsp;million. Additionally,
there were no amounts due to this individual as of December&nbsp;31, 2023 and 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company engages the services of its Chief Executive Officer&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> Mr.&nbsp;Andy Thacker, through a consulting firm that is wholly owned by Mr.&nbsp;Thacker. He has been engaged for various projects such as information technology projects and project
management. Total compensation paid to the consulting firm under this arrangement was $0.1&nbsp;million for each of the years ended December&nbsp;31, 2023 and 2022. Additionally, the Company reimbursed Mr.&nbsp;Thacker directly for travel and
travel-related costs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBSEQUENT EVENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events from December&nbsp;31, 2023, the date of these consolidated financial statements, through March&nbsp;15, 2024, which
represents the date the consolidated financial statements were issued, for events requiring adjustment to or disclosure in these consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisitions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;2, 2024, BioTE
Medical, LLC executed an asset purchases agreement with Simpatra, LLC for a purchase price totaling $4.5&nbsp;million for the purchase of certain intellectual property and intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2024, BioTE Medical LLC entered into a definitive purchase agreement with F.H. Investments Inc. (&#147;Asteria Health&#148;) a privately
held 503B manufacturer of compounded bioidentical hormones. The Company expects to close in early 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Repurchase Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;24, 2024, the Company&#146;s Board of Directors approved a share repurchase program authorizing the repurchase of up to $20.0&nbsp;million its
outstanding Class&nbsp;A common stock. The program grants management the authority to repurchase the Company&#146;s Class&nbsp;A common stock in the open market, in privately negotiated transactions or by other means in accordance with applicable
state and federal securities laws. The timing of any repurchases under the share repurchase program is at the discretion of management and depends on a variety of factors, including market conditions, contractual limitations and other
considerations. The share repurchase program may be expanded, modified, suspended or discontinued at any time, and does not obligate the Company to repurchase any dollar amount or number of shares. As of March&nbsp;11, 2024, the Company repurchased
502,318 shares of its outstanding Class&nbsp;A common stock totaling $2.7&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g822744g00k80.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g822744g00k80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g822744g00k80.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %U2^67(X0DE-! 0      &$< 5H  QLE1QP"   "   < E  "')R,SDQ
M,# T' (% $!-:6-R;W-O9G0@5V]R9" M($)I;W1E("T@075G=7-T(#(P,C(@
M4RTQ("T@4$]3($%-($99,C R,R Q,"U+($-O #A"24T$)0      $'NZ(8&]
M5(BBMALJP@M*50,X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6             IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      -!    !@              4    +@
M   & &< ,  P &L .  P     0                         !
M      "X    4                      !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    4     !29VAT;&]N9P   +@    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   %
M4F=H=&QO;F<   "X     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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MS_5<KBG!MD!! (ZJ224=VL))9)*(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 /_B__])0T-?
M4%)/1DE,10 !";[,_OX>  B <$%$0D4"$   <')T<D--64M,86(@!]  !P :
M  4 *0 U86-S<$%04$P     041"10                    $  /;6  $
M    TRU!1$)%
M               *9&5S8P   /P   !T8W!R=    7     K=W1P=    9P
M   403)",    ;   *(&03)",@   ;   *(&03)",0  H[@  *(&0C)!,  !
M1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M=  '[]P  )"19&5S
M8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V,@
M
M                              !T97AT     $-O<'ER:6=H=" R,# P
M($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U6@  O&<  )(P;69T
M,@     $ PD   $                    !                     0
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M: ;&" 8),@I2"V4,<@UX#GH/>A!Z$7D2=1-P%&@57A92%T48-QDI&C0;/1Q
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MY(&9B7ZFVH#@=ONC$X!C8ZB?FX F3U.<?X C.72:!8!,'Z&9EH$7  "4CH
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MWHA)?,^O&H;N:U6JHX7M61ZF>H4T1>&BQH3,,/J?[(3$%X&@'(8$  "/RX
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MU*_;>E>L ZNK:.FG>:@Q5M^C2Z6P0_R?E:2>+YR<AJ Q%Q6<%X^;  "-Q8
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M(XY?<.FWO(R58&NRAHLF3SJMLHHE/0"I:HF3*/:F2(GC#]JG!(D"  ",C(
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M+;2;;^VTF[ M7X>O4:SZ3GNJ<*M</("F(*?U*-RBR)N@$+"BN(M(  "+ZX
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M>)0'9AW <)'P5FJZEY!)1B&U%8\D-,2P58[?(5JM((]["<RL0H:@  "*6(
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MU:XBNREV;*DHHS5W&:1^BKUWVJ B<9AXIYP35VQY:YAF.I9Z I6N%%9Y9XW
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MWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2 ,H>,;(: +H:!4PR 0(6.-N>
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MB9SS?OR?%IHU;5:;VI>V6OB8VI6&1Z"6.9/E,KN4.Y.)&8245I#J  ")!X
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MQ7NT=C2KGGN098ZGLGN64_ND$7O(03B@Z7P:+(^>R7QI$E2@G7RO  "(Q(
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MU:)+<VBGI9]*8L:CK9RG46Z@ 9J./QN<OYEZ*Q":1IB4$@F;#(PR  "&7H
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M_8'T:EZT)H$N6I:OCX"U2?:K3(!T.!JGK(!L)!.E@8"4"M^F@X$F  "%:X
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M6J<>:,:P:Z/V60^KLZ%E2)JG7I_E-Q2CII\*(ZJ@_)@="\"@M(?R  "$>X
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M<X>>7Q>]$89G4"6WU(6%0%ZS 84"+TJO H3?&ZVM'86$!1*JFX-N  "#'X
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MX:N37PFY.*A;4"JSS*8S0(6NUZ3.+[FJL*!%'+.H,9-G!LBE1H26  "#'(
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M1=6!2H<3*RR!>(9^!Q2!^(0HP52"O9EAKMB"#9;]FW6!>I2=ARF!!9)1<AN
ML) M7#6 A(Y410" :(R\*GB A(P)!J. YH1]P#"![:.^K;B!0*"6FE> JYUD
MAA2 .)I%<1Q_YY=:6U%_MI3"1$1_H9*T*==_L)(3!D1__H0]OT2!2:XWK,N
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MZHD?A,:2QX@-<O:0S8</8!N/$X9!3#F-EH65-L",?H4;'/R,W85F  "&.X
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MX+5;@2./KK#S;SB-H:R_7*J+V*E223>*8*=(-%*),*+7&S>)&))G  ""A(
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M?(]">$>:H8V]9W27]XQ85=&5@8L:0OR3>XHU+FR2#(G1%,J3&XE   "";(
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M>V\7;UVH W O7WFDP'%+3HRANW)H/$&?-W-W)\V=]W0D#2^@N'/%  ""?X
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MEI3-;)BC!9+L7+J?H9$Y3 F<A8_1.C*9W8[T)EN8/X];#4*9)XCW  "  (
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MR76,8Y&PGG7I5(JLJ79B1':I"7;P,NNF)G=U'L2E,'>2!B"E(7C%  "  (
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M$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z'GZ?+I*G!TZ=>(3Q  "  (
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M<GM%6":YM7K]2=:U)'KW.HBQ WL2*9ZM\GLX%6ZMWGL$ *.GTWTN  "  (
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MS)X:5[&TU9ON262P%IHZ.CJKTIFV*;>H?9AY%H6G38\Z HV@LX&Z  "  (
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MNDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6 0G?=67" 4'BF0I. >'E:*"Z
M_'G(!,B"#'K2N1Q_#G[-I\)^^7ZWE9A^WWZ<@B1^V'Z&;<]^W'Z#6'E^^'Z-
M0;I_)WZ2)VY_CGY\!&* D7Z2M[Q]E(C5IEQ]AH?NE Y]?(;^@,E]@885;)!]
MGX5,5V%]S(280,Q]_X/V)JA^1(.$! E_2('4MFU\69+AI0M\4)$XDK]\4(]_
M?X1\78W(:W=\@(PM5FA\OHK'/_Y\](F0)?]]&(D& [Y^+X*(M55[8IT,H_-[
M7IJCD:A[7I@>?G5[;I6;:GE[E9,\58I[SY$>/T9\"8]U)6A\#X\  WY]08)<
MM'5ZGJ=)HPUZG:0FD+QZF:#5?8IZIYV(::!ZU)IU5,Y[$I>_/JQ[/I7&).Q[
M*I0@ TE\?8(YL\QZ"[&@HEAZ#*W&C_AY_ZFO?,)Z!*69:-QZ,:'=5!IZ>9ZZ
M/AEZHYSD)']Z:IA2 QY[W8(<LUQYI[P@H=)YI[>8CU9YC;*^?!1Y@ZWI:#EY
MJ*F74XQY[J9!/9=Z&J-\) MYS9A? OQ[7H($K-B+O6G:G/F*@&N[B_V)?FUP
M><"(J6\(9FF'\7"84>R'8G(D.^B'('.%(;&']71.  "'@7<DJ_.* G-EG >(
M^'15BNZ(#'4R>+F'/W8(97&&C7;B40>&!G>\.Q&%P'AX(/:&:GC'  "%E7L5
MJO"(:GS;FM6'>WSYB=F&F'T+=YV%VGTA9'&%-'U&4"F$N'UU.E&$<GV9(%6$
M]'V0  "#YGZ*J=&&]H9:F:2&#X6WB)"%/H4 =HN$AH138WF#[8/#3UR#>8-)
M.::#.(+C'\:#F(*X  "";X  J*6%PX_;F)B$X(Z*AX.$%XTB=6*#9XNV8F^"
MUHID3FN"=8E*..&",HAN'S*"9HA[  "!+H  IZN$UYE^EY:#^I=^AH&#,)5<
M=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!6(W=  " ((  IN*$'*,RELB#
M1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z'E& ;))7  "  (
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M8GM]?B&.QGNG;0"-6'O86N",#7P81XZ+ 7Q?,GZ*8WR1&'Z+?'QL  " 6H
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MV*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&BYM)+^:%O9HI%KZ%X8]A  "  (
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M;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"*=Z/XH"I#]*1DH"J  "  (
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M]*K<;I&2FJ>H7H*05J213;2.6Z)1.\^,QJ#U*!^+KYLA#QR+^8HW  "  (
M@XFI$V@W=CRE]FG@:!6C'FMX6.*@>&S^2(N>#FYR-K*<-6^W(EZ;XW!:"%B=
MKW @  "  (  @Q*G\G!G==ZDUG%'9ZVAYW(L6(&?)W,62#"<JW/^-F>:PW3+
M(BN:1W4>"(";='4Q  "  (  @I:FEGAH=3^CB'BB9R*@DWCE5^^=TGD]1[";
M5'F@-@"99WG^(>N8S'H5")V99WJG  "  (  @@"E0H!0=)"B.H  9E^?3G^V
M5TZ<C'^"1QR:&']I-8N8*7]?(:&7=7]8"*Z7BW^3  "  (  @62D)8A'<_"A
M)(=X9;6>/(:M5I^;>87Q1I:8^H5<-1N7#X4"(5J60H44"+R5WX/1  "  (
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M.&D(7("LY6J,3ABIO&P"/H>FXFU<+3VDZVYK&+FEEVYL 8FBJG "  "  (
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M=8QR6J^FXXM83%^C>8I8/1Z@:(F:+%^>&(EH&-*=MHF# R.8MH(?  "  (
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M.6[84/6V0F^<0T6R=W!N-%NO+G$Q(W.M2G&<#K6NZ'#F  "=P'@I  "  (
M:<V\YW5D79VXVG6 4-6TSW6X0R:P[789-%&MD'9\(Y&KB':N#QRLR'8F  "<
MB7PB  "  (  ::B[<GQK76&W9GP>4(>S77OI0O*O=WO>-"VL%'OP(Y.I\GOX
M#V>JXGO8  ";:'^A  "  (  :7JZ,8-_736V(X+:4%:R%8)+0K2N*X'7-!2J
MMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (  :4ZY/(J[71ZU'(G)4$2Q (C<
M0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(    "  (  :2FX?Y'^712T
M1Y#(4#^P&(^"0I2L&XYL,_&HFXWA(Z>F,HY%$"*F68KI  "8WX    "  (
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M99&5?@I].I /;/)]&8YW6O5]#HSX1]=]&8NQ,QQ])(K=&<=\^XIF  "  (
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M>)<7<H6$B94Y8F>#J9-&46V"\I&*/U6"99!"*V^!^Y =$>6"'HP9  "  (
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MB'2E:M*1V75D6WN0478>2PR.]7;4.2Z-^G=T)0Z-U'>["QR.R'=]  "  (
MA4B3L'P6=_Z1_'Q,:<R077QS6J:.VGR72DN-C'S .)&,E'SE))R,6'SF"P&,
MO'T,  "  (  A&^27819=RJ0L80':/B/&(.A6<:-FH,Q2:B,08+). 6+48*'
M)#B*_H)G"NV*\8'N  "  (  @[J11XS(=G*/J(OO:#^.#XKT61B,B8GK20:+
M+HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (  @R:0=)5$=?&.W9/P9[R-.Y)B
M6(:+J)#%2&N*38]H-Q2)0HZ8(YZ(LH[&"L:('8=)  "  (  @K&/UIW.=7:.
M0IP%9SJ,EYGO6 2*]I?,1^J)DY8:-H^(C)5K(S2'Z905"K:'$(<^  "  (
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MNWIA7LV9>'J<4'R76'K<0.R5@7L=+].4/'M/&_>49WLQ!'21P'Q,  "  (
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MC:![7(N5)YY<3AR2S)Q$/M*0Q)L9+B>/2YGP&P>.S9)&!-B+4H-&  "  (
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MKW]04X&AV7\K1>.?)G\$-S&<T'[T)IV;<'[R$I*<AG[C  "2Z(    "  (
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M?&)22:&RD&08/&&OPV7#+;NMC&<E')*M1&>X"%RNI&=K  "36'+8  "  (
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M@8.72*.K)(,J.YNG\8+!+6^E2(*#'26D$(*@"B>CS((Y  "-XX    "  (
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M/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#,U9O_YMX&L1N1Y(9  "  (
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M?X+S=H1WZH*P9DUX4H)251]XQX'[0I9Y2(&T+E=YDH%V%.EY38%3  "  (
MDM1UI(Q+A*EV)HN'=81VEXJ195AW!HF#5#IW?HB#0>!W]H>N+<9X,(<M%(%W
MQH:F  "  (  D@=T@I6)@]MU#)0C=+=U?9)\9)%U[I#!4WUV;(\I04%VXHWA
M+5IV_(U3%#EV?HL6  "  (  D6ISH)[,@S=T,)S*= MTGIIX8^=U")@34M=U
MAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "  (  D/UR_:@<@KISCZ6*<WUS]**3
M8U5T49^/4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "  (  BRR(?EWP?A&'
MK6#';].''6-J8$>&N&7;3W2&<6@G/2N&9FH[*+R&[6NY#@:(_FM'  "  'G3
MBE&&-&:M?3J%I&BU;NR%+6J:7W.$SFQB3KJ$BFX//(^$?&^/*$"$WW"/#=>&
M26_U  "  'U8B5Z$!V]3?!V#I'"C;>V#0G';7G>"\W+Z3=^"NW0+.]B"L73Z
M)[."]W6'#9Z#YW3O  "  (  B$^"%'?H>OJ!Q7B7;+B!>'DJ782!,GFH30"!
M#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (  ATJ 5H"+>?V &X"C:\)_WX"6
M7(M_IH!N3&=_>X!).JA_?8 M)MQ_CH 0#5)__G_H  "  (  AFA_!XE/>39^
MV(C3:P)^FX@C6\)^7H=62XU^-X:7.?U^+(8))E%^)(79#0U^>H2C  "  (
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M&HW.7^.&)XS*47>%,(NG0AF$:8JR,6"#WHHR'BF#HXJ)!HN"\X1L  "  (
M>02'*I;=;+F&5)6Q7UV%690G4/6$59)\09J#@Y$Q,-2"^)#(';B"FX_6!HF!
MY81K  "  (  >**&DI]-;%*%OIW+7NJ$N)O&4(*#I9FB03:"PI@E,(:")I>V
M'8&!KY/S!GV!%(1C  "  (  <:^;V%RR9?&9]U]"63N88&&T2TZ6_&/[/ J5
MVF8'*N*5?6>>%BZ7A6?'  "3#6F_  "  ']*</>:#F2,96>81V9O6+26HFA
M2N&5(VGX.[:3ZFN#*J^3;FRK%C"5%VR4 "^0OFZV  "  (  <$^8$VQ"9**6
M:FV.6 Z4RV[,2C^336_[.S22$7$)*E:1@G'*%A62W'&% '..<'0S  "  (
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M%Y(U51*.>9$!1VF,TX^Q.+R+=([3*'"*GH\$%1F*QXR@ 1J&T8"^  "  (
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MXG)Z3&B<R7,\/W6:T7/U,1&92'2-()"8WG3##(Z:&715  ")%'OE  "  (
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MKI8D2L67;)3O/;V5*).L+ZN32I-G'[&26Y'O#+^1[(B?  "$G(    "  (
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M@G:*002E_W;J-(JCIG<S)KJA]7=M%@FB77<I!,*?!GCA  "$/H    "  (
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M.YFA=8YE#I=U96YFPY4Z5%YH;9,]0B]ITI&R+I-J+I$E%E9J%8WE  "  (
MDF9@3:3SA"YB7:)G=/MD*9^$9-EEUIR<4]AG>IH70<%HV9A3+B)I&)=@%>5I
M3([.  "  (  CGQXYUBQ@2=Y4EP)<K=YX5\H8OYZA&(34@%[,634/YU[[V=>
M*SQ\Q6E;$-Y^4&E@  "  '8)C5)UX6&Z@!!VF61 <9QW4F:;8?UX#VC341]X
MSVKK/MUYE6S3*I]Z1VY $(A[A6WV  "  'H?C!US&VJU?KUT"6QY<'MTXVX=
M8.5UNV^B4#)VCW$2/AIW77)=*@MW[7-%$#UY$'++  "  'VUBM5PDW.R?6MQ
MJ'3 ;RERH76M7^ASC7:'3T]T>G=+/6=U3W?[*8YUO7AI$ -V['?P  "  (
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M?YZT:PIKGIQ16]!LH9G>2Z=MG9?2.D5N7Y:N)Q5N"95E#J=PD8GH  "  (
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M"WK<8XQX>7M)52QXVGN91;1Y/WOA-(MYJ7P;(1EYP'P@"*I[H7R6  "  (
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M?X C6%)_58 G2K5_(8 ,/ =^^'_P*[-^Z7_E&#-^\W_H HU_O7_X  "  (
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M%&#]40F0(6,X0\R/465.-1>.S&<?)#Z/'&A;#VF1;6?Z  "&(FYD  "  (
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MYH1W36B'((0O0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (
M8]Z'@(Q%60V&[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "
M (    "  (  8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J
M#MN"78H+  "  (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:
M?5^^&DF;S6"X!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y
M.968P&-R*U&8%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69
M&V7\19^7O6>B.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (
M6K:80&M:4#B6YVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "
M 'ME  "  (  6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A
M!S&0*G7>  "  '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0
M!'K?&7&0+7K,!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C
M-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1
M.H@[0N>/YH?$-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (
M6#>1CH_E3@F0<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "
M (    "  (  4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(
M  "@"&!\  "  '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC
M;6(K#L>ELF('  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48
M+A&A?F9Y(!.A!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B
M66G>.:2@MFL!+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (
M3DNB"V]Q1"N@:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "
M (    "  (  3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=>
M '&3VGI4  "  (    "  (  37.?$WU50W^=@WVB.*N;SWVP++>:-WV>'R:9
M77V,#M&9Y7VU +"2"7[.  "  (    "  (  322> X190TJ<<X1Q.(&:MH0R
M+)F9"(/?'PJ8$H/D#JJ8=X-[ +60F8![  "  (    "  (  3/&=*8N/0RB;
ME(N&.&29T(L(+(:8$(J.'Q.6\XJO#MF7'HA$ -V/9X"6  "  (    "  (
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M 81D>"M8,8/Z:!5;)8."5PQ=XX,21-5@)(*Y,1I@](*!&4AAI8*A  "  (
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M77$/  "  'JSC+=>Z&]N?U-A:'#7</YCJW(E8:%EQG-84/YGPW1X/QMI8W6
M*W%IZW9%$I)L1W8,  "  'Y'BT5<#'BX??)>M7EI;ZUA('G\8&!C67IU4!!E
M;'KF/D=G%WM1*M!G:'N=$C1J>GMO  "  (  BA%9H(((?-)<:H(';J)>\H'?
M7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L$>9H]X$[  "  (  B1E7F8M/>^=:
M?8J>;<5=&(F\7I9??XC(3F1AKH?M//IC2X="*>EC)X;_$;-GL(9#  "  (
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M 6<7:%AM@VDR68UN[FLI29AP0&S_."-Q7FZ>)()QO&^R"V5U@F^*  "  'V
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MU(_V8V1BT(Z[50QDE(UK19]F'HQ0--1G"HNE(BYEV(OI"K-MZH<\  "  (
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M.FU]7+IR3V[^3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (
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M&I2.6/=I<),B2V5J@Y&>/+UK6)" +(IKA9!?&=!JM(Z(!&QXAX+]  "  (
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MD'+U45UX)7/U1%%XHG31-B-Y"W6-)<AY8'8#$?5Y^'6>  "  'GB  "  (
M9W-TH'G%7'!U>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "
M 'X)  "  (  9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D
M$:EUVH&)  "  (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=S
MNX>+)')SB8>;$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;
M0A-R2XZS- MR?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+
M[53<2G>+J5?]/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP
M7X^)4EC^52N)$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "
M &XI  "  (  7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]
M":.'46CK  "  '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#
MB6V<'..$)&X8"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%
M.HN!%7)O+,"!)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_
M"G>%1CU_'W@<.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (
M6SQ\\'X]4-=]3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "
M (    "  (  6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;
M"5)\7(/?  "  (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z
M=8M(&V)YV8LR"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*
M,R:5 ECZ),^5=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R3
M1%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (
M4LN1#%X_2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "
M ';D  "  (  4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ=
M A^*\&RD  "  'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*
MBG ]$?Z+OF_F BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-
M+^J(C'6/(FF(:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'
MN'LM.UB'5'MU+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (
M3V"&8X'$18B&4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "
M (    "  (  3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D
M M>!M('L  "  (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A
M<U>_"*.C&UAE  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%
M)X^=KUN\&46>H5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<
M+5VL,L*;;U^.)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (
M1@>:/&(Z/(29;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "
M 'V   "  (  1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO
M  "'QG0O  "  (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4
M ''0")*2*7)D  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6
M)/B2 7>\%VB2'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1
M]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (
M0X"1!(3&.B60SH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "
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MX7P79C941WQO5]]75GRU2'M9]GSY-[);D'U#)/9:S'V)#5)I?'X)  "  (
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MSX'&6^%8L8&F3E!;,H%S/Z!=)H%/+W5=Q(%+'0Q>?H&(!MAT;X%I  "  (
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MNX:/47E>"X871*!?XX6)-HEA"(4I)K1@884F% 9E5(5$ 3!]_H#.  "  (
M9YY7+8[&7,5: (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^
M-8"X  "  (  9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-
M#,R H%UX  "  &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY
M@F!3(1QZ9V(1#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0
M/R]U#V/7,/IUYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO
M468T2K!PEV@=/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (
M7X1J7&OH50-L!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "
M 'FR  "  (  7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]
M"_1QF7<?  "  'W3  "  (  79ADDWMX4TMFE7OS2!MH,WPZ.])I7WQB+C-I
MZ'R+'GII'7RL"]=OPGT]  "  (    "  (  7.=B2H,R4J1D;8-!1WUF(8,'
M.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[  "  (    "  (  7&)@;8KL4B9B
MJHJE1O]D;HGU.LQEE8DM+4MEV(C,':AE)HDJ"UEM/H:J  "  (    "  (
M6/.#7$Q@3JN#ED_=0X2$!%,^-PJ$FE9A*+R%@%D"%U:'B5I<!'&'U5NB  "
M &DU  "  'X:5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#
M!(V$"&!N  "  &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^
M F.1%FM^^V0O!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D
M-%AY]V>:)HAZ?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU
M4FK./U5V+VPV,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (
M4R9Q+'"K24-R;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "
M (    "  (  4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF
M!)!X2GMS  "  (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O
M4G^)%$)P.G^P!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X
M,3EMSH7S)!%M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-
M:DXV.-6-@U%I++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (
M2Y.)RU&40CB)YE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "
M '&.  "  (  2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_
M  "#5&6Z  "  ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$
M,66K"XB$MV7"  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW
M*1Z 3VI7&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\
ML&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (
M1OAY,71=/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "
M (    "  (  1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM
M  "  ']X  "  (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V
M<H);"LYXM8(&  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4
M(:J945$[$GF<,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25
MCE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (
M/D&2%E5X-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "
M 'ET  "  (  /6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z
M  "  &Y6  "  'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-
M$&9G IF)Q6B'  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK
M'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%
M_G#O)_B&=W%Y'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (
M.GR"NW<*,5V#SW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "
M (    "  (  .@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_
M  "  (    "  (    "  (    #__P  __\  /__  !M9G0R      0#"0
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MJ>JJXJO;K-6MT*[+K\>PQ+'"LL&SP;3"M<6VR+?-N-.YV[KCN^V\^+X$OQ'
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M@Q\FKXF(@D>7F*[.DP.)/*HOD+IZG*67CI=KQZ$&C)9<[9QUBK%..I?DB.%
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MC*-GL+77BL];#*]6B2U.H*BFA[E"B:'-AF4W+YJDA1@LUI,P@^8D'(N8@M:
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MIV50D7NU<6>FCXNBMFGEC9Z/?&P>B[M[]6YOB>AH3'#CB"A4XG-UAE-!P79
MA%HO<GE8@AO&7V0<F]:T,F9]F0.A?6C&EAJ.36L0DR]ZX6UTD$QG9&_^C6I4
M,W*RBGA!2W6<ATDO.'C/@[3%6V,FIA*S-66/HEN@?6?<GG*-46HNFGAY_6RE
MEH9FI6]$DHA3GW(,CF1 ZG42B?XO"'A<A1W$F6)PL""R=F3<JX&?LF<EII2,
M@&EWH81Y,VOXG'EE^&ZLEV)3'W&)DA- EW2@C&\NX'?]AE7$&F'WN>NQ]&1@
MM%*?&6:?KE>+V&CHJ"UXD6MKH@=E;6XIF]!2IW$5E5Q /W1 CHPNP'>PAUK
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M?R4F6())?V:5-8?+AE>($(;(A=)Z1X72A2ML H3EA&Y=?(0,@[%.VX-6@P-
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MGK)N?XJ\FS)A68C?EUU4-(<LDX='0H6IC[$Z\80SB]@O38+GA^HE$(&SA!N
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M8[^?46QY9HR,PFZ9:4UYPW##;!-FEG,(;O!3GW5R<?) Z'@@=3PO"'LL>0+
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M=3Q?*VQZ=LA-TG *>&P\YW/M>D M(7@K?%6QY%GI><:B&5U6>BN1S6"A>I6
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M>Q@Q18SH?!<J.HG8?2,C\8;W?C8>Y(1L?S58]IHB?=!1$9?/?B=(_)4=?E%
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M=2<F^'R->5&2@61A9WB&"6;J:<9X_FEA; =K%VOD;D)<TVZ-<(I.=7%P<NY
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MW7H-9PU/EWL6:D=#2WQ ;:DWA'V+<3HL8G\1=1\BI("]>5A\C'1298]Q\G6
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M?/DHCG;!?GF/(TJ.?CR"]4^7?G%V.%2#?IIHZ%E^?KU;2EZU?N5-FF0X?QU
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M5/YJ[F]P64->JW&/7912#G/.8?Y%978^9I<Y/'C?:VHMK7O2<*\C>W[X=GN
M8F=A60!U<6FX7))IWVP;8"5=SFZ38[]177$O9VY$Y'0":T<X[W<';U,MHWI9
M<\ CP'W,>)9^[V.+84AT%69.9"-HSVD*9OY<WFO7:=Q0HV[,;,Y$8''];^,X
MIG5@<R,MFGD)=K$C_'S#>HM]B& -:8ERPF,M:ZAGFF8[;<=<#FE6;^I/^VRD
M<A9#\G K=& X<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;
M#&<F==9/26K =S]#9&Z=>, X'W*D>E@MB';D?!DD77L6??5[)UI3>;MPK5W]
M>G!EM6&8>PY:1F5$>Z!.I&DA?#Q# FT\?.TWZG&)?:\M?W8(?H4D@GIO?V-Z
M2%@.@8YOY5OP@9!E U_"@6A9J6.H@2U.'&? @/M"HFP6@-@WQW"5@,0M@'5,
M@+0DH7GD@*!YFU8NB1EO25I B&YD<5X_AWY9*6)1AG!-J6:;A6Y"/FLGA'DW
MCV_4@Y M?72R@J DNGES@:UY'E2TD$INUECMCOUC_ET.C458OF% BV!-566K
MB8E"!VI=A\$W8&\WA@(M8W1 A#XDSGD8@HIW;',&405L\71752MB''7,6616
MU7=57;%+0GCP8AT_LGJQ9KTTKWR8:Y@J5W[$<. A9($3=IEUV&\86+UKSW#5
M7$QA+G*>7^)6&W1S8X5*MG9B9T,_5GA^:S TAGK!;T\J;'U$<\LAO7_:>)UT
MAVMQ8()JE&V28VI@-&^M9E9507'1:4M*#G03;%@^XW:&;XPT3WDA<NPJ=7OR
M=I8B"G[(>GMS3&@>:#EI9VJ2:G5?%VSY;+54?&]D;OM);''\<5,^>W3"<\LT
M(7>N=F4J?WK)>3@B37W9?"]R'V4I;^-H4F?E<7->(&J0<P!3HFU"=(M(]G >
M=BD^*G,R=^$T!'9F>; JD'G$>ZDBA7T,?;=Q(6*<=W9G@F67>&%=<&A_>3=2
M^FMP>@1(7FZ)>MX]T7'8>](SU75+?-@JD'CF??(BM7Q@?P]P4V!K?M)FQ6.<
M?QE<QV:Y?S5296G@?T!'WVTQ?U<]>7"U?X(SNG17?[TJF7@H?_TBW'O1@#AO
ML%Z9A>5F-&'WA8U<065!A.]1\&B3A#-'>&P1@X0](6_)@N<SC7.5@EDJH'>*
M@<<B_'M=@3)O.5TDC*IEQV"JB[];UF06BF51CF>(B-M'+FLEAV \\V\ A?DS
M9W+XA)\JCG<7@T8C%7L @?]LTGK-415C2GN'52Y9;7QB66!/*7U%7:]$I'XM
M8B4Z,'\M9M4P58!*:[XG.(&:<0X?@(,$=K)K:'<?6%5B1'@\6^58E7E>7X-.
MA'J"8S5$+WNS9PDY[GT$:P\P2GYR;T<G:( 2<]8?[(&_>*)J0'.G7Z!A+74?
M8I=7NW:+99A-QG?T:*A#I7EP:]8YFGL2;R\P,'S0<K(GBGZY=GL@28"A>FMI
M*'!Z9M]@'7(]:3A6NW/M:Y=-#76>;@1#$7=H<(DY/7E7<S$P#7MA=?HGH7V-
M>/@@F7^J? IH)&VD;@M?,V^I;\95Y'&9<8),1G.,<T-"I'65=1@X\W?.=PXO
M]GH;>1DGNGR&>T@@WG[7?7QG.VLJ=29>7VUM=D15+6^9=U1+MW'$>&%"-70'
M>7TXS79R>KDO\GCZ? 8GU'N@?68A%WXE?L%F?&D'?!%=PVN'?)A4JVWG?/A+
M1G!!?4M!SG*U?; XA'54?BXOY'@%?KXGYWK>?T\A1GV2?]=EY&<]@KE=.6GN
M@JQ4+VQ\@EQ*WF[^@?)!=G&<@9PX.G1J@5POP'="@2XG]7H_@/LA;'T:@,%E
M<F7+B1Q<T&BDB(-3RVM8AX!*AVW[AE-!.'"WA3LX%W.EA#LOJ7:E@TPG\7G(
M@E\ABWRZ@8!BA(+<4.%9](+Q5/=1%(,@62I'TX-+78,^6X-N8@TU X.;9M8L
M38/;:]@D8H1#<34=U83$=L=A0W]J5[=9 W_=6T]01X!*7OM'-H"J8L0]]($(
M9K8TU8%[:M\L6X(";S@DJH*Q<]X>4H-Q>*5@0WP=7I!8#'SA89Y/A'V09+E&
MCWXN9^P]@'[0:T,TF'^,;LDL6H!<<G8DXH%/=F$>OH))>EM?5'D.95Y7(GH7
M9]E.I7L#:E]%\'OD;/H]!WS.;[(T5'W2<I$L3G[I=8\E#8 <>+L?'(%)>^=>
M<'9/;!]63G>8;@9-XWC!;_-%1GG<<>H\I7L&=  T%WQ.=C8L0GVC>($E,'\1
M>NH?:X!N?4==I7/D<LM5EW5L="%-1W;.=6Y$PG@A=L$\07E^>"@S^GKT>:XL
M17R!>T8E4WXH?.D?K7^W?GI<]'')>414\G./>@A,MW4H>K)$3G:K>UD[ZG@U
M?!0ST'G8?.8L77N%?<HE>7U??J\?XW\??X!<9G "?XQ4B'('?\=,9W/1?\9$
M&75S?[([QW<<?[LSIGCL?]TL0GK!@!0ECWR\@$ @#WZD@%Q;_&Z0A9I4)'"_
MA4Q,"W*TA)Y#SW1X@]$[EW8\@R,SD7@I@H\L/7HB@@\EFWQ"@8P@,GY"@0]8
MBHLZ4&%0^(J45(%)&HH 6+Y W8E>72LX<8BG8=,P,H?N9L$HG8=":^0AV(:V
M<54<8(91=ME7<8?]5M=0%8>X6H%(3(=:7D5 /H;B8BXX$(989D@P$H77:IXH
MOX5F;R B-84;<^(<[83Q>*=6F(3574E/.X388'5'G(2X8[,_J(1V9Q,WKX0H
M:IPOZH/H;E@HU8.Y<C8B@8.O=D8=9X.^>DQ5TH'=8Z].=H(=9E-&W((W:0<_
M(X(T:]@W4((H;L\OOX(L<>PHX((_=24BOH)R>($=T(*V>\=5$7\I:@U-P7^K
M;"9&.7_^;DP^EX Q<((W"H!A<N$OFX"D=5\HZ(#T=^XB\8%@>I$>*8'4?1=4
M7WS$<%M-'7V*<>I%L7X7<WH^+7Y\=14VOG[<=LTOB']->*<H\W_2>HLC'(!T
M?'0><X$7?CM3Q7JS=GE,E'NX=X!%0GQ[>'0]V7T,>6XV>WV7>H,O:WXR>[(I
M"'[6?.XC1'^J?B$>L(![?S-307CG?%E,%GHO?-9$U7LF?2T]AGO@?8(V0'R,
M??(O.GU2?G@I WX/?PXC;W[_?Y8>X7_]@ -2X'=Q@AY+S'CV@A=$H'H?@;\]
M<7KM@5@V57NC@1HO:'Q\@/@I)WUC@.@CBGY^@,X?"'^8@*Q.V)/]3Z-(2I*$
M4])!<9$16!TZ/8^%7*0RX8W9878KNXPC9I,E08IZ:^0?E(CV<6\;&8>T=N=-
MS)#Z5;E'4H_M67U @(ZO75\Y?8T_87$R;(NM9<$KEHH=:D\E;(B?;P,@ (=2
M<^4;M89'>*=-%(WX6\M&C(TL7QP_U8PI8H0XZHKH9APR$8F):>,K>8@Q;> E
MD(;M<?<@6X7==B\<.X4)>CY,>(L18=!%ZHI\9*0_,8FO9X\X>XBL:I\QR8>)
M;> K989O<48EKX5J=, @J(27>$T<KX/X>ZI+VHA>9\Y%4X@0:B$^KH=[;(@X
M$(:H;P@QHH6_<;DK7(3B=(HESX07=V(@[(-]>D$=$(,0?.Q+087O;<=$QH7Q
M;Y4^0(69<6XWQ(3V<UXQ<X0Y=7 K8X.)=Z0E\(+Q>=HA)H*,? D=88).?@-*
MO(/0<Y-$3(0@=-P]Y(0"=B(WAH.+=WLQ3(+U>/(K6H)M>H(F$H'W?!<A6X'
M?9P=I(&N?N]*3(( >2]#YX*7>?(]E8*O>I\W5H)>>U@Q+8'J?#(K18&+?2 F
M&H$R?A8AA($9?OD=VH$L?[1)^X!\?J5#EX%2?ML]58&=?N8W,8%L?ODQ)($/
M?S K5(#*?WPF*("6?]$AFH">@!L>!8#$@%0  /__  #__P  __\  &UF=#$
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M__^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MCV?5?H]GU7Z/9]5^CV?5?H]GU7Z/9]5^CV?5?H]GU7Z/9]5^C_^C.2K_GT9
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MUJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UO^C.2K_H$9
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MJXW)?ZN-R?^G-2K_HT)!_ZP\3?^W-E?RQ3-?X=8V8\WC,7RZTS^1J<A4H9_
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M2?^A3%CYI4UF[Z=/=>:I4X/>J%J0U:9BG,^C;*;)H':NQ9Y_M<&<A[J^EXK
MNI"-QK:+DLNTB)K.LH:DT:: I-&@@:?-GX&GS)^!I\R?@:?,GX&GS)^!I\R?
M@:?,GX&GS)^!I\R?@:?,GX&GS)^!I\R?@:?,GX&GS/^A."+_GD4W_YY,2?^B
M2U?YIDQF\*E.=.>K48+?JU>.UZI?FM"H::3+I7.LQJ-\L\*@A+F^G(C N9:,
MQK61DLNOC9C/JHJATJ"$H].;A*;.FH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-
MFH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-FH2GS?^A."+_GD4W_YY+2?^C2E?Z
MITME\*M,<^BM3X#@KU2-V:Y<F-*M9J'-JW"IR*IYL,.G@;>^H83 M9N)QJZ5
MC\RHD97/HHZ>TIJ)HM.6AZ7/E8>FSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>F
MSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>FSO^A-R+_GD0W_Y]*2?^D25;ZJ$ED
M\:Q+<NFP37_ALU&+VK-:E=2S8Y[/LVZER[-XJ\.L?+>XI8&_KYZ&QJB9C,NA
ME9+0FY*;TY6.HM21C*70D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+
MILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSO^A-R+_GD0W_Z!)2/^E2%;[JDAD\JY)
M<>JR3'WBMD^)W+A7DM:Z89K3O6V@R;AUJ[ZP>K:SJ7^_JJ*$QJ*=BLN;FI#/
ME9>9TI"5HM2-D*70C)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,
MD*;/C)"FSXR0IL^,D*;/C)"FS_^A-R+_GD0W_Z!)2/^F1U7[JT=C\[!(<.NU
M2GSDNDZ&WK]5C]K#8)72Q&V<Q;MSJKFS>+:NK7V_I:>"Q9VBB,N6GX[/CYR6
MTHN<HM.(E:30B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/
MB92ESXF4I<^)E*7/B92ES_^B-R+_GT0W_Z%(2/^G1E7\K$5B]+)&;NRX2'KF
MOTR#X<=3BMS-8H[.R&R;P+]QJK2W=[6IL7R^GZR!Q9>GALJ0I(S.BJ*5T8:B
MH=*$FZ70A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JE
MSX6:I<^%FJ7/A9JES_^B-B+_GT,W_Z)&1_^H1%3]KD-A];5$;.Z\1G?IQ$M_
MX\]4A-G498C(RVN:NL)PJ:ZZ=[2CM'R]FJ^!PY*LA<B+J8K,A*>2SX"FG-"
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MICHT_[(S/?? +D+DTB]!S^0N5;_O,VNOX3M^H-9*C9;.6YF0R&FAC,-SJ(G
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M@X%=WX.!7=^#@5W?@X%=WX.!7=^#@<O0"0.ZX@L3J/\4)IK_(3>-_S%%A/]
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MGU!0_Z!37?>@6&GOGUUUZ)UD@.&:;HO;EG>4U9& G-".B:/,B8^IR825KL>
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M655B_%Y87OMD6UOY:%U9^&Q>5_=P8%;W<V%5]G9B5/5X8E/U>V-2]'UD4?2
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M94CSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9LV[!0"]QP8
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MCH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR B,N;@(C+FX"(RYN
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M;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;_^)$ '_G0X VJ\( ,V[" #$QP<
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M;V&5[&]AE>QO897L;V&5[&]AE>QO897L;_]W$@'_B1$!_YD1 /.H#@#7M0H
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M1$#G^$- Y_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$ L+@! *3$ @"9T 4
MC^$* (GQ&@&!\2@%>/(R#'#R.Q-I\D,98O)*'USS4"-6\U<G4O->*T_S92U,
M]&PP2?1S,D;T>S1#](0V0?6.-S[UF3D]]J0Z._:P.SKWOSPY^,\\./?H/#CW
M[#PX]^P\./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\  )C* 0",V 0 A/H.
M 'S[&P)T^R8%;/PP"F7\.!!>_4 56/Y'&5/^31U/_U0@2_]:(DC_825%_V<F
M0O]M*$#_=2H]_WTK.O^&+3C_D2XV_YLO-/^F,#/_LC$R_[XR,?_0,C'_UC(Q
M_]8R,?_6,C'_UC(Q_]8R,?_6,K*O  "EN@  F,8  (O2  !_WP( >?\1 6__
M&0)G_R($8/\L!UK_- Q4_SP/3_]#$TK_215'_T\70_]5&4#_6QL^_V$<._]F
M'CG_;1\V_W0@-/]](3'_AB,O_Y$D+?^;)2S_I28K_Z\F*O^[)RG_OB<I_[XG
M*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0< :_\/ 6+_%@);
M_QX#5/\F!4[_+@9)_S4(1?\\"T'_0PT^_T@.._].$#C_4Q$U_U@2,_]>$S'_
M9!0N_VH5+/]R%BK_>A<G_X,8)?^.&23_F!HC_Z :(O^J&R'_K1LA_ZT;(?^M
M&R'_K1LA_ZT;(?^M&YJ^  "+R@  ?M<  '#C  !G_P0 7O\- %;_$@%/_QD"
M2?\@ T/_)P0__RX%.O\T!C?_.@<S_S\',/]$""[_20DL_TX)*?]3"B?_6 HE
M_UX+(_]D"R'_; P?_W0-'?]]#AO_APX9_X\/&/^9#QC_FQ 8_YL0&/^;$!C_
MFQ 8_YL0&/^;$/],*@/_2#,%_T\T!O]4-PC_6D$._UQ*%O]:5!W_5V D_U1K
M*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+ /_]"R4#_0=5!
M_T'D0?]![D+_0?9"_T']0O]"_T'Y1/]!]$;_0N]'_T+O1_]"[T?_0N]'_T+O
M1_]"[T?_0O]-*0/_2C($_U$R!O]7-@C_7#\._UY)%O]=4QW_6EXD_U=I*O]3
M=2__4($T_TV--_]*ESK_2)\\_T>G/?]&KC__1;5 _T2]0?]$QD+_0]%"_T/B
M0_]#[$/_0_5#_T/\0_Q$_T/U1_]#[TC_1.M)_T3K2?]$ZTG_1.M)_T3K2?]$
MZTG_1/]-*0/_3# $_U0Q!?]9- C_7ST._V%'%O]@4AW_75PD_UIG*_]6<S#_
M4W\T_T^*./]-E#O_2YT]_TJD/_](K$#_2+-!_T>[0O]&PT/_1LY$_T7?1/]%
MZD7]1?-%^T7[1?=&_T3P2?]%ZDK_1N5+_T?E2_]'Y4O_1^5+_T?E2_]'Y4O_
M1_].*0/_3RX$_U<N!?]=,@?_8SL._V5&%O]E4!W_85DD_UUD*_]:<##_5GPU
M_U.'.?]0D3S_3IH__TVB0/]+J4+_2K!#_TJW1/])P$7_2,I&_4C;1OI(YT?X
M2/)']4CZ1O%)_T?J2_](XTS_2=Y-_TK>3?]*WDW_2MY-_TK>3?]*WDW_2O]/
M* /_4BP$_UHL!?]A+P?_9SH._VI$%?]J3AS_9U<D_V)A*_]>;3'_6W@V_U>#
M.O]4C3W_4I9 _U">0OY/I43\3JU%^TVT1_I,O$CY3,=(]DO42?-+Y4GP2_!)
M[4SY2.E,_TKA3O]+VD__3--0_TW34/]-TU#_3=-0_TW34/]-TU#_3?]0* /_
M52H$_UTI!?]E+0?_;#@-_V]"%/]O2QS_;%4C_VA>*O]C:3'_7W0V_5Q_._M9
MB3_Y5I)"]U2:1/53HD;T4JE(\E&Q2?%0N4KO3\-+[D_/2^M/XDOG3^Y+Y$_X
M3=]/_D[54?]/SE+_4,E3_U#)4_]0R5/_4,E3_U#)4_]0R5/_4/]1)P/_6"<$
M_V$G!/]J+ ;_<38,_W1 $_]T21K_<E(B_VY;*?UH9##Y97 V]F%[._->A4#P
M6XY#[EF61NQ7GDCJ5:9*Z%2M3.=3M4WE4[].XU/,3N%3WT[=4^U/V%+W4=%3
M_5+*5/Y3Q%;_4[]7_U._5_]3OU?_4[]7_U._5_]3OU?_4_]2)P/_6R4#_V4D
M!/]N*@;_=C0+_WH]$?]Z1AC_>$\@^W18*/9O82_Q:VPV[6=V/.EC@$#F8(I%
MY%V22.%;FDK?6:)-W5BJ3]I7LE#85KQ1U57(4M)5VU/.5NM3RU;V5<96_5:_
M6/U6NEG]5[9:_5>V6OU7MEK]5[9:_5>V6OU7MEK]5_]3)@/_7R(#_VDA _]S
M* 7_>S(*_W\[$/^ 1!;[?DP>]'M4)>YV72WI<6@TY&UR.^!I?$'<985&V&*.
M2M1?EDW179U0SERE4LQ:K53)6;96QUG"5\99T%?"6>98OUGS6;M:^UFU6_M:
ML%W[6JU=^UFM7?M9K5W[6:U=^UFM7?M9K5W[6?]6) /_8B #_VT@ _]W)@3_
M?S (_X0Y#?V&013UA4D;[H)1(N=]6BKA>&0RW'-N.M1N=T'0:H!'S&:)3,AD
MD5#%8IA3PV"@5<!>J%B^7;%9NUV\6[E<R5RW7.!<M%WO7+!>^5VK7_E=J&#Y
M7*5A^5RE8?E<I6'Y7*5A^5RE8?E<I6'Y7/]8(@/_91X#_W$? _][) /_A"X'
M_XDV"_B+/A'OBT87Z(A.'N&$5R;9?F$QT7AJ.LMS<T+&;WQ(PFR$3;YIC%&[
M9I-5N&2;6+5CHUJS8:Q<L&"W7JY@Q%^L8-A?J6'K7Z=A]U^B8_=?GV3W7YUD
M^%Z=9/A>G63X7IUD^%Z=9/A>G63X7O];( +_:!P"_W0= O]^(P/_B"L%_8TT
M"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7& 3K5NB%*R:X]6
MKVF76JQGGURI9:A?IF2R8:1DOV*B9-!BH&3G8IYE]6*:9O5AF&?V8)9H]F"6
M:/9@EFCV8)9H]F"6:/9@EFCV8/]='P+_:AH"_W<< O^"(0+_BRD$^9$Q!^^5
M. OFEC\0W91'%]*.423*B%LOPH-D.;Q^;$&W>71(LG5\3JYRA%.J;XM7IFV3
M6Z-KFUZ@:J1@G6BN8YMHNF29:,MEEVCC9)5I\V23:O1CD6OU8I!K]6&0:_5A
MD&OU89!K]6&0:_5AD&OU8?]?'0+_;1@"_WH; O^%'P+_CB<#]94N!>N9-0CA
MG#L,UIA#%LR33R+$C5@NO8=A.+:":4&P?G%(JWIY3J=W@%.C=(A8GW&06YMO
MF%^8;J%BE6VK9))LMV:0;,9FCVS?9HYM\66,;O-DBV[T8XIN]&**;O1BBF[T
M8HIN]&**;O1BBF[T8O]A' +_;Q8"_WP: ?^('@'_D20"\IDK!.>>,07=H#8)
MT9Q!%<>732&_D58MMXQ?-[&'9T"K@FY(I7YV3J![?5.<>(58F':-7)1TE5^1
M<IYBCG&H98MPM&>)<,-HAW#;9X9Q[F:&<O)EA7+S9(1R]&.$<O1CA'+T8X1R
M]&.$<O1CA'+T8_]C&@+_<14!_W\8 ?^*' '\E"$"[IPG N.B+ /8I#((S)]
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M9F&0X69AD/)E8X[S9&2,]&-DC/1C9(ST8V2,]&-DC/1C9(ST8_]Q$ '_@@\
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M54JS_E9*L_Y62K/^5DJS_E9*L_Y62K/^5OJ' @#6F   R:4# +VO P"SN $
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M7'%ZXEQQ>_-:<7O[67)Z_%AR>OQ8<GK\6')Z_%AR>OQ8<GK\6/]G$0'_=0\
M_X,. /2.#0#;F0H U*$+ ,RD%0#"I"<#N*(V"K">0A6GFDP?H)=4*9F37#&3
MD&,XC8UJ/XB*<42#B'A)?H9_37J$B%%V@I%5<X&;6&^ IEIM?[1<:W_%7&N
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M5EN1_E5;D/Y56Y#^55N0_E5;D/Y56Y#^5?]S"0#UA 0 V)$# ,R<!0##I04
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M0T.\_T-#O/]#0[S_0]:-  #&FP  N*4  *VN  "BM@  F+\" (W(!@"#T0L
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M430%_U(^"/]22@W_4%42_TUA%_]*;1O_2'@?_T6#(O]#C23_0I4F_T&=)_]
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M#]QO4Q?4:UX?SF9G)LIC<2O&8'DPPEZ!-+]<B3>]6I$ZNEF8/+A8H#ZV5ZA
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M3X!JXT^ :_1.?VO_3']K_TM_:_]+?VO_2W]K_TM_:_]+?VO_2_]>$ '_:PX
M_W8. /N #0#JB T VX\, -"2%0#'DB<"OH\V"+:,0A&NB$T:J(16(J* 7BJ<
M?64PEWIL-9-W<SJ/=7L^C'."0HARBT:%<)-)@F^=3']NJ$Y];K5/>VW&4'IN
MX%!Y;_).>6_^37EO_TQY;_]+>6__2WEO_TMY;_]+>6__2_]@#P#_;0T _WD,
M .Z#"P#;BPD U)$* ,R5$P#"E24"N9,T![&/01"JC$L9HXA4(9V$7"F7@6,O
MDGYJ-8Y\<3F*>G@]AGB 0H-VB$5_=9%)?'.;3'ERIDYV<K-0=7+#4'-RW5!T
M<_!/='/]371S_TQT<_],='/_3'1S_TQT<_],='/_3/]B#@#_;PP _'L* -Z&
M!@#5C@@ SY0) ,>8$0"^F",!M98R!JV3/P^FD$D8GXQ2()B)6BB3AF$NCH-H
M-(F!;SF%?W8]@7U^07U[AD5Z>8])=GB93'-WI$YQ=[%0;W;!4&YWV5!N=^]/
M;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H \'X& -J(!0#0
MD < RI<( ,*;$ "YFR$!L9HP!JF7/0ZAE$<7FI%0'Y2-6">.BU\MB8AF,X2&
M;3B A'0]>X)[07B A$5T?XU(<7V72VU\HDYK?*]/:7N^4&A\U5!H?.U/:7S[
M3FE\_TUJ>_],:GO_3&I[_TQJ>_],:GO_3/]F"@#_=0@ X8$" -2+!0#+DP8
MQ)H& +V>#@"UGQ\!K)XN!:2;.PR=F$45EI5.'H^35B6)D%TLA(YD,G^+:S=Z
MBG(\=HAY0'*&@41OA8I':X.52FB"H$UE@:Q.8X&\3V*!T4]B@>M.8X'Y36.!
M_TQD@/]+9(#_2V2 _TMD@/]+9(#_2_]I" #[> 0 W(0! ,^/! #&EP4 OYT%
M +>A# "OHQP IZ(L!)^@.0N8GD,4D9M,'(J85".$EEPJ?Y1B,'J2:35UD' Z
M<8YW/FV-?T)IBXA&98J226*)GDM?B*I-7HBZ3ER(SDY=B.E-78?X3%V'_TM>
MAO]+7H;_2UZ&_TM>AO]+7H;_2_]M!0#J?   U8@  ,J2 P#!F@, N: # +&F
M"0"IIQD HJ<I YJE-@F2HT$2BZ%*&H2?4B%^G5HH>9M@+G299S-OEVXX:Y9U
M/&>4?4!CDX9#8)&01ER1G$E:D*E+6)"X3%>0S$Q7D.=+5X_W2E>._TI8CO])
M6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@( LJ0  *FJ!0"B
MK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!JGVPT99YS.6&=
M>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7_T=1EO]'49;_
M1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@  *&P  ":LA$
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M#RKVJQ I]KP0*/;.$2?WYA$G]?$1)_7Q$2?U\1$G]?$1)_7Q$:.H  "6L@
MB+L  'O%  !OS@  8M<  %;>  !.\ < 2OH0 $;[&0!"^R(!/_PJ 3O],@(X
M_3D"-?X_ S+^1@,P_TP$+O]3!2O_6@4I_V(&)_]K!B3_=@<C_X(((?^0""#_
MG0D?_ZL)'O^Z"1W_R0D<_]T)'/_="1S_W0D<_]T)'/_="9BP  "*N@  ?,0
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M/Y1:Y3^26_4^D5O_/I!<_SV07/\\CUS_/(]<_SR/7/\\CUS_//]5$0#_7PT
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M0G9K_T%V;/] =FS_0'9L_T!V;/] =FS_0/]="@#_:0< ['0# -I\! #0@P8
MR8@' ,.*#P"ZBR !LHHO!*N(/ JDA4<2G8%0&9A^6!^3?%\ECGEF*HIW;2Z&
M=70R@G1\-G]RA#E\<8T]>7"60'9OH4)T;JY$<FZ]17!NT45P;^M$<&_Z0W%O
M_T%Q;_] <7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78  -1_ P#+A@4 Q8L&
M +Z-#0"UCQX KHXM Z:,.@F?B441F89.&).#5AZ.@%TDB7YD*85\:RV!>G(R
M?7AY-7IW@CEW=HL\<W65/W%TGT)N<ZQ$;'.[16MSSD5K<^E$:W/X0VMS_T)L
M<_]!;'/_0&QS_T!L<_] ;'/_0/]A!0#Z;@$ W7D  -"" @#'B00 P(X$ +F1
M# "QDAL J9(K Z*0. B;C4,/E(I,%XZ(5!V)A5LCA(-B*("!:2U\?W Q>'YW
M-75\?SAQ>X@\;GJ2/VMYG4%H>*I#9GBX1&5XS$5E>.=$97CW0V9X_T)F>/]!
M9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C , NY$# +.4"0"L
MEA@ I98H IV4-@>6DD$.D(]*%8J-4AR$BUHB?XE@)WN'9RQWA6XP<X-U-&^"
M?3=L@88[:7^0/F9^FT%C?JA#87VV1&!]R41??>5#8'WV0F!]_T%A??] 87W_
M0&%]_T!A??] 87W_0/]G  #C=   TG\  ,>( 0"^CP( MI4! *Z8!@"FFA4
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M(#O#O"$ZP]4A.\+N(3G ^2(XO_\D.+__)#B__R0XO_\D.+__)+V1  "PFP
MI*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$ 5= N 5'0.0).
MT$,$2]!,!DG04PA&T%L+0]!C#4'0:P\^T'41/-& $SK1C!0XT9H6-M&I%S71
MNQ<TTM(7-=#L%C3/]Q@SSO\:,\[_&C/._QHSSO\:,\[_&K.9  "FH0  FJD
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M!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,   &K)  !=T@
M4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R< (_\M "#_,P >
M_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_AP(._Y8"#?^D @S_
ML (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D  %[3  !0VP  0^
M #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX &/\C !7_*  3_RT
M$?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$ _X$! /^/ 0#_FP$
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M*:Y*ZBJK2O@KJ4K_*ZA+_RNG2_\KITO_*Z=+_RNG2_\KITO_*_])$@#_4 X
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M-85<_S2$7/\SA%S_,X1<_S.$7/\SA%S_,_]3"@#_708 ]68$ -]M P#5<@8
MT'4) ,EV$0# =R( N'8Q [%T/@>K<4D.IFY2%*%L6QF=:6(=F6=J(I9F<263
M9'@HD&-_*XUAARZ*8) PB%^9,X5?HS6#7J\V@5Z^.(!>T3A_7^HW?E_Z-GY@
M_S5^8/\T?F#_-'Y@_S1^8/\T?F#_-/]5" #_8 0 Z&D  -IP P#0=04 RG@'
M ,-Z#P"[>Q\ LWHO JQX/ >F=48-H7-0$YQP6!B7;F =DVMG(9!J;B6-:'4H
MBF=\*X=FA"Z$9(TQ@6.6-']CH39\8JTW>F*[.7EBSCEX8^@X>&/X-WAD_S9X
M9/\U>&3_-7AD_S5X9/\U>&3_-?]7!0#_8@$ X6P  -1S @#+> 0 Q7L% +Y]
M#0"V?AT KWXL JA\.0:A>40,G'=.$I=T5AB2<ET<CG!D((IN:R2';'(HA&MZ
M*X%J@BY^:8HQ>VB4-'AGGS9V9JHX=&:Y.7-FRSIR9N8Y<F?W.')G_S=R:/\V
M<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P, P'\$ +F # "Q
M@AH JH(J J. -P6=?4(+EWM+$9)X5!>-=EL;B71B((5R:22!<7 G?F]W*WMN
M?RYX;8@Q=FR2-'-KG#9P:J@X;FJW.FUJR3IL:N0Z;6OU.&UK_S=M:_\V;6O_
M-FUK_S9M:_\V;6O_-O];  #K9P  V7$  ,QY  ##?@( NX(# +2$"0"MA1@
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M+4>9NBU&FM M1ICK+4:7^2Y&EO\N1I;_+D:6_RY&EO\N1I;_+M%W  #!A
MMHX  *J5  "@FP  E9\  (JD  !]J0  =ZL0 '.K'@!OK"P!:JLW!&6K00=A
MJDD+7:E1#UJI6!-7J%\64Z=F&5"G;AQ-IG8?2J6!(4BEC"1%I9DF0Z2H)T*D
MN"A!I,XG0:/J)T"B^"A H?\I0*#_*4"@_RE H/\I0*#_*<E^  "ZBP  KY0
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M#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4  (FM  !\M
M<+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$ .=@[ #C910$V
MV4T!-=E6 C/:7@(QVF@#,-MS!"[;?P4LVXT%*MR=!BG<K08HW<$&*-W>!B?;
M[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT  'ZT  !QO   9<,
M %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H +N8S "WF/  KYT0
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M 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P  #/A   IY0
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M$<TW\1/*-_L5R#?_%L8W_Q?%-_\8Q#?_&,0W_QC$-_\8Q#?_&/\[%P#_0!,
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M)9E+_R292_\DF$O_))A+_R282_\DF$O_)/](# #_3P@ _U8( /5;"0#I7@H
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M*GI<_RIZ7/\J>ES_*O]1  #R6P  WF0  ,]J  #';@( P' $ +IP# "R<1H
MJW$I :5P-P.?;D('FFQ+#)9J5!&2:%P5CF9C&(ME:1N(8W >A6)X(8)A?R2
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M  #8:0  QW(  +QY  "S?P  JX(  *&"  "9@PX E(0= (Z$*P&(@S8$@X)
M"'Z 20QY?U$0=7U8%')\7QAN>V4;:WIL'FAY=")E>'TE8G>')V!VDBI==9XL
M6W6K+EITNR]9==$O673L+EET^BU:=/\L6G3_*UIT_RM:=/\K6G3_*^9A  #1
M;0  PW8  +E]  "O@P  IH8  )R&  "4B P CHD9 (F)* &#B30#?H<^!WF&
M1PMTA4\/<(16$VV"71=I@6,:9H!J'6-_<B!@?GHC77V$)EI\CRE8>YPK5GNI
M+%1[N2U3>\XM5'KJ+51Z^2Q4>?\K57G_*E5Y_RI5>?\J57G_*N%E  #,<0
MOWH  +2"  "KAP  H8H  )6+  "-C0D AXX6 (*/) %]CS$">(X[!7.-1 EO
MC$P-:XI4$6>)6A5DB&$888=H&UZ&<!Y;A7@A6(2")%6$C292@YHI4(*G*D^"
MMRM.@LPK3H+H*TZ!^"I/@/\J3X#_*4^ _RE/@/\I3X#_*=MJ  #'=0  NG\
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M'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9   )Z6  "3FP
MAY\  'ND  !OJ   8ZP$ %^M$0!<K1\ 6JXK %>N-@%4KD #4:U(!4ZM3P=+
MK5<)2:U>"T:L9@U$K&X/0:QX$3^KA!,\JY$5.JN@%CFKL!<XJ\,7.*KA%S>I
M\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8  )>;  "+H0  ?Z8
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M!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X  %3#  !)QP
M/LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#< '^%  ![A2@ =
MXE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3Y>\!$^/Z 1/C
M^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*   ]SP  ,],
M "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U !/P/0 1\$8
M$/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD "/7M  CU[0 (
M]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   QV   )]T  !_A
M   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^,  (_S@ !O]!
M  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.  #_SP  _\\
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M ^P=[@/I'OD$Z![_!>8>_P;E'O\&Y1[_!^4>_P?E'O\'Y1[_!_\K'P#_+1P
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M$;4V_Q*T-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L _T,- /]'$ #_2!0
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M'8I+_QV*2_\=BDO_'?]%  #_30  Y50  -E9  #/6P, REL& ,1:#P"[6QX
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M)6!FN29?9LTF7V;H)F!F^21@9O\C8&;_(V%F_R)A9O\B86;_(NA8  #38P
MQ&L  +EQ  "P=0  IW<  )YU  "6=@T D'<9 (MX)P"&=S,"@78]!'QU1@=X
M<TX+=7)5#G%Q7!%N<&,4:V]J%FEN<1EF;GH<8VV#'F%LCB%?:YHC76NG)5MK
MMR9::\HF6FOG)5MK]R1;:O\C7&K_(EQJ_R)<:O\B7&K_(N-;  #.9@  P&X
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M(4M\]"%+>_\@2WO_($M[_R!+>_\@2WO_(-!G  # <@  M'L  *J"  "@A@
ME8@  (>(  !\B@  =HP. '*-&@!NCB< :HXR 6:-/ -CC40%8(Q,"%R+4PI:
MBUH-5XIA$%2):!)1B'$53XAZ%TR'A1I*AI(<2(:@'4:&KQY%A<(>187?'D6$
M\AY%@_X>18+_'D6"_QY%@O\>18+_'LIM  "Z>   KX$  *6'  ":BP  CXT
M (&.  !TD0  ;I,* &F4%0!FE2( 8Y4N 6"5. )<E4$$691)!E:44 A4DU<*
M49->#$Z29@],DFX129%X%$:0@Q9$D) 80H^>&4"/K1H_C\ :/X_<&C^-\1H_
MC/T;/XO_&S^+_QL_B_\;/XO_&\)S  "U?@  JH<  )^,  "4D   B),  'N5
M  !LF0  99L$ &"<$ !=G1T 6YXI %B>- %5GCT"4IU% U"=305-G50'2YQ;
M"4B<8PM&G&L-0YMU#T&;@!$^FHT3/)J;%#J:JQ4YFKT5.9K9%3F8[Q8YE_P6
M.);_%SB5_Q<XE?\7.)7_%[MZ  "OA0  I(P  )B1  "-E0  @9H  '6=  !H
MH   6Z0  %:E# !3IA< 4:<C $^G+P!,IS@!2J=! 4BG20)&IU $0Z=8!4&G
M7P8_IF@(/:9R"CJF?0LXIHH--J69#C2EJ0\SI;L/,Z74#S.D[@\RHOL0,J'_
M$3*A_Q$RH?\1,J'_$;2"  "HC   G9(  )*7  "&G   >:$  &VE  !AJ0
M5:P  $NO!0!'L!  1; < $2Q)P!"L3( 0;([ #^R0P$]LDL!.[)3 CFR6P,W
MLF0$-;)N!3.R>08QLH<'+[&6""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM
M_PLJK?\+*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@  &2M  !9L0  3;0
M $*X   [N@H .+L3 #>\'@ UO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!
M++YH 2J^= (IOH(")[^1 R:_H@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4B
MN_\%(KO_!:22  "8F   C)X  ("E  !SJP  9[   %NU  !/N0  1+P  #K
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M )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0  +LT  "71   >U0
M%MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $
MZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L[P  [.\  .SO (>G
M  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8  !O;   3WP  #N,
M  SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX
M /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT   ^-   /C0 'NO  !M
MN   8,   %+(  !$S0  -]$  "O7   AW   &.   !'D   ,YP  !^\   3Z
M   !_P,  /\(  #_#0  _A   /X4  #_&@  _R$  /\I  #_,P  _SX  /]+
M  #_6P  _VP  /^   #_D@  _Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0
M_QHE /\5)P#_$2X _Q Z /\.1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*AP'_
M"HX!_PJ5 ?\*FP'_": !_PFE /\)JP#_";$ _PFX /\)P0#^"<P _ G> /D)
MZP#U"?8 \PG_ /(*_P#Q"O\!\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$ _QXA
M /\9) #_%RP _Q4W /\31 #_$5 !_Q!< ?\.9P'_#G(!_PY[ ?\.A '_#HL!
M_PZ2 ?\.F '_#IT!_PZC ?X.J '\#JX!^PZU /H.O@#X#LD ]0[; /(.Z@#N
M#O4 [ [_ >L/_P'J#_\!ZA#_ >D0_P'I$/\!Z1#_ ?\B'P#_(AP _R$< /\?
M( #_'RD _QPT /\:0 #_%TP!_Q58 ?\48P'_$VX!_Q-W ?X3@ '\$X@!^A*.
M ?D2E0'X$IH!]A*@ ?42I@'T$JP!\Q*S ?$2O 'P$L<![1+8 >D3Z 'F$_4!
MY!3_ >(4_P+A%?\"X17_ N 5_P+@%?\"X!7_ O\E&P#_)A< _R06 /\E' #_
M)B4 _R0P /\A.P#_'T@ _QU4 ?T;7P'Y&FD!]QIS ?09? 'R&80!\1F+ >\9
MD0'N&9<![!F= >L9HP'I&:H!Z!FQ ><9N@'E&<4!XQG5 =\:Z '<&_4"V!O_
M M4<_P/4'/\#TQS_!-(<_P32'/\$TAS_!/\I%P#_*A, _RD2 /\L& #_+"$
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M#J(W_PZB-_\.HC?_#O\W!P#_.P( _T # /)"!0#I0@D Y3\. -@^%@#.0"<
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M&VQ6N!QK5LL=:E;F'&I7]QMJ5_\::E?_&6M7_QEK5_\9:U?_&>M,  #85@
MR%X  +QB  "S90  JV4  *-B  "<8@X EF,< )%D*0",8S4!B&(_ X1A2 6
M8% '?5]7"7I>70MW760-=5QK$'-<<A)P6WL4;EN$%VQ:CQAJ6IH::%JG'&9:
MMAUE6L@=95KD'65:]AQE6O\;95K_&F5:_QEE6O\995K_&>A/  #360  Q&$
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M'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_&MM9  #'8@  NFH  *]P  "F<P
MFG,  (]P  "'<04 @7(1 'QS'@!X<RH =',U 7!S/P-M<D<%:G%.!V=Q50ED
M<%P+8F]C#E]O:A!=;G(26FU\%5AMAA=6;),95&R@&U)KKQQ1:\$<46O<'%%K
M\1M2:_X:4FK_&E)J_QE2:O\94FK_&=1<  ##9@  MFX  *QT  "B=P  EG8
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M%D%]_Q9!??\607W_%L)J  "U=0  JGT  )^"  "2@P  A80  'F%  !JB0
M9(H# &",$ !=C1L 6XXG %B.,@!5CCL!4XY# E".2@-.C5(%3(U9!DF,8 A'
MC&@*18MR#$*+?0Y BHD//HJ8$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&
M_Q,[AO\3.X;_$[QQ  "O>P  I8,  )F'  ",B   ?XD  '.,  !ED   7),
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M!:>)  ";CP  D90  (29  !XG@  :Z(  %^F  !3J@  2*T  #VP   TLP,
M+[4. "VU%@ LM2  *[8I "JV,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P B
MN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/
M  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8  #6Y   LO   )+\&
M !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\
M$\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+
MG   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!   CQ0  &\D! !3,
M!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))  G350 )TV( "--R
M  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8  =7V (Z=  " I
M<ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9S@  $M(   W6 0 )
MVP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A1P  XE0  .-C  #C
M=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G (.D  !UK   :+,
M %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0  "]T   7A    Y
M .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0  [T4  /!3  #Q9
M\78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M  !JM0  7+T  $_$
M  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8   #J    [@   .X
M  #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,
M /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_%2$ _Q$A /\-) #_
M"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\
ME@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z
M .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD
M_PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[
M ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$
M_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P
M /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8
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M L ;_P+ &_\"P!O_ O\F#@#_)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@
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M$'Q%N1%[1<L1>D7F$7E&]Q%X1O\0>$;_$'A&_P]X1O\/>$;_#_ _  #?20
MS4\  ,%3  "X5   L5(  *M.!0"D3A$ GD\@ )E0+0"54#D!DD]# 8Y.3 .+
M35,$B4U:!89,80:$2V@(@DMN"8!*=@M^2GX,?$F'#GI)D0]X29P0=DFH$G1)
MMA)S2<@3<DKC$W%*]1)Q2O\1<4O_$7%+_Q!Q2_\0<4O_$.Q#  #93   R%,
M +U7  "T6   K%<  *52 0">4P\ F%0< )-4*0"/5#4 BU-  8A32 *%4E $
M@E%7!7]07@9]4&0(>T]K"7E/<@MW3GL-=4Z$#G--CA!Q39D1;TVE$VU-LQ1L
M3<44:T[A%&M.]!-K3O\2:T[_$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:
M  "P7   IEH  )]6  "85@T DE<9 (Y8)@")6#( AE@] 8)710)_5DT#?%54
M!7E46P9W5&$(=5-H"7-3< MQ4G@-;U*!#VU2BQ!K49<2:5&C$V=1L11F4<,5
M95+>%652\A1E4O\395+_$F52_Q)E4O\295+_$N1*  #/4P  P%H  +5>  "L
M8   HEX  )I9  "26@L C5L6 (A<(P"$7"\ @%LZ 7U;0P)Y6DL#=EE2!'18
M6 9Q6%\';U=F"6U7;0MK5G4-:59^#V=6B1%E59428U6A%&)5KQ5A5<$68%7;
M%F!6\15@5OX48%;_$V%6_Q)A5O\285;_$N!-  #+5@  O5T  +)A  "H8P
MG6$  )5=  "-7@D AUX3 (-?( !_7RP >U\W 7=>0 )T7D@#<5U/!&]<5@5L
M7%P':EMC"6A;:PMF6G,-9%I\#V):AQ%@69,27EF@%%U9KA5;6;\66UG8%EM9
M[Q5;6?T47%G_$UQ9_Q)<6?\27%G_$MQ0  #'60  NF   *]D  "D90  F60
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M$DYE_Q).9?\23F7_$LQ:  "\8P  L&H  *5O  "8;@  C&T  (!L  !W;0
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M#+9O  "J>   GW\  )!^  "#?P  =X   &N"  !>AP  58H  $Z,!@!*CA
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M 2*EE@$@IJ@!'Z6[ 1ZEUP$>I.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C
MBX\  'V1  !OE   8Y@  %>=  !-H0  0Z4  #BH   PJP  **X' "2O$  C
MKQ< (:\A ""P*0 ?L#$ 'K Z !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:R
MD  5LJ( %+*V !.RS@ 3L>L $Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<
M '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0  (+@  !BZ!P 4O X
M$[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *
MOID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE
M  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.
M  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD  ,MH  #+>0  S(P
M ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5
MLP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.   $T@(  -,*  #3
M#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1
M  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0  9+   %:W  !)O
M/,   "_$   DQP  &\L  !//   -T@  !]8   #;    W@   -\#  #@"0
MX0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #N
ME   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D  $O    ]Q0  +\D
M "3-   9T0  $=8   O;   #W@   .$   #E    Z    .D   #J    ZP8
M .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@  _%L  /UM  #]@
M_I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!( #_ "@ _P U /\
M00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "<
M /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L [0#W .P _P#K /\
MZ@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_
M $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0 CP#R )0 \0"9 /
MGP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U ., _@#B /\ X0#_
M .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48
M_P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J )$ Z "6 .< G #F
M *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#
M_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A,
M /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX
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M ?\B! #_(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH T!LX ,L=10#''5
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M!)4OO023+\\$D3#H!8\P^ 6-,?\%C3'_!8PQ_P6,,?\%C#'_!?\M  #J-0
MW#H  ,X]  #&/   P#<" +LS#0"S-!D KC8G *DW- "E-T  HC=* )\W4P&=
M-EH!FS9A 9DV: *7-6\"E35U Y0U? .2-80$D#6-!(\UE@6--: %BS6K!HHU
MN0:(-<H'AS;E!X4V]@>$-_\'@S?_!X,W_P>"-_\'@C?_!_0R  #C.P  TD$
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M#6Q%[PQK1?T+:T;_"VM&_PIK1O\*:T;_"N5   #/20  P4\  +52  "K4@
MH4\  )M*  "42@P CTL7 (M,) "'3"\ A$PZ (%,0P%^2TL!>TM2 GE*6 -W
M2E\$=4EF!7-);09Q274';TE^"&U(B EK2),+:DB?#&A(K0UG2;T-9DG4#F5)
M[0UE2OP,94K_"V5*_PME2O\+94K_"^!$  #+30  O5(  +)6  "F50  G%(
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M#5=4_PQ75/\,5U3_#-%-  # 5@  LUP  *=>  ":70  CUP  (98  !_60
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M"[]<  "Q9   IFH  )9I  "):0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8
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M!#)_F@4Q?JH&,'Z]!C!^V@8P?? &,'O]!C![_P8P>O\&,'K_!K!L  "D=0
ME'4  (9U  !Y=@  ;G<  &-Y  !7?0  3X$  $>$  !"A@P /X<3 #V('0 \
MB"< .XDP #J).  XB4  -XE( #:)3P TB5@!,XEA 3&); $OB7@"+8F' BR)
MEP,JB*<#*8BZ RF(U ,IANX#*87\!"F$_P0IA/\$*83_!*IT  ">>P  CGH
M (!Z  !T>P  :'X  %V!  !2A0  28D  $&,   YD 4 -9$/ #.2%P RDB$
M,9(I #"3,@ NDSH +9-! "R32@ KE%( *I1< "B49P GE',!)92" 224DP$B
MDZ0!(9.W 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\  "7@   AW\  'N
M  !N@@  8H4  %>)  !-C@  0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB
M "2>*@ CGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\
M%Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !G
MBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I
M(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL
M  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C   >HT  &R1  !@E0
M5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /M0H #;80  RV%@ +
MMA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W>P  MXX  +>A  "V
MM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<  &6<  !8H0  3*8
M $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4  \$-  #!$0  P1<
M ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P  Q8$  ,65  #%J
MQ;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V
M   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'  #,#0  S1$  ,T6
M  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,  -:'  #6FP  UJT
M ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%N   .+P  "N_   A
MP@  %\8  !#)   *S    M    #4    UP   -@   #:!0  VPL  -P.  #>
M$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN
M  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP   +,0  "#(   6S
M#M    ?4    V0   -T   #A    XP   .0   #F    YP$  .D'  #K#
M[!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[
MJ0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7
M /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *(
M\P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H
M /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\ .P#_ $< _P!3 /T
M7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E
M .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\ W0#_ -T _P#< /\
MW #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q
M &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .( E@#A )P WP"B -T
MJ0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_
M /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P [P!) .H 4P#G %T
MY !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#,
M *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4
M"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@
M -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL
MO@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_
M%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-
M8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8 +<.H "V#JD M ^T
M +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\ IQ/_ /\:  #_&P
M^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_%$L O!14 +D570"W
M%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7G "I%Z8 IQBP *88
MO0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_ ?\=  #W(0  Z"0
M -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4 L!Y/ *T>5P"K'E\
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M W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_ ^TO  #;-P  R3T  +X^  "S/
MK#@  *<S! "B,A$ G30= )DU*@"5-34 DC5  (\U20"--5  BS57 (DU7@&'
M-60!A31K 80T<@*"-'D"@#2" GXTBP-]-)8#>S6A!'DUK@1X-;X%=S;4!78V
M[05T-_P%=#?_!'0W_P1T-_\$=#?_!.<U  #2/0  PT(  +A$  "L0@  I#X
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M!V!%_P9@1/\&8$3_!M9!  ##20  MDX  *=/  ";30  DDL  (Q'  "%1P0
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M!L5.  "V5@  IUH  )A9  "+6   @5<  '=4  !P50  :E8& &97$ !B5QH
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M!3]BF@8^8JH&/6*\!SQBU@<]8>\&/6']!CY@_P8^8/\&/F#_!KE9  "K80
MFF$  (MA  !_80  =&$  &EA  !?8@  660  %1F"0!19Q$ 3F<: $QH) !+
M:2T 26DV $AI/@!&:D4 16I, $-J5 %":EP!0&EE CYI;P(\:7L#.VF)!#EI
MF 4X:*@%-VBZ!3=ITP4W:.X%-V?\!3AF_P4X9O\%.&;_!;1>  "G90  E64
M (9D  !Z90  ;V4  &1F  !9:   4FH  $UL! !);@X 1VX6 $5O( !$<"D
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M 2*"R0$B@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0  @W$  '9Q  !L<@
M8'4  %9X  !,?   0X   #N#   SA@  +8D* "J*$0 IBQD )XLB ":+*@ E
MC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-B@ ;C9P &8VN !B,
MQ  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78  ')W  !E>0  6GP
M %"   !&A   /(D  #2,   MD   )9," !^5#  =EA( ')8: !N7(@ :ERH
M&9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0F)8 $)BI  Z8OP .
ME]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^  !?@0  5(8  $J*
M  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I
M  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX !*.A  *CM  #HLL
M Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8C   39$  $*6   X
MF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O
M*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9
M  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F   19T  #NB   PI@
M)ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@  NA,  +L9  "[(0
MO"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^GP  O;,  +['  "^
MW@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L  #*O   HM   'K8
M !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X  ,<2  #(&   R1\
M ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP  SZ8  ,^X  #/R
MS]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ   =O0  $\    W$
M   &QP   ,H   #.    T    -$   #2 @  TP@  -4,  #6$   V14  -L<
M  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,
M .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2R   #,L   //
MTP   -@   #<    WP   -\   #A    XP   .0#  #F"   Z T  .D1  #L
M&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9  #XI0  ^+   /BP
M /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &<
M_0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q )X \ "D .X JP#M
M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'
M$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K
M /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\
MX "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_
M PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@
M;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "< -4 HP#3 *L T0"U
M ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@
M_P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A %D W@!A -L : #7
M &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$
MO "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD%
M /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %, S@!; ,L 8P#( &H
MQ@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S
M ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+
M P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K
M +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8
MI@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;
M#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.
M:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'>
M )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P
MQ!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D%ED HA9@ *$69@"?
M%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;
M[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD  ,<J  "\)@  MB
M +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V<
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M FTQ_P)M,?\";3'_ M\R  #).0  NSX  *P]  "A.@  FC<  )4S  "0,0H
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M \A"  "X20  ITL  )A*  "-20  @T<  'U#  !V0P  <40* &U$$@!J11T
M9T4G &1%, !B13@ 8$4_ %]%1P!=14T 6T54 %I&6P%91F,!5T9L 59&=@)4
M1H$#4T:. U)'G 101ZL$4$>]!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%
M  "U30  HTT  )5,  ")2P  ?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD
M %])+0!=234 6TD] %E)1 !724H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#
M3DJ, TU*FP1,2ZH$2TN\!$I+TP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R
M4   H$\  )%/  "%3@  >TT  '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-
M*@!833( 5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!3DYG 4Q.<@)+3GT"24Z+
M TA.F01'3Z@$1D^Z!$9/T01&3^T$1D[\!$9._P-'3O\#1T[_ [U,  "N4@
MG%$  (U1  "!40  =U   &Y,  !G3@  8D\  %U0#0!:4!0 5U$> %51)P!3
M43  45(X %!2/P!.4D8 35)- $Q350!*4UT!25-E 4A3;P)&4WL"15.) T-3
MEP-"4Z<$05.X!$%3SP1!4^P$05+[ T)2_P-"4O\#0E'_ [I/  "J5   F%0
M (E4  !]4P  <U,  &E1  !B4@  7%,  %A4"@!451( 4E4; $]6) !.5BT
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M C%CR (Q8N<",6'X C%A_P(R8/\",F#_ JY<  ";70  BET  'Q=  !P70
M9ET  %Q>  !28   3&(  $5E  !!9@H /F<1 #QH&@ [:"( .6DK #AI,@ W
M:CH -FI! #5J20 T:E( ,VI; #%J90 P:G !+FI^ 2UJC@$L:I\!*VJP 2IJ
MQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA  "58   A&   '=@  !L80  8F$
M %AC  !.9@  1V@  $!K   Z;@4 -F\. #1P%0 S<!X ,G$F #!Q+@ O<34
M+G(] "UR10 L<DT *W)7 "IR80 I<FT )W)[ "9RBP D<IP!(W*N 2-RPP$C
M<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D  !H90  7F8  %1I
M  !);   0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX
M "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X
M&GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C:@  66P  $]O  !%
M<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%
M.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O
M !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<   4W,  $EW  ! ?
M-X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0
MD3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.
M]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T  $.!   YA@  ,(H
M "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,
M YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@  F[\  )K;  ":[
MFO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,   RD0  *94  "&9
M   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT
M  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4  *C+  "GY   I^\
M *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   JG@  (:(  !FF   2
MJ0  #:P   >O    L@   +,'  "S#   LQ   +05  "T&P  M2(  +8K  "W
M-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^  "WT@  M^8  +?J
M ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP  &:\  !&S   +M@
M!+D   "\    O@   +X   "_!@  P L  ,$/  #"$P  PQD  ,0@  #%*0
MQS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3
M  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P   J_   !P0   ,0
M  #(    R@   ,H   #,    S0,  ,X(  #0#0  T1   -,6  #6'@  VB@
M -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@  X+X  .## &:?  !9
MI@  3*T  #^T   RN   )+P  !B_   0PP  ",<   #*    S0   -$   #5
M    V    -D   #;    W0   -\   #A!   XPH  .4.  #G$P  ZAP  .TG
M  #P-0  \48  /)8  #S:P  \X   /24  #THP  ]*X  /2R /\ $P#_ !$
M_P 1 /\ %0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W
M '@ ]0!^ /0 A #R (D \0". /  DP#N )D [0"? .P I@#J *X Z "X .8
MQ0#E -L XP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P -
M /\ $@#_ !L _P H /\ - #^ $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0
MZ@!Z .D ?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#> *H VP"T -D P #6
M -  TP#H -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\ #0#_  D _P * /\
M#P#_ !8 ^P B /< +P#T #L \ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U
M -P >@#: (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D
MQ0#B ,0 \@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y
M !$ \0 = .L *0#G #8 XP!! -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L
M=0#) 'L R "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#:
M +8 [0"T /H M #_ +0 _P"T /\ M #_ /\$  #_    _P   /\ !@#L  T
MY0 6 -X (@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\
M '4 N@![ +D @0"W (< M0". +, E0"R )X L "G *X L@"L +\ J@#1 *@
MZ "H /< IP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,  .@   #A  < U0 0
M ,T &P#' "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\ L@!E +  :@"O '
MK0!V *P ? "J (( J0") *< D0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<
M!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/  #."P  R ,+ ,(
M$P"\ A\ MP,L +,$-P"P!4( K09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ
M * (=P"?"'X G0B% )L)C@":"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8
MCP[_ (X._P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q
M"Q< K TD *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40
M<@"3$'D DA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_
M (,5_P""%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$
MH!0> )P5*@"9%34 EA8^ )061P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(
M%W0 AAA\ (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=
M_P!X'?\ >!W_ .4B  #0*0  ORP  + J  "G)P  H",  )T?  ":&@X E1P8
M )$=) ".'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP @!]B '\?:0!]('
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M <TT  "\.P  J3H  )LZ  "0.   B34  (,R  !_, $ >R\. '<P%@!T,"$
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M 5$]EP%//:8"3CZW DX^S0)./ND"33[Z DX^_P%./?\!3CW_ < _  "N0P
MG$,  (Y#  ""0@  >D   ',]  !M/   :#T% &0]#@!A/A< 7CXA %P^*0!:
M/C$ 6#XY %<^0 !5/T8 5#]- %,_50!20%P 4$!E $] ;P%.07H!34&' 4M!
ME@%*0:4"24*U DE"RP))0N@"24+Y DE!_P))0?\!24'_ ;U#  "J10  F$4
M (I%  !_10  =D,  &]   !H0   8T$! %]!#0!<010 64(= %=")@!50BX
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M CI.Q@(Z3N0".TWV CM-_P$[3/\!/$S_ ;--  ">3   C4P  '],  !T3
M:DP  &!*  !92P  5$P  %!-!0!,3@X 24\5 $=/'@!%3R8 1% N $)0-0!!
M4#T 0%%$ #]12P ^45, /5)< #Q29@ Z4G( .5)_ 3A2C@$W4IX!-E*O 352
MQ $U4N(!-E+U 391_P$V4/\!-U#_ :Y/  "93P  B4\  'M/  !P3P  9D\
M %Q.  !43P  3U$  $I2 0!&4PP 0U02 $%4&P! 52, /E4K #U6,@ \5CH
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M "-B_0$D8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60  6EH  %!<  !(7@
M06   #IC   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D
M:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI
M_  <:/\ '&C_ )5<  "#7   =5P  &E=  !?70  5EX  $QA  !#9   /&<
M #5J   O;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@ '70P !QT.  ;=$
M&G1* !ET5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3
M<?\ $W'_ (Y@  !]8   ;V$  &5A  !;8@  460  $AG   ^:P  -VX  #!Q
M   I=0  (G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$
M !!_3@ /?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T
M"WK_ (9E  !W90  :F4  &%F  !6:   3&L  $)O   Y<P  ,7<  "IZ   C
M?@  '($  !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)
M2  %B50 !(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:  "&[   AO4  (;Z
M 'YJ  !Q:@  9VL  %ML  !0<   1G0  #QX   S?0  *H$  ".%   <B
M%8P  !"/   ,D@8 !I,,  *3$0  E!8  )0=  "4)   E2P  )4U  "50
ME4P  )99  "6:0  E7H  )6.  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP
M  !M<   8'(  %1U  !)>0  /WX  #6#   LB   (XT  !N1   4E   #Y<
M  J:   $G0,  )X)  "?#@  GQ(  * 7  "@'0  H24  *(M  "B-P  HT,
M *-0  "C7P  HW$  *.$  "BF0  HJT  *'"  "AW   H>L  *#R '-V  !F
M=P  67L  $V   !"A0  .(L  "Z0   DE0  &YH  !2>   .H0  ":0   *G
M    J@   *L$  "K"@  K T  *T1  "M%@  KAP  *\D  "P+0  L3D  +%&
M  "R50  LF8  +)Y  "RC@  L:,  +*W  "QR@  L>   +'I &Q^  !?@@
M4H<  $:-   [DP  ,)D  ":>   <HP  $Z<   VK   'K@   +(   "U
MMP   +@   "Y @  N0@  +H,  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"
M20  PUH  ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4
M #^;   SH@  **@  !VM   4L0  #;8   :Y    O    +\   ##    Q
M ,4   #&    QP   ,D$  #*"0  RPT  ,T1  #/&   TB$  -4M  #6/
MV$T  -E?  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ
M   LL0  (+<  !6[   -O@  !,(   #%    R0   ,T   #0    T@   -(
M  #5    U@   -D   #;    W@4  . *  #B#P  Y18  .@@  #L+0  [3X
M .U1  #N90  [WH  .^/  #PGP  \*L  /"S /\ $ #_  X _P . /\ $@#_
M !T _P I /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$
M?P#P (0 [@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S ., P #A -( X #J
M -\ ^0#= /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@
M_P D /X ,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C
M '\ X@"% .  B@#> )  W "6 -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T
M] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P % /\ # #\ !0 ]P ?
M /( *P#O #< ZP!" .< 3 #D %4 X != -T 9 #: &H V !P -4 =0#2 'H
MT "  ,\ A0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"]
M /P O #_ +P _P"\ /\ O #_ /\   #_    _P   /D !P#Q !  Z@ : .0
M)0#? #$ VP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z
M ,  @ "^ (8 O "- +H E "Y )P MP"E +4 L "S +T L0#/ *\ Z "N /@
MK@#_ *T _P"M /\ K0#_ /\   #_    _0   .X  0#C  P V@ 4 -$ 'P#,
M "L R  V ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8 :@"T &\ LP!U +$
M>@"P ($ K@"( *T CP"K )@ J0"A *< JP"E +@ HP#( *( X@"A /, H #^
M *  _P"@ /\ H #_ /\   #V    Z@   .    #3  8 R0 / ,( & "] "0
MN0 O +8 .@"T $, L0!, *X 4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C
M 'L H0"" *  B@"> ), G "= )H IP"8 +0 E@## )4 W "4 .\ DP#[ ),
M_P"3 /\ D@#_ /D%  #J"P  W T  ,L*  #"!0  O  * +8 $0"Q !P K@ H
M *H ,P"G #T I !% *( 30"@ %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8
ME0!^ ), A@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&
M"/\ A@C_ .\/  #>%   RA4  +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'
M+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY
M (@+@@"'"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\
M>Q#_ .87  #1'@  O1T  *\<  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1
M#R\ CQ Y (P000"*$$@ B!!/ (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1
M?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_
M -P?  #&)0  LR4  *4C  "<(0  EAX  )(9  "1% L C104 (D5'P"&%BD
M@Q8S ($7/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q
M&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F
M  "]*@  JRH  )TJ  "3*   C24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN
M '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$
M9B&- &4BF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V
M+P  I"\  )8O  ",+0  A2H  ( H  !])   >B(- '8C%0!S(R  <20I &\D
M,@!M)#H :R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>*
M %THEP!;*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P
MGC,  ) S  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E
M*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8N
ME0!4+J, 4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38
M (LV  "!-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$
M7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.
M,Z$ 33.Q $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y
M  !\.0  =#<  &XT  !I,P  93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U
M %4T/ !3-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\
M2#BP 4<XPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X
M/   <#H  &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X
M.0!-.$  3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN  $4[C@!$/)X 0SRN
M 4(\P@%"/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@  C3X  '\^  !U/@
M;#T  &8Z  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,.R@ 2SLO $D\-@!'
M/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _C0 _0)P /D"M 3U
MP $]0-T!/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$  'Q!  !Q00  :$
M &$\  !;/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4 1D L $1 ,P!#0#H
M0D%" $%!20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z1)L .42K 3E$O@$X
M1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#  !N0P  94,  %U
M  !60   44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_
M #Q&1P [1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D
M-$CP #1'_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J1@  844  %E$  !1
M1   3$8  $A'  !$1PH 04@0 #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+
M1  V2TP -4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO
M "],_0 O2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20  74@  %5(  !,20
M1TH  $)+   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P
M4$H +U%2 "Y17  M46< +%%U "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0
M_  J4/\ *D__ )Q*  ")2@  >DL  &U+  !C3   6DP  %%,  !(30  0T\
M #U0   Y4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8
M*59/ "A760 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C
M5?\ )%7_ )9-  "$3@  =4X  &E.  !?3P  5D\  $U0  !%4@  /U,  #E6
M   S6   +UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS "1=.@ C74, (EU,
M "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\
M'%O_ )!1  !^40  <%$  &12  !;4@  4E,  $I4  !!5P  .UD  #5;   N
M7@  *& # "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD-@ ;93X &F5' !EE
M40 895T %V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_
M (E4  !X50  :U4  &!6  !75@  3U<  $99   ]7   -E\  #!B   I9
M(V<  !UJ!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3;3D $FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  /_B
M__])0T-?4%)/1DE,10 $"5%7  !'6   /EL  #9?   N8@  )F8  !]J   9
M;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z
M.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"  !XWP  >.\  '?W
M &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;   ('   !ET   3=P
M#GL   E^   $@0(  (((  "##0  @Q   (04  "%&0  AB   (8H  "',0
MASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@
M  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L  !*    -@P  "(<
M  **    C0   (X$  "."0  CPT  ) 0  "1%   DAD  ),@  "4*0  E3,
M )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R   D^(  )/N &%E  !6
M9@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-   &D0   )0   "8
M    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8  "C(   I2D  *8V
M  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$  *3D %ML  !/<
M0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<    H    *,   "F
MJ    *D   "J    K    *T$  "N"0  L T  +$1  "S%P  M2   +8K  "W
M.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0 %1V  !(?   /((
M #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@   +(   "V    N
M +@   "Z    NP   +T   "^    P 4  ,$+  ##$   QA8  ,D@  #*+@
MRSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#  !!B@  -9$  "F9
M   >H   $Z8   RL   #L0   +8   "Z    O@   ,(   #&    R    ,@
M  #*    RP   ,T   #.    T    -(!  #5"   V0X  -T5  #A(0  XC$
M .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_
M !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /  8P#N &D [ !O .H
M= #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A
M -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_    _P ! /\ # #_ !(
M^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9
M '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,< L #& +X Q #4 ,(
M[@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P   /H !P#Q  \ ZP 8
M .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\
MQ !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q
M /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H  @#A  P UP 3 -
M'0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !? +< 9 "U &D M !N
M +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$ I #! *, W "A /(
MH0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+  @ PP 0 +T & "Y
M "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *< 7@"F &, I0!H *,
M;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[
M )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  ( LP , *T $@"J !P
MIP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3
M &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8 QP"% .0 A #U (0
M_P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ ' *  #@"= !8 F@ @
M )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D
MA0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y -T > #Q '< _0!X
M /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4 "@"1 !$ C@ 9 (L
M(P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J
M '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8 ;0+M &P#^@!L _\
M; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'!0P A $3 ($!' !^
M B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&
M;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_
M ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\
M<@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B
M#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;
M  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B
M &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W(
M5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">
M(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6
M)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ
M $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0
MB"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5
M'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@
MA0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH
M '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24
M32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _
M)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M
M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I
M $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y
M.2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E
M,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J
M+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"?
M #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0  =S(  &LR  !B,@
M6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X
M+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XT
ML  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0
M %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT
M,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H
M.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W  !;-P  5#<  $TV
M  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR
M "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,(
M(SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8.@  43D  $HY  !$
M.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^
M-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'>
M !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/   33P  $<\  ! /
M.#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @
M1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&J0 81KX %T7< !A%
M\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\  $0_   ]0   -D$
M #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@
M&4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  3
M2OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"   Z0P  ,D4  "U'
M   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E !10+  3430 $E$]
M !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H
M#D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V2   +TH  "E,   D
M3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q8
M0P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*  57Y@ %5_, !E;\
M '-&  !D1P  64@  %!(  !(2   04D  #I*   R30  *U   "52   @50
M&E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %8"L !& T  -@/0 !
M8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*
M  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8  "!9   :7   %5\
M !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28  &DN  !I.   :4,
M &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW   9NX  &;W &9/  !:
M3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB   490  $&@   QK
M   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H  !S,0  <SP  '1(
M  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L  '#T &%3  !64P
M3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /;P  "W(   9V
M>0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  " *@  @#4  (!!  "
M3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ %Q8  !46   25H
M #]=   U80  +&4  "-J   ;;P  %',   YW   )>P   W\   ""    A
M (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@  CRP  (\X  "/1@
MCU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=  !.7P  0V(  #AF
M   N;   )'$  !QW   4?   #H$   B%    B0   (T   "0    D@   ),
M  "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,  * N  "@/   H$P
M *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !':   /&T  #%S   G
M>0  '7\  !2%   -BP  !I    "4    F    )P   "?    H0   *(   "D
M    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C  "R,0  LD(  +)4
M  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P  -7H  "J!   ?B
M%8X   Z5   &F@   )\   "D    J    *P   "O    L0   +$   "S
MM0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&
M70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\
M  >E    J@   *\   "S    MP   +P   "_    P0   ,(   #$    Q0
M ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@  W2H  -X\  #?4
MX&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\ # #_ !, _P = /\
M* #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y
M .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,  SP#: ,X \0#, /\
MRP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[ !  ]@ 9 /( ) #O
M "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X
M>0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_
M +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T Y  4 -\ 'P#; "D
MV  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z
M 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H
M_P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1 ,< &0#$ ", P0 M
M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &, K !H *L ;0"I ',
MJ !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@"; .X F@#_ )H _P"9
M /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0 % "Q !X K@ G *L
M, "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B )L 9P": &T F !S
M )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8 BP#Y (H _P"* /\
MBP#_ /    #;    QP   +H   "P    J  * *0 $ "@ !@ G0 A )L *@":
M #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@
M=0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_
M .    #&    M0   *H   "B    FP % )4 #0"2 !, D  < (T ) "+ "T
MB@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z
M 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$
M  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6 ($ '@!_ "< ?0 N
M 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T <0!C &\ :P!N '0
M; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K
M#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '< & !U "$ <P I '$
M, !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z
M & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX 6P;_ +40  "A$@
MD1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F
M!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*
MA0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@
M 'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P
M7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-
M$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>
M  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N
M %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\
M1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H
M(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6
M, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N=
M #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P  >"0  &PE  !C)0
M7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#
M'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?>P X((L -R&; #8A
MK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<  &@H  !?*   6"<
M %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P /R C #X@*0 \("\
M.R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P
M)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J  !<*@  52H  $\I
M  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20? #<D)@ V)"P -24S
M #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT
M*BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9+0  42T  $PL  !'
M*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J
M-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8
M "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P  3B\  $@N  !#+0
M/RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I
M+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R
M[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$  $4Q  ! ,   .S
M #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH
M(S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =
M-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S   ],P  -S,  #$T
M   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H !\X,  >.#< '3E
M !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH
M&#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z-@  -#8  "XX   J
M.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_
M1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_
M 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0  ,3H  "L\   G/0
M(C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 0
M14X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y
M  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX  "A    C0@  'T0
M !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH
M"DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@
M/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%   ?1P  &DD  !5,
M   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R  12.P #4D8  5)2
M  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X  %#W &A   !;00
M4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;30  %E   !%3   .
M500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9-@  64$  %E-  !:
M6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V &-$  !610  344
M $5%   _10  -T<  "])   H3   (D\  !M2   650  $5@   U:   )70,
M!%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0  8CL  &)'  !B50
M8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(  !220  2D@  $-(
M   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6    AC   #9@$  &<&
M  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30  &U   !M3@  ;5T
M &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.30  2$P  #Y.   U
M40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N    <    '(#  !R
M!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH
M  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40  0E(  #A5   O60
M)EX  !YB   69P  $&L   MO   %<P   '<   !Z    ?    'X   !_ @
M@ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*/@  B4T  (E?  ")
M<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H  #)?   H9   'VD
M !9O   0=   "GD   )]    @0   (4   "(    B@   (P   "-    CP
M ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-   FT0  )I6  "::@
MF8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ   A<0  %W<  !!]
M   )@P   8@   ",    D0   )4   "8    F@   )L   "=    GP   *
M  "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D  *U+  "M7P  K7<
M *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9?P  $(8   F-
MDP   )@   "=    H0   *4   "H    JP   *L   "N    KP   +$   "S
M    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)   #"5   P6L  ,&#
M  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D   "I<   "=    HP
M *@   "M    L@   +8   "Y    NP   +P   "^    P    ,(   #$
MQ@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #920  VEX  -MU  #;
MC   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y
M /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X W@!S -P >0#: '\
MUP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_
M /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X 'P#K "H Z0 T .,
M/0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"
M ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\
MK@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2 "0 SP N ,L -P#'
M $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\
M@0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_
M /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H
ML !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A &P H !S )X >@"=
M (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<
M  #D    T    ,$   "W  ( KP + *L $0"G !D I0 B *, *P"B #, GP [
M )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8 D !M (\ = "- 'T
MC "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$ /\ A #_ .4   #-
M    O    *\   "F    G@ ' )H #@"6 !0 E  = )( )0"1 "T D  U (T
M/ ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"!
M 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\ =0#_ -    "[
MJP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!]
M #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ', :0!Q '$ < ![ &X
MAP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_ ,    "L    G (
M ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "( =  I ', , !Q #8
M<  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A
M )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'  "@"0  D L  (0+
M  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C &@ *@!G #$ 90 V
M &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P
M5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R
M$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X )0!= "L 7  Q %H
M-P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069
M $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%
M9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1
M"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,
MJ0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@  &P9  !C&0  71@
M %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30
M20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [
M$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=  !>'0  6!P  %,;
M  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W
M $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84 -A66 #06IP T%KH
M,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:(   4R   $X>  !*
M'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6
M.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0
M "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P  3R(  $HA  !&(
M0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q
M&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@
MZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4  $<D  !"(P  /R$
M #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L
M*R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C
M)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G   _)@  .R0  #@B
M   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25!
M "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@
M'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \*   -R<  #0F   P
M)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J
M2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_
M 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P  -"H  # J   K*@
M*2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9
M+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J
M  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T  "PM   G+P  )"\
M "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T
M$S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C
M+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ   D,@  (3,  !TU
M @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7
M  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0
M4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A-@  '3@  !DY   5
M.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^/  +/T< "C]2  @_
M8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W &DS  !;-   4#4
M $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P  &CP  !8_   2000
M#D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #14(  D5.  !%6P
M16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V  !7-P  3#@  $,X
M   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(  !)$   .1P0 "TD)
M  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX  $Q)  !,5P  3&8
M $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2.P  2#L  $ [   Z
M.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+   +3@, !U (  )1
M#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%  !34@  4V$  %-R
M  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@  13X  #X^   X/@
M,$   "E"   C1   '4<  !=*   230  #E    M3   &50(  %<'  !8"P
M60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<30  7%L  %QL  !<
M@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(  #Q"   T0P  +$8
M "5)   >3   %T\  !)3   .5@  "ED   5;    7@   & $  !A"   8@P
M &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@  9U4  &=F  !G>@
M9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='   O2@  )DT  !]1
M   850  $ED   U<   (8    F,   !F    :    &H   !K!   ; @  &T,
M  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X  '-?  !T<@  <XH
M '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I4@  (%8  !A;   2
M7P  #60   =H    :P   &\   !R    =0   '8   !W    >0(  'H&  !\
M"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16  "#:@  @X$  (*9
M  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7   &6(  !)G   ,;
M!7$   !U    >0   'T   "!    @P   (4   "&    B    (D   "+!
MC0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "58   E78  )20  "3
MIP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\   QU   $>P   (
M  "%    B0   (T   "1    DP   )0   "6    F    )H   "<    G@
M * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@  J&T  *:'  "GG@
MIK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%    BP   )$   "6
M    FP   )\   "B    I    *4   "G    J0   *L   "M    L    +(
M  "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$  +QZ  "[E   NJD
M +JY #=J   K<   ('@  !:    -B   !8\   "6    G    *(   "G
MK    +    "S    M@   +<   "Y    NP   +T   "_    P@   ,4   #(
M    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N  #4A@  U)L  -.K
M /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8
MZ0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+
M )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\
M  #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!'
M ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L
MM@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I /\ I@#_ /\   #_
M    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4 ,@#  #H O !" +D
M2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S *D >P"G (0 I0".
M *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\ F0#_ /P   #N
MW0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M #0 J0 \ *8 0@"D
M $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )< = "5 'T DP"' )$
MDP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_ .T   #8    Q0
M +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X EP U )4 / "3 $(
MD0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"% '8 A "  (( C "
M )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D   #!    L0   *0
M  "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O (4 -@"# #P @@!!
M (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ),
M< "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O    H    )0   ",
M    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '< , !U #8 =  [ '(
M0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T &8 @ !E (X 8P"=
M &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@    D0   (8   !^
M>0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I #  :  V &8 .P!E
M $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %<
MJ !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0
M &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L 70 P %L -@!: #L
M60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !,
M +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -  !H#0  8@P  %\*
M  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [
M $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (  10"0 $0 H0!# +(
M0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@$0  6A   %8.  !4
M#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#
M/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?&
M #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0  5!0  % 3  !-$0
M2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^
M"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-
MXP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@  $H6  !'%0  11,
M $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT
M-@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K
M$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:  !"&   /Q<  #X4
M   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)"
M "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;  )17& "45Y  E%?8
M)A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^'   .AH  #@8   W
M%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5,  J%3< *18_ "@6
M2  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_
M 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@  -QT  #0<   R&0
M,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A
M&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=
M  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R   # ?   M'0  *QT
M "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T
M&R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D
M(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB   I(0  )B$  "0A
M!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X !@D00 7)$L %B57
M !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$ $B7] ' B  !A)
M5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F)   (B4  !\E P =
M)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J
M8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[ &PD  !=)@  42@
M $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*   'BD  !LJ   8*P<
M%BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,
M+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G  !:*0  3BH  $4K
M   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT  !@N   5+P0 $C$*
M ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T( "3-.  @S6P &-&H
M!31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6+   2RT  $(M   Z
M+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R   2- , #S8)  PX
M#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*   Y5P  .64  #EW
M   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@  2"\  #\P   X+P
M,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /.0, ##L(  @]#0 %
M/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _4P  /V$  #]S   _
MAP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(  #PR   U,@  ,#$
M "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P, "$$(  1##   0PX
M $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@  1ET  $9N  !%@@
M19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU   S-   +C0  "@U
M   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&  !)"@  2@T  $L0
M  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@  $UI  !-?0  3)0
M $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q-P  *CD  "0[   >
M/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1"   4@L  %,.  !4
M$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C  !6=P  5HX  %6E
M  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/   )C\  !]"   910
M$T@   Y+   +3P  !5$   !4    5P   %@!  !:!0  6P@  %P,  !=#@
M7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A<   8(@  &"@  !?
MMP  7M0  %WN $=    _/P  .C\  #%    I0P  (48  !I*   33@  #E$
M  I5   $6    %L   !>    80   &,   !D 0  900  &<(  !H"P  :@X
M &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:   ;7\  &V8  !LL
M:\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4   .6   "%P   )@
M    9    &<   !K    ;0   &\   !P    <@   '0"  !U!@  =PH  'D.
M  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<  'R0  ![J   >L
M 'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '90   &H   !N
M<@   '8   !Y    ?    'X   !_    @0   (,   "%    AP,  (H(  ",
M#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&  ".GP  C;4  (S-
M #U.   R40  *%8  !Y<   58@  #F@   =N    =    'D   !^    @@
M (8   ")    C    (X   "0    D@   )0   "6    F    )L   ">!@
MH0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "CE   H:L  *&_ #97
M   L7   (6(  !=I   /<   !W<   !^    A    (H   "/    E    )@
M  ";    G@   )\   "B    I    *8   "H    JP   *T   "P    LP0
M +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP  MZ$  +>S #!B   E
M:0  &G   !!X   )@    (@   "/    E@   )L   "A    I@   *H   "N
M    L    +$   "T    M@   +@   "[    O0   ,    ##    QP   ,L#
M  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98  ,RI /\   #_
M_P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I $  Y@!( .( 3@#?
M %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,
MHP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_ /\   #_    ^P
M /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X
MP@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L
M *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T   #V    ZP   -\
M  #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \ +, 0P"P $@ K@!.
M *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T G@"( )P E0": *,
MF "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F    T0   ,(   "X
M    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\ / "= $( FP!' )D
M3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "! (H C0"( )L A@"L
M (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+    N@   *P   "B
MG  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"&
M $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4
MMP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@   )H   "2    B@
M (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4
M=0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I (T : "= &< K@!F
M ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H   "!    ?    '8
M! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U &H .@!I #\ : !$
M &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (< 6P"6 %H J !9 +T
M60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S    ;@   &H  0!G
M  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X -0!= #H 7  ^ %L
M1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0
M $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P  8@$  %\   !=  0
M6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2 #0 40 Y %  /P!/
M $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4 G0!% +  1 #' $0
MZ !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D  %4'  !4!   4@ '
M %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #  2  U $< .@!& $
M10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \ *L / #! #L X  [
M /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,  !+"P  2@@" $D$
M"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q #X -@ ] #P / !#
M #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\
M,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!
M!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%
M1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W
M 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@  /!   #H. 0 Z#08
M.@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L
M"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2
M  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,  #41   S$ , ,PX(
M #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX
M) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D
M%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5   N$P  +1$$ "P0
M"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6
M !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0
M5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J%@  *!0! "83!P E
M$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5/P :%DD &194 !@7
M80 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T
M $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0  )!@  "(7!  @%PH
M'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2
M'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;  !:'0  3A\  $4?
M   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L  !T; 0 ;&P< &1P-
M !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P
M#2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z
M(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@   6( 0 %" + !(A
M#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-  LD60 *)&< "21X
M  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0  22,  $ C   X(P
M,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3) , $24(  \F#0 .
M)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H50 %*60 !"ET  ,I
MAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4  #TE   U)0  +R4
M "HD   F)   (B,  !\C   ;)   &"4  !0F   1* , #RD(  PL#  *+!
M""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@  +F   "YQ   MA
M+9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG   S)P  +2<  "@F
M   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'  DP#  &,0X  S$2
M  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT  #-M   S@0  ,I8
M #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P*@  *RD  "<H   C
M*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U"P "-@X  #<0   X
M%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI   Y?0  .),  #BH
M   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+   *BL  "4K   @+
M&RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@  / T  #T/   ^$@
M/Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _>   /X\  #ZF   ^
MO0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X  "(O   =,   &#(
M !,U   0-P  ##H   D\   %/@   $$$  !""   0PL  $0-  !&$   1Q0
M $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P  1XH  $:B  !%N0
M1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T   9-@  $SD  ! \
M   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5
M  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0  $^=  !.M0  3=(
M $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4/@  $$$   Q$   '
M1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7"P  60X  %L1  !=
M%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J
M #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P  "TH   5.    40
M %0   !7    6@   %P   !=    7P   & $  !B!P  9 L  &8.  !H$@
M:QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !FJ   9<(  &3C #T]
M   W/   +CT  "5    =1   %DD  !!-   *40  !%4   !:    70   &
M  !C    9@   &@   !J    :P   &T   !O @  <08  '0*  !V#@  >1,
M 'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP  =;<  '32 #Q!   R
M0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G    :P   &\   !R
M    =0   '<   !Y    >P   'T   !_    @@   (0#  "'"0  B@X  (X3
M  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T  (?% #9'   L2P
M(D\  !E5   06P  "F$   %G    ;0   '(   !W    >P   '\   "#
MA@   (@   "*    C0   (\   "1    E    )<   ": 0  G0<  *$-  "E
M%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW #!0   E50  &UL
M !)B   +:0   7    !W    ?0   (,   "(    C0   )$   "5    F
M )H   "<    GP   *$   "C    I@   *D   "L    L    +0'  "X#@
MNA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;   >8@  %&D   QQ
M   ">0   ($   ")    CP   )8   ";    H    *0   "H    JP   *P
M  "O    L@   +0   "V    N0   +P   #     Q    ,@   #-!P  TA
M -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_    ^P   /H   #\
M  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X 20#: $\ U@!4 -,
M60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@##
M +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W    \@   /    #G  ,
MX0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X
M %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$
MV0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP   -,   #(    P0 )
M +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $, J !( *8 30"D %(
MHP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3 )X D0"P )  R ".
M /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@   "N    J  $ *4
M# "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0
M (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8 ?P"G 'T O !\ .,
M? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9    DP   (\ "0"-
M  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P
M3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T
M &P _P!K /\ :0#_ ,    "K    FP   (\   "'    @    'P ! !Z  P
M>  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K
M $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X
M_P!> /\ 70#_ *P   "9    B@   '\   !W    <0   &T   !J  @ :0 .
M &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D 8  ^ %\ 0P!> $@
M70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2
M /\ 4@#_ )T   "+    ?    '$   !I    9    &    !>  4 7  + %L
M#P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !)
M $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\
M1P#_ )    !^    <    &8   !>    60   %8   !3  $ 4@ ( %  #0!/
M !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@ . !' #X 1@!$ $4
M2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0## #T Y@ ] /L /@#_
M (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0  20 $ $< "@!&  X
M10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z
M $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&
M  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4! #\!!P ^  L /0 .
M #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4 -  \ #, 0P R $P
M,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L .X + #\ '<*  !G
M#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@) P W!0@ -@(- #4!
M$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X "P 0  K $D *@!2
M "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@ )0#W '(-  !B#@
M5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N
M!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&
M7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S &T.  !>$0  4A(
M $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@, *@T' "D+"P H"0X
M)PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;
M#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45
M   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $ ",."  C#0P (@P/
M " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH
M$Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7%   2Q8  $(7   Z
M%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1!@ =$ D '! - !L/
M$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y
M  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@  21@  #\9   W&0
M,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4
M$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7
MAP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH  #T:   U&P  +QH
M "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$
M#Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %
M&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<   S'   +!P  "<<
M   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3
M  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX  A]N  $?@   'Y4
M !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P'@  *AX  "4=   A
M'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A
M%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K   C?@  (Y,  "*G
M   BO   (=<  "'M %4=  !('P  /B   #4@   N(   *"   ",?   @'@
M'1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &)0T !"40  (F%
M)AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G>P  )Y   ">E   F
MNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$  "(A   >(   &Q\
M !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T  "L/   L$@  +!<
M "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P  +(T  "RD   KN@
M*]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B   =(@  &2(  !4C
M   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .   R$   ,Q4  #,;
M   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH  #*A   QN   ,-8
M ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;)0  %B8  !(H   0
M*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X#@  .A(  #H7   Z
M'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>   XM@  -]0  #;O
M $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0  $RL  ! N   -,
M"3(   4U   !-P   #D"   [!0  / @  #X+   _#0  01   $,4  !#&P
M0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _L@  /L\  #[O #\L
M   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(   TU   (.   !#H
M   \    /P   $$   !# @  104  $8(  !("P  2@X  $P1  !-%@  31X
M $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0  2,H  $?L #LP   S
M+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]   "0    $,   !&
M    2    $H   !,    3@$  $\$  !1!P  4PL  %4.  !8$@  61D  %@B
M  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(  %+F #@S   Q,@
M+#$  "4R   =-0  %C@  !$\   ,0   !T0   !'    2@   $T   !0
M4P   %4   !7    60   %H   !< P  7@<  &$+  !D#@  9A,  &<<  !F
M)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[< #4W   P-0  *#<
M " Z   8/0  $4(   Q&   &2@   $\   !3    5@   %D   !<    7P
M &$   !D    90   &<   !I    ; $  &X&  !Q"P  = \  '<5  !W(
M=BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z   K.P  (C\  !I#
M   22   #$T   52    5P   %P   !@    9    &@   !K    ;@   '$
M  !S    =0   '<   !Z    ?    '\   ""!   A@H  (H/  ",%P  BR0
M (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E1   '$D  !-.   -
M5   !%H   !A    9@   &L   !O    =    'D   !]    @    (,   "%
M    AP   (H   ",    CP   )(   "6    F0(  )X)  "B$   HAH  *$I
M  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@  %50   Y;   %8@
M &D   !P    =P   'T   ""    A@   (L   "/    DP   )4   "7
MF@   )T   "@    HP   *8   "J    K@   +(   "W"@  NQ$  +H?  "Y
M,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(   =J    <P   'L
M  ""    B0   )    "5    F@   )\   "C    I@   *@   "K    K@
M +    "S    M@   +H   "]    P@   ,<   #, 0  TPL  -05  #3)@
MT3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$   #S  4 ]  , /(
M$P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!>
M ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\
MI0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?    V0 ) -( $ #/
M !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\
M70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V )L U "9 /D E@#_
M (T _P"( /\ A #_ .@   #?    V0   ,D   "_    N  $ +4 #0"S !(
ML0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 "> $P G !1 )L 5@"9
M %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D Q0"( .X A@#_ '\
M_P!Z /\ > #_ -D   #-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
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M______________________________________________________\
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
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M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQPLJO+<+:KRV^\J\APP*O$<<"JQ''
MJL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K_DA(!_Y8G"O^6.QS_E$LP
M_Y!90_^/8U3ZCFED\8UP<NF+>G[BB8*)W(6)DMB"CIG4?Y.>T7V7HL][FZ;-
M>9ZHS'>BJLMVI:S*=*FMR7.MKLERLJ_)<;>OR'&\K\)SO:Z^=+VOOG2]K[YT
MO:^^=+VOOG2]K[YTO:^^=+VOOG2]K[YTO:__DQ(!_Y<G"O^8.QS_E4LP_Y%9
M1/^18%7ZD&9D\(]M<^B-=X#AC("+VXB'E-6%C9S2@I&ASW^6ILQ]F:G+>YVL
MR7FAKLAWI;#'=JFQQG6MLL9TLK/&<[FSPG6ZL[QUNK.X=KJSN':ZL[AVNK.X
M=KJSN':ZL[AVNK.X=KJSN':ZL[AVNK/_E!$!_Y@G"O^9.QS_EDLP_Y)91/^2
M7E7ZDF1E\)%J=.>/<X'@CGV,V8N%EM2(BY[0A9"DS8*4J<I_F*W(?9RPQWN@
MLL9YI+3%>*BUQ':NML1UM+;!=K>VO'>WMK=WM[:S>+>VLWBWMK-XM[:S>+>V
MLWBWMK-XM[:S>+>VLWBWMK-XM[;_E1$!_YDG"O^9.QS_ETHP_Y-81/^47%7Z
ME&%E\)-G=.>1<(+?CWJ.V(V#F-*+BJ#.AX^GRX23K,B!E[#&?YNSQ'V?M<-[
MI+?">:FYPG>ON<)VM;F\>+:XN'BVN+-XMK>P>;>WL'FWM[!YM[>P>;>WL'FW
MM[!YM[>P>;>WL'FWM[!YM[?_EA$!_YHG"O^:.QS_ETHQ_Y151/^6657ZEEYE
M\)5D=.>3;(+>D7:.V(]_F=&-B*+-BHZIR8>2KL:$EK/$@9JVPGZ?N<)[I+K!
M>:JZP7>QNKUXM;JW>+6YLWFUN:]YMKBL>K:WK'JVMZQZMK>L>K:WK'JVMZQZ
MMK>L>K:WK'JVMZQZMK?_EQ$!_YLF"O^;.QS_F$DQ_Y931/^85U7ZF%ME\)=A
M=.>6:(+>DW*/UI%[FM"/A*/+C8RKQXJ1L<2&E;;#@YFXP7^>NL%[I+O >:N\
MOW>SO+AXL[NR>;2[KGFUNJMZM;FH>[:XJ'NVN*A[MKBH>[:XJ'NVN*A[MKBH
M>[:XJ'NVN*A[MKC_EQ$!_YLF"O^<.AS_F$DQ_YA11/^:5%3ZFUAD\)I==.>8
M8X+>EFV/UI-WFM"1@*3*CXFLQHV/L\.)E+?"A)BZP'^>O+][I;Z_>:Z^N7BR
MOK)YLKVM>K.\J7NTNJ9[M;FD?+:XI'RVN*1\MKBD?+:XI'RVN*1\MKBD?+:X
MI'RVN*1\MKC_F!$!_YPF"O^<.1S_F4@Q_YE/1/^<4E3[G55C\9U:<^>;7X'>
MF6F/UI9RFL^3?*7*D86MQ9"-M,.+DKC!A9:[OX"=OKU[I<&[>:_!LGJPP*Q[
ML;ZH>[.]I7RTNZ)]M;F@?;:XH'VVN*!]MKB@?;:XH'VVN*!]MKB@?;:XH'VV
MN*!]MKC_F1$!_YTF"O^=.1S_F4<Q_YM-0_^>3U/[GU)C\:!6<NB?6X#?G62.
MUYIMFM"7=Z3*E(&MQ9**M<*.D+F_AY6]O8"<P;M[I\2S>JW$JWNOPJ9\L;^C
M?;*]H'ZTNYY_M;F<?[:XG'^VN)Q_MKB<?[:XG'^VN)Q_MKB<?[:XG'^VN)Q_
MMKC_F1$!_YXF"O^=.!S_FD<Q_YQ+0O^@35+\HE!B\J-3<>FC5W_@H5Z,V)YG
MF-";<:/*F'NMQ96%M,*2C;J^BI*_NH&;Q;=\J<FK?*O'I'VNPZ!^L,"=?[*]
MFX"SNYF!M;J8@;:XF(&VN)B!MKB8@;:XF(&VN)B!MKB8@;:XF(&VN)B!MKC_
MFA$!_YXF"O^>.!S_FD8R_YY)0O^B2E']I$U@\Z90;^JG5'WAIEB*VJ1BEM*A
M:Z'+G76KQIJ L\*8BKJ\CH_"MH.9RZQ]ILZB?ZK)G8"MQ)J!L,"8@K*^EX.S
MO)6#M;J4@[:XE(.VN)2#MKB4@[:XE(.VN)2#MKB4@[:XE(.VN)2#MKC_FA$!
M_Y\F"O^>-QS_FT8R_Y]'0?^D2%#^ITI?]*E,;>NK4'OCK%2'W*M<D]2I99W.
MIF^GR*-ZL,.?A+B[EHO$L(R9SJ"#I-&9A*G*EH6MQ92%K\&3A;&^DH6SO)&%
MM+J1A;6YD86UN9&%M;F1A;6YD86UN9&%M;F1A;6YD86UN9&%M;G_FQ$!_Y\F
M"O^?-QS_FT4R_Z%%0/^F1D__JD==]JU):^VP3'CFLT^#W[15CMFU7Y?3M6F@
MSK5VI\&K?+:PGX7$H962SI2.H]*0BZC+CXJLQHZ*K\*.B;&_CHFRO8Z(M+N.
MB+6YCHBUN8Z(M;F.B+6YCHBUN8Z(M;F.B+6YCHBUN8Z(M;G_FQ$!_Z F"O^?
M-AS_G$0Q_Z-#/_^H0T[_K41;^+%%:/"V2'3INTQ^X\!1A]_&6X[6R&N4QKUQ
MIK6S>+6EJ('#E)^-S8F<HM*'E*?,B)&KQXF/KL.)CK# B8VROHJ,L[R*B[2Z
MBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+K_G! !_Z$F"O^@-AS_
MGD(Q_Z5 /O^K0$S_L4!9^K=!9/.]1&_NQ4EWY<Y2?-W68G_,SFB2O,5NI*N[
M=K2:L7_!BJJ*RW^GG<^ GZC,@IFKQX.5K<2$DZ_!A9&QOX:/L[V'CK2[AXZT
MNX>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+O_G1 !_Z(F"O^@-1S_H#\P
M_Z<]/?^N/$K_M3Q5^KT]8/#&0F?FT4ILWMY.=LW:5X>^T&*6KL5NI:&\>;*5
MM(.]AJV(QGNJE,IXJZC)>Z*KQWZ<K<2 F:_"@9:PP(*4LKZ#DK.\@Y*SO(.2
ML[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[S_GA !_Z(F"O^A-!S_HCPN_ZHZ
M._^R.$?\NS=1\L4Z6.;105S;WD)IS>)&?+[748RNS%^;H<-MJ)B\>;*1M82[
MA;&)PGRND<5XKI_%=:VLQ7BEKL1ZH*_"?)RPP'Z9L;Y_EK*]?Y:RO7^6LKU_
MEK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKW_GA !_Z,E"?^B-!S_I3DM_ZXU./^X
M,T+TPS-*Y] X3MG>.5K+YCUNON!"@*[44)"ARU^=F,-MJ)&]>;&+N(.X@[2(
MO7VQD,%YL9K!=;&EP7*OK\)UJ*_!=Z.PP'F?L;][G+*]>YRRO7N<LKU[G+*]
M>YRRO7N<LKU[G+*]>YRRO7N<LKW_H! !_Z0D"?^C,AS_J#0K_[,O-/F_+3SI
MS2] V=XO2LKG-%^]ZCISK]Y!@Z'349&7RV"=D,1NIHR_>JV&NX&S?[B'N'JV
MC;MWM96\=;6?O'*TJ+UNL[*^<:RROG2GLKYVH[*]=J.RO7:CLKUVH[*]=J.R
MO7:CLKUVH[*]=J.RO7:CLKW_H1 !_Z4C"?^D,1S_K2XG_[DI+^[()C/:W"8W
MRN<L3[WR,F.OZ#EUH=U"A);44Y"/S6*:BL=PHH;#>JB OX"M>[V%L7:[B[1S
MN9*U<;F:MG"YH[5MN:NV:KBTN&NRMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZL
MMKANK+:X;JRVN&ZLMKC_HQ !_Z<B"?^E+QO_LR<B],(A)MW8'23+YR,\O?(J
M4Z_S,F:AYSMVE=Y&@XW65HV'T&26A,MQG'_(>*%ZQ7ZE=L*#J7+!B:MOOX^M
M;+^6KFN^G:YJOZ:N:+^NKF6]N+!EN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[!E
MN;NP9;F[L&6YN[#_I1 !_Z@@"/^L)A?\NQT:X]$3&<SE&2F]\B)!K_TJ5:'S
M-&:6Z3]TC.%+?X7;68B U6:/?-%OE'?.=IESRWR<<,F!GVW(AZ%JQXRC:,:2
MI&;%F:5DQ:"E9,6HI6/&LJ1@Q+NF8,2[IF#$NZ9@Q+NF8,2[IF#$NZ9@Q+NF
M8,2[IF#$NZ;_J!  _ZH>"/^S'1'LR0X/SN,.%;[R&"VO_B)#H?\M59;T.62,
M[$5OA.51>7[@7(!YW&>&=-ENBG#6=(YLTWF1:=)_DV?0A)5DSXJ78LZ/F&#-
ME9E?S9R:7LVBFUW-JYM<S;2:7,VTFES-M)I<S;2:7,VTFES-M)I<S;2:7,VT
MFES-M)K_JP\ _ZT:!_+ #0C.TPH&OO .&J_^&3"A_R1#E?\R4HOX/UZ#\4MH
M?>Q6<'?H7W9QY&5Z;.%L?FG?<H%FW7B$8]Q]AF';@HA?VH>)7=F,BUO8DHQ9
MUYB-6-:>C5?6I8Y6U:R.5M6LCE;5K(Y6U:R.5M6LCE;5K(Y6U:R.5M6LCE;5
MK([_KPT _[<. \W)" &^V D)KOT0'*'_'"^5_RD_B_\W3(+^159\^5!>=?19
M9&[Q7VEH[F1M9.MJ<&'J<'-?Z'5U7>=Z=UOF?WA9Y81Y6.2)>U;CCGQ5XI-]
M5.*8?E+AGGY1X:5_4>&E?U'AI7]1X:5_4>&E?U'AI7]1X:5_4>&E?U'AI7_Q
MM @ SL & +W.!P&NX <+H/\2')3_("N*_R\X@?\]0WK_24MS_U)1;/Y75V7[
M75MA^6->7O=H8%OU;6)8]')D5O-W9E7R>V=3\8!H4?"$:5#PB6I/[XYK3NZ3
M;$SNF6U+[9]N2^V?;DOMGVY+[9]N2^V?;DOMGVY+[9]N2^V?;DOMGV[1N0,
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MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
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M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
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M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
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M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
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M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
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M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
MPZ,# +JJ @"SLP$ K+P* *:]'0&>O"\&EKH\$8VX1QR%M5 G?;-9,':Q8#AO
MKV@_::UP16.K>4I>JH1/6JF04E6HGE52IZ]74:C&5U"GZE=0I?Q74Y_]5U6:
M_597EOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(  -*1  #&G0  NZ8!
M +*N  "JMP$ HL(% )S$& "5PRH$C<(Y#87 1!A]ODXA=;Q6*FZZ7C)HN68X
M8K=N/EVV>$-8M8)'5+2/2U"TG4Y-LZY02[3%4$NSZE!*L?]13*O_4DZE_U)0
MH?]249[_45&>_U%1GO]149[_45&>_U'_=@  W8D  ,J7  "^H@  LZH  *FS
M  "@O ( F,8& )',$@"+S"4"A,LT"7S)0!)UR$H;;<=3(V?%7"IAQ&0P7,-M
M-E?"=CI3PH$_3\&.0DO!G45(P:Y&1\'%1D?!ZD9$OO])1;G_2D>S_TM)K?],
M2JO_3$JK_TQ*J_],2JO_3$JK_TSI?P  T9   ,*>  "UIP  JJ\  *"X  "6
MP0( C,L' (35#0" U1X!>=4N!7+4/ QLTT<49=)0&U_162%:T6(G5=!K+%'0
M=3!-SX$T2<^.-T;/G3E$T*X[0M#&.T/0ZCI S?T^/LO_0$##_T)!O?]#0KG_
M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
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M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
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M46I\_T]K>_]-;'G_3&QY_TQL>?],;'G_3&QY_TS_7@P _VP! .9Z  #6A@
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M1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-  "^F   LZ   *JG  "AK@
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M+3;*_RW%D   MIT  *BE  "<K0  C[8  (.^  !WQP  ;,\" &+6!P!:Y X
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M"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G__PD9__\)&?__"1G__PFBIP
MD[$  (6[  !VQ@  :=   %O:  !.X   0^4  #[[ 0 Z_PP -O\3 #+_&P O
M_R, *_\J 2C_,0$D_S<!(?\_ A__1@(<_TX"&?]8 Q;_8P,3_W #$O^!!!'_
MDP00_Z<$#_^]!0[_X 4.__8%#O__!0[__P4.__\%#O__!0[__P65KP  AKH
M '?%  !HT   6ML  $SA  ! YP  -_,  #+_   N_P< *O\. ";_$P C_QH
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MZ$"\(N= RB/D0=\CX$'O)-Q _"?80/\IU#__*L] _RK'0O\JPD/_*L!#_RK
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M0)I9[#^86?X_EUK_/I1;_SR16_\[CUO_.H];_SJ/6_\ZCUO_.H];_SK_3!(
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M1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_5 P _U\  /)L  #==@
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M/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y  #(A   OHP  +:3  "NEP
MIIL$ *"=%P":G2D"DYPW"(R:0Q"&F$T8@)95'WJ4729UDF4L<)!L,6R.=39G
MC7XZ8XN)/E^*E4%<B:-$6HFT15B)RT58B.U$6(C_0UF&_T%;@_] 78'_/EV
M_SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B   N9$  +"7  "GFP  GJ$
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M-TF:_S?B=   RH,  +R/  "PF   I9X  )ND  "0JP  A;$  'JX! !VN10
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M&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(_R$OR/\A+\C_(2_(_R&^CP
MKYH  **A  "6J0  BK   'VX  !QOP  9L8  %O, @!0T@< 1]H, $;<& !%
MW"< 1-TU 4'=0 (_WDL#/=Y5!#K?7P8XWVD'-=]V"3/@A LQX)0,+^&F#2[A
MO XMXN .+=[X#RO=_Q(JW/\4*=K_%BC:_Q8HVO\6*-K_%BC:_Q:SF   I:
M )FG  "+L   ?K@  ''   !ER   6<X  $[3  !$VP0 /^D- #WI%P [ZB,
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M @C_U0('__0"!___ @?__P('__\"!___ @?__P*1K0  @K@  '/"  !DS
M5M4  $C=   [X@  ,.<  "?N   C_P  (/\$ !S_#  9_Q$ %O\6 !/_&P 1
M_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0  /]B 0#_<P$ _X<! /^= 0#_
ML@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$  &7,  !6V   1]\
M #GE   MZ@  (^X  !S]   8_P  %?\  !'_!  /_PL #?\.  G_$0 &_Q4
M _\:  #_(   _R8  /\N  #_-P  _T$  /]-  #_7   _VT  /^"  #_E@
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M)+A&\"6U1O\GLD;_)[!&_R>N1O\GJD?_)J=(_R:G2/\FITC_)J=(_R;_0!0
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M-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP _U0  /M>  #B90
MV&L! ,]N!0#,< @ QG(2 +YS)@&W<S8$L7!$"JMN3Q&F:UD8H6EA'9UG:B*9
M97(GEF-Z*I-B@RZ08(PQC5^5-(I>H#:'7JTXA5V\.8-=U#F"7O X@5__-H!?
M_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D _U8  .YA  #=:0  T6\
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M-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\  -YJ  #-<P  PWH  +M^  "U@0
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M,EE]_S+O8   VVX  ,=Z  "[@P  LHL  *B0  "?DP  E)8  (V9#@")FAX
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M*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27_RM$E_\K1)?_*T27_RO7<@
MPX   +:,  "JE   GYD  )2>  ")HP  ?J@  '"N  !JL X :+$= &6Q+ %A
ML3@#7;!#!EFP3 I5KU0.4J]=$4ZN915+KF\82*UY&T6MAAY"K)4@/ZRE(CZM
MN2,]K=@B/:OU(SRI_R4[I_\F.Z;_)CND_R8[I/\F.Z3_)CND_R;,>@  NX@
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M!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@  H)T  )2D  "&K
M>;0  &R[  !@P@  5,8  $C+   ^T   -=4$ "W="@ LX1, *^(? "GC*@ H
MY#4 )^0_ ";E2@ DYE4 (^9A 2'G;@$@YWX"'NB0 AWII (;Z;P"&NKB AKF
M_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0  (BL  !ZM0  ;+T
M %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C\!$ (?$9 !_Q(@ =\BL
M&_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/^:H!#OG& 0[Y[0$-
M]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU  !MO@  7\8  %+-
M  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3 !3_&@ 2_R$ $/\H
M  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8  /^M  #_R@  __
M /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@R   4M   $/7   W
MW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_$0 )_Q8 !O\<  /_
M(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5  #_K   _\<  /_H
M  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2TP  0]L  #7A   IY@
M'NH  !7N   0^   #O\   O_   (_P  !/\&  #_"@  _PX  /\1  #_%0
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M"-XM\0K;+/X,UBW_#M0L_P_2+/\0T2S_$,\L_Q#.+?\0SBW_$,XM_Q#_,AD
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M(9]'_R">1_\@GD?_'YM'_QZ:1_\>FD?_'II'_Q[_0 T _T8$ /],  #X4@(
MZ%4$ .%5" #B50T U549 ,Q7+ #%5SP"OU9*!KI550JV4U\.LE)H$J]0<16L
M3WD8JDZ!&JA-BAVE3)(?HTR<(*%+IB*?2[$CG4O ))M+V"692_ EEDS_))5,
M_R243/\CDTS_(I%-_R&13?\AD4W_(9%-_R'_0@H _TD  /]1  #F5P  W5L!
M -5<!0#26PD RUP4 ,->* "\7C@"MEU&!K%;40JM65L/J5AD$Z96;!>C570:
MH%1]'9Y3A1^;4HXBF5&7))=0H2:54*TGDE"\*)%0T"B.4.PHC5'^)XM1_R:+
M4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10< _TL  /!5  #?6P  TV   ,QA
M P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE7U</H5U@%)Y<:!B;6W ;F%EX
M'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4RRN%5>DKA%7\*H-6_RB#5O\G
M@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\  .=8  #98   S60  ,9F 0#!
M9@0 NV8. +1I( "N:3$"J&@_!:-F2@J?950/FF-=%)=A91B38&T<D%YU'XY=
M?2*+7(8EB%N0*(5:FBJ#6:8L@%FT+7]9QRY]6>8M?%KZ+'M:_RI[6_\H>UO_
M)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(  .-<  #28P  QV@  ,!K  "Z:P(
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M*&5J_RC]4P  XU\  ,YI  #!<0  MW<  *][  "G?0  GGT  )A^$0"3@"(
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M+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z_R=4>O\G5'K_)U1Z_R?H7@
MT&L  ,!V  "T?@  JX4  *&)  "7BP  B8T  (./" !^D!< >Y$G 7:1- -R
MD#\&;8])"VF.40]EC5D38HQ@%UZ+:!M;BG$>5XE[(52(AB11AY0G3X:B*4V&
MM"I+ALPJ2X7N*4R$_RE,@_\H3(/_)TV!_R9.@?\F3H'_)DZ!_R;A8P  R7
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M&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?_QS$>   M84  *F/  "=E0
MDIH  (:?  !ZHP  ;J@  &*L  !5L   4+(. $ZR&P!-LR@ 2[,U $FS/P%&
MLTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.-;*:#S.SK1 RL\40,K+I$#&P
M_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX  *&5  "6F@  B:
M 'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X /KXK #R^-@ [OT$
M.;]+ 3>_5 (UP%\",\!J!#' =P4OP(8&+<"7!RO J@@JP<((*L#G!RF]_0HH
MO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC   I90  )F:  "-H0  ?Z<  '*M
M  !FLP  6K@  $^[  !$OP  .L0" ##)"  NRA$ +<H= "S+*0 KRS4 *\Q
M "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/I0(@T+T"(,_D A_-^@,>R_\$
M'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H  )"A  ""J   =*\  &>V  !;
MO   3L   $/#   YQP  +\P  "?0!  ?U@H &]H0 !O;&@ :VR8 &MPQ !G=
M/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3XK$ $N// !+@]  2WO\!$=W_
M 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0  :+@  %N_  !.Q
M0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J%  1ZQT $.LF  [L,  .
M[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3QY  "\?T  N__  /M
M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(  $W(  ! S   --$
M "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4 !_L<  3\)  !_"P
M /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0  _.L  /S_  #]_P
M_?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1   RUP  )]T  !WA
M   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2  #_%P  _Q\  /\G
M  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(  /_G  #__   __\
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M -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_&RD _QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA. ?\%6P'_ V@!_P)T
M ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;( _P&Z /\!Q #_ =$
M_P#D /\ \0#_ /P _ '_ /P"_P#\ _\ _ 3_ ?P%_P'\!?\!_ 7_ ?P%_P'_
M'R8 _R$B /\@(0#_'B, _Q@G /\3, #_$3P!_PY* ?\-5P'_"V,!_PIO ?\*
M>@'_"H0!_PJ- ?\*E '_"IL!_PJB ?\*J '_"J\!_PJW ?\*P #_"LP _PK@
M /L*[P#W"OH ]0O_ ?4,_P'T#?\!] W_ O0-_P+T#?\"] W_ O0-_P+_(B(
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M"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$ _S4, /\V!P#_.@L
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M&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+  #=40  T50  ,I4 0#&4@4
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M''!:_QS_2   YU(  --;  #%8@  NV8  +-H  "L:   I68% )]G% "::24
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M)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F_QY@9O\>8&;_'F!F_Q[O3P
MVEP  ,9E  "Z;0  L'(  *=U  "==   E',  (UT#0")=AP A7<K 8%W. -\
M=D,&>'5,"71T5 UQ<UL1;G)C%&MQ:Q=H<',:96]\'6)NAR!?;90B76RB)%IL
MLB59;,<E6&SH)5EL_2-9:_\A6FO_'UMK_QY;:O\>6VK_'EMJ_Q[K4P  TV
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M'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\_QS680  PFX  +1X  "J@
MGX4  )2'  "(AP  >XD  '",  !KC@T :(\: &:/*0!BD#4!7X\_ UR/2 59
MCE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH818J9&D.*JAM"BK\;08KA&T&(
M^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P  O'0  *]^  "EA@  FHH
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M#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1  "1E@  A9P  'B@  !KI0
M7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A #*V+  QMS< ,+=! "^X2P N
MN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,DN;0#([G2 R.W] 0BM?\%(;3_!B&S
M_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(G0  >Z,  &ZH  !AK0  5;$
M $JT   _MP  -+L  "N^ P DP@P (L(4 "+#'P APRH (,0T !_$/P >Q4H
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M  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \QP  ,,L  "7/   <U
M%-D   [=   )X0   N4   #I!@  Z0T  .D1  #J&   ZR$  .TK  #O-P
M\44  /)6  #S:   \WX  /27  #UL   ]M   /?S  #W_P  ]_\  /?_  #W
M_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0  (]8  !G<   1X   #.,
M  3G    Z@   /4   #T    ]04  /4+  #V#P  ]A0  /@=  #Z)P  _#0
M /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_[0  __D  /_Y  #_^0!X
ML   :+H  %G#  !+RP  .]$  "W8   AW0  %N(   [F   (Z@   .T   #P
M    ^    /\   #_    _P   /\   #_!@  _PP  /\0  #_&   _R(  /\P
M  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP  _]4  /_5  #_U0#_$R@
M_Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_ &D _P!T /\ ?@#_
M (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\ P #_ ,P _P#? /\
M[ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_%B4 _Q8B
M /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (0
M_P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^ ,@ _0#9 /L Z0#Z
M /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D _P#_&B( _QH> /\8
M'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K /\ =@#_ '\ _P"(
M /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0 ]0#2 /, Y@#R /0
M\0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_'AT _QX9 /\<%P#_
M%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&<0#_!GH _P:# /X&
MBP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<  [07. .L%Y #I!O, Y@C_
M .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_(1@ _R$3 /\@$0#_&Q(
M_QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.:P#V#G4 ] Y^ /(.A@#P
M#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T Y0_, .$/XP#=$/, V1'_ =82
M_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_)1, _R40 /\D#0#_(PX _R,4
M /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P79@#I%W  YA=Y .07@0#B%XD
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M"*@M_PBH+?\(J"W_"*@M_PC_+P@ _S$  /\U  #V-P  ZC8" .<S" #D+P\
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M$7]'_Q'_.P  [D,  -Q,  #,40  P50  +E4  "T40  KDT+ *A/&0"C42D
MGE(W 9I20P*744X$E%%6!I%07@F.3V8+C$YM#8E.=0^'37X1A4V'$X),D16
M3)P6?DNI%WQ+N!A[2\T8>4SK&'A,_A=W3/\5=TS_%'=,_Q-W3/\2=TS_$G=,
M_Q+_/@  Z$<  -50  #&5@  O%@  +19  "M5@  IU,' *%4%0"<5B4 F%<T
M 9170 *05TH$C593!HI56PF'5&,+A%1J#H)3<A" 4GH2?5*#%'M1CA9X4)D8
M=E"F&710M1IS4,D:<5#H&G!1_!AP4?\7<%'_%7!1_Q1Q4/\3<5#_$W%0_Q/U
M0   Y$L  ,]4  #!6@  MUT  *]>  "G6P  H5@# )M9$@"66R( DEPQ 8Y<
M/0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y5W<3=E: %716BQ=R5989;U6C
M&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5_Q5K5?\4:U7_%&M5_Q3R0P
MWT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>$ "08!\ C&$N (AA.@*$
M8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03<%M]%6Y:B!=K6I09:5FA&V=9
ML!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E6?\495G_%&59_Q3O1@  VE(
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M'%1G]AI49O\856;_%U5E_Q969?\55F7_%59E_Q7B40  RET  +MF  "O;
MIG$  )EP  ".;P  @VX  'UP!0!X<A( =7,A ')S+P%O<SH";'-$!&ER3 9F
M<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55;HL74VV9&5%MJ!I/;;L;3FW9&DYL
M]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50  Q6$  +=J  "L<0  HG4
M )1T  ")=   ?',  '9U  !Q=Q  ;W@= &QY*P!I>3<!9GE  V-Y205@>%$'
M77=8"5MW8 Q8=F@.575Q$5)U?!-0=(@63727%TMSIAA)<[D92'/5&4ER\QA)
M<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@  P&8  +-O  "H=@  G7D  (]X
M  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B@#(!7X ] ER 1@-:?TX%5W]5
M!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[I!9$>[<60WO2%D-Z\A9#>?\5
M0WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL  *YT  "D?   EWX  (I]  !_
M?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX 6(<X 56'0@)3ATH#4(=2!4Z&
M6@=+AF()285L"T:%=PU#A(,/0822$3^$HA(]A+43/(3/$SR"\!(\@?\2/8#_
M$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$  *I[  "?@@  DH(  (6"  !Y@P
M;88  %^*  !8C0$ 5(X/ %*/&P!0CR< 3Y S $V0/0%+D$4"29!. T:05@1$
MCU\%0H]H!S^/<PD]CH +.HZ/##B.H TWCK,.-H[,#C:-[PXUB_\.-8G_#S6(
M_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9AP  C(@  '^(  !RB@  9HT
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M QJK_P.HB   FX\  )&4  "$F@  =I\  &BB  !;I0  3ZD  $2M   YL
M+[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4O4  $[Y+ !*^6  2
MOF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z_P$0NO\!$+K_ 1"Z
M_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0  #JV   ON0  );P
M !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC( !LL^  7+2P $S%H
M \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !RO\  <K_  '*_P"7
ME@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_   CPP  &\8  !/*
M   -S0  "-$   '4"0  U X  -45  #6'@  V"<  -DQ  #;/@  W$L  -U;
M  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P  W_\  -__  #?_P"-G0
M?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')   8S0  $-$   O5   $
MV@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I+P  ZSP  .U+  #N
M70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\  /#_  #P_P"!I0  <JT
M &.U  !4O0  1L0  #?(   JS   ']   !75   .V@  !]X   #B    Y@
M .D   #J    [    .X%  #O#   \1   /,7  #U(   ^"L  /LY  #]2@
M_EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U  #_]0!TK@  9;<  %;
M  !'R   .,T  "K2   =V   $]T   SB   #Y@   .D   #L    \    /,
M  #T    ]@   /@   #Z    _0<  /\-  #_$@  _QL  /\H  #_-P  _TH
M /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_#R0 _PXB /\+(0#_
M R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (0 _P", /\
MD@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3 /\ YP#_ /0 _P#_
M /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$ _Q > /\-'0#_!Q\
M_P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\ C@#_
M )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D X@#X /  ]P#\ /8
M_P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,: /\0&0#_"QD _P =
M /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _@"# /P B@#Z )$
M^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\ W #N .P [0#Z .L _P#J
M /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3$P#_#A, _PL: /\'
M) #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^ /( A0#Q (P [P"3
M .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B .D X0#W -\ _P#= /\
MW0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_$@X _Q(5 /\/'P#_
M#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"@ #F X< Y .. .(#
ME0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N< T CX ,X*_P#,"_\ RPS_
M ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_&0L _Q@1 /\6&0#_$B0
M^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L->P#9#8, U@V* -0-D0#2
M#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D PA+Y +\3_P"]$_\!O!/_ ;P3
M_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_(04 _Q\, /\<$0#V&!P [!4H
M .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6=0#)%WT QQ>% ,48C #$&)0
MPAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV ;(=_P*P'?\"KQW_ JX=_P*N
M'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P  \24# / A"P#H'!( WAD= -0;
M+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z(W@ N2-_ ;<CAP&U(X\!M"27
M ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F_P.C)O\#HB;_!*$F_P.A)O\#
MH2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\  -DK! #6(@H SB,6 ,8F)P#
M*#8 NRI$ +@K3P"U+%D LBQB ; L:@&N+7(!K"UZ JHM@0*I+8H"IRV2 Z4M
MFP.D+:4$HBVQ!* MP 2?+=@$G"[O!9DN_P:7+_\&EB__!I4N_P65+O\%E2[_
M!94N_P7_+   _RX  .HU  #=.0  T3D  ,HV  #'+P8 P2T1 +HP(0"T,C$
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M#7]!LPY^0<8.?$'D#GI"^0UY0O\,>$+_"WA"_PMX0O\*>$'_"GA!_PKV-@
MYD   -%(  ##30  N4X  +%-  "I20  I$4& )]&$P":2", EDDR ))*/@&/
M2D@"C$I1 XI)602'26 %A4EH!X-(;PB!2'<*?T> "WU'B@UZ1Y4.>$:B#W9&
ML!!U1L(0<T;@$')']P]Q1_\.<4?_#7%'_PQQ1_\+<4;_"W%&_POS.0  X$0
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M%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3_PWG1   SU   +]8  "S70
MJ%\  )Q=  "26P  BU@  (5:"@"!6Q8 ?5PD 'I=,0!W73P!=%U& G%=3@1O
M7%4%;%Q=!VI<9 EH6VP+95IU#6-:?P]A68L17EF8$EQ8IQ1;6+@465G0%%E8
M\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC2   RU,  +M;  "P80  I&(
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M#TIE_PY+9?\-2V3_#4MD_PW15   OEX  +%G  "F;0  EVP  (IK  !_:P
M<VL  &UM  !H;@P 97 7 &)Q) !@<3  7G$Z 5QQ0P)9<4L#5W%3!%5P6@92
M<&('4'!K"4YO=0M+;X(-26Z/#T=NGQ!%;K 11&['$4-MZA!$;/\/1&O_#D5K
M_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A<0  DG   (5O  !Z;P  ;G
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M"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_  !J@   7H,  %.'  !*BP
M08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)  #:220 TDU( ,Y-< 3&39P$O
MDW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$)X[_!2>-_P4GC/\%)XS_!2>,
M_P6Q=   I7X  )F%  "*A   ?80  &^%  !CB   6(L  $V/  !#DP  .I<
M #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L )YY5 ":>80 EGFX
M(YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_ AZ9_P,>E_\#'I?_ QZ7_P.J
M?0  GH4  ).+  "%B@  =8L  &B.  !;D0  4)4  $:9   [G0  ,J   "JC
M   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :J4$ &:E, !BI6  7JF8 %JIV
M !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E_P$3I?\!$Z3_ 1.D_P&CA@
MEXP  (V1  !]D@  ;94  &"8  !4G   2*   #ZD   TIP  *JL  "&N   9
ML0  $K,'  ^U$  .M1< #K4A  VU*P -M38 #+9!  NV3@ *MEP ";9L  BV
M?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (L_\ ";+_  FR_P":C0  D),
M (28  !TG   9:   %>D  !+J   0*P  #6P   JLP  (;4  !BX   1NP
M#+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##0@  PU   ,1?  #$<0
MQ(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##_P"3E   AYH  'B@
M  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L   !##   *Q@   \H
M  #,!0  S P  ,T1  #.&   SB$  - J  #1-0  TT,  -12  #48P  U7@
M -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6_P"*FP  >Z(  &RI  !>
ML   4+8  $*Z   TO0  *,$  !W$   4QP  #<L   ;.    T@   -<   #9
M    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,  .="  #H5   Z&<  .E^
M  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP  ;JL  %^R  !1N@
M0L   #3#   GQP  &\L  !+/   +TP   M@   #=    X0   .0   #E
MYP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y00  ^E4  /IJ  #[
MA   ^YT  /RV  #\T@  _>T  /WT  #]] !QK   8;4  %*]  !$Q   -,D
M ";-   :T@  $-@   C=    X0   .4   #H    [    .\   #Q    \P
M /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_+P  _T$  /]6  #_;0
M_X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<> /\ '0#_ "  _P E /\
M+@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"' /\ C@#_ )0 _P":
M /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /  _@#] /T _P#] /\
M_0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_ !H _P ? /\ *@#_
M #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\ B0#_ )  _P"6 /\
MG #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y /, _P#R /\ \P#_
M /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0 _P 9 /\ )0#_ #(
M_P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W (L ]@"1 /0 EP#S
M )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U .8 _P#G /\ Y@#_ .4
M_P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5 /\ ( #_ "P _P Z
M /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8 Z@", .@ DP#G )D
MY0"@ ., IP#A +  WP"Z -T R0#; .  V #P -< _@#5 /\ U #_ -, _P#3
M /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#&@#_ "8 _0 S /0
M0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (  W "' -H C@#8 )4 U "<
M -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#% /\ Q '_ ,,!_P#$ ?\
MQ '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\!Q\ \0,K .< .0#B
M $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$B0#(!9  Q@68 ,0%
MH #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_ +0-_P"T#?\ M W_
M +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8 XPDB -H), #3"CX
MS@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\#XT NA"5 +@0G0"W
M$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5_P"F%/\!IA3_ :84
M_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8 ,L1* #%$S< P!1$
M +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:@ "N&H@ K!N0 *L;F0"I&Z,
MIQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__ 9H?_P&:'O\!F1[_ 9D>_P'_
M(@  _R$  .PG  #@*@  U"D  ,TD  #*' @ Q!D2 +T<(@"W'C$ LR ^ *\A
M20"M(E, JB-< *@D9 "F)&P I"1S *,D>@"A)8(!H"6+ 9XEE &=)9X!FR:J
M 9DFMP&8)LD"E2?F I(G^0*0*/\"CRC_ HXG_P*.)_\"CB?_ HXG_P+_)@
M\BD  .,Q  #2-   R#0  , P  "[*0( N",. +$F' "L*"L J"HX *0K1 "A
M+$X GRU7 )TM7P";+6<!F2UN 9@N=0&6+GT"E"Z& I,ND *1+IH#CRZF XTN
MLP.,+L4#BB_A!(<O]@2%+_\$A"__ X0O_P.#+_\#@R__ X,O_P/[*0  ZS$
M -DX  #)/   OSP  +8Y  "P,@  K"T+ *<O%P"B,28 GC,T )HT0 "8-4H
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M"FQ![@EK0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P  UD(  ,1)  "W30
MJTT  *!*  "81P  DT(  (Y##0")11H AD8H (-'- " 2#\ ?DA( 7M(4 )Y
M2%<"=TA? W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8"FE&I@MG1K8+9D;,"V5&
M[ MD1_\)9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8  +]-  "S40  I5$
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M"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H6P  F5H  (U8  "$5P
M>U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL] 65;10%C6TT"85I5 U]:7 1=
M6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-3UC##4Y8Y Q.6/L+3U?_"4]7
M_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C7@  E5T  (E<  !_6P  =ED
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M!S]D_P?#5P  LV$  *=I  "6:   AV<  'MG  !Q9P  96@  %QJ  !8; $
M5&X. %)O& !0;R0 3G N $UP. !+<4$ 2G%) 4AQ40%&<5D"1'!B T)P; 1
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M BV!CP,L@:$#*H&V RF!T@,I?_,#*7W_ RE\_P,I>_\#*7O_ RE[_P.Q:@
MI70  )5V  "%=0  >'4  &UU  !A=P  5WH  $Q^  !#@0  .X4  #6("0 R
MB1$ ,8D; #"))0 OBB\ +HHX "V+00 LBTH *HM4 "F+7P HBVL )HMZ 22+
MBP$CBYX!(HNS 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P
M (][  " >@  <WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP
M))03 ".4'  BE28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8
MEYD %Y>N !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!
M  ![@   ;((  %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J ,
M !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY(
M#*.G  JBP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !S
MB   98L  %B.  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN
M#  'K1( !JT;  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=
M  "NM   KM4  *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@
M798  %":  !$GP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0
MN X  +D4  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\
MJ0  O,0  +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,
M $>H   [K0  ,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H
M ,4.  #&%   QQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP
MS;4  ,[:  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV
M   PN0  )+P  !F_   1P@  "L4   +)    S    -    #1    T@$  -,(
M  #5#0  UQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4
M .7   #EY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   C
MPP  %\<   _*   'S@   -$   #6    W    -\   #@    X@   .0   #F
M P  Z D  .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM
M  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@
M#=(   38    W0   .$   #D    Z    .L   #M    [P   /$   #S
M]@   /@#  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_
MKP  _\,  /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!&
M /\ 4P#_ %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$
M_P"H /\ KP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T
M /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\
M3@#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C
M /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\
MZ@#_ .H _P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_
M %0 _@!? /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P
MI@#J *X Z "Y .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_
M .$ _P#_#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X
M\@!9 .\ 8@#L &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#;
M *H V "T -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P
M_P#_$ P _PP' /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3
M .$ 7 #> &4 VP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4
MQ@"O ,0 NP#" ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_
M$04 _PX  /\*  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\
M5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K
M +8 MP"T ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%
M_Q   /\/  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]
M!%D NP5A +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*
MM0"H"L4 I@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,
M .\8  #D&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E,
MKQ!; *T08P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<
M$\, FQ3> )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C
M  #5)0  RB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6
M * :70">&V4 G1ML )L<<P":''L F!R# )<=C0"5'9< DQZB )(>KP"0'K\
MCQ_8 (P@\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z'@  ZR8  -HM  #*
M,   OBX  +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB/@"9(T@ ER11 )4D
M60"3)6  DB5G ) F;@".)G8 C29_ (LFB &*)Y,!B">> 88GJP&$)[L!@RC1
M 8 H[@%^*?\!?2G_ 7PH_P%\*/\!?"C_ 7PH_P'U)   XRX  ,\U  #!.
MM#8  *LQ  "E+   HB8& )XF$P"9*"$ E2HN )(K.0"/+$0 C2U, (LM5 ")
M+EP ARYC (8N:@&$+G(!@BYZ 8$OA %_+X\"?2^: GLOIP)Z+[<">"_, G8P
MZ@)U,/X"<S#_ G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P
M *(X  "<,P  F"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@
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M!%U _P-=0/\#74#_ UU _P/?.0  R$,  +E*  "I2P  FTD  )!'  "(1
M@T$  'Y!!@!Z0A$ =D,> '1%*@!Q134 ;T8_ &U&1P!K1D\!:D96 6A&70)F
M1F4"9$9M V)&=@1@1H($7D:.!5Q%G 9;1:P&64:_!UA&WP981O<%5T7_!%=%
M_P171/\#6$3_ UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44
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M TE0_P/*2   N5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @
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M SQCD 0Z8J$$.6*T!3ACS04X8N\$.&'_!#A@_P,X7_\#.5[_ SE>_P.\50
MK5\  )Q@  "+7P  ?5\  ')?  !H7P  76   %5B  !/9   2V8* $EG$@!'
M:!T 16@G $1I,0!#:3D 0FI" $!J2@ _:E( /6I; 3QJ90$Z:G ".&I^ C9I
MC0,T:9\#,VFR S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60
M )9D  "&8P  >&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@
M/6\B #QP*P Z<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M
M<9P"*W&O BIQR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H
M  " 9P  =&<  &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@<
M #)X)0 Q>2X ,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!
M(WJL 2)ZQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![
M;   ;VP  &5L  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"
M'@ E@B< )((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I
M !B$P0 8@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0
M:W$  %YS  !4=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9
MC1X &(XG !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/
MNP -C^  #HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@
M %A[  !-?@  0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0
M#)H=  N:)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !
MF<\  IGP  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%
M  !%B0  .XT  #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46
M  "F'P  IB@  *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,
M *7I  "E_   I?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]
ME@  ,IH  "B>   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R
M%P  LQ\  +,H  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<
M  "T]P  M/\  +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI
M*J@  ""L   6L   #[0   FW   !N0   +T   "^    O@8  +\,  # $
MP18  ,(=  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'
M[   Q_X  ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<
M !:Z   .O0  !L    ##    QP   ,D   #*    S    ,T#  #."0  T X
M -(3  #4&P  V"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0
MW_,  -__  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&
M   #R0   ,P   #0    U0   -D   #:    W    -X   #@    X@4  .0+
M  #G$   ZA@  .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\
M /3S  #T] !JJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2
MUP   -P   #@    Y0   .<   #I    ZP   .T   #O    \0   /,   #V
M!P  ^0X  /P6  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8
M  #_VP#_ !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H
M_P!D /\ ;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_
M +0 _@"_ /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .<
M_P#_ !0 _P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@
M /\ : #_ '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X
M\@"Y /$ QP#O .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_
M Q  _P . /\ #0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@
M8P#U &L \P!R /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S
M .$ P #@ -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT
M_P ) /\ !@#_  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G
M &4 Y !L .( <P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T
MN0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$
M /\   #_  0 _P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\
MT0!G ,X ;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z
M ,( N0#; +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\
M  #^    ]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@
M +X 9P"\ &X N@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T
MJ@#0 *@ ZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J
M"0  X@0  -H !P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +
M8@"N &@ K !O *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/,
M )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0
MSA$  ,8-  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B
M"F, H IJ )\+<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .
MZ@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT
M +<7  "S$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX
ME1-E ),3; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""
M&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB
M  "E'   I!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@
M (@=9P"&'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+( >R#% 'DAY !W(OD
M=B+_ '4B_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V,0  J2X  * J  ";
M)@  F"$! )4>$ "0(!L C2$H (DC,P"')#T A21& (,E3@"!)E4 ?R9< 'XF
M8P!\)VL >R=S 'DG? !X*(< =BB3 '0HH %R**\!<2G! 6\IX %M*?<!;"G_
M 6LI_P%K*?\!:RC_ 6LH_P'H*   T#(  , X  "N-P  H34  )@R  "2+0
MCBD  (LG# "'*!< @RHC ( K+P!^+#D ?"Q" 'HM2@!X+E$ =RY8 '4N8 !S
M+V< <B]O ' O>0%O+X,!;2^0 6LOG0%I+ZP!:#"^ 6<PVP%E,/4!9##_ 6,P
M_P%C+_\!8R__ 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC
M (,N"0!_+Q, >S ? '@R*P!V,S4 =#,^ '(T1@!P-$X ;S55 &TU7 !L-60
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M.@X ;3P8 &L]) !I/B\ 9S\X &4_0 !D0$@ 8D!/ &% 5P!?0%X!74!F 5Q
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M D9(_P)'1_\"1T;_ D=&_P+&0P  MDP  *),  "13   A$L  'E*  !P20
M:48  &1'  !?208 7$H0 %I+&P!83"4 5DPO %5-. !334  4DU( %%.3P!/
M3E< 3DY? 4Q.:0%*3G,"2$V  D9-CP-%39\#0TVQ T)-R -!3>H#04S_ D%,
M_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@  @$X  '5-  !L3   8TH
M %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.4CT 35)% $Q230!*4E0
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M 3)8_P&V5   I%D  )!8  " 6   <U<  &E7  !@6   5%D  $Y;  !(70
M0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W8TL -F-4 #1C70 S
M8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@_P$K7_\!*U__ 2M>
M_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7   45X  $E@  !#8@  /&4
M #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8 +6I/ "QJ60 K:V4
M*6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C9O\!(V;_ 21E_P&L
M8   F&   (5@  !V7P  :E\  &%@  !78   36,  $1F   ]:   -FL  #!N
M!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')* ")R5  A<V  ('-M
M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\ &V[_ 1MM_P&F9@
MD64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W;P  ,',  "EV   B
M>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\3@ 6?%H %7QG !1]
M>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_ !)W_P">:P  BFH
M 'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>   *7L  ")_   ;@@
M%(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,AU, "X=A  J'<0 )
MAX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"_P"5<0  @V\  '1N
M  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4  !N)   4C   #X\#
M  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL  )-9  "3:0  DWL
M )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-=P  ?74  '!T  !B
M=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4   .EP  "9L   &=
M"   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0  "@7P  H'$  *"'
M  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0  >'P  &E\  !;?P
M3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &I    *<   "I P
MJ0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O5   KV8  *][  "N
ME   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80  &&'  !3BP  1I
M #F6   NFP  (Z   !JD   2J   #*P   2O    L@   +8   "W    MP(
M +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2   P%H  ,%N  #!A@
MP:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4  !+F@  /:   #&E
M   EJP  &J\  !&S   +N    KL   "^    P0   ,0   #%    Q@   ,<
M  #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P  -9@  #8=P  V)(
M -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#J@  -;   "BV   <
MN@  $;X   G!    Q0   ,@   #+    SP   -(   #3    U@   -@   #;
M    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1  #N9P  [X$  .^<
M  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@  *KX  !S"   0Q@
M!\H   #.    T@   -8   #<    X    .,   #D    Y@   .@   #K
M[0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_50  _VX  /^*  #_
MI   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9 /\ )0#_ #( _P _
M /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4 _P"+ /\ D0#_ )@
M_P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V /\ ]@#_ .\ _P#G
M /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\ ( #_ "T _P Z /\
M1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"& /8 C #U )( \P"9
M /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\ YP#_ .4 _P#= /\
MU0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_ "@ _P U /\ 0 #Z
M $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .< A@#F (T Y "3 .(
MFP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_ -( _P#. /\ R0#_
M ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "( \P N .\ .@#L $4
MZ !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1 (< SP". ,T E0#+
M )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X _P"^ /\ O0#_ +L
M_P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G -T ,P#9 #X TP!)
M ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (  O0"( +L D "Y )@
MN "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N /\ K@#_ *X _P#_
M @  _P   /T   #R    Z    -X # #3 !4 S  A ,@ + #$ #@ P0!" +T
M2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0"" *P B@"J ), J "=
M *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\ G@#_ )X _P#_!@
M^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T #$ L0 [ *X 10"L
M $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X A0"< (X F@"8 )@
MI "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_ (\ _P#]"@  \ X
M .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D I0 T *( /@"? $<
MG0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0!(H C@25 (P%H0"*
M!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+_P#V$   YA<  -(<
M  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN )8*. "4"T$ D@Q*
M ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H< @PZ3 ($/GP" $*T
M?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O%P  VR$  ,8D  "T
M(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2,@")$SP AQ-$ (44
M3 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/ '88G !T&*H <QF[
M '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(   T"D  +PK  "K*@
MGB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^'#< ?!U  'H=2 !Y
M'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PAF !K(:< :2*X &@B
MSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\  +0Q  "C,   EBX
M (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#, <R4\ '$E0P!P)DL
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M 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\  "2/   A3L  'LZ  !T-P
M;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q %TX.@!;.$$ 6CE( %DY4 !7
M.5< 5CI? %0Z: !3.G, 43I_ 4\ZC0%..IT!3#JN 4LZPP%*.N4!23K\ 4DY
M_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P  @3X  '<]  !P.P  :C@
M &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6/3X 5#Y& %,^30!2/E4
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M 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'  !C1@  6T,  %9%  !21P
M3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"3$T 04Q6 $!,7P ^
M3&H /$QV #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+_P$U2O\!-DG_ 39)
M_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20  54@  %!*  !,2P  24P'
M $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H .U%3 #I17  X46<
M-U%S #51@@ S49,!,E&E 3!1N@$O4=H!+U#V 2]/_P$P3O\!,$[_ 3!-_P&T
M30  G4T  (I-  !Z30  ;DT  &1-  !;30  44T  $M/  !&4   0E(# #]3
M#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V5D< -590 #-660 R5V0 ,%=Q
M "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5_P J5/\!*E/_ 2I2_P&O40
MF%$  (51  !V4   :E   &!0  !840  3E(  $=3  !!50  .U@  #A9"@ U
M6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$, +5Q, "Q<5@ K76  *5UM "A=
M?  F78X )%VA "-=M0 B7=( (ESS ");_P C6O\ (UG_ "18_P"H50  DE0
M (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P  -ET  #!@!0 M80X
M*V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B9%P (61I !]D>0 >
M9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?_P"A60  C%@  'M8
M  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,  "IF   D:0D (6H0
M "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@ %VQE !9L=  4;(8
M$VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"970  A5T  '5<  !H
M7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M   >< $ %W,+ !5T
M$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?  UU;@ ,=8$ "W65
M  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@  ?V$  '!A  !D80
M6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7>0  $7P$  U_#  +
M?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_9P  ?WD  '^.  !_
MHP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<  &MF  !A9@  5&<
M $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P  #(8"  :)"@ !B0\
M (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P  BW$  (N&  "+G
MBK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL  !:;0  3F\  $)S
M   X=P  +GL  "6    =A   %8@  !",   +CP  !)(   "4!@  E0P  )40
M  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@  )E]  "9E   F*L
M )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3=@  1GH  #M_   P
MA   )H@  !V-   4D@  #I8   F9   !G    *    "A    H@8  *(,  "D
M$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER  "HB0  J*(  *B\
M  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@  /H<  #*-   GD@
M'9<  !2<   .H   !Z0   "H    JP   *X   "O    L    +$$  "S"@
MM X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[?0  NI<  +JQ  "Z
MT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<  "J=   ?H@  %:<
M  VL   %L    +0   "W    NP   +X   "_    P    ,$   ## 0  Q <
M ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@  T8@  -"D  #0P0
MT>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M   6LP  #K@   :\
M    P    ,,   #&    RP   ,T   #.    T    -$   #4    U@   -H"
M  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@  .N4  #KKP  Z\P
M .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .P@  !,4   #*
MS0   -$   #8    VP   -\   #@    X@   .0   #F    Z0   .L   #N
M    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"  #_G0  _[4  /_+
M  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\ _P [ /\ 1P#_ %(
M_P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^ ), _0"9 /L H0#Z
M *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D _P#@ /\ V #_ -,
M_P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V /\ 00#_ $P _P!6
M /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T [P"4 .T FP#L *0
MZ@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1 /\ S #_ ,@ _P#_
M  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L .P#W $8 \P!0 .\
M60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@". -P E0#: )X U@"H
M -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\ OP#_ +P _P#_  (
M_P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G $  X@!* -T 4@#9
M %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8 CP#$ )@ P@"A ,
MK0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_ +  _P#_    _P
M /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D RP!# ,< 3 #$ %0
MP0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R )( L "; *\ IP"L
M +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0 _P#_    _P   /4
M  #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ] +4 1@"R $T L !5
M *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P H "6 )\ H0"= *X
MFP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_    ]0   .<!  #4
M    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8 /P"C $< H0!/ )\
M50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1 )  G ". *D C "X
M (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@  Z0P  -0.  ###
MMPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6 $$ E !) )( 4 "0
M %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0 F "" *4 @ "T 'X
MR !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4  ,45  "T%   J1$
M *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP B 1# (8%2P"%!E$
M@P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W"J, =0JS ',+QP!R
M#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=  "I'   G1H  )46
M  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^ 'P.1@![#DT >0]3
M '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:( :Q*R &D2QP!H$^<
M9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@(P  E"$  (L?  "&
M&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(600!Q%D@ ;Q=/ &X7
M5@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO & :Q !>&^0 71S[
M %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0  C"@  (,E  !](@
M>1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H'D0 9A]+ &4?4@!C
M(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<BP !6(^$ 52/Y %0C
M_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T  'PK  !V*   <B8
M &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$ 7R9( %TF3P!<)U8
M6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/*=X 3BGW $TI_P!-
M*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P  !P+0  :RL  &@I
M  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$ %<M3 !5+5, 5"U;
M %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L 2"_V $<O_P!'+O\
M1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K,@  9B\  &(N  !?
M+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R20!0,E  3C-8 $TS
M80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T $(T_P!",_\ 0C+_
M $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@  83,  %TR  !9,@(
M5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*-TX 23A6 $<X7P!&
M.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX_P ]-_\ /3?_ #TV
M_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<  %@V  !4-P  43@+
M $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L 1#Q3 $(\7 !!/6<
M/SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X._\ .#O_ #@Z_P"V
M/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z  !/.P  3#P( $D]
M$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1 #U!6@ \060 .D%P
M #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\ ,S__ #0^_P"Q0
MFD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*0   1D$% $1"#@!"
M0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&6  V1F( -49N #-&
M?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_ "Y#_P"L0P  ED,
M (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10  048! #Y'#  \2!,
M.D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P2U\ +TMK "U+>@ L
M2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'_P"G1@  D48  ']&
M  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL  #=,"0 U31  ,TX8
M #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P *%!H "=0=P E4(@
M)%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A20  C$D  'I)  !L
M2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2!  M4PT +%04 "I4
M'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E !]6=  >5H4 '%:8
M !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30  ADT  '5-  !H30
M74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F6@D (UL0 ");%P A
M7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==<  578$ %%V5 !-=
MJ@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$  '!1  !D40  65$
M %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80, &F,, !AD$0 79!D
M%F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .97T #661  QEI0 *
M9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5  !?50  5E4  $Y5
M  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL% !!M#0 .;A( #6X:
M  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8  FZ*  !MGP  ;;8
M &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<60  4UD  $A:   _
M70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW"@ %=Q   7<5  !W
M'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$  !XF0  =[   ';-
M  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@  35\  $)B   Y90
M,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "   @0T  ($1  ""%P
M@QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$DP  @ZH  (+%  "!
MZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<  #QK   Q;P  *',
M "!W   8?   $7\   R#   &AP   (H   ", P  C D  (T.  ".$0  CQ<
M ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP  D:(  )&\  "0Y0
MC_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V   J>P  ((   !>%
M   0B0  "XT   21    E0   )@   "9    F@,  )L(  "<#0  GA$  )\6
M  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH  *&S  "@V   H/8
M )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   AB@  %X\  !"4   *
MF0   9T   "@    I    *<   "H    J0   *H   "L!@  K0L  *\0  "P
M%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H  "TQ@  L^T  ++_
M  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@  $)\   FD    J0
M *T   "P    M    +<   "X    N0   +L   "\    O@(  , (  #"#@
MQ!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*N   RMT  ,KU  #*
M_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";    "U    N0   +T
M  #!    Q@   ,@   #)    RP   ,P   #.    T    -(   #4!0  V0P
M -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ   Y<4  .7G  #F]@!6
ME   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%    R0   ,T   #2
M    U@   -H   #;    W@   .    #B    Y    .<   #I    [0   / *
M  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\  /W'  #]Y #_  X
M_P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_ $T _P!7 /\ 7P#_
M &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D G #W *4 ]0"O /0
MO #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_ ,H _P#_  H _P &
M /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $< _@!1 /L 60#Y &$
M]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H )\ Y@"I ., M0#B
M ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X _P#_  , _P   /\
M  #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+ .P 5 #H %L Y@!B
M ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@ SP"B ,T K@#+ +P
MR0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_    _P   /\   #_
M    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4 30#1 %4 S@!; ,L
M8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"< +D IP"W +4 M0#(
M +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_    _P   /X   #Q
MY0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\ $X N@!5 +< 6P"U
M &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *< H "E *T HP"^ *$
MVP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _    .X   #@    T
M ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@ J !/ *4 50"C %L
MH@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5 *< DP"W )$ S "0
M .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L   #)    O0   +4
M @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !) )8 3P"4 %4 DP!;
M )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *( A0"Q (, Q "! .0
M@ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W!P  K ,  *8   "@
M  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D 20"' %  A@!5 (0
M6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L '8 O@!U -T <P#T
M ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$   G@X  )<+  "3!@
MD  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\ $L >@!1 'D 5P!W
M %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#NP!I!-8 : ;Q &@'
M_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4  (L2  "&$   A P"
M (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48 < I, &\*4P!M"UD
M; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@#=@ 7@[S %T._P!=
M#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:  ![%P  >!,  '@0
M!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%) &813P!D$58 8Q)=
M &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4 517S %05_P!4%?\
M5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S'@  ;QL  &X7  !M
M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T82P!<&5( 6AE: %D9
M8@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ $P<_P!,'/\ 31S_
M $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)   :"$  &8>  !D&P@
M8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4($\ 4R!7 %$A7P!0
M(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C_P!%(O\ 1B+_ $8A
M_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8  %\D  !=(@0 6R$.
M %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP 3"94 $LG7 !))V8
M2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _*/\ 0"?_ $ G_P"W
M+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH  !7)P  5"<, %(H
M$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1 $4L6@!$+&0 0BUO
M $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\ .BS_ #HL_P"R,
MFS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1+   3RT) $PM$0!*
M+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q5P ^,6$ /3)M #LR
M>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_ #4P_P"M,P  EC0
M (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0  23$& $<R#P!%,Q8
M0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y-E\ -S9K #8V>  T
M-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T_P"I-@  DC8  ( W
M  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8# $$W#0 _.!0 /C@<
M #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT ,CMH # [=@ O.X<
M+3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D.   CCD  'PZ  !N
M.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\"P Z/!$ .#T9 #<]
M(0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F "M =  I0(0 *$"7
M "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P  BCP  '@]  !J/0
M7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T00\ ,D(6 #%"'@ O
M0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%<0 C18( (D65 "!%
MJ  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\  '1   !G0   7$
M %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT *T@2 "I(&@ I2"(
M*$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =2G\ &TJ2 !I*I@ 8
M2KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#  !C0P  6$,  %!#
M  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0 ").%@ A3QT ($\E
M !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P %%"/ !-0I  14+H
M$5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?1P  54<  $U'  !&
M1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6$0 95A@ %U8@ !96
M)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,  U7H  +5[8 "U;4
M  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@  44H  $I*  !#2@
M.TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 07A, $%X:  Y>(@ .
M7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->FP "7K$  EW,  )=
M[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX  $=.   ^3P  -E$
M "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q  !F<5  5G'  $9R0
M F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0  9JP  &7'  !EZP
M9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3   Y50  ,%@  "A;
M   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2  !O&   <!\  ' G
M  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<  &_!  !OYP  ;OP
M &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R70  *F$  ")D   :
M:   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z$P  >QD  'P@  !]
M*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ  ![X@  >OH  'G_
M  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P  (VL  !IO   3<P
M#G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P  B!,  (D9  "*(0
MBRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")V   B/<  (C_  "'
M_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@  !-]   -@0  !H4
M  ")    C0   )    "2    D@   )0%  "5"@  EPX  )@2  ":&   FR$
M )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0  FO   )G_  "8_P!E
M:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,   $D0   )4   "9
M    G0   *    "A    H@   *0   "E 0  IP<  *D,  "J$0  K1@  *\B
M  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8  *S\  "L_P!><0
M3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=    H@   *8   "J
MK@   +    "Q    LP   +0   "V    N    +H$  "\"@  OA   ,$7  ##
M)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R  ##_P!6?   1X(
M #J(   LCP  ()8  !2=   -HP   ZD   "N    L@   +<   "[    OP
M ,(   #"    Q0   ,8   #(    R@   ,T   #/    T@@  -4.  #;&
MW2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@] !.BP  0)(  #*9
M   EH0  &*@   ZO   %M0   +H   "_    Q    ,@   #.    T0   -0
M  #5    V    -H   #=    WP   .(   #D    YP   .L%  #O#@  ]!D
M /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_  L _P ( /\ "0#_
M  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\ 6@#_ &( _P!I /\
M;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J /( MP#O ,D [0#F
M .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0 _P   /\   #_  4
M_P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W %P ] !C /( :0#P
M &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .  L #= ,  V@#< -@
M] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P   /\   #_    _P *
M /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8 X0!< -X 8P#< &@
MV0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$ +< P0#, ,  ZP"^
M /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\   #Z    \@ % .H
M#@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6 ,0 7 #" &$ P !G
M +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\ K@#! *T X "K /<
MJ@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H    W    -  "@#*
M !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +  50"N %L K !A *H
M9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X )H T "9 .\ F #_
M )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2    Q0   +L !0"U  X
ML  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"< %4 F@!: )@ 8 "6
M &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H Q0"( .8 AP#[ (8
M_P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP   *H   "C  H GP 1
M )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\ B@!4 (D 6@"' &
MA@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z -L > #U '@ _P!X
M /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L   "6  4 D0 - (T
M% "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/ 'P 50!Z %L >0!A
M '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X ; #N &L _P!K /\
M:P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "( @  A0 ) ($ $ !_
M !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '  4 !N %8 ;0!= &P
M9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I &  _ !@ /\ 8 #_
M &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0  >0D! '@#"P!U !$
M<P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E!%( 8P59 &(%80!@
M!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*^P!5"O\ 50K_ %8*
M_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A   &T-!0!M"0T :@D4
M &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\ 6PU6 %D-7@!8#F@
M5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-$/\ 31#_ $T0_P"\
M&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04  !D$ @ 8@\0 %\0
M& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3 %$36P!0$V4 3A1P
M $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\ 117_ $45_P"U'P
MGB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;%P( 6A4- %<6% !5
M%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:6 !(&F( 1QIM $4;
M>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_ #X;_P"O(P  F"0
M (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0  4QP+ %$<$@!.'1H
M31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"(%\ 0"%J #\A=P ]
M(8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A_P"J)@  E"<  ($I
M  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"(' $HB$ !((A< 1R,?
M $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP .B9G #DF=0 W)X0
M-2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E*0  CRH  'TL  !O
M+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G#0!"*!0 02@< #\I
M(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME #,K<@ Q*X( ,"R4
M "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+   BRT  'DN  !K+P
M8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]+!$ .RT9 #HN(0 Y
M+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP<  L,(  *C"2 "DP
MI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS   '8Q  !H,@  73(
M %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1  -C(6 #4R'@ S,R4
M,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G-7X )360 ",UHP B
M-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T  !E-   6C4  %$U
M  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3 "\W&P N-R( +3@I
M "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP (#J. !XZH@ <.K<
M&SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A-P  5S<  $XW  !(
M-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\&  H/1\ )CTF "4]
M+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^, !@_H  6/[4 %3[2
M !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@  4SH  $LZ  !%.@
M/SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A0AL ($,C !]#*@ >
M0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$G@ 11+, $$30 !!#
M\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T  $@]  !"/0  /#T
M #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921< &$D> !=))@ 622X
M%4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,2K  "DK*  M)[  ,
M2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5    _0   .4$  #)"
M   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9 !!0(0 /4"D #E Q
M  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L  E#%  -/Z  #3_L
M!4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \1   -44  "Y'   G
M2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8'  '6"0 !E@L  58
M-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?   !6Y0  5OD  %7_
M  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2   ,$H  "E-   B4
M'%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&   8!\  & G  !@,
M8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?X@  7OD  %W_  !=
M_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$  "-4   <5P  %EL
M !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D  &HA  !J*0  :C0
M &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0  :/<  &?_  !F_P!I
M40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=   68   $&0   QG
M   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;  !V(P  =RP  '<X
M  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4  '/_  !R_P!C5@
M6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0;   "G    1S
M=@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$&P  A20  (8O  "&
M/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_  " _P!?6P  5EH
M $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0   7X   "!    A0
M (@   "*    BP   (T!  ".!@  D L  )$/  "3%   E1L  )<F  "7-
MET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2_P!=80  3V$  $)D
M   V:0  *FX  !]T   5>0  #G\   >$    B0   (X   "2    E@   )@
M  ":    FP   )T   "?    H0,  *,(  "E#0  IQ,  *D<  "J*   JCD
M *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6:   2&P  #IP   N
M=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C    IP   *H   "K
M    K0   *\   "Q    LP   +4   "X!0  N@P  +T2  # '   P"T  ,!
M  "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=   0'D  #)_   EAP
M&8X  !"5   'G    *(   "G    K    +    "U    N0   +P   "]
MOP   ,$   ##    Q@   ,@   #*    S0(  - +  #5$@  UB$  -<T  #8
M20  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D  "N0   =F   $J
M  JG    K@   +0   "Y    O@   ,(   #(    RP   ,X   #/    T@
M -0   #6    V@   -T   #?    X@   .8   #J"@  [Q,  / E  #R.@
M\U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\ !0#_  L _P 0 /\
M%P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D /\ :@#_ '  _0!V
M /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0 Z0#D .< ^0#F /\
MY0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_  ( _P + /\ $@#_
M !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X 8P#L &D Z@!O .@
M=0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4 ,\ \@#- /\ S #_
M ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_    _P & /D #P#U !<
M\P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4 &, T0!H ,\ ;@#,
M '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D Z "X /T MP#_ +8
M_P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP ! .0 # #> !, V0 <
M -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P N0!A +< 9P"U &T
MLP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C /4 HP#_ *( _P">
M /\ F@#_ )< _P#_    _@   .\   #?    T    ,< !P#!  \ O  7 +D
M( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !: *, 8 "A &8 GP!M
M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L D0#_ )  _P"0 /\
MC #_ (H _P#\    [    -D   #'    N@   +$  @"K  P IP 2 *0 &P"A
M "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )  6@"/ %\ C0!F (L
M;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y '\ _P!_ /\ ?P#_
M 'X _P#Q    V    ,(   "S    J    *    "9  < E0 . )( %0"0 !X
MC@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_ %D ?@!@ 'P 9P!Z
M &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '  _P!P /\ < #_ '$
M_P#A    Q    +    "B    EP   )$   "+  ( A@ + (, $0"! !@ ?P A
M 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0 < !: &\ 8@!M &H
M:P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C /\ 8P#_ &0 _P#/
M!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '< #@!U !, <@ ; '$
M(P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6 &, 70!B &4 8 !O
M %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\ 6 #_ %D _P#"#
MJ@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K !  :0 6 &< '@!E
M "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H 60!8 &( 5P!L %4
M> !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_ $X#_P"X$   H1(
M (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P 8001 %X#&0!<!"$
M6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0"5\ 3@EI $T)=@!+
M"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,_P"P%   F18  (<8
M  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P- %<,% !5#!P 4PTD
M %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX 1P]H $4/=0!#$(0
M01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I&0  DAL  ($<  !R
M'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0$ !.$1@ 3!$@ $H2
M)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E #X5<@ \%8$ .A62
M #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'   C1X  'L@  !M(0
M8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'%Q4 11<< $08) !"
M&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;;P U&WX ,QN0 #(;
MH@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(  '<C  !I)   7B0
M %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!( /QT9 #X=(0 \'B<
M.QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O('P +2&. "PAH  J
M(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F  !E)P  6R<  %,G
M  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6 #@B'@ V(R4 -2,K
M #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H *"6, "8EGP D);,
M(R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B*@  5RH  $\J  !)
M*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G&P Q*"( ,"@I "\H
M,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ* "$JG0 ?*K( 'BK,
M !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+   5"P  $PL  !&+
M02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L+!\ *BTF "DM+0 H
M+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !POFP :+[  &"_* !@N
M[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\  $DO  !#+P  /BX
M #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P )3(C "0R*@ C,C$
M(3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4,ZX $S/( !,S[  4
M,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R  ! ,0  .S$  #8Q
M   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@ !XW)P =."X &S@V
M !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T #CC'  XXZP 0./\
M$#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]-   .#0  #,T   M
M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<](P 6/2L %3XS !0^
M/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!  H]Y  +/?L ##S_
M  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P  -3<  # W   J.0
M)3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 01"< #T0O  Y$.0 -
M1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#X  #0_8 !$+_  9!
M_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH  "T[   G/0  (4
M !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B, "$HK  =*-  %2CX
M!$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0  2?4  $C_  !(_P!R
M/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E    C0@  '44  !='
M   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F  !1+P  43D  %%$
M  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4  $__  !/_P!L0
M74$  %%!  !'00  0$   #E    R00  *D,  "1&   >2   %TL  !).   .
M40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:*0  6C,  %H_  !:
M3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_  !7_P!E10  6$4
M $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84   $E,   Y6   *60
M!%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P  9"T  &0X  !D10
M9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@_P!?2@  4TH  $I)
M  !#2   .4D  "],   G3P  'U(  !A5   260  #5T   A@   "8P   &8
M  !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28  '$Q  !P/@  <$X
M '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:3P  4$X  $A-   ]
M3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K    ;P   '(   !T
M    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H  " -0  @$4  ']6
M  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65   3E,  $)4   W5@
M+%H  ")?   88P  $6@   MM   #<@   '8   !Z    ?0   (    "#
MA    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2+   DCL  ))-  "1
M8@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H  #M=   O80  )&8
M !EL   1<@  "G<   )]    @@   (8   "+    C@   )$   "3    E0
M )<   "9    FP   )T$  "?"@  H@\  *06  "F(0  IC$  *9#  "E5P
MI'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I   G;@  &W4  !%\
M   +@P   (D   ".    DP   )@   "=    H0   *0   "E    IP   *D
M  "K    K0   +    "R    M0@  +@.  "\%@  O"4  +PW  "[3   NF0
M +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ??P  $X8   N.   !
ME0   )L   "A    I@   *L   "P    LP   +<   "W    N@   +P   "_
M    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K  #40   TU@  --T
M  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0  #9D   .@    IP
M *X   "S    N    +T   #"    Q@   ,H   #*    S0   ,\   #2
MU0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M,P  [DL  .]D  #O
M@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P . /\ %0#_ !X _P I
M /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L ^P!Q /D =P#X 'X
M]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B /\ VP#_ ,L _P#!
M /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\ $ #_ !D _P C /\
M+@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J .0 < #B '8 WP!]
M -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\ Q0#_ +L _P"T /\
MK0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I
M #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,(
M?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_
M )P _P#_    _P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L
MQ@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H
M '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )
M_P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N
M *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '<
MD@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S
M    XP   ,P   "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8
M+P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z
M 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F
MRP   +<   "H    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0""
M #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\
M?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N
M *4   "7    C0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L
M<0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@
M (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#
M  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L
M &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($
M5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^
M#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D
M+0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"-
M $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$
M:Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/
M "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #
MG  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0
M %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L
M1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W
M#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88
M  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN
M #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+
M+1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,
M&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3
M,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7'
M "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@
M0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q
M&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :
MZ  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$
M #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C,
M*AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;
M'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C
M   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X
M ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P
M%R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q
M)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH
M/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_
M !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*
M*B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7
M+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L
M_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP
M "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T,
M$3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W
M*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R
M   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*
M  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@
M8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7
M.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^
M4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,
M % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0
M$#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@
M1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX
M  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!
M  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<
M $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  !
M.P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/
M!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C
M  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@
M-ST  "\^   G0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @
M6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !>
M<0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(
M "E%   A2   &DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(
M &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@
M:H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--
M   ;40  $U4   Y9   (70   6$   !D    9P   &H   !L    ;@   '
M  !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D
M 'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   3
M7   #6$   9F    :@   &\   !R    =@   'D   !\    ?0   '\   "!
M    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,
M  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@
M!7    !V    >P   '\   "#    AP   (H   "-    C@   )$   "3
ME0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">
MH   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($
M  "'    C0   )(   "6    F@   )T   "?    H0   *0   "F    J
M *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP
MM+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":
M    H    *4   "J    K@   +$   "R    M0   +<   "Z    O    +\
M  ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL
M ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":    H0   *<   "M
MLP   +D   "^    P@   ,4   #&    R0   ,P   #.    T@   -4   #:
M    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU
M  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H
M_P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O
M )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T
M_P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ]
M /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H
MSP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_
M    _P   /T   #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8
M/@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"-
M +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_
M^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W
M #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T
MD0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [
M -X   #)    O    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@
MG  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "'
M )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$
M  "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X
M (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X
M<P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">
M    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4
M-P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7
M &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-
M@P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F
M #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8
MHP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0
M &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #(
M6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !*
M +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&
M  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S
M $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L
M0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5
M"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4
M- !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^
M #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$
M2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \
M!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%
MW0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(
M $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4
M-0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E
M#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4
M   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z
M "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?<
M'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U
M%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4
M/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_
M !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@
M+QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @
M&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48
M_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP
M "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0
M&1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z
M'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?
M   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-,
M !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P
M9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =
M)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH
M5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0
M %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*
M%BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (
M+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H
M  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX"
M ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP
M #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!
M+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT
M!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH
M   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P
M-BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &
M.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^
M=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$
M "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H
M $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P
M18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS
M   F-   (#4  !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+
M  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4
M $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A
M.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/    400  %('  !4
M"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:
M  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00
M%40  !!(   +2P  !4X   !1    5    %<   !9    6P   %T"  !>!@
M8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !C
ML0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X
M  I2   #5@   %H   !=    8    &,   !E    9P   &D   !K 0  ;04
M &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0
M<,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?
M    8P   &@   !K    ;P   '(   !U    =P   'D   ![    ?0   ( #
M  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(
M ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O
M=    '@   !\    @0   (0   "'    B    (L   ".    D    ),   "6
M    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E
M  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =    'L   "!    A@
M (L   "0    E    )<   "9    G    )\   "A    I    *<   "J
MK0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M
M]0 W7   *V$  !YH   3<   "W@   "     AP   (X   "5    F@   )\
M  "D    J    *P   "M    L    +,   "U    N    +L   "_    PP
M ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O
M:0  (W   !9Y   -@0   8L   "3    FP   *(   "H    K@   +0   "X
M    O0   ,    #"    Q0   ,@   #+    S@   -$   #6    VP   -\
M  #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_
M_P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_
M $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8
MIP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P
M /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@
MZ0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@##
M *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0
M  #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !'
M ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0
MJ "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?
M    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L
M1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M
M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_
MLP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1
M $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P
MN@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0
M )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T
M>P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I
M ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((
M  ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \
M &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X
M60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M
M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L
M/ !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#:
M $T ^P!- /\ 30#_ $T _P"J    E    ((   !U    :P   &0   !@
M70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!.
M #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $(
M\0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@
M %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@
M0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X
M /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#
M  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z
M #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D
M+P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^
M" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #(
M/@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_
M "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0
M-@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J
M!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'
M_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \!
M # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$,
M(PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![
M$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0
M P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!,
M !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P
M914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E
M$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !84
M5@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@
M %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$
M'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0
M&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <
M  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL%
M !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX
M"AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"
M'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@
M"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I
M  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0
M-R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .
M)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G
M>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0
M "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L
M""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@
M+(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF
M   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .
M   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D
M #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E
M)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V
M#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?
M   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0
M'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0
M/A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^
MMP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\
M !4Q   1,P  #38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X
M $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M
M1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X
M   -.P  "#X   -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.
M  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<
M $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '
M1    $@   !*    30   %    !3    50   %<   !8 @  6P8  %T+  !?
M#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX
M  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P
M %,   !6    60   %P   !?    80   &,   !E    9P$  &H%  !M"@
M< X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H
M_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$
M  !E    :    &L   !N    <0   ',   !U    >    'L   !^ P  @0H
M (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _
M1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V
M    >@   'X   "!    @P   (8   ")    BP   (X   "2    E0$  )D)
M  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P
M+$X  "!3   560  #6    -G    ;@   '0   !Z    @    (0   "*
MC@   )(   "5    EP   )H   "=    H    *,   "G    JP   *\   "T
M"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L
M !AA   .:0  !7$   !Y    @0   (@   "/    E    )H   "?    I
M *@   "I    K    *\   "S    M0   +D   "]    P0   ,8   #+
MT0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q
M   '>P   (0   "-    E0   )T   "C    J0   *\   "T    N0   +P
M  "^    P@   ,4   #(    S    -    #4    V@   -\   #D    Z@
M .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\
M  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L
M5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0
M -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S
M\P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#>
M %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@
MZ0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP
M .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X
MN@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V ">
M /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\
M  "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!,
M )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\
MA0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=
M  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (<
M2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_
M &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%
M@@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P
M $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &
M_P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@   '@   !S    ;P !
M &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $(
M7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0
M /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<   !C    8    %T
M!0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!"
M $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\
M10#_ $4 _P"?    B0   '@   !L    8@   %L   !6    4P   %$  @!/
M  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0
M1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_
M #P _P"3    ?@   &X   !A    6    %$   !,    20   $<   !%  4
M1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y
M $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #,
M_P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P (
M #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $,
M+P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!
M!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #,
M"@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !)
M "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0
M: P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L
M! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!
M40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X
M %4/  !*$   0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H
M)@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9
M"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1
M  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+
M " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P
M$@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#
M%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/
M#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K
M  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@
M-Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5
M$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4
M>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@
M "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T
M$!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !
M&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:
M   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/
M  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@
M !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C
M'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@
M$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">
M   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0
M'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$
M)1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   E
MMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X
M !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$
M "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0
M*=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@
M   3(0  $",   XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3
M   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X
M "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1
M)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [
M%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\
M   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+
M"B\   8Q   !-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0
M11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^
M_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<
M   Z    /    #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,
M % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^
M,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$
M    1P   $D   !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5
M  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@
M,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0
M4P   %8   !9    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O
M&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<
M "@Y   >.P  %3\   Y$   '20   $T   !2    5@   %H   !>    8@
M &4   !H    :P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0
MA!T  ((L  " /@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!
M   71@  #TL   =1    5P   %P   !B    9@   &L   !O    =    '@
M  ![    ?@   (    "#    A@   (H   "-    D0   )8#  ";#   G1,
M )LA  ":,P  ETD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   0
M4P  "%H   !A    :    &X   !T    >0   '\   "$    B0   (T   "1
M    DP   )8   "9    G0   *    "D    J    *P   "R P  MPT  +<7
M  "U*   LCX  +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@
M &H   !S    >P   ((   ")    C@   )0   ":    GP   *0   "F
MJ0   *T   "P    LP   +<   "[    P    ,4   #+    T00  -4.  #3
M'0  T#(  ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T
M  "'    D    )<   ">    I    *L   "Q    M@   +H   "\    P
M ,0   #(    RP   ,\   #4    V@   .    #F    ZP   /$&  #P$P
M[B<  .P_  #J6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8
M# #Z !$ _P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!>
M /, 9 #Q &H [@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\
MK0#_ )X _P"6 /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R
M  P ^  2 /< &P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -
M7 #- &( R@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_
M )  _P"( /\ @P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  <
MT0 . -$ %0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P
M %L K@!A *P :0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ ((
M_P![ /\ =@#_ '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP +
M *P $0"M !@ K0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %,
MDP!9 )$ 80"/ &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M
M /\ :@#_ &@ _P#/    P0   +D   "M    H    )@   "4    D0 & )
M#0"0 !( CP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2
M 'H 60!X &( =@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\
M7@#_ %P _P"^    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W
M  X >  4 '< &@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8
M40!D %H 8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_
M %$ _P"P    GP   (T   !_    =    &X   !J    9@   &4 ! !C  L
M8P 0 &, %0!C !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5
M %, 4P!< %( : !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $<
M_P"B    C0   'P   !N    90   %X   !9    5P   %4  0!4  < 4P -
M %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P
M1@!6 $0 80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4
M    ?P   &\   !C    60   %$   !-    2@   $@   !'  0 1P * $8
M#@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0
M #D 6P X &D -P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(
M=    &4   !8    3P   $@   !#    /P   #T    \  ( /  ' #L #  [
M  \ .P 2 #H %P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\
M5@ N &, +0!S "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;
M %T!  !1 @  2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T
M,0 0 #$ $P P !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F
M %X )0!N "0 @@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&
M  !+!P  0@@  #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 .
M "D $0 H !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H
M'@!I !T ?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&
M"P  /0L  #4+   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "(
M#P A !( (  6 !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F
M !8 >  5 (\ %0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0
M.0T  #$-   L#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <
M!!  &P04 !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#
M=0 0 HH $ &B  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\
M "X/   H#P  ) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X
M%@D2 !4)%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,
M"(@ "PB?  H'MP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1
M   E$   (1   !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0
M !$,%  0#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88
M!0V=  0,M  ##-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C
M$@  'A$  !L1   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/
M$@ -#Q< #! =  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<
M   /M   #M0   [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P
M'!,  !D2   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *
M$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2
MM   $=<  !'U   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0
M !<4   4$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A,
M!!88  ,6'P "%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M
M%=D  !3W   3_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85
M   3% , $A,& ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6
M   ;'   &R0  !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L
M !CY   7_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3
M%04 $14$  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @
M&0  ("$  "$J   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ
M   <_P!-&0  /QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P(
M$!@!  T9 0 +&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@
M)AX  "<G   G,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A
M_P!('0  /!X  #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P
M  L=   ('P  !"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH
M "XC   N+@  +CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$
M(   ."$  "XA   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C
M   #)0   "<    I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?
M   V*0  -C8  #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)
M-"0  "LD   D(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J
M+0   "\    R    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  !
M)0  0#$  $!    _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@
M "DG   C)0  'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@
M #@    [    /@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P
M3"L  $LZ  !*3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I
M   C)P  &R@  !0J   .+0  "C    0S    -P   #H    ]    0    $,
M  !&    2    $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4
M %DT  !81@  5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >
M+0  %B\  ! R   *-@   SH    _    0@   $8   !)    3    $\   !2
M    50   %@   !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL
M  !I/0  9U(  &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0
M$3D   H]   "0@   $<   !,    4    %0   !8    6P   %\   !B
M90   &@   !K    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^
M-0  ?$D  'MA  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4
M  )+    40   %8   !;    8    &4   !I    ;@   '(   !V    >0
M 'P   !^    @@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P
MED   ))9  "1<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;
M    80   &@   !N    <P   'D   !^    @P   (@   ",    CP   )(
M  "5    F0   )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4
M *]-  "J:0  J(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M
M=0   'P   "#    B0   (\   "5    FP   *    "C    I@   *D   "M
M    L0   +4   "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!
M  #*7   Q7P  ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B
M )    "8    GP   *4   "M    LP   +@   "Z    O@   ,(   #&
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M_________________________________________P
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M_?[_;69T,0     #!"$   $                    !
M     0    $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP='A\@(2(C)"4F
M)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*2TQ-3D]045)3
M5%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W>'EZ>WQ]?G^
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MLW&[>[-QNWNS<;M[LW&[>[-QNWNS_ZLD!?^K+PW_NC@2\\E!&^3:22C8Z$Q
MSO-15\#O66NNY&%ZH-QGAI34:Y"+SVZ7A,QPG'W)<Z!XQG6C<\1XIF["?*EN
MPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["
M?*ENPGRI;L)\J6["?*ENPGRI_ZTD!?^P+PO[P#@/ZM!!%]KB1BC,[DQ!P_E0
M5;7S6&:EZ6%TE^%G?HW;:X:%UV^,?]1RD7K1=91USWB7<<U[FFS,?IQLS'Z<
M;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQL
MS'Z<;,Q^G&S,?IQLS'Z<_Z\C!/^V+0GQR#8,W=P]$\WJ1BK!]DM MO]/4:KW
M6&";[V%KC^AH=(7D;7M_X'& >=YT@W7<>(9RVGN);MA^BVO6@HUKUH*-:]:"
MC6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-
M:]:"C6O6@HUKUH*-_[$C!/J_+ ;CU"\'SN8[%L'S12NT_TD]J/].3)[]5UB1
M]F%AAO%I:7_M;VYYZG1R=>AW=7'G>G=NY7UY:^2 >VGCA'QIXX1\:>.$?&GC
MA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$
M?&GCA'QIXX1\_[4B ^O+(@+0XR<'PO$Z&;3^0BJF_T8YF_]-19+_5D^&_F)6
M?OIJ7'?W<&!S]75C;_-X96WR?&=J\7]H:/"":F;OA6MF[X5K9N^%:V;OA6MF
M[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;O
MA6MF[X5K]L(; =3?$0'"[R8+M?PZ&J?_/B>9_T0SC?]+/87_545\_V%+=?]J
M3W#_<%)L_W54:OYY5FC]?%=F_']89/R"6F/[AEMC^X9;8_N&6V/[AEMC^X9;
M8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC
M^X9;U,\* ,3M$@*U^R8-J/\V&9G_.R.,_T$L@/]*-'C_4SIQ_U\_;/]I0VC_
M;T5E_W1'8_]W2&+_>TEA_WY*7_^!2E[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$
M2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+
M_Y\B!?^=+0S_GC@5_ZA!'O^Q22O_ME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.
MFW^FR).$L<*-B+F^B(R_NH.1Q;=_E\NT?:#/KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B
M!?^=+0S_GC@5_ZA!'O^Q22O_ME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^F
MR).$L<*-B+F^B(R_NH.1Q;=_E\NT?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=
M+0S_GC@5_ZA!'O^Q22O_ME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$
ML<*-B+F^B(R_NH.1Q;=_E\NT?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_
MGC@5_ZA!'O^Q22O_ME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-
MB+F^B(R_NH.1Q;=_E\NT?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5
M_ZA!'O^Q22O_ME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^
MB(R_NH.1Q;=_E\NT?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!
M'O^Q22O_ME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_
MNH.1Q;=_E\NT?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!'O^Q
M22O_ME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_NH.1
MQ;=_E\NT?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!'O^Q22O_
MME,\_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_NH.1Q;=_
ME\NT?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!'O^Q22O_ME,\
M_[A=3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_NH.1Q;=_E\NT
M?:#/KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!'O^Q22O_ME,\_[A=
M3_NV9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_NH.1Q;=_E\NT?:#/
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!'O^Q22O_ME,\_[A=3_NV
M9F/NM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_NH.1Q;=_E\NT?:#/KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!'O^Q22O_ME,\_[A=3_NV9F/N
MM&]WXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_NH.1Q;=_E\NT?:#/KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31_Y\B!?^=+0S_GC@5_ZA!'O^Q22O_ME,\_[A=3_NV9F/NM&]W
MXJQUB=BD>YG.FW^FR).$L<*-B+F^B(R_NH.1Q;=_E\NT?:#/KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31_Y\B!?^=+0S_GS@5_ZI 'O^S22O_N5(\_[M<3_JZ963MN&UXX;!S
MB]6H>9S,GWVJQ9>!M;^1A;ZZC(G%MH>/S+*#EM*O@:#6IWZBTZ=^HM.G?J+3
MIWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G
M?J+3_Y\B!?^>+0S_H#<4_ZM 'O^T22O_NU(\_[U;4/J^9&3LO&QYX+5RC=.M
M=Y[*I'JMPIQ^N;R6@L.WD(?*LHN,TJZ'E=BF@YW:H8*AU:&"H=6A@J'5H8*A
MU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5
M_Z B!?^>+0S_H3<4_ZQ '?^V2"O_O5$\_\!:4/K!8V7LP6IZWKEPC]*Q=:'(
MJ'BPP*%[O+F;?\>TEH3/L)2-U:N1E]J@B9S<FHB@UYJ(H->:B*#7FHB@UYJ(
MH->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7_Z B
M!?^>+0S_HC<4_ZU '?^W2"K_OU$\_\):4/G$8F7KQ6E[WKYND-&V<Z/&KG:S
MOJ=YP+BC?\FTH8;/K)R-U:.6E-J:D9S<E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5
MCI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8_Z B!?^?
M+0S_HS<4_ZY '?^X2"K_P5 \_L594/?(8&;KRF=\W<-MD<^\<:7%M'2UO;!Y
MP+:L?\BNIX7/I:&*U9R<D=J5F9S<CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8
MCY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8_Z$B!?^?+0S_
MI#<4_[ _'/^Z2"K_PU [^\A84/7+7V;ISV9\W,EKDL[#;Z;!NG*UMK)VP*RL
M>\BDJ'_.G*2%U)2@C=B-GYG;BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?
MV(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8_Z$B!?^@+0S_IC83
M_[$_'/^[2"G^QD\[^,M74/+07F;GU&1]VL]ID\C%;::ZNW"TK;-SOZ.M=L>:
MJ'K-DJ5_THJBAM>$H)'9A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2B
MG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7_Z$B!?^@+0S_IS83_[,_
M'/^]1RG\R$X[]<Y63^[576;DVF)]T])HDL'&;*2SO&^QIK5RO)RO=,23JW?*
MBZ=[SX.D@=1]HHO6>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[
MHY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75_Z(A!?^@+0S_J#82_[0_&_^_
M1RCYRTXZ\M-53^K<6V;@X&%]S--GD;O(:Z*LOFZOH+=PN)6R<\"-KG;%A:IZ
MRGZH?\YXIH?1=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2
M=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2_Z(A!?^A+ O_JC82_[8^&_W"1RCU
MS4XY[ME43N;C6678XF![Q=5FC[3*:I^EP6VKF;IOM)"U<KN(L77 @:YXQ7JL
M?<ETJH3+<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+
MS'&IB\QQJ8O,<:F+S'&IB\QQJ8O,_Z,A!?^B+ O_K#41_[D^&OG%1R?PT4TX
MZ>!23.+I5V3.Y%]ZO==FC*W,:IN?Q&RGD[YOKXJY<;6#MG2Z?+-WOG:Q?,)Q
MKX+$;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZN
MA\9NKH?&;JZ'QFZNA\9NKH?&_Z0A!?^C+ O_KS40_[P^&/3)1B7JV$TVXN=/
M3-SO56/&YE]XM-IEB:70:9:8R&RAC<-OJ(6_<:Y^NW2R>+EWMG.W>[ENM8"\
M:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YK
MM(6^:[2%OFNTA;YKM(6^_Z4A!/^D+ O_LS4/^\$^%^W/1B+AWTLTV.M/3,_S
M5&*\Z%YTJ]YDA)W4:9"1SFV9A\EOH(#%<J5ZPG2I=,!XK'"^>Z]KO("R:+N$
MLVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S
M:+N$LVB[A+-HNX2S_Z8A!/^H*PK_N#0-\\<]%.3811[6YDDUR_%.3,3W4U^Q
M[%UPH>)D?97;:8>*U6Z/@M!QE7O-=)IVRW>=<<EYH&W'?:)IQ8&E9L2%IF;$
MA:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%
MIF;$A:9FQ(6F_Z@@!/^N*@C\OS,+Z<\\$-?A0A[*[4DUO_A-2K?[4ENF\5UI
MF.EE=(SB:GV#W6^$?-ISB7?7=XQSU7J/;]-]D6S1@)1HT(269<^'EV7/AY=E
MSX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/
MAY=ESX>7_ZH@ _^U*0;PR#$'VMTS#,OJ0B&^]D@ULO],1JG_456;]UU@CO!E
M:H7K;'%]YW%V=^1V>G/B>7UOX7Q_;-^ @6G>@X-GW8>%9=R)AF7<B89EW(F&
M9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89E
MW(F&_ZT? _F_)0/?UB("R^@R#[[T02*P_T4SI/]*09S_44V/_EU6A?EF7GWT
M;F1V\G-H<N]X:V[N?&UL[7]O:NR"<&?JA7)EZHES8^F,=&/IC'1CZ8QT8^F,
M=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT
M_[8< NC-% ',YAT$OO,Q$K'_/B*C_T(OEO](.HW_4$2$_UQ+>_]G473^;E9O
M_'-9;/MX6VGY?%UG^']>9OB#7V3WAF!B]HEA8?:,8F'VC&)A]HQB8?:,8F'V
MC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB\\0/
M ,[:"P"]\QT'L?\R%*/_.A^5_S\JB?]&,X#_3SIX_UM <?]F16S_;4AH_W-*
M9O]W3&3_>TUB_W].8?^"3V#_A5!>_XE17O^+45[_BU%>_XM17O^+45[_BU%>
M_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM1S,L) +[F
M# &O_QX)I/\P$Y7_-1R'_SPD?/]$*W/_33%L_U@U9_]C.6/_:SMA_W$]7_]U
M/EW_>3]<_WQ 6_]_05K_@D%9_X9"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"
M6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"_YD?!?^6*PO_
ME382_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%
MD:;+@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382
M_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+
M@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^
M&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6L
MQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H
M1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9
ML<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_
MKE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5Y
MGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T
M_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"
M=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T_Z];
M1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"=J.Y
MP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T_Z];1?^M
M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"=J.YP'2J
MO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T_Z];1?^M95?X
MJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"=J.YP'2JO+UQ
MLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H
M[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&__YD?!?^7*PO_ES82_Z$^&O^J1B7_L% T_[%:1?^P9%?WK&UI[*=W
M>^&>?8K9EH.7T8Z)HLN(CJO'@I.QQ'Z7M\%ZG+N^=Z*_O'6JPK5QKL.S<J_!
MLW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S
M<J_!_YD?!?^7*@K_F#42_Z,]&O^L1B7_LT\T_[191O^T8UCVL6QKZJUU?=^C
M>XW5FX&<S9*&J,>+BK'"A8^YOX"4OKM\FL.Y>:''M7:IRJUUK,:K=JW$JW:M
MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$
M_YH?!/^8*@K_FC02_Z4]&?^N1B7_M4XT_[=81O^W85GUM6ILZ;)S?]VH>)#3
MGWZ@RI:"K,2.A[>^B(R_NH.1Q;=_F,NT?*'/JWBESZ5YJLBD>:S&I'FLQJ1Y
MK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&_YH?
M!/^8*@K_FS01_Z8]&?^O127_MTXT_[I71O^[8%GTN6EMY[9Q@=RL=I/0I'NC
MR)I_L<"3A+R[C(G%MXB0R[2&F<ZRAJ31I'RDT9]]J<J>?:K(GGVJR)Y]JLB>
M?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(_YL?!/^9
M*@K_G#01_Z<\&?^Q123_N4TT_[Q71OZ^7UGTO6=NY[IO@MJQ=)7/J'FFQ9]]
MM+Z7@<"YE(K&M9&2RZ^-F,^JBJ'2GH*CTYF!J,R8@JG*F(*IRIB"J<J8@JG*
MF(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*_YL?!/^9*@K_
MG301_ZD\&/^R123_NTTS_[]61OW!7EKSP69OYK]M@]FV<Y?-K7>HQ*5[M[ZA
M@\"VFXG&KI6/S*B1E<^BCI[2F8>BTY2&I\V3AJC+DX:HRY.&J,N3AJC+DX:H
MRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+_YL?!/^9*@K_GC,1
M_ZH\&/^S123_O$PS_\%51OO$75KSQ65OY<-LA-B[<9C,LG6KPZU\MKFE@;^P
MGH;&J)F,RZ&5DM";DIO3E(ZBU(^*ILZ/BJC+CXJHRX^*J,N/BJC+CXJHRX^*
MJ,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+_YL?!/^:*@K_GS,0_ZL\
M&/^U1"/_ODPS_L-51?G'7%KQR61OY<AJA=;!;YK*N72JOK!ZMK.I?[^JHH3&
MHIV*RYN:D,^5EYG2CY2BU(J0ILZ*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*
MCZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,_YP?!/^:*@K_H#,0_ZP\&/^V
M1"/_OTPR_,941?;*7%KOS6)PY,UHAM/%;9K%O'.JN;1XM:ZM?;ZEIX+%G:*(
MRY6?CL^/G);2BYRBTX:5ILZ&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,
MAI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,_YP?!/^:*0K_HC,0_ZT[%_^W1"/_
MP4PR^<E31?/-6EKLTF!PX-!FAL[(;)K OW&IM+AWM:FQ?+Z?K('%EZB&RI"D
MC,Z*HI71A:*ATH&<ILZ!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JG
MS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,_YP>!/^;*0K_HS,0_Z\[%_^Y1"+]PTLQ
M]LQ21/#265GHVE]PV]5DALG,:IFZPV^HK;MTM**T>;V8KWW#D*R#R(FIB<R#
MIY'/?J:<T'VDILU\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRB
MJ,M\HJC+?**HRWRBJ,M\HJC+_YT>!/^;*0K_I3(/_[$[%O^\1"'ZQDLQ\]%1
M0^O:5UGCWUUOT]MCA<+/:9>QQ&VGI+QPLIBU=+N.L7C"AJU]QH"K@LIZJ8K-
M=JB4SG:IH\QWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IW
MJZC*=ZNHRG>KJ,IWJZC*_YT>!/^<*0K_IS(/_[,[%O^^0R#URDLO[M900N;A
M5E?<Y%MNR]YC@[K1:)2IQVRCF[YNKI"X<;>&M'2]?K!XPG>N?,9RK(/);:N,
MRFVKF<ENK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_'
M;JR?QVZLG\=NK)_'_YX>!/^=*0G_J3(._[8Z%/K"0Q_PSDHNY]U/0.+I4E?2
MZ%IMP>!B@+'49Y&ARFN>E,-NJ(F]<;" N72V>;9WNG2T>[UNLH' :K"(PF>P
MDL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6
MPV:PEL-FL);#_Y\>!/^>*0G_K3$-_[HZ$_3'0AWHU4HKW^1,/]?L45;)[EEK
MM^-A?*C89XN:SVN7C<ENH(/$<:=[P'2L=;UXL'"[>[-LN8"V:+B&N&2WC[EC
MMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.V
MD;ICMI&Z_Z >!/^A* C_L3 +^\ Y$>S.0AG?WT<HT^E,0,KQ456^\EAHK>9A
M=Y[=9X22U6R/A\]OEG[+<YQXR':A<L9YI&[$?*=IPH&I9L"&K&*_C:UAOX^N
M8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYA
MOX^N_Z(= _^F)P?_MR\)\L<X#>'80132YD8JQ_!,0+[X4%.R]5=CHNMA<)7C
M9WN*W6V$@=AQBWK4=9!TTGF3<-!\EFS.?YEHS(.;9,N(G6'*C9]@R8^?8,F/
MGV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?
M_Z0= _^M)@7[OBT&YM T"-/B/!;'[D8KN_E*/K#^3T^F^E=<F/%A:(SK:'&#
MYFYX>^)S?77?>(%QW7N$;=M_AVK:@XEGV8:*9->+C&'6D(Y@U9&.8-61CF#5
MD8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&._Z<<
M _^U(P/NR28#U=\I!\?L/!FZ^$0KK?](.Z/_34F:_U=4C?EA783T:F5\\'!J
M=NUV;G'K>G%MZ7YT:^B"=FCFA7=FY8AY8^2,>F'CD7Q@XY)\8..2?&#CDGQ@
MXY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\_ZL; O?
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M;53NM&U4[K1M5.ZT;53NM&U4[K1M5.ZT;53NM&U4[K1M_Z,0 /&Y# #.R0D
MQ-\+ +;W'P:L_S(2H/\['93_02>*_T<Q@?]..7K_6#]S_V)%;O]L26G_<TQF
M_WI/8_^ 46#_AE->_XQ47/^255K^F%=9_9U85_RD657[JUI4^[%;5/NQ6U3[
ML5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;\*\( ,V_!P# S0@ M.X.
M JG_(0B?_S$1DO\W&H?_/B)]_T4I=?]-,&[_535I_V Y9?]J/&'_<3Y?_W=
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M:?\J#F#_,A)9_SH54_]"%T[_21E+_U$:2/]8'$;_71U$_V,=0_]G'D'_;!]
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M?[.>C8#"GHN S)J+@=*2BH#8B8F VX:)@-N&B8#;AHF VX:)@-N&B8#;AHF
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M>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X_WH5 O^.$@'_GQ, _[ 3 ._ $ #9U P
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MFR(W_Z0B-O^M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8
M )_$  "2T@  A.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/
M0_]($4#_3A(]_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L
M_Y,8*_^<&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,
M  "$W   >/<  &[_"@%C_Q "6O\5 U+_'01+_R0&1O\L"$'_,PD\_SH*.?]
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MCW=GFXM^;I:(AG.0A8YXC(*6?(B H("$?ZN"@7^X@W]_RH2!@>%]@8'F=H&
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MMD)&],=#1?3?0T3T\$-$\OI"1/+Z0D3R^D)$\OI"1/+Z0D3R^D)$\OI"T:(
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M'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4  )K"  ",SP
M?]X  ';_!0!L_PX!8O\4 EK_&P-3_R0%3?\K!T?_,PE#_SH*/_]!"SO_1PPX
M_TT--?]3#C/_6 \Q_UX/+_]D$"W_:Q$K_W,1*?]\$B?_AA(E_Y 3)/^9$R/_
MHQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4G+X  (W+  !^V@  <.8
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M]UYBF?=>_W,0 ?^%# #ZE@H VZ4& -&Q" #+NP@ QL<+ +W'( *RQ3(+J,%
M&9Z^2B>4NE,TB[9:/H.T84=\L6A/=:]O56^M=EIJJWU?9:F&8V&HD&==IYMJ
M6:>H:U>GN&Q6I\QL6*CI:%JG]&-;H_A>7*/Y75RC^5U<H_E=7*/Y75RC^5U<
MH_E=_W@- /^+"0#?G , TJD& ,FT!P#"O@8 O,P( +7-' &KRR\)H<@]%I?%
M2".-PE$OA+]8.GR\7T-UNF9*;[AM4&FW=%5DM7Q:7[2%7ENSCV%7LYID5+*G
M95*RMV91L\QF4K/I8U2R]U]5KOI;5JW[6E:M^UI6K?M:5JW[6E:M^UI6K?M:
M_WX) /*1 @#6H0( RJT% ,"W!0"XP@4 LL\) *O4%P"CTRL&F= Z$H_.11^%
MRTXJ?<E6-'7'73UNQ65$:,1L26/"<TY>P7M36<&$5E7 CUE2OYM<3[^H74V_
MN%Y,P,U>3,#J7$Z_^5E/O/Y54+K^55"Z_E50NOY54+K^55"Z_E50NOY5_X4"
M -V8  #-I@( P;$# +>Z P"NQ@8 I],* *#=%0"9W2@$D-LW#H;90AE]UDLD
M==14+6W27#5GT6,\8=!K05S/<D98SWM)5,Z$35#.CU!-SIM22\ZI4TG.N51(
MS\]42,[K4TG.^%!*R_].2LK_34K*_TU*RO]-2LK_34K*_TU*RO]-YX\  -&?
M  ##JP$ M[0" *V_ P"CRP8 F]D* )3E&@&-Y2L&A.0U#7OC/Q9SXD@>;.%2
M)F;A6BQ@X&(R6^!J-E?@<CI3WWL]4-^%0$W?CT-*X)M%2."H1D;@N$=%X<Q'
M1>#H1T7?]D9%WO]$1=[_1$7>_T1%WO]$1=[_1$7>_T1%WO]$V9<  ,>F  "X
ML   K+D! *+% @"8T08 C^L- (GN'P* [BL&>.TT#'#M/1-H[4898NU.'EWM
M5R-9[6 G5>UH*E+M<2U/[7DO3.V#,DKNC31'[I@U1>ZE-T/OLSA"\,0X0?#?
M.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ   +JK  "MM
MH<   );, 0"+V04 A/@1 7SX'P)T^"D&;/@R"F3X.P]>^4,36/E+%U/Y4QI0
M^5L=3?ID'TKZ;"%(^G0C1OI^)43[B"9!^Y,H0/N>*3[\JRH]_+DK._W+*SO]
MXBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@  *ZP  "AO   E<@
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M#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,  %_V  !6_P
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MJ#<-O*-$&K.>3R>JF5@SHY1@/9R0:$66C&],D(EV4HN&?5>&A(5;@H*.7WZ
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M44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4  -25  #'HP
MNJP! +"T  "GOP, GLD& )74"P"0U1T!B=0N!H#2/!!XT$89<<]/(6K.6"ED
MS5\O7\QG-%K+;CE6RG<]4LJ 0$_)BT-,R9=%2<FD1T?)LTA&RLA(1LKF1T?)
M]T5'R/]#2,?_0DC'_T)(Q_]"2,?_0DC'_T)(Q_]"WHT  ,N<  "]IP  L;
M *:Z  "<Q , D\\' (K=# "%WQT!?M\L!7;>-PMOWD,3:-U-&F+<52!=VUTF
M6-ME*E3:;2Y0VG8R3=J -4K:BS='VI<Y1=JD.T/;M#Q"W,@\0MOE.T+:]#I"
MV?XZ0]C_.4/8_SE#V/\Y0]C_.4/8_SE#V/\YT)8  ,&C  "RK   I[4  )S
M  "1R@, A]8' (#I$0!YZ2 "<NDL!6OI-@IDZ3\/7NE(%%GI41E5Z%H<4>EB
M($[I:R-+Z70E2.E])T;IB"I#Z9,K0>J@+4#JKRX^Z\ N/>S;+CWJ[RX]Z/PN
M/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0  G+P  )#'  "$
MT@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),]5442?9=%T;V
M91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;YXR(V^/,B-O?\
M(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0  (//  !WVP
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M5EN6\U!=E_],7Y?_1V"6_T9@EO]&8);_1F"6_T9@EO]&_W # .N!  #6CP
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M-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP  *"T  "6O@
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M$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<  %+_"0!-_Q$
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M1B<"_THI _]++P3_3#D&_TM%"/](40O_1EX._T1L$?]">1/_0845_T"/%_]
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M4&I^\TEM@/]#;H'_/V^!_SQO@?\\;X'_/&^!_SQO@?\\_V0( /]R  #A?P
MTXD! ,J2 P##F 0 O9X$ +:@$P"NH"<"I9TV"9V:0Q.6ETT<CY-5)(F172N$
MCF0Q?XQK-WJ*<CMVB'E <H:"1&Z%BT=J@Y5*9X*A362"KD]B@K]/88+:3V2$
M\DEFA?]#:(;_/VJ&_SQJAO\\:H;_/&J&_SQJAO\\_V<$ /9V  #<@@  SHT
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M/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH  +.A  "JIP
MH:X  )>U!@"2MA@ C+4J X6T-PE^LD(1=[!,&'&N5!]LK5LE9ZMB*F*J:2]>
MJ7$S6JAZ-U:G@SI3IHX]4*:;0$VEJ4%+I;I"2Z;10DNE[3]-I?P\3J3_.4^D
M_S=/I/\W3Z3_-T^D_S=/I/\WY'H  ,^)  #"E0  MI\  *RE  "BK   F+,
M (Z[ @"(O1( @[TE 7R\,P9VNS\-;[I)%&JX41IEMUD?8+9@)%RU9RE8M&\L
M5+-X,%&S@C--LHTV2K*:.$BQJ#I&LKDZ1;+1.D:Q[3E'L/PV1[#_-$BO_S-(
MK_\S2*__,TBO_S-(K_\SVX(  ,>0  "[G   KJ,  *2J  "9L0  C[D  (3
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M)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<  &_.! !DU@D
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M@ 47_X\%%O^?!A7_KP84_\ &%/_6!A/_Z083_^D&$__I!A/_Z083_^D&EZ\
M (BZ  !ZQ0  ;,\  %[:  !0X   1.8  #SU   W_P0 ,_\- "__$P K_QH
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M1'AL\SYY;O\X>F__-'MP_S!\</\P?'#_,'QP_S!\</\P_UL( /]F  #G<@
MVGL  ,^" P#)AP4 Q(H& +R,%0"TBR@"K(DX!Z6%1!">@DX8F']7'I-\7R2.
M>68JBG=M+H9U=#*"='PV?W*$.7QQC3UY<)= =F^B0G-NKT1Q;L!%<&[917)P
M\3]S<O\Y=7/_-79T_S%V=/\Q=G3_,79T_S%V=/\Q_UT& /]I  #B=   U'T
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M-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<  +Z/  "VE0
MKID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]ZCUXE=8YE*G&,;"YM
MBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%ZC]<AOLZ7H;_-E^'
M_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP  +F3  "PF0  J)T
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M+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P  (:R  !]M@T
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MH! RVK$1,=O'$3':YQ$PV/82,-;_$R_4_Q,OU/\3+]3_$R_4_Q,OU/\3LYH
M *:A  ":J0  C;$  ("Z  !TP0  :,D  %S/  !2U0, 2-P( $7E$@!#Y1X
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M A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX  (2X  !VP@
M9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$ (/\7 !W_'0 9
M_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%_W0! _^% 0+_
ME@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!  !HS   6M<
M $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0 !'_%  /_Q@
M#?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX  /]M  #_?@$
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M_PCU*/\(]2C_"/4H_PCU*/\(_S(E ?\W(@'_.B$!_SLC ?\[*0+_.S0"_SE
M!/\V307_-%H&_S%F!_\P<PC_+G\)_RZ)"O\ND@K_+9D+_RVA"_\MIPO_+:X+
M_RVU#/\MO@S^+<D,^RW9#/@MZ OT+O0+\2[^"^\N_PON+O\+[2[_"^PN_PKL
M+O\*["[_"NPN_PKL+O\*_S4B ?\['@'_/QT!_T ? ?]")@'_0C$"_T \ _\^
M2 7_.U4&_SEB"/\W;@K_-GD+_S6$#/TTC0W\-)4-^C2<#ODSHP[W,ZH/]C.R
M#_4SN@_S,\4/\C/2#^XSY0_J-/(/YS3]#^4T_P_D-/\.XC7_#N(U_PWA-?\-
MX37_#>$U_PWA-?\-_SD> ?\_&@'_0Q@!_T8: ?])(P'_22T"_T@X _]%1 7_
M0U '_T!="?L^:0OX/70-]3Q_#O,[B _Q.Y 0[SJ8$>TZGQ+L.:83ZCFN$^DY
MMA3G.<$4YCG.%>(YXQ7>.?$5VSK\%-@Z_Q/5._\2TSO_$M([_Q'2._\0TCO_
M$-([_Q#2._\0_ST; ?]#%@#_2!0 _TP7 ?]/'P'_4"@!_T\S O]-/P3[2DH&
M]4=7"?%&9 SM1&\.Z4-Y$>="@Q/D08L4XD"3%N _FQ??/Z(8W3ZJ&=L^LQK8
M/KT:UC[*&](^WQO./N\;RS_[&LE _QC'0/\7QD'_%<5!_Q3$0?\4Q$'_%,1!
M_Q3$0?\4_T$7 /]'$@#_3!  _U(4 /]6&P#_5R0!_U8N OA4.0/Q444&ZT]2
M">9-7@SA2VD0W4ET$]E(?1;51H88TD6.&M!%EAS.1)T=S$2E'LI#K1_(0[8@
MQD/#(<5#TR'!0^DAOD3W'[Q%_QVZ1O\;N4?_&;A'_QBX1_\7N$?_%[A'_Q>X
M1_\7_T04 /]+$ #_40X _U<1 /];%@#_71X ^5TH >];,P+G63\$X%=-"-I4
M60W34F02SE!N%LI.=QG'3( <Q4N('L)*D"# 2I<AODF?([Q(IR2Z2+ EN$B\
M)K=(RR>T1^,GLDGS);!*_R*N2_\?KDS_':U,_QNM3?\:K4W_&JU-_QJM3?\:
M_T<1 /]/#0#_5@P _UP. /]@$@#]8A@ \&,A .9B+ '>8#H#U%Y(!\U;5 W'
M6%\3PU9I%[]4<AN\4GH>N5&"(;90BB.T3Y$ELDZ9)[!-HBBN3:LJK$RV*ZI,
MQ"RH3-LLIDWO*J1/_2:D4/\CHU'_(*-2_QZB4O\=HE+_':)2_QVB4O\=_TH/
M /]2"@#_6@D _V + /]E#@#U9Q$ Z&@8 -UG) #29C4"RF1$!\-A4 V]7EL3
MN5QD&+5:;1RQ6'4@KE=](ZQ5A"6I5(PHIU.4*J52G2RC4J8MH5&Q+Y]1OC"=
M4=$PFU'J+YI3^BJ:5?\FF5;_(YE6_R&95_\?F5?_'YE7_Q^95_\?_TT- /]5
M!@#_704 ^V0' .]I"0#I:PP X6P0 --M'@#);#$"PFI ![MG3 VU9%<3L&%@
M&:Q?:1VH77$AI5QX)*):@">@68<JG5B0+)M7F"Z95J(PEE6L,I15N3.35<HS
MD57E,Y%7]RV16?\ID5K_)9%;_R.16_\AD5O_(9%;_R&16_\A_T\+ /]7 @#_
M80( ZF@! -YM! #8< @ U7 + ,MR&P#"<2X"NF\]!K1L20VN:503J6==&:1D
M91VA8FTAG6%T)9I??"B87H,KE5V++9);E#"06YXRC5JH-(M9M36*6<8VB%GA
M-HA<]#"(7?\KB5[_*(E?_R6)7_\CB5__(XE?_R.)7_\C_U$) /]:  #U9
MX&P  -=Q P#0= 8 S74) ,1V%P"\=BH!M'0Z!:YQ1@RG;E$2HFM:&)YI8AV:
M9VDAEF5Q)9-D>"B08H KC6&(+HM@D3&(7YHSAEZE-8->LC>"7L(W@%[<.(!?
M\C.!8?\M@F+_*8)C_R:"9/\E@F3_)8)D_R6"9/\E_U,& /]=  #G9P  VV\
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M+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@  ,1^  "\@@$
MMH0! *Z%#@"GAB  H(4P YJ"/0B3@$@/CGU1%8E[61J$>6 ?@'=G(WQU;B=Y
M='4J=G-]+G-RAC%P<9 T;7"<-VIOJ#EH;[<Z9V_+.F=PZ3=I<?HR:W+_+6QS
M_RIL<_\H;'/_*&QS_RAL<_\H_UP  .=H  #5<P  R7L  ,""  "XA@  L8@
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M*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4  ):8 0"0F1,
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MG21!J*TE0*C )3^HWR4_IO0C0*7_(D"E_R% I/\@0*3_($"D_R! I/\@RGX
M +N+  "OE0  I)L  )FA  ".I@  @JP  '>Q  !JM@  8[@. &&X'0!>N"P!
M6K@X E>X0@53N$L(4+=3"TVW6PY*MF,01[9K$T2U=19"M8$8/[6.&CVUG!P[
MM:P<.K7 '3FUWQPYL_0<.;+_'#FQ_QLYL/\;.;#_&SFP_QLYL/\;P88  +23
M  "GF@  G*   )&G  "%K0  >;,  &VX  !BO0$ 5L(' %/#% !2PR, 4,0P
M 4W$.P)*Q$4#1\1.!47$5P="PU\)0,-H"SW#<@T[PWX/.,.,$3;#FQ(UPZL3
M,\/ $S/#X!,SP?43,L#_%#*__Q0QOO\4,;[_%#&^_Q0QOO\4N)   *N9  "?
MH   DZ<  (>N  ![M   ;KL  &/   !8Q0$ 3<H% $3/# !#T!< 0M E $#0
M,@ _T3T!/=%' 3O14 (YTED#-M)C!#32;@4RTGH',-*(""[2F DMTZD)+-.^
M"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@  **?  "6I@
MB:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ  --\; #+@)P Q
MX3( ,.$] "[B1P MXE !*^): 2KC90(HXW$")N1_ R7DCP,CY:$$(N6T!"'E
MS00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@_P4?X/\%I)X  )BE  "+K@  ?;8
M '"^  !CQ@  5LL  $O0  ! U0  -MP  "_E!P M[1  *^X8 "GN(@ G[RL
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M  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,  $?;   ZX
M+N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q  !/\3  '_&
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M(J!)^!Z?2_\;GDO_&9U,_Q>=3/\6G4S_%IU,_Q:=3/\6_T<+ /]- @#_5 (
M]UH$ .M=!P#G70L X5P0 --='@#*73 !PUP_!+U:3 BW6%<,LU9@$:]4:12L
M4W$7J5%X&J=0@!RD3X<>HD^/(*!.F"&>3:$CG$VK))I-N"693,@FEDSB)I5.
M]2*43_\?E%#_')11_QJ44?\8E%'_&)11_QB44?\8_TD( /]0  #[6   Y5X
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M(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH  ,EN  #"< $
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M(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8   *" !P"9@1<
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MG"A/A*HJ382\*DV$URI-@_$G3X/_)%"#_R)0@_\?4(/_'U"#_Q]0@_\?WFD
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M'#NCTAL[HN\;.Z#^&CN?_QD\G_\8/)__&#R?_Q@\G_\8Q'P  +:)  "JD@
MGY<  )6<  ")H0  ?:8  '&J  !DK@  6K$( %>Q% !5LB, 4[(P 5"R.P)-
MLD0#2[%-!4BQ50=%L5T)0[%E"T"P;PT^L'H/.["'$3FOEA,WKZ84-J^X%#6P
MT10UKN\4-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4  *^0  "CEP  F)T
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M 1C;_P(7VO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP  >;,  &RZ  !?P0
M4L8  $;*   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6
MZCD %>M# !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [PLP -\,T #._L  SM
M_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P  %_$  !2R@  1<X
M #G3   OV   )=T  !WA   8[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T
M"_HU  G[/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP  _+4  /S1  #\[0
M_/P  /S]  #\_0  _/T BZL  'VT  !NO0  8,8  %+-  !$T@  -]@  "S=
M   BX0  &>4  !/J   0^@  #O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G
M  #_,   _SH  /]%  #_4P  _V(  /]U  #_B@  _Y\  /^S  #_QP  _^4
M /_E  #_Y0  _^4 ?[0  '"]  !AQP  4]   $/6   VW0  *N(  !_F   6
MZ@  $.T   SZ   )_P  !O\   +_!   _PD  /\-  #_$   _Q0  /\:  #_
M(0  _RD  /\T  #_0   _TX  /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y
M  #_N0  _[D _R I ?\B)P'_(B<!_Q\J ?\9, '_$CD!_Q!% ?\-4P'_#& !
M_PIM O\)>0+_"80"_PF. ?\)E@'_"9T!_PFC ?\)J0'_"; !_PBW ?\(O@'_
M",@!_PC6 ?\(Y@'_"/$!_PC[ /\(_P#_"/\ _PG_ ?\)_P'_"?\!_PG_ ?\)
M_P'_"?\!_R,F ?\E) #_)20 _R,G ?\=+ '_&#4!_Q5" ?\24 '_$%T"_PYJ
M O\.=@+_#H "_PZ* O\.D@+_#IH"_PZ@ O\.I@'_#:T!_PVS ?\-NP'_#<4!
M_PW1 ?\-XP'_#>\!_@WZ ?H-_P'Y#O\!^0[_ ?D._P'X#O\!^ [_ ?@._P'X
M#O\!_R8C /\H( #_*"  _R8B /\B* '_(#(!_QP_ ?\93 '_%UD"_Q5E O\3
M<0+_$WP"_Q.& O\3C@+_$I8"_Q*= O\2HP+_$JD"_Q*P O\2MP+_$L$"_Q+,
M ?T2WP'Y$^T!]1/X ?,3_P'R$_\!\1/_ O 4_P+P%/\"\!3_ O 4_P+P%/\"
M_RH? /\L' #_+!L _RL= /\I) #_*"\!_R4[ ?\B2 '_'U0"_QUA O\;;0+_
M&G<"_QJ! O\:B@+_&I("_QJ9 OT:GP+\&J8"^QJL OD:M +X&KT"]AK( O,:
MVP+O&NH"[!OW ND;_P+H&_\#YQS_ ^8<_P/E'/\#Y1O_ ^4;_P/E&_\#_RT;
M /\P%P#_,14 _S 6 /\Q( #_,"H _RXV ?\K0P'_*$\"_R9< O\D9P+\(W(#
M^2-\ _<BA0/U(HT#\R*5 _(BFP/P(J(#[R*I ^TBL0/L(KD#ZB+% ^@BU0/D
M(^D#X"/V!-XC_P3;)/\$V23_!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T
M$@#_-A$ _S<3 /\Y&P#_."4 _S8Q ?\S/0'],4H!^"Y6 O0M8@/P+&T#[2MW
M ^HK@ 3H*H@$YBJ0!.4JEP3C*IX%X2JE!> JK07>*K8%W"K"!=HJT@;5*^<&
MT"OU!\TL_P?++/\'R2S_!\@L_P?'+/\&QRS_!L<L_P;'+/\&_S42 /\Y#@#_
M.@T _SX0 /] %@#_/R  _STJ /D[-P'R.$0![#91 N<U7 /C-&<#X#-R!-TS
M>P7:,H,&UC*+!M0RDP?2,9H(T#&A",XQJ0G,,;()RS&\"LDQR@K&,N$+PC+Q
M"[\S_@N],_\*NS/_"KHS_PFZ,_\)NC/_";HS_PFZ,_\)_SD0 /\]"P#_0 D
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M%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2_T4  /]+  #I4P  WE@  --;  #-6P0
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M%W%=_Q=Q7?\7_4\  .59  #38@  QV@  +UL  "V;0  KVP  *=K"P"@;!D
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MG"-<:ZHE6FN[)EELTR9:;.\C6VS_'UQM_QQ=;?\:76W_&5UM_QE=;?\9Z%H
M -)F  ##;P  N'8  *][  "F?@  G7X  )%\  "*? \ A7T> (%]+0%\?#D#
M=WI#!G-Y2PEP>%,,;'=:$&EV81-F=6@68W1O&&%S>!M><H(>6W*-(%EQFB)7
M<:@D57&Y)51QT"54<>XB5G'^'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI
M  "_<P  M'H  *M_  "B@@  F(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H%
M!6Y_20AJ?E +9WU7#F1\7A%A>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B
M4'>W(T]WSB-/=^PA4'?]'E%W_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[
M=P  L'\  *>$  "=AP  DH<  (2'  !]APD >(@6 '2()@!PB#(";(<]!&B&
M1@9EA4X)8855#%Z$7 ];@V,268)K%5:!=!=3@'X:4(")'$Y_EAY,?Z4@2G^V
M(4E_S"%)?NL?2G[\'$M^_QI+?O\93'[_&$Q^_QA,?O\8U6<  ,-S  "V?
MK(0  **)  "8BP  C8T  'R-  !UC@0 ;X\2 &V0(0!ID"X!98\Y F*.0@1>
MCDL'6XU2"EB,60Q6BV$/4XMH$E"*<11-B7L72HF'&4B(E1M&B*,=1(BT'4.(
MRAU#A^H<1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T  +UX  "Q@@  IXH
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M#2^F_PTOI?\-+Z7_#2^E_PTOI?\-MH0  *J.  ">E   E)D  (>>  ![HP
M;Z@  &.L  !7KP  2[(  $&U!@ ^MA$ /;8> #NV*0 ZMS0 .;<^ #>W1P V
MMU !-+=: 3*W9 (PMV\#+K=\!"RWBP4JMYP%*;>N!BBXQ04HM^8%)[7Y!R:S
M_P<FLO\()K+_"":R_P@FLO\(KXT  **4  "7F@  BZ   'ZF  !QJP  9;
M %FT  !-MP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD *L0S "G$/0 HQ4<
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M  #F_P  YO\ DZ$  (6I  !WL0  :;D  %O   !.Q@  0<H  #7.   JT@
M(=8  !G;   2WP  #>,   OQ"  )\PX !_,3  3R&@ "\B(  /(J  #R-
M\C\  /),  #R7   \FT  /*"  #RF   \ZT  //&  #TY0  ]/8  /3[  #T
M^P  ]/L AZD  'FR  !JN@  7,(  $[)  ! S@  ,],  "C8   >W0  %>$
M  _D   *Z   !?,   /] 0  _ @  /L-  #[$0  ^Q8  /P>  #\)@  _#
M /T\  #^20  _EH  /YM  #_@@  _Y@  /^L  #_P   _]@  /_D  #_Y
M_^0 >[(  &R[  !=Q   3\T  $#2   RV0  )MX  !OB   2Y@  #.H   7M
M    ]    /\   #_    _P   /\$  #_"0  _PX  /\2  #_&   _R$  /\K
M  #_-P  _T8  /]8  #_:P  _X   /^5  #_I@  _[,  /^[  #_NP  _[L
M_QLF /\<) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_
M ($ _P"* /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\
MWP#_ .P _P#X /\ _P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C
M /\?(0#_'B$ _QDC /\3*0#_#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!
M_P.' ?\#CP#_ I8 _P*< /\"H@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_
M .H _ #V /@ _P#W O\ ]P/_ /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B
M' #_(1P _QX? /\8) #_%2\ _Q(\ /\020#_#E8!_PQB ?\+;@'_"WD!_PN"
M ?\+BP'_"Y(!_PJ9 ?\*GP#_"J4 _PJK /\*L@#_"KL _0K& /L*U #W"N<
M\PKT / *_P#O"_\ [@S_ .T,_P'M#/\![0S_ >T,_P'M#/\!_R4; /\F& #_
M)1< _R$8 /\@(0#_'BL _QHW /\710#_%%$!_Q)> ?\1:0'_$70!_Q%] ?\0
MA@']$(X!_!"5 ?H0FP'Y$*$!]Q"H ?80KP'T$+< \Q#" /$0T #M$.4 Z!'R
M .81_@'D$O\!XQ+_ >(2_P'B$O\!X1+_ >$2_P'A$O\!_RD6 /\J$P#_*1(
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M"*@S_P>H,_\'IS/_!Z<S_P>G,_\'_S<' /\Z  #_/@  ^D$! /%!!@#Q/PT
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M#H!+_PZ 2_\._T,  .Q+  #=4P  SE@  ,1:  "]6@  N%<! +%4#@"J5AX
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MG!MH6:H<9EJZ'65:T1UE6NX;95O^%V9;_Q5F7/\39US_$F=<_Q)G7/\2[4X
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M'55GRAU59^@;5F?[&%=G_Q97:/\46&?_$UAG_Q-89_\3X5@  ,MC  "]:P
MLG(  *EV  "@>   EG<  (AS  "!<PL ?'07 'AT)@!T=#(!<',] FUS1@1J
M<DX'9W%5"61P7 MA<&,.7V]J$%QN<Q):;GP55VV(%U5LE!E3;*,;46RS'%!L
MR!Q/;.<;46SZ&%%L_Q52;/\44FS_$U)L_Q-2;/\3W%P  ,=G  "Y;P  KW8
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M$S^!_Q) @/\10(#_$$" _Q! @/\0QFL  +=V  "L?P  HH4  )>)  ",BP
M@8T  '..  !ECP  78\) %J0% !8D"$ 5I$M %.0. %1D$$"3I!) TR04 1*
MCU@%1X]@!T6.:0E"CG,+0(U_#3Z-C0\\C9P0.HVL$3F-P1$XC>$0.(OV$#B*
M_P\YB?\/.8G_#CF)_PXYB?\.OW(  +)]  "GA@  G(H  )&.  "&D0  >I,
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M!!^L_P0?K/\$JHL  )V1  "3EP  AYP  'JB  !MIP  8*L  %6O  !)L0
M/K0  #.W   JN@, )+P- "*]%0 AO2  (;TJ ""],P ?OCT 'KY' !V^4@ <
MOUX &K]L !F_?  8OXX %\"A !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z
M_P(4NO\"H9(  ):8  "*G@  ?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T
M "K    AQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5(
M#<Y@  S.<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )
MR_\ F)@  (V>  !_I0  <:P  &2S  !7N0  2KT  #[    RPP  *,8  !_*
M   7S0  $=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2
M  #>8@  WG,  -Z(  #?G0  W[,  -_.  #@[@  W_H  -__  #?_P  W_\
MCY\  (&F  !SK@  9;4  %B]  !*P@  /<4  #')   FS   '=   !34   .
MV0  "=T   /A    XP<  .,-  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L
M4@  [&(  .UV  #NC   [J$  .^W  #OT0  [^L  /#V  #P]@  \/8 A*<
M '6O  !GMP  6;\  $O&   \R@  +\X  "32   :V   $MP   S@   %XP
M .<   #K    ZP   .T%  #N"P  \!   /$5  #S'@  ]"<  /<S  #Y0
M^E$  /MC  #\=P  _8T  /VC  #^M@  _LD  /_?  #_WP  _]\ =[   &BY
M  !:P0  3,H  #S/   NU   (MH  !?>   0X@  ">8   #I    [    /
M  #V    ]@   /<   #X    ^@<  /L-  #]$0  _QD  /\C  #_+P  _SX
M /]/  #_8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_
M$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\
MCP#_ )8 _P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S
M /X _@#] /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX
M_Q @ /\*)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_
M )( _P"8 /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H T #X ., ]P#Q /8
M_ #T /\ ] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0;
M /\.(0#_#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X
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M /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5 /@/8 #T#VH
M\0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\ X ZX -X.Q0#<
M#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2_P'*$O\!_R</ /\G
M# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/ .H76@#F%F4 XQ9N
M . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL SABU ,P8P0#+&-(
MQQKH <,;^ ' &_\!OAS_ ;T<_P*\'/\"O!O_ KP;_P*\&_\"_RL, /\K!0#_
M*P, _RT) /\L#@#_*14 ]R8@ .XC+0#G(3H X1]( -L?5 #5(%\ T2!H ,X@
M<0#,(7D RB&! <@AB '&(8\!Q"&6 <,AG@'!(J8!OR*O ;TBNP*\(\H"N2/C
M K4D] *S)/\#L23_ Z\D_P.O)/\#KB3_ ZXD_P.N)/\#_R\& /\O  #_,@
M_S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED PRIB < J:P&]
M*G,!NRIZ KDJ@@*X*HD"MBJ0 K0JF .S*J$#L2JJ Z\KM02N*\0$K"O;!*@L
M[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(  /\S  #Y.   Z3D
M .(Y  #>-0< WBX- -$O&P#),2P PS,[ +TS2 "Y-%,!MC-< ;,S90*P,VT"
MKC-T ZPR>P.K,H,$J3**!*<RDP6E,IL&I#*E!J(RL >@,KX'GS+1!YPSZ@>:
M,_L'F#3_!Y<T_P:6-/\&EC3_!98T_P66-/\%_S4  /\X  #J/@  WT(  -5"
M  #//P, S3@( ,4X%0"].B8 MSLV +(\0P"N/$X!JCM7 J<[8 .E.F<#HSIO
M!*$Z=@6?.7T&G3F%!YLYC0>9.)8(F#B@"98XJPJ4.+@*DSG*"Y$YY0N/.O<*
MC3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10  U$D  ,M*  #%
M1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;06($F$!J!99
M<0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_X Z$/_0-@T#_
M"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\  ,-0  "\3@
MMTD! +%&#@"J2!P I$DL *!).@";244!F$A. I1'5P.21UX%CT9E!HU&; >+
M17,)B45["H=$@PN%1(T,@T27#H%#H@]_0Z\0?D/ $'Q$VA%[1/$/>D7_#7I&
M_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0  +U5  "V5   L%
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M#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\  )9:  "/6A
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MD1)38I\34F*N%5%BPA508N$546+V$E%B_Q!28O\.4F+_#5)B_PU28O\-V58
M ,1@  "W:   K&X  *-Q  ":<P  CW$  ']K  !X:P4 <FL2 &YL'P!K;"P
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M$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0  +=N  "K=@
MHGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"  58 K %.!-@!1
M@#X!3X!& DV 3@)+?U4#27]=!49_9@9$?G (0GY["3]^B L]?9<,/'VG#3I]
MN@XZ?M8-.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D  +)T  "G?   G8$
M )*$  "'A@  >X<  &Z'  !@AP  58<! %"(#@!.B!H 38DF $N), !)B3H
M2(E" 4:)2@%$B5("0HE: T"(8P0]B&T%.XAX!CF'A@@WAY4)-8>F"C2'N0HS
MA],*,X;P"3.%_PDSA/\),X/_"3.#_PDS@_\)N7   *UZ  "B@@  EX<  (V*
M  "!C   =8X  &B/  !:D   3Y$  $>2"@!$DA, 0Y,? $&3*@! DS0 /Y,]
M #V310 [DTT!.I-6 3B37P(VDVD#-)-U S*2@P0PDI,%+I*D!BV2MP8LDM$&
M+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B   D8P  (>0  !Z
MDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ TGBP ,YXU #*>
M/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>M0(CGLX"(YWN
M R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(  '^6  !RF@
M99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB( )JHL "6J-0 D
MJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9J\H &:KL 1FH
M_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>  !HH@  7*8
M %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A !:W*@ 5MS0
M%+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0 #;CG  ZV^P .
MM?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>JP  4J\  $:R
M   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%'@ (Q2@ !\4R
M  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2  #%[P  Q?P
M ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M   1K@  #J[   N
MO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@  T1X  -(G  #3
M,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6X   UO,  -;^
M  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$  "W$   BQP
M&<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0  .$<  #B)
MY"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0  Z>(  .GR  #I
M]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.   6T@  #]8
M  C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1  #O&   \2$
M /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(  /K:  #ZWP
M^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -WP  !>,   #F
M    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z#@  _1,  /\<
M  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y  #_O   _[P
M_Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D _P!E /\ < #_
M 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_ +@ _P#" /\
MS@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H _P#Z /\ _Q0<
M /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_ '8
M_P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0 ^0"] /@ R0#W
M -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P /\ _Q<8 /\5
M%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z
M /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X .X PP#L -,
MZ@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\ _QH3 /\8$0#_
M%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z &P ]0!U /(
M?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .( OP#@ ,T W@#C
M -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0 /\<#0#_%PL
M_Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8 Z@1O .8#=P#D
M!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0!LD S@?@ ,P(
M\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@!@#_' , _QT*
M /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI -D-<0#5#7D
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M ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0  -HS  #3+@,
MTB4* ,DE%P#!)R< NRDV +8J0P"R*TX KRM7 *PK8 "J*V<!J"MO :8K=@&D
M*WT!HRN$ J$KC0*?*Y4"GBN? IPKJ@.:*[8#F2S' Y<LX@.4+?4$DBW_ Y$M
M_P.0+O\#D"W_ Y M_P.0+?\#_S   /(S  #D.@  UCT  ,P\  #'.0  PS$%
M +TN$0"U,"$ L#(P *LS/0"G,TD I#-2 *$S6@&?,V(!G#-I IHS< *9,W<"
MES)_ Y4RAP.3,I $DC*:!) RI06.,K$%C3/"!HLSW :)-/(&AS3_!88T_P6&
M-/\$A33_!(4T_P2%-/\$_#,  .LZ  #<00  S40  ,-$  "]00  N#L! +(W
M#@"K.!P I3DK *$Z. "=.T0 FCM- 9<Z5@&4.ET"DCID I Z:P...7(#C#EZ
M!(HY@@6).8L%ASF5!H4YH >#.:T'@CF\"($YTPA_.NX(?3K^!WP[_P9\._\%
M?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20  KT,  *D^"P"B
M/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%/VT$@S]U!8$_
M?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1 _P=T0/\&<T#_
M!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH  *!$!P":110
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MD0Q>4)X-7%"M#EM1P Y:4=X/6E'U#%I2_PI;4O\)6U'_"%M1_PA;4?\(WTH
M ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H >E<5 '97(@!S6"X
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M#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0  +Y>  "Q90
MIVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4 8&4P %YE.@!<
M94(!6F5* EAD40)69%@#5&1?!%)D9P508W$'3F-["4QCB I*8Y<+2&.F#$=C
MN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@  +IB  "N:0  HVX
M )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$ 6FHM %AK-@!6:S\!
M56M' 5-J3@)1:E4#3VI=!$UJ905*:6X&2&EY!T9IA@E$:94*0VBE"T%IMPQ
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M!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X  (V   ""@0
M=H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C( 0(([ #Z"0P ]
M@DL .X)3 3F"7 $W@F8"-8)Q S."?P,Q@8X$,(&?!"Z!L04M@<@%+8'I!"U_
M_ 4M?O\%+7W_!2U]_P4M??\%LVX  *AX  "=?P  DH,  (B&  !]AP  <(@
M &.)  !5B@  2XH  $&* @ [BPX .8L7 #B,(@ WC"P -HPU #2,/0 SC$8
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M 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$  $RD  ! I@
M-:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L #;$U  VQ0  ,
ML4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %K_X !J[_  :N
M_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M   UKP  *[$
M "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK  "^-@  OD$
M +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8  +W_  "]_P
MO?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   JN   (+L  !>^
M   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+*P  S34  ,Y!
M  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X  #._@  SOX
MB)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@  %<8   [)   (
MS    -    #3    U0   -8&  #8#   V1$  -L6  #<'P  WB@  . T  #B
M00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E\P  Y?, ?*,
M &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$   35    V@
M -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H  .\D  #R,0
M]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP  ]]\ <*P  &&T
M  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B    Y0   .D
M  #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6  #_(0  _RX
M /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\ _PT< /\*&P#_
M AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_ '< _P!_ /\
MAP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\ R0#^ -T _0#M
M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9 /\-%P#_!A8
M_P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '( _P![ /\ @@#_
M (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T -( \P#G /(
M]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/$@#_"Q( _P 2
M /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V /D ?0#W (0
M]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L YP#A .4 \0#C
M /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_#0T _P</ /\"
M%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T > #K '\ Z0"%
M .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9 -0 [ #2 /D
MT0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4 _PX+ /\,$0#_
M!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#> 'D VP"  -D
MA@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4 Z ## /8 P0#_
M , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,% /\1#0#_#A0
M^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7, R@5Z ,@%@0#&
M!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U"_< LPW_ +$-
M_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46!0#V$0T ZPX5
M .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT +L/>P"Y#X(
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M HDG_P&))_\!^BD  .PP  #=-@  S3@  ,0W  "^,@  NBL" +4E#@"N)QT
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MDP5K/J &:CZN!FD_P =G/]X'9S_U!F9 _P5F0/\$9D#_!&8__P1F/_\$Y3T
M ,]&  "_3   M$\  *I0  "B3P  F4H  )%$  "*00T A$(9 (!#)@!]1#(
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M"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@  ,)1  "U5P
MJEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@ :% R &50.P!C
M4$, 85!* 5]040%=4%@"7%!? EI09P-84'$$5U![!550B 934)8'4E"E"%!0
MMPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L  +]4  "R6@  IUX
M )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0 8E0O &!4. !>5$
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M!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH  )5M  "*;0
M?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@ 361  $MD2 !*
M9$\!2&17 49D7P)%9&@"0V1S T%C?P0_8XX%/6.>!CQCL 8[9,8&.V3F!CMC
M^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\  )%R  "&<@  >W$
M &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0 1VH] $5K1 !$:TP
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M B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0  %^$  !1A
M1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X *85' "B&4  G
MAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>@O\!'H+_ 1Z!
M_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,  !,C0  0(X
M #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%  !V120 <D50
M&I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\ %(W_ !2,_P$4
MC/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%EP  .9@  "Z9
M   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>00 0GDP #YY8
M  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_  N9_P +F?\
MG(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H   ,*$  ":C   =
MI0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "JD0  :I0  "J
M7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G_P  I_\ E8L
M (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL  !VM   4L
M#K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D  +A&  "X5
MN&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P  MO\ CY(  (*7
M  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X   -NP  !KX
M  #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z  #)1P  R5<
M ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T A9D  '>?  !H
MI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #QP   ,H   #-
M    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=.0  WDD  -Y:
M  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$  &NH  !<KP
M3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP   -D   #<
MW0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P  \#H  /%+  #Q
M7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ  !0N0  0;\
M #+$   DR   %\P   [0   &U0   -H   #>    X@   .8   #I    Z@
M .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD  /\Z  #_30
M_V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_ !< _P : /\
M(0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\ @P#_ (H _P"0
M /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J /L ^ #Z /\
M^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !, _P 4 /\ &@#_
M "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_ (4 _@"+ /T
MD0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\ \P#N /\ [0#_
M .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0 /\ %@#_ "(
M_P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\ \P"& /$ C #O
M )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#? /L W@#_ -T
M_P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\ $@#_ !T _P I
M /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"  ., A@#A (P
MWP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8 R@#_ ,H _P#)
M /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_ !8 ]P B .\
M, #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -  @ #. (< S "-
M ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^ +D _P"X /\
MN #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1  Z  : ., * #=
M #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_ ($ O0"( +L
MCP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%_P"J!O\ J0;_
M *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2 -0#( #-!"T
MR 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L KPB" *X)B@"L
M"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<#_\ FP__ )L/
M_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+%@# #24 N@XR
M +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%] *$1A0"?$HX
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MF &!):0!@":R 7XFQ0%])^(!>R?W 7DH_P%X*/\!>"C_ 7@H_P%X*/\![RL
M -TS  #*.0  OCL  +0Z  "M-@  IB\  *$H!P";)Q, EB@@ )$I+0".*C@
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M V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L  ,=#  "Y20
MKDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L <CPU &\]/@!M
M/48 :SU- &D]4P!H/5H 9CUA 60]:0%C/7(!83U] F ]B0)>/98#73ZE UL^
MM@1:/LP$6C_L!%D__@-9/_\#63__ ED__P)9/O\"UC\  ,-'  "U3   JE
M *!0  "73P  CDL  (1%  !Z0 8 =3\1 '% ' !M0"@ :T$R &E!.P!G04(
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M!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L  )A<  ".7
M@UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H 5$U! %-.2 !2
M3D\ 4$Y7 4].7P%-3F@!3$YS DI/?P))3XT#1T^=!$9/K@1%3\,$1%#D!$1/
M^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX  )5@  "+8   @%X
M ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C< 3U(_ $Y21@!-4TT
M3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1 5,$$/U3B!#]4^ -
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M C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP  &=I  !<9@
M460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4 .V1- #ED50 X
M9%\ -F1I 35D=@$S9(4!,665 C!EIP(O9;L"+F7: BYD] (N8_\"+V/_ B]B
M_P(O8O\"LUX  *=F  "<;0  DW$  (AS  !]<P  <G(  &1P  !8;@  36P
M $)J P \:0X .FH6 #EJ(  X:B@ -FLQ #5K.0 T:T$ ,VQ) #)L4@ Q;%P
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M:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[_P 7>_\ I'(
M )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@  #*(   HB
M((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP $HM8 !&+90 0
MBW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .AO\ GWL  )2!
M  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2   ADP  &90
M !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0  :77@ %EVX
M Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\ F((  (Z(  "%
MC   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9G@  $J    VB
M @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D5@  I&4  *-W
M  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H  (F.  ![D@
M;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@  #*P   6N
MKP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3   LEL  +)L  "R
M@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5  !QF@  8Y\
M %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@   "[    NP
M +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\  ,-@  ##=
MPXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !EHP  5Z@  $FM
M   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'    R    ,D
M  #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3  #99@  V7P
M -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K   2[(  #RW   N
MN@  (;T  !7    -Q   !<<   #*    S@   -(   #5    U@   -D   #;
M    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N5@  [VL  .^$
M  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP  "_    @Q
M%,@   S,   "T    -0   #9    W@   .(   #E    Y@   .@   #I
M[    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@  _UH  /]Q  #_
MB0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\ '0#_ "@ _P W
M /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+ /\ D0#_ )<
M_P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\ ]P#_ /< _P#W
M /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_ "0 _P R /\
M/P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H C #Y )( ^ "8
M /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_ .D _P#I /\
MYP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\ _P L /\ .@#_
M $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L (T Z@"3 .D
MF@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -< _P#5 /\ U0#_
M -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F /< - #T $
M\@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (< V@"- -8 E #4
M )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P## /\ PP#_ ,,
M_P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H +0#F #H X@!%
M -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"' ,0 C@#" )8
MP "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\ L@#_ +$ _P"Q
M /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3 #( S@ ^ ,H
M20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0 B "R )  L "9
M *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_ *( _P"B /\
M_Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H OP W +L 0@"W
M $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D (L H@"4 *
MG@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)_P"4"?\ _!$
M /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N *X(.@"J"40
MIPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8 E@R0 )0,F@"2
M#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'$?\ ]AD  .<@
M  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0,P"=$3X FA%'
M )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+ (<4E@"&%:(
MA!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\ [R$  -TI  #*
M+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1&C@ CAI! (L;
M20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>D0!Z'IX >!^K
M '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@  -(P  #"-0
MMS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C( @R,\ ($C1 !^
M(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$FC0!O)ID ;B:G &TG
MN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X  ,LV  "\.P  L3T
M *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T >2HW '<J/P!U*D<
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M E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P  )I,  "12P
MAT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP 73I# %LZ2@!:
M.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K )./L$"33[A DT^
M^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1  ".3P  A$L
M 'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY  %4_1@!4/TT
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M 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD  &U3  !B3P
M5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8 1$Q. $--5@!"
M35\ 0$UJ #]-=@$]3H0!/$Z4 3M.I0$Y3[D".4_4 CE/\@$Y3O\!.4[_ 3E-
M_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA  "#80  >%X  &E8  !?5@  5%(
M $Q/"P!)3Q( 1U < $50)0!#4"T 0E U $%1/ ! 440 /U%, #Y25  \4ET
M.U)G #I2<P X4X(!-U.2 353I $T4[<!,U31 3-3\0$T4_\!-%+_ 312_P$T
M4O\!ME(  *E:  ">8   E&0  (MF  " 90  =&,  &9>  !<7   45@  $=5
M!P!"51  0%48 #]6(0 ]5BH /%8R #M6.0 Z5T$ .5=) #A740 W6%H -5AE
M #18<0 R6( !,5B0 2]9H@$N6;4!+5G/ 2U9[P$N6/\!+E?_ 2Y7_P$N5O\!
MLE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@  35\  $-= @ \
M6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P7E< +UYB "U>
M;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=_P$H7/\!K5P
M *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<  #]E   U8PD
M,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950 )V5? "9F:P D
M9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A8_\!J6(  )YJ
M  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN   P;0, *6P-
M "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY; !UN9P <;G8
M&FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\ I&D  )IQ  "0
M=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K=P  (G8' !UV
M#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X8P 2>'( $7B#
M !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$  )5X  "+?
M@G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@  '((  !2""0 1
M@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )@VP "(-^  :#
MD0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^  "&@P  ?84
M &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X   ^/ P *D P
M!I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4  (]V  "/B@
MCI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""B0  =(P  &:/
M  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;   "G D  )P.
M  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN  "<@0  G)<
M )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD   :I0  %R7  !/
MF@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H    J00  *D*  "I
M#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L=P  JXX  *ND
M  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP  %&@  !$I
M-J8  "JH   >J0  %*L   VN   &L    +(   "U    M0   +4#  "V"0
MMPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P  O8$  +V9  "]
ML   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J   XK0  *J\
M !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,   #$    Q@8
M ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,  -*+  #2I
MT[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   JM@  ';D  !*\
M   *OP   ,,   #&    R0   ,T   #/    T    -(   #4    U@   -D"
M  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\  #KE0  ZZP
M .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P   $<0   G(
MS    ,\   #3    V0   -T   #@    X0   .,   #E    YP   .H   #L
M    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_@P  _YL  /^N
M  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T /\ 00#_ $T
M_P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ), _P"9 /\ H #_
M *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0
M_P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N /\ / #_ $@ _P!3
M /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *(
M\0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4
M /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\ -@#_ $( ^P!. /<
M5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP". .4 E0#C )P X0"D
M -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\
M_P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P #P [0!' .D 40#E
M %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D
MJ #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(
M /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0
MS0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U
M *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P _P"K /\ _P0  /\
M  #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5
M +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H J0"2 *< G "E *8
MHP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P"; /\ _P<  /8)  #I
M"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +, /0"P $8 K0!/ *H
M5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N
M ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0
MS14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B #\ H !( )T!4 ";
M E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'
MN@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14  . =  #-(   P2$
M +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5
MC U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z
M$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH
M  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[ (030P""%$L @!11
M 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D
M;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?
M+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<
M4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D
M &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.   JCD  *$X  "8-0
MD"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H
M)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI
M]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\  )P_  "3/   BC8
M ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$
M7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2
M+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$  "/00  A3P  'LW
M  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4
M %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\
M3#3_ $PS_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+1P  @4(  '<]  !M
M-P  9#() & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T
M60!/-6$ 335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_
M $8X_P!&-_\ P3X  +)%  "F2@  G$T  ))-  "(2P  ?D<  '-"  !I/0
M7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!)
M.5\ 2#II $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\
M_P%!//\ OD(  *])  "C3@  F5   (]1  "%4   >TP  &]&  !E0@  6CT"
M %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP
M0SYG $(_<P! /X$ /S^1 #Y H@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]
M/_\!ND4  *Q,  "A40  EU0  (U5  "#5   >%$  &Q+  !A1P  5D(  $]
M# !,/Q, 24 < $= ) !&0"P 1$ S $- .@!"04( 04%) $!"40 _0EH /D-E
M #U#<0 [0W\ .D2/ #E$H  X1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\
MMTD  *E0  ">50  E%@  (M9  " 6   =E8  &A0  !=3   4T@  $I%"0!&
M1!$ 1$09 $)$(@!!12D /T4Q #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(
M;@ V2'P -4B- #1)G@ S2;$ ,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P
M *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@  4$X  $9*!0! 20X
M/DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q
M37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18
M  "970  CV$  (9B  ![80  <%\  &);  !86   3E4  $-1 0 [3PP .$\3
M #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@
M*5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G4?\ K%4  *!<  "6
M8@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8   U5@@ ,540 #!6
M%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA: "589P D6'4 (UF&
M "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\ J%H  )UB  "39P
MBFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q7@, *ET- "A=$P F
M71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@
ME0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&   )EH  "0;@  AG
M 'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P  (V8( !]F#P =9A4
M'&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0
M:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX
M  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7
M !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$
M!G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F
M?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\!  ,? P "GP1  E\
M&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ
M  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@   >8,  &R$  !>A0
M488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &B0H  8D/  ")%
MB!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(@0  AY4  (>K  "&
MQ   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D  &.+  !6C0  28\
M #R1   PD0  ))$  !J2   2DP  #90   :5    E@8  )8,  "5$   EA4
M )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>   E8X  )6D  "4O
MD]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4  !,EP  /YD  #*:
M   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'  "C#   HQ   *05
M  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80  *6;  "DLP  H]
M */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;
MI0  $:<   JI   !JP   *T   "O    L    +    "P!0  L0L  +(/  "S
M%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D
M  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0  )JL  !JM   0KP
M";(   "T    MP   +H   "\    O0   +X   "^    P (  ,$(  #"#0
MQ!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,G   R[4  ,S.  #,
MZ0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4  !"X   'NP   +X
M  #!    Q    ,@   #+    RP   ,T   #.    T    -(   #5 P  V H
M -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0  YJ4  .:\  #FTP
MY^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$    QP   ,L   #/
M    U    -@   #<    W0   -\   #A    XP   .4   #H    Z@   .T&
M  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4  /RJ  #\NP  _<L
M_P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_
M &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H
MM0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P ,
M /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$
M_ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O )T [0"E .P KP#J
M +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\
M 0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C
M .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )< W "? -D J0#6 +0
MTP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^ /\ _P   /\   #_
M    _P   /L "P#V !, \0 @ .T + #J #@ YP!# ., 30#@ %8 W != -D
M9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[
M +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\ _P   /\   #_
M]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#!
M &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$ G "O *< K0"S *L
MQ0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P   /P   #Q    Z
M .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@ M0!0 +, 5P"P %X
MK@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"? *$ G0"M )H O "8
M -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %  #C!P  U04  ,P
M  #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!* *, 40"A %< GP!=
M )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L C@"G (P M@"* ,D
MB #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1$@  Q1$  +T.  "V
M"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4 2@"3 %$ D0!7 (\
M70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A
M 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P
MI T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!
M!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-
M]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28  *@D  "@'@  F1@
M ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@
M<P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C
M%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M  "8*   D"(  (D;
M  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99
M &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\
M61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y
M'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=
M7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_
M %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.   @S(  'HM  !R)@
M:B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4
M)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH
M_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD  '4S  !L+0  8R<(
M %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T
M3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%
M+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K
M#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D
M $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\
MNSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C.0  6C0  %(P# !/
M,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T
M;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT
M *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@  5CD  $TU"0!)-!$
M1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y
M.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*
M  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6
M #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7<
M,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P/O\ L4<  *1-  "9
M4@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5  P _/@T /#X3 #H^
M&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*%
M "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\ KDH  *%1  "75@
MC5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z0PH -D,1 #1#&  S
M0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&9  I1W( *$># "9'
ME0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\  )]5  "46@  BUX
M (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@< ,$D. "Y)%0 M21T
M+$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?
M3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:  "27P  B&,  'YD
M  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @
M "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT &E-] !E3D  84Z0
M%E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q
M:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8
M(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ !):C0 16J$ $%JW
M  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P  @FT  'AN  !N;P
M8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 2
M8"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MBB0 *89T "6&R  AA
MRP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,  '5U  !J=   7',
M $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$
M"FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA   :I@  &JM  !IQ@
M:><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![  !C>P  5GH  $EZ
M   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/  !V%0  =AP  '8D
M  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),  '2H  !SP   <^,
M '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;@@  3H(  $&"   U
M@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""$0  @A<  ((>  ""
M)@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B  !_N@  ?]T  '[T
M  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@  18L  #F,   LC
M(8P  !>,   0C0  "8X   */    D ,  (\)  "/#@  CQ(  ) 8  "0'P
MD"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".LP  C=   (SP  "+
M_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<
M  ^8   (F0   )L   "=    G0   )T#  "="0  G0T  )X1  ">%P  GQ\
M )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP  G<8  )WI  "<^0
MG/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?   7H   #J(   >D
M    I@   *@   "J    J@   *H   "K 0  JP<  *P,  "M$   KA8  *\>
M  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H  *_=  "O\@  K_T
M>)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .JP  !:X   "P
ML@   +4   "W    MP   +@   "Y    N@   +P#  "]"0  O@X  , 4  ##
M'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D
M %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP   +H   "]    P
M ,0   #&    Q@   ,@   #)    RP   ,P   #.    T 8  -,-  #8$P
MW!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G
M  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<   #*    SP   -,
M  #6    UP   -H   #<    WP   .$   #C    Y@   .D!  #L"P  \!(
M /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN   ^,D _P - /\ "P#_
M  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\
M<0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2
M /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\ _P ' /\ ! #_  (
M_P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U
M '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@ JP#F +8 Y #' .(
MXP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P   /\   #_    _P !
M /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %< Z0!> .8 90#D &P
MX@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#)
M .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\   #_    _@   /<
M"0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K
M ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@ N0"V +< R "U .8
MLP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z    \0   .@  P#@
M  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T 60"Z %\ N !E +<
M:@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N *4 O@"B -@ H #R
M )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K    X0   -8   #+  D
MQ0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D
M &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0 M@"2 ,H D #I (\
M_ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $  ,0   "]  ( M@ -
M +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %( F !8 )8 70"5 &,
MDP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_
M /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+  "O P  J0 ' *,
M$ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C
M (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L = #4 '( \ !R /\
M<@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C$   G0H  )<!"@"1
M !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8
M9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_
M &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT
M@ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H
M"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0
M_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\  ((8  ![$04 =0T/
M '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T 81!3 %\16@!>$6(
M7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2
M%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3
M$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G
M %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\
MP2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;
M&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>
M;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(
M *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@  7B0" %<@#0!4(!0
M42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!"
M)'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]
M  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H  %$E"P!-)1$ 2R49
M $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78
M.RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<
M1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J
M'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^#
M #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\ L3X  *1$  "92
MCTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [
M+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\T
MDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$  *)(  "73   C4X
M (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL .3,1 #<S&  V,Q\
M-#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H
M.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+  "43P  BU(  (%3
M  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D
M "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:(
M(CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "24P  B58  ']7  !U
M5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]$P K/1H *CXA "D^
M*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U
M !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06   AEL  'U<  !R6P
M9U@  %M4  !14@  2$X  #U*   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B
M1"P (40T "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(
MS@ 51^\ %D?_ !=&_P 71O\ HE(  )=8  "-70  A&   'IA  !P8   95X
M %E:  !/6   1%0  #E1   O3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@
M&DLP !E+.  72T( %DQ, !5,5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /
M3>X $$W_ !%,_P 13/\ GE<  )1=  "+8@  @64  '=F  !M9@  8V0  %9A
M  !*7@  /UL  #58   K5@  (E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L
M !%2-  14CX $%-(  ]35  .4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.<
M"E/[  M2_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K;   7VH  %)G  !%
M9   .F(  #!@   F7@  '5T  !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;
M,  *6SH "5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH  !;P   6N(  %KV
M  %:_P "6?\ EV0  (YK  "$;@  >W   ')R  !G<0  67   $QN  ! ;
M-6L  "II   A9P  &&8  !%F 0 ,90H !V4/  1E%  #9!L  F0C  !D+
M9#4  &1   !D3   9%H  &1I  !D>P  9(\  &.D  !CNP  8MT  &+T  !B
M_P  8?\ DVP  (EQ  " =0  >'<  &UX  !@=P  4G8  $9U   Y=   +G0
M "-R   :<0  $G$   UQ   &<0@  ' -  !P$@  <!<  &\?  !O)@  ;S
M &\[  !O1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P
M:_\ CG,  (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\
M   3?   #7P   9]    ?04  'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT
M  ![0   >TX  'M>  ![;P  >H0  'J:  !YL0  >,X  '?O  !V_@  =O\
MB7H  (%_  !X@@  :X,  %V%  !/A@  0H<  #6(   IAP  '8<  !2'   -
MB   !HD   "*    B@   (D&  ")#   B0\  (D3  ")&@  BB(  (HL  "*
M.   BD8  (E6  "):   B7P  (B4  "'JP  AL8  (7J  "%^P  A/\ A8(
M 'V&  !OB   88L  %.-  !%CP  .)$  "N1   ?D@  %)(   V3   $E
M )8   "7    F    )<   "7!0  EPL  )@.  "8$P  F1H  )DB  ":+@
MFCT  )E-  "97@  F7,  )B+  "8HP  E[P  );B  "6]P  E?\ @(D  '*,
M  !DCP  5I,  $B6   ZF0  +)H  !^;   4G   #)X   .?    H0   *,
M  "E    I0   *4   "E    I@(  *<(  "G#0  J!$  *D9  "K(P  JS$
M *M!  "L4P  K&<  *N   "JF@  JK,  *K0  "I[P  J?L =8\  &>4  !9
MF   2IP  #R?   MH@  (*,  !.E   +IP   :D   "K    K@   +$   "R
M    L@   +,   "T    M0   +8   "X!   N0L  +L0  "]&   OR0  +\U
M  # 1P  P%L  ,!R  # C0  P:8  ,#!  "_XP  OO, :I<  %N<  !-H0
M/J4  "^I   AJP  $ZT   NP    LP   +4   "X    O    +\   #!
MP0   ,,   #$    Q@   ,<   #)    RP   ,X(  #1#P  U1@  -@G  #9
M.0  VDT  -MD  #;?@  W)D  -RP  #<R0  W., 79\  $^E  ! J@  ,J\
M "*R   4M0  "K@   "[    OP   ,,   #&    RP   ,X   #1    T0
M -0   #6    V0   -L   #>    X    .0   #G!@  ZPX  .\9  #P*@
M\C\  /-5  #T;0  ](@  /2A  #TM@  ],< _P ) /\ !@#_  < _P , /\
M$0#_ !P _P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X
M /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D \0#+ /  Z #N /L
M[0#_ .P _P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_    _P $ /\ #@#_
M !< _P C /\ +P#_ #L _0!& /H 4 #W %@ ] !? /( 9@#P &P [P!R .T
M> #L 'X Z@"% .D C #G ), Y0"< ., I@#A +$ WP#! -T W0#; /0 V0#_
M -8 _P#/ /\ Q #_ +T _P"Y /\ _P   /\   #_    _P   /\ "P#\ !,
M]P > /0 *@#R #4 [@!  .D 2@#F %( XP!9 .  8 #> &8 W !L -H <@#7
M '@ U !^ -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4 S0## .L P #^ +\
M_P"^ /\ M@#_ +  _P"M /\ _P   /\   #_    ^0   /( !@#K  \ Y@ 9
M .$ ) #> "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$
MOP!W +T ?@"[ (8 N0". +< F "U *, LP"P +$ P@"N .  K #W *L _P"J
M /\ J #_ *, _P"@ /\ _P   /\   #U    ZP   .$   #6  P SP 3 ,H
M'@#& "D P@ S +\ /0"[ $4 N !- +8 5 "S %H L0!? +  90"N &H K !P
M *L =P"I '\ IP"' *4 D0"C )P H "I )X N "< ,X F@#N )D _P"7 /\
ME@#_ )8 _P"3 /\ _0   /$   #E    V0   ,T   #$  8 O0 / +< & "S
M "( L  L *T -@"I #X IP!& *0 30"B %, H !9 )\ 7@"= &0 FP!J )H
M< "8 '< E@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_
M (8 _P"& /\ \P   .,   #1    Q0   +T   "V    K@ + *@ $@"D !P
MH  F )P +P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"(
M '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '<
M_P!W /\ YP<  -$,  ###0  N P  *X(  "H    H@ % )L #@"6 !4 D@ ?
M (X * "+ #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L
M> !S '8 ?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J /P :@#_ &H _P!J
M /\ VA   ,84  "X%@  K14  *02  "<#@  E@<  )  "0"* !  A0 8 ($
M(0!^ "H >P R 'D .0!W $  =0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N
M &D =P!G (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\
MSA@  +T=  "P(   I1\  )L<  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R
M ", ;P K &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%
M<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\
M +8E  "I*   GB@  )0E  "+(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T
M9 HE &(*+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2
M#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K
M  "D+P  F2\  (\M  "&*0  ?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ?
M %@0)P!6$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@
M2!.' $83EP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@
M-   E34  (LT  "!,0  >"L  &\F  !F(   7AD! %<4#0!4%!, 410; $\5
M(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F#
M #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\ M3   *@V  "<.0
MD3L  (<Z  !^-P  <S(  &HM  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&
M&B8 11LM $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?
MD@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\
M (4_  ![/   <#@  &<R  !=+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R(
M/B I #T@,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q
M):( +R6V "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^  "60@  C$,  ()#
M  !X00  ;CT  &,X  !:,P  42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F
M #8D+  U)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J
M*BJT "DJSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "41@  BD<  (!'  !V
M10  ;$(  &$]  !7.   3C,  $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H
M*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS
M "0OS0 D+^X )2__ "4O_P F+O\ J3\  )U%  "220  B$L  'Y,  !T2@
M:D<  %Y"  !4/0  2SD  $$T   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J
M+BX *2XU "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XS
MRP >,^T 'S/_ " S_P A,O\ ID,  )I)  "030  AD\  'Q0  !S3P  :$P
M %Q&  !20P  23\  #\[   V-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL
M)#,R ",T.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9
M..L &CC_ !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4  !Q4P  9E   %I,
M  !020  1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P
M !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D
M%#S] !4\_P 6._\ H$L  )51  "+50  @E@  'E9  !N6   9%8  %A1  !.
M3P  14L  #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_
M-0 6/SX %3]( !1 4P 30&  $D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\
M !!!_P 00/\ G5   )-6  ")6@  @%T  '9>  !L70  8EL  %97  !,50
M05$  #9.   L2P  (T@  !M%"0 71 \ %404 !1%&P 312( $D4I !%%,0 1
M13L $$9%  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&
M_P +1O\ FE4  )!;  "'8   ?6(  '-C  !J8@  8&$  %->  !'6@  /%<
M #)5   H4@  'U   !=.!  13 P #TP1  Y,%P .3!X #4TE  Q-+@ +33<
M"DU"  E-30 '3EH !DYI  1.>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "
M3/\ EEL  (UB  "$9@  >F@  '%I  !H:0  7&<  $]D  !"80  -U\  "U<
M   C6@  &E@  !)7 0 -5@D "54.  =5$P &51H !%4B  -5*@ "530  %4^
M  !52@  5E<  %9E  !5=P  58L  %6@  !5M@  5-0  %3Q  !3_0  4_\
MDV(  (IH  " ;   =VX  &]O  !C;@  5FP  $EJ   ]:   ,F8  "=E   =
M8P  %6(   YA   )8 @  V -  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?
M10  7U,  %]A  !><@  7H<  %V<  !=L@  7,\  %SO  !;_0  6_\ D&H
M (9O  !]<@  =70  &IU  !==   3W,  $)R   V<   *V\  "!N   7;0
M$&P   IL   ":P8  &L+  !J#P  :A0  &H:  !J(0  :2H  &DT  !I0
M:4X  &E<  !I;0  :((  &B8  !GK@  9LH  &7M  !E_   9/\ BW$  ()V
M  !Z>0  <'L  &)[  !5>P  2'H  #MZ   O>@  (WD  !EX   1=P  "G<
M  -W    =P(  '<(  !V#0  =A   '85  !V&P  =B,  '8N  !U.@  =4<
M '56  !U:   ='P  '22  !SJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V
M?P  :($  %J"  !,@@  /X,  #*$   E@P  &H,  !&#   *@P   H,   "$
M    A0   (0#  "#"   @PT  (,0  "#%0  A!P  (0F  "$,@  A#\  (-/
M  "#8   @G4  (*,  "!I   @+T  '_C  !^^0  ?O\ @H   'J$  !LA@
M7H@  %"*  !"BP  -8T  ">-   ;C0  $8X   J.    CP   )$   "2
MD@   )(   "2 0  D@<  )(,  "2$   DQ4  ),=  "4*   E#8  )1%  "3
M5P  DVL  )."  "2G   D;8  )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y
M $63   WE0  *98  !R7   1F   "9D   ";    G    )X   "@    H
M *    "@    H0   *$$  "B"0  HPX  *04  "E'0  IBH  *8Z  "F3
MI6   *5X  "ED@  I*P  *3)  "CZP  HOH <XX  &21  !6E0  1YD  #F<
M   JG@  ':   !&A   (HP   *4   "G    J0   *P   "N    K@   *X
M  "O    L    +$   "R    LP8  +4-  "W$P  N1X  +DN  "Z0   NE0
M +MJ  "ZA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =
MJ   $:H   >L    KP   +$   "T    N    +L   "\    O    +X   "_
M    P    ,(   #$    Q@   ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=
M  #4=@  U)(  -6K  #5Q   U.( 6YT  $RB   ]IP  +ZP  !^O   1L0
M![4   "X    NP   +X   #"    QP   ,H   #,    S    ,X   #0
MT@   -4   #8    VP   -\   #B    Y@L  .L3  #L)   [3@  .Y.  #O
M9P  \((  /"<  #PL@  \<4 _P # /\  0#_  0 _P ) /\ #P#_ !@ _P D
M /\ , #_ #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\
M]@"% /4 C #S )0 \@"= /  IP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9
M /\ RP#_ ,( _P"] /\ _P   /\   #_    _P   /\ # #_ !0 _P @ /\
M*P#^ #< ^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_
M ., A@#A (X WP"6 -T H #; *P V "[ -0 T0#3 /  T #_ ,X _P#( /\
MO0#_ +8 _P"R /\ _P   /\   #_    _P   /T " #W !  \P : .\ )@#M
M #$ Z  [ ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L
M?P#) (< QP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_
M *D _P"E /\ _P   /\   #^    ]0   .P  P#E  T WP 5 -H ( #4 "H
MT  U ,L /@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z &P N !R +8 > "U
M (  LP"( +$ D@"N )X K "J *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L
M_P"8 /\ _P   /L   #P    Y0   -@   #.  D QP 1 ,( &@"^ "0 NP N
M +< . "T $  L0!( *X 3@"L %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@
MH "! )X BP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+
M /\ ^0   .L   #=    SP   ,8   "\  0 M0 - +  %0"L !X J  H *4
M,0"B #D GP!! )T 2 "; $X F0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z
M (P @P"* (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\
M[    -H   #)    O@   +8   "N    IP ) *$ $ "< !@ F  B )4 *@"2
M #( D  Z (T 00"+ $< B0!- (< 4@"& %@ A != (( 9 "! &L ?P!S 'T
M?0![ (@ > "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_ '  _P!P /\ WP4
M ,H*  "\"P  L0D  *@$  "A    FP # )0 # "/ !, B@ ; (< ) "$ "P
M@0 S '\ .@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L
M (( :@"/ &D G0!G *X 90## &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2
M  "R$P  IQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5 'H '@!V "4 =  M
M '$ - !O #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P
M7@") %P F !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J
M'0  GQP  )49  "-%   A0\  'X)  !W 0H <@ 0 &X %P!J !\ :  G &4
M+@!D #0 8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"%
M %( E !0 :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\ OQT  + B  "C)0
MF24  (\B  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9
M!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)
MD@!'"J, 10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P
M (HJ  " )@  =R$  &X;  !F%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D
M30PO $P,-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^
M$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q
M  !\+0  <B@  &DC  !A'0  618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K
M $,1,0!"$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\
M-16S #05S0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X
M-   ;BX  &4J  !<)   5!X  $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5
M+0 [%30 .18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ
M "T;R@ M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P  BCP  ( \  !V.0
M:S0  &(O  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T
M&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>B  I'YL *!^N "<@
MQP F(.H )R#^ "@@_P H(/\ J38  )T\  "2/P  AT$  'U   !T/@  :3H
M %\U  !6,   32L  $0E   [( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT
M+1\T "P@.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A
M)>@ (B7] "(D_P C)/\ ICH  )H_  "/0P  A44  'M$  !R0P  9S\  %TZ
M  !3-@  2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q
M "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8
M'"G[ !TI_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P1P  9D0  %H_  !1
M.P  1S<  #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I
M-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ
M !@M_P 9+?\ H4$  )5'  "+2P  @DT  'A-  !N3   9$D  %A$  !/0
M1CT  #TX   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;
M+CP &B]& !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q
M_P 3,?\ GD4  )-+  ")3P  @%$  '92  !M4   8DX  %9)  !-1@  1$,
M #L_   Q.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H
M%#1$ !,T3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /
M-O\ FTD  )%/  "'4P  ?E8  '56  !J50  8%,  %5/  !,3   0DD  #A%
M   N00  )#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!
M  XZ3  -.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4 "#SP  D[_P *._\
MF$X  (Y4  "%6   ?%L  ');  !H6@  7E@  %-5  !)4@  /DX  #1+   J
M1P  (40  !A" P 20 L $#\0  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!
M2@ '058 !D%E  1!=@ #08H  4&?  !!M   0=   4'N  %!_  "0/\ E50
M (Q9  "#7@  >6   '!@  !F8   75X  %%;  !%5P  .E0  "]1   E3P
M'$P  !1*   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #2#$  D@[  !(1P
M2%,  $AB  !(<P  2(8  $B;  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@
M  " 8P  =V4  &YF  !E9@  660  $Q@  ! 70  -5L  "I9   @5P  %U4
M !!3   +4@< !5$-  %0$0  4!8  % =  !0)0  4"X  % X  !00P  4%
M %!>  !0;P  4(,  $^8  !/K@  3LD  $[K  !-^P  3?\ CV$  (9F  !]
M:0  =&P  &QM  !A:P  4VD  $9G   Z9   +V,  "1A   :7P  $EX   Q<
M   &7 8  %L+  !:#P  6A,  %H9  !9(0  62D  %DS  !9/P  64P  %E:
M  !9:P  6'X  %B4  !7JP  5\4  %;I  !5^P  5?\ C&@  ()M  !Z<
M<G(  &=R  !:<0  3'   #]N   S;0  *&L  !UJ   4:   #6<   =G
M9@,  &8)  !E#0  91$  &05  !D'   9"0  &0N  !D.@  8T<  &-5  !C
M9@  8WH  &*0  !AIP  8,$  %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@
M &!X  !2=P  17<  #AV   K=@  ('0  !9S   .<P  !W(   !R    <@
M '$%  !Q"@  <0X  ' 1  !P%P  <!X  ' G  !P,P  ;T   &]0  !O8
M;G0  &Z+  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[  !S?0  97X  %=_
M  !)?P  /'\  "^    B?P  %WX   ]^   '?@   '\   !_    ?P   'X
M  !^!0  ?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T
M 'R$  ![G   >K8  'G:  !X]0  =_\ @'\  '>"  !I@P  6X4  $V&   _
MB   ,HD  "2)   8B0  #XD   >*    BP   (P   "-    C0   (P   ",
M    C ,  (P(  "-#0  C1$  (T7  ".(@  CB\  (X_  "-4   C60  (Q[
M  ",E0  BZX  (K-  ")[P  B?\ >X4  &V(  !>B@  4(T  $*/   TD0
M)I(  !F3   .E   !I4   "6    F    )H   ";    FP   )L   ";
MFP   )P   "=!0  G0L  )X0  "?%P  H"0  * T  "@1@  H%D  )]P  "?
MB@  GJ4  )["  "=Z   G/D <(P  &&/  !3D@  1)8  #:9   GFP  &9P
M  ^=   %GP   *$   "C    I0   *@   "I    J0   *D   "J    JP
M *P   "M    K@$  + )  "R#P  LQ@  +0G  "T.0  M4T  +1D  "T?@
MLYH  +.T  "SU0  L_  9),  %67  !'FP  .)\  "FB   :I   #J8   2H
M    JP   *T   "P    M    +8   "X    N    +D   "Z    O    +T
M  "_    P    ,,   #%!P  R0\  ,H:  #++   S$   ,U6  #.;P  S8L
M ,RH  #,P@  S.( 6)L  $F@   ZI0  +*D  !RK   /K@  !+$   "T
MMP   +H   "^    PP   ,8   #(    R    ,H   #+    S0   ,\   #2
M    U0   -D   #=    X04  .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7
M  #LK@  [,( _P   /\   #_    _P & /\ #0#_ !4 _P A /\ + #_ #@
M_P!# /\ 3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O
M (\ [0"7 .L H0#I *T YP"] .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P
M_P"V /\ _P   /\   #_    _P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ]
M /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ', WP!Y -T @ #: (@
MV "1 -0 FP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K
M /\ _P   /\   #_    _P   /@ !0#R  X [@ 7 .H (@#F "P X0 W -T
M0 #8 $D TP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "*
M +X E "\ )\ N0"L +8 O@"T -T LP#W +$ _P"P /\ J #_ *( _P"> /\
M_P   /\   #Y    [P   .8   #?  L U@ 2 -  ' #, "8 R  P ,0 .@#
M $( O0!* +L 4 "X %8 M@!; +4 80"S &8 L0!L +  <@"N 'H K "" *D
MC "G )@ I0"E *, M "@ ,L GP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P
M /8   #J    W0   ,\   #'  8 P  / +L %P"W "  LP J +  ,P"M #L
MJ@!# *< 20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4
M )  D@"= )  K ". +\ C #B (L ^@") /\ B0#_ (8 _P"# /\ ]    .0
M  #4    R    +\   "U  $ K@ + *D $@"E !L H0 C )X + "; #0 F  \
M )8 0P"4 $D D@!. )  4P". %D C0!> (L 9 ") &L AP!S (4 ?0"# (@
M@0"5 '\ I !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U /\ Y0   -$   ##
M    N    *\   "H    H  & )H #@"5 !4 D0 > (X )@"+ "T B  U (8
M/ "$ $( @@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0".
M &\ G0!M *X ; #$ &H YP!I /T : #_ &@ _P!I /\ U0,  ,,'  "V"
MJP8  *(   ";    E    (T "@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U
M #L = !! '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &< < !E 'L 8P"( &(
MEP!@ *< 7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T  +D0  "L$0  H1
M )<-  "/"   B    (( !0![  T =P 2 ', &@!O "$ ;  H &H +P!H #4
M9P [ &4 00!C $8 8@!, &  4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4
M *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6
M  "'$0  ?PT  '<&  !Q  @ :P . &< % !D !L 80 B %X *0!= "\ 6P U
M %D .P!8 $$ 5@!& %4 30!3 %0 4@!< %  90!. '  3 !] $L C0!) )X
M2 "P $< QP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">(@  DR(  (D?  "
M&@  =Q4  &\0  !H"P  800* %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\
M-0!. #L 3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M
M #T$Q  \!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0  CBD  (0G  ![(P
M<1X  &D8  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$
M!S8 0P@] $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,
MP@ S#.0 ,PWY #,-_P T#?\ K2<  * L  "5+P  BR\  ( N  !W*@  ;24
M &0@  !<&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3(
M.@TX #@-/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K
M$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT  !T,0  :BL  & G
M  !8(0  3QL  $<6  ! $0D .Q / #D0%  W$!L -A A #00)P S$2T ,A$T
M #$1.P P$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>,
M)1;Z "86_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4
M*   3"(  $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5
M.  I%D  *!9* "<75  F%V  )!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX
M " :_P @&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P  93<  %LR  !2+0
M22@  $ C   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C
M&CX (AM' "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?
M_P ;'O\ H3@  )4]  "+00  @4(  '="  !M0   8SP  %DW  !/,P  1BX
M #TI   U)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL
M'1]% !P@3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6
M(_\ GCP  )-!  ")1   ?T8  '5&  !L1   8D$  %<\  !-.   1#0  #PP
M   S*P  *B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1"
M !8E30 5)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\
MG$   )%%  "'2   ?4H  '1*  !J20  8$8  %5!  !,/@  0SH  #HV   Q
M,@  *"T  " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I
M2P 1*E< $"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40
M (])  "%3   ?$X  '-/  !I3@  7DL  %-'  !*1   0D   #D]   O.
M)30  !TP!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -
M+U4 ##!C  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-
M  "#40  >E,  '%4  !G4@  75   %),  !)2@  0$8  #5"   K/@  (CH
M !HW 0 2- D #S,.  XS$P -,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5(
M!39@  0V<0 "-H0  #:9   VKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!
M5@  >%@  &]9  !E6   6U4  %%2  !'3P  /$P  #%(   G1   'D$  !8_
M   0/ < "SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>
M   \;@  /($  #R7   \K   .\4  #OG   [^   ._\ D5(  (A8  !_7
M=ET  &U>  !C70  6EP  $Y8  !"5   -U$  "U.   C2P  &DD  !)&   -
M1 8 !T,,  -#$   0Q4  $,;  !#(P  0RL  $,U  !#0   0TT  $-;  !#
M:P  0WX  $.4  !"J@  0L,  $'F  !!^0  0?\ CE@  (9>  !]80  <V,
M &MD  !B8P  5V$  $E=   ]6@  ,E@  "=5   >4P  %5$   Y/   )304
M DT+  !,#@  3!,  $L8  !+'P  2R@  $LR  !+/0  2TD  $M7  !+9P
M2GL  $J0  !)IP  2<   $CD  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ
M  !>:0  4&8  $-D   W80  +%\  "%=   86P  $%D   I8   #5P,  %<)
M  !6#0  51   %45  !4&P  5",  %0M  !4.0  5$4  %13  !49   4W<
M %.-  !2I   4;T  %#B  !0^   3_\ B&<  ']K  !W;@  ;W   &5P  !7
M;@  2FP  #UK   P:0  )6@  !IF   19   "V,   1B    8@$  &$&  !@
M"P  8 X  %\2  !?%P  7QX  %XH  !>,P  7D   %Y/  !>7P  77(  %V(
M  !<H   6[D  %K?  !9]P  6/\ A&X  'QR  !U=0  :W8  %UU  !/=
M0G,  #5S   H<@  '7   !-O   ,;@  !&X   !N    ;@   &P"  !L!P
M:PL  &L.  !K$@  :AD  &HB  !J+0  :CH  &E)  !I6@  :6P  &B#  !G
MFP  9K4  &78  !D]0  9/\ @'4  'IY  !P>P  8GL  %1\  !&?   .7P
M "Q\   ?>P  %'H   UZ   $>@   'H   !Z    >@   'D   !Y 0  > 8
M '@+  !X#@  >!,  '@:  !X)0  >#(  '=!  !W4@  =V4  '9\  !UE0
M=*\  '/.  !R\0  <?\ ?GT  '6   !G@0  6((  $J#   \A   +H4  "&%
M   5A0  #84   .%    A@   (<   "(    B    (<   "'    AP   (<$
M  "'"0  APX  (@3  "('   B"D  (@X  "'2@  AUT  (9S  "&C0  A:<
M (3%  "#[   @OX >(0  &J&  !<B   38H  #^,   QC@  (X\  !:/   -
MD    I$   "2    DP   )4   "6    E@   )8   "6    E@   )<   "7
M    EP<  )@-  "9$P  FA\  )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ
M  "7X@  EO@ ;8H  %^-  !0D   09,  #.6   DEP  %I@   V9   !FP
M )T   "?    H0   *0   "E    I    *4   "E    I@   *<   "H
MJ0   *H$  "L#   KA,  *XA  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "M
MS0  K.\ 89$  %.5  !$F   -9P  ":?   7H0  #:,   "E    IP   *H
M  "L    L    +(   "T    LP   +0   "U    MP   +@   "Y    NP
M +T   "_ 0  PPL  ,45  #%)0  QCD  ,=/  #':   QH4  ,:B  #&O
MQMX 59D  $>=   XH@  *:8  !FH   -JP   *T   "Q    M    +<   "Z
M    OP   ,$   #$    PP   ,4   #&    R    ,H   #-    SP   -(
M  #6    VP   . ,  #A&   XRL  .1!  #E6@  YG0  .:1  #EK   Y<0
M_P   /\   #_    _P ! /\ "@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z
M %  ]P!7 /4 70#T &, \@!I /  ;P#O '0 [0![ .L @0#I (D Z "2 .8
MG #D *@ X@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P
M /\   #_    _P   /\ !@#_  \ _  8 /@ (P#T "X \  X .L 0@#H $H
MY0!1 .( 6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#*
M *$ R "O ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\
M  #_    ^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R -, / #/ $0 S !+
M ,D 40#& %< Q != ,( 8@#! &< OP!M +T = "[ 'L N0"$ +< C@"T )D
ML@"G *\ MP"M -  JP#R *H _P"I /\ H0#_ )L _P"7 /\ _P   /\   #T
M    Z0   .    #5  @ S@ 0 ,D & #% "( P0 K +P -0"Y #T M@!% +,
M2P"Q %$ KP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\ *( A@"@ )( G@"?
M )P K@"9 ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\ _    /    #C
MU    ,@   "_  , N0 - +, $P"O !P K  E *D +@"E #8 HP ^ *  1 ">
M $H G0!0 )L 50"9 %H EP!? )8 9@"4 &P D@!U )  ?@". (H BP"7 (D
MI@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0   -T   #,    P0
M +@   "N    IP ) *( $ "> !< F@ ? )< )P"4 "\ D0 W (\ /0"- $,
MBP!) (D 3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U
M *\ <P#' '( [ !Q /\ < #_ '  _P!N /\ W0   ,D   "\    L0   *D
M  "A    F0 # ), # ". !( B@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!"
M 'D 2 !X $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L :@"( &@ EP!F *@
M90"\ &, X0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O!0  I0(  )P   "4
M    C0   (8 " "!  X ?  4 '@ &P!U ", <@ I '  , !N #8 ;0 \ &L
M00!I $< : !, &8 4@!D %D 8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T
M %8 T !5 /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P  FPX  )(+  ")!0
M@@   'L  @!U  L <  0 &P %@!H !T 9@ C &, *@!A #  8  V %X .P!=
M $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L
MQ@!* .H 20#^ $D _P!) /\ N1(  *H6  ">%P  E!8  (H3  "!$   >0L
M '$#  !K  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L
M4 !! $X 1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!# )< 00"I $  OP _
M .( /P#X #X _P _ /\ LAD  *0>  "8'P  CA\  (0<  !Z&   <A(  &H.
M  !B"   7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \
M $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ), . "E #8 N@ V -L
M-0#T #4 _P U /\ K"   )\D  "4)@  B28  '\D  !U(   ;!L  &05  !<
M$   5 P! $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"
M/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P
M "P(_P L"/\ J"4  )LJ  "0+   ABT  'LK  !R)P  :"(  %\=  !7%P
M3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q
M"4$ +PE) "X*4P L"EX *PML "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-
M_P E#?\ I"H  )@O  "-,@  @S(  'DQ  !O+@  92D  %PD  !3'P  2QD
M $,3   \$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T
M)PY& "8.4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >
M$?\ H2\  )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ  !0)0  2"   #\:
M   X%0  ,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%#
M " 23@ >$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\
MGC,  ),W  "(.@  ?CL  '0[  !K.   830  %<O  !.*P  128  #TA   T
M'   +1<% "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H6
M2P 9%E< %Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8
M )$[  "&/@  ?#\  ',_  !I/0  7SD  %4U  !,,   0RP  #HG   R(@
M*AX! "(9"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3
M&U4 $AMC !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_
M  "$0@  >T0  '%#  !H0@  7CX  %,Z  !*-@  03(  #DM   Q*0  *"4
M " @!@ :'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%,
M#B!A  TA<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#
M1@  >4@  '!(  !G1@  7$0  %(_  !).P  0#@  #@T   O,   )RP  !XG
M P 6(PH $B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>
M  DF;P ')H( !B:6  0FK  #)L0 !";E  0F]P &)O\ E4(  (I'  "!2@
M>$P  &],  !E2P  6T@  %!$  !'00  /SX  #<[   M-@  )#$  !LM   3
M*@< #R@-  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K
M;  !*W\  "N4   KJ0  *\$  "OC   K]@  *O\ DD8  (A+  !_3P  =E$
M &U1  !C4   6DT  $]*  !'1P  /D0  #-    I/   (#@  !<T   1,04
M#"\,  DN$  '+A4 !B\;  4O(P #+RL  C U   P/P  ,$P  #%9   Q:0
M,7P  #&1   QIP  ,+\  ##A   P]0  +_\ D$L  (90  !]5   =58  &M6
M  !B50  6%,  $Y0  !%30  .DD  "]%   E0@  '#X  !0[   ..04 "3<+
M  0V#P !-A,  #89   V(   -BD  #8R   W/0  -TD  #=7   W9P  -WD
M #>/   VI0  -KT  #;@   U]0  -?\ C5   (16  !\6@  <EL  &E;  !@
M6P  5UD  $Q6  ! 4@  -4X  "I+   @2   %T8  !!#   +000 !$ *   _
M#@  /A$  #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4   ^9   /G8  #V,
M   ]HP  /+L  #S>   []0  ._\ BE<  ()<  !Y7P  <&$  &AA  !?80
M5%X  $=;   Z5P  +U4  "52   ;4   $DT   Q+   &2@,  $D)  !(#0
M1Q   $<4  !&&@  1B(  $8L  !&-P  1D,  $91  !&8   17,  $6)  !$
MH   1+@  $/<  !"]0  0O\ B%T  ']B  !W90  ;F<  &=H  !;9@  3F,
M $%A   T7@  *5P  !]:   55P  #E8   =4    4P$  %(&  !1"P  40X
M % 1  !/%@  3QX  $\G  !/,@  3S\  $]-  !.70  3F\  $Z%  !-G0
M3+4  $O8  !*]0  2O\ A64  'QI  !T;   ;6X  &)M  !4:P  1VD  #IG
M   M90  (F0  !AB   08   "5\   !>    7@   %T#  !<"   6PP  %H/
M  !:$P  61D  %DB  !9+0  63H  %E(  !86   6&L  %>!  !7F0  5K(
M %72  !4]   4_\ @6P  'EP  !S<P  :',  %IR  !,<0  /W   #)O   E
M;@  &FP  !%K   ):@   &H   !I    :0   &@   !G P  9@@  &8,  !F
M#P  910  &4<  !E)P  9#0  &1#  !D4P  9&4  &-[  !BE   8:T  &#-
M  !?\0  7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0  -G@  "EX   <=P
M$78   IU    =0   '4   !V    =0   '0   !T    <P(  ','  !S#
M<A   '(5  !R(   <BP  '([  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L
M[0  :_\ >WL  ')^  !D?@  57\  $>    Y@0  *X(  !Z!   2@0  "H$
M  "!    @@   (,   "#    @P   ((   ""    @@   ((   ""!0  @@H
M ((/  ""%P  @B,  ((R  ""0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@
M?/P =H(  &B#  !9A0  2X<  #R)   NB@  ((L  !.+   *BP   (P   "-
M    CP   )$   "2    D0   )$   "1    D0   )$   "2    D@(  ),)
M  "4#P  E!D  )0G  "4.   E$P  )-B  "3?   DY@  )*S  "1V   D/8
M:H@  %R*  !-C0  /Y   #"2   AE   %)4   J6    EP   )D   ";
MG0   )\   "@    H    *    "@    H0   *(   "C    I    *4   "F
M!P  J!   *@<  "H+0  J4   *E6  "I;P  J8L  *BH  "GQP  INP 7X\
M %"2  !!E@  ,YD  ".<   4G0  "I\   "A    HP   *8   "H    K
M *X   "O    KP   +    "P    L@   +,   "T    M@   +<   "Z
MO0<  +\0  "_'P  P#,  ,!)  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;
M   UGP  )J,  !:E   +IP   *H   "M    L    +,   "V    NP   +T
M  #     OP   ,$   #"    Q    ,8   #(    R@   ,P   #/    TP
M -H'  #;$P  W24  -X[  #?4P  X&X  -^,  #=J0  W<( _P   /\   #_
M    _P   /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$
M60#O %X [0!D .L :0#I &\ YP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q
M -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\ _P   /\   #_
M_P   /\  @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8
M %@ U !> -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8 D #" )L P "I +X
MN@"[ -D N0#W +@ _P"T /\ J0#_ *( _P"= /\ _P   /\   #_    ]@
M .X   #G  H X0 1 -P &@#7 ", T  N ,L -P#' #\ Q !& ,$ 30"_ %(
MO0!8 +L 70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F
M ,@ I #M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P   #N    XP   -@
M  #-  4 Q@ . ,$ %0"] !X N0 G +4 , "R #@ KP!  *P 1@"J $P J !1
M *< 5@"E %L HP!A *$ 9P"? &X G@!V )L @ "9 (P EP"9 )0 J "2 +P
MD #? (X ^P". /\ BP#_ (8 _P"# /\ ^    .D   #<    S    ,$   "X
M    L@ * *P $0"H !@ I0 A *( *0"> #( G  Y )D /P"7 $4 E0!* )0
M4 "2 %4 D !: (\ 8 "- &< BP!O (D > "& (0 A "1 (( H "  +( ?0#,
M 'P \0![ /\ >@#_ '< _P!U /\ Y@   -,   #&    NP   +$   "G
MH0 % )L #0"7 !, DP ; )  (P", "L B@ R (@ . "& #X A !$ (( 20"!
M $X ?P!3 'T 60![ &  >0!H '< <0!U 'P <P") '  F !O *D ;0"_ &L
MY@!J /\ :0#_ &D _P!G /\ TP   ,,   "U    JP   *,   ";    D@
M (P "@"' !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@
M;P!- &T 4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!? *( 7@"V %P U0!;
M /< 6P#_ %H _P!: /\ Q0   +8"  "I @  GP   )8   ".    AP   (
M!0!Z  P =0 1 '$ & !N !X :P E &D *P!G #$ 9@ W &0 / !C $$ 80!'
M %\ 30!> %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L 40"N %  R !/ .X
M3@#_ $X _P!- /\ NPH  *P-  "@#0  E0P  (P(  "# @  ?    '4   !N
M  @ :0 . &4 $P!B !D 7P ? %T )0!; "L 60 Q %@ -@!6 #L 50!! %,
M1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\
M $( _P!" /\ LA$  *44  "9%0  CA,  (01  ![#0  <P@  &P   !E  ,
M7P + %L #P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!&
M $@ 10!0 $, 60!! &, /P!O #X ?@ \ )  .P"C #H N  Y -D . #U #@
M_P X /\ K!<  )\;  "3'0  B1P  '\9  !U%0  ;!   &0,  !=!@  5@ &
M %$ # !- !  2@ 5 $< &@!% "  1  F $( *P!! #$ /P V #X /0 \ $0
M.P!+ #D 5  W %\ -@!K #0 >@ R (P ,0"> #  LP O ,X +P#O "X _P N
M /\ IQX  )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#
M" !%  T 00 1 #X %@ \ !L .@ A #D )@ W "P -@ R #0 .  S #\ ,0!'
M #  4  N %L +0!G "L =@ J (@ * "< "< L  F ,D )0#J "4!^P E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
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M______________________________________________\
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M^?K[_/W^_VUF=#$      P$A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M________M8!5, H &6"R_______________________________/=#4+
M"E*G______________________________^6-        $^G____________
M__________________9I'0  "0P&"5*Q____________________________
M_\L[#A,U3%M-3%[#_____________________________ZE@-F"&G[:LJ;C9
M_____________________________^"7C;[E________________________
M_______________M^?__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z]G*O,?_________________________
M_________\^:@6U:1HCJ________________________________Q'P^)A
M %2P_______________________________@@SP      "Z'[?__________
M__________________^L4Q       !=MUO__________________________
M__N ,0        EAS/___________________________]): @        !=
MS/___________________________Z@U          !<T_______________
M_____________WT-          !4UO__________________________[GU%
M          !$U/___________________________*ID+P(   0B-TE8SO__
M_________________________^FD:T$H/V-_E:>ZVO__________________
M____________U;*LLLSD^O______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________Y;N7
M=V+(_________________________________]N>9S8*  *,____________
M____________________R'\_!0    !>S___________________________
M___9@3D        \JO____________________________^>3          C
MD/___________________________]QO&@         0??G_____________
M_____________Z](            ;^[__________________________X03
M            9.;_________________________[%$             5][_
M________________________N!4             2-;_________________
M________=!0             .,_________________________YHEH3
M        (\7_________________________WYM<+           #;K_____
M_____________________^^Q?54Y(A$' 0(1(K+_____________________
M_________]^_I9F8FJ"LO=K_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^.^G8!\^___________________________
M______*WA%<P#@ =K/______________________________THI,%0
M<O/____________________________6?S8         2\G_____________
M______________J1/@          +ZO__________________________\!:
M            &I7__________________________XTD            "(3_
M________________________YUX              '?_________________
M________M"4              &K_________________________?0
M         %OT_______________________]*P               $SK____
M__________________^E                 #SA____________________
M__\P#                "W9_____________________YF*82<
M     "?7_______________________MOHE5)P           "7<________
M__________________[*G79=2CPR+2PP.4?>________________________
M_______]YMW6TM#3V>3_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[]2[
MUO_________________________________GN(]J2R\5;_______________
M________________Y*%G- <     /,G____________________________6
M@CL         $I?__________________________^V%,0           &__
M_________________________Z9"             %#A________________
M________[&D              #?)________________________LR\
M         "*V________________________>0               !"G____
M___________________R-                 "9____________________
M__^I                  ",______________________]&
M      !______________________]\                   !T________
M_____________Y<                   !J_____________________\X
M                  !C______________________\I(@$
M  !A______________________^YHX!7-Q<           !H____________
M_______________ZTZZ4AGQU<7!R=X&4____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____]NZG8)I:=/______________________________\B393T9    '9[_
M___________________________;CDP3         &[_________________
M_________]M\+            $77_________________________XLJ
M         "*T________________________PD0               .7____
M____________________?0$               !_____________________
M___G-@                !J______________________^=
M      !8______________________]&                  !'^/______
M_____________^D                    UZ?___________________Y8
M                   EV____________________[P
M   8SO___________________^L                    /PO__________
M__________\                    *N?____________________\G
M               *M?____________________]P                   -
MN?_____________________@G(QP54(S)AL4#PT.$AHFO_______________
M______________GDV-+.S,O,S];@_/______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^O3O./_________________
M_______________2J85E2"P2 87____________________________QJW$\
M#P       $_@_________________________]5_-0           !^R____
M____________________XW4=              ")____________________
M____D",               !G_______________________50P
M      !(]O____________________^*                   NW?______
M______________\X                   7R/___________________[X
M                   $MO___________________YP
M    I?___________________[H                     D___________
M_________]P                     @O____________________\
M                =/____________________\3
M:/____________________]"                    8/______________
M______]Z                    7?_____________________1
M            8?______________________)                   9O__
M____________________R:R9B7UV<6QI9V9G:W!ZC/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^+%JI%Y87?_____
M________________________W:9W4"P,     #'$____________________
M_____^"23A,           "/________________________TG =
M      !@_______________________N;P\                WXO______
M______________^6'                  4P/____________________]
M                    H____________________ZX
M    B?___________________YX                     <O__________
M_________[P                     7____________________]H
M                3?____________________H
M._____________________\.                    *OG_____________
M______\S                    &^G___________________]>
M            #]O___________________^/                    !M#_
M___________________0                     ,K_________________
M____*P                   ,C_____________________@
M         ,O_____________________]Q8!!04# 0       08-&,O_____
M__________________SKX=C/S,W/T-+4U]SBZO______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________QVL;_______________________________'&HX1H
M33(8 !6K__________________________^Y?$88          !Q________
M________________UWPO               [X______________________?
M9 D                ,M?____________________]T P
M    C?___________________\45                    :O__________
M_________YD                     2____________________[8
M                ,/W__________________]<
M&>?___________________8                     !=/_____________
M______\.                     ,'___________________\O
M             *____________________]2                     )[_
M__________________]Y                     ([_________________
M__^E                     (#____________________8
M         '3_____________________-@                   &W_____
M________________?                    &G_____________________
MUPT                  &C______________________W
M     &'_______________________]0/$9.5%E=861H;'!V?HG_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^_5NZ.+<UJ5________________________
M___XOXYD02$%      !2_/______________________]YU6&
M   7P?_____________________E;!8                 C?__________
M__________]C                    7O___________________YT
M                -?S__________________Z$
M$=G__________________\H                      +O_____________
M_____^X                      *'___________________\,
M             (K___________________\M                     ';_
M__________________]-                     &3_________________
M__]O                     %+___________________^4
M         $#___________________^\                     ##_____
M_______________J#@                   "+_____________________
M1                    !7_____________________@0
M      OU____________________R L                   +L________
M_____________UX                   #E_____________________\D<
M                  #:______________________^= 0             '
M#A?%________________________U;F\P<?.U=OAYNWT^_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M^-_/_____________________________^S&I8AM5#LA!P RWO__________
M_____________]>262D             H/______________________B38
M                9_____________________]F
M,O;__________________Y4                      \C_____________
M_____Z<                      *#__________________]<
M             'S___________________\                      %[_
M__________________\E                     $/_________________
M__](                     "S___________________]J
M         !C___________________^+                      7S____
M______________^O                      #A___________________5
M                      #/____________________)
M      "^____________________5                     "N________
M____________BP                    "?____________________RPX
M                  "2_____________________U<
M  "&_____________________ZH*                  !Y____________
M__________]M                  !F_______________________W50
M              !%_________________________VHC*S4_2E5@:G5^AY&<
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______HS[:=@VE.N?_________________________LLH-<.AT"
M>_______________________Q6TI                0/______________
M______^#&P                  !\O__________________Y(
M             )C__________________Z0                      &K_
M_________________]T                      $'_________________
M__\.                     !W___________________\Y
M          #H__________________]@                      #.____
M______________^%                      "W__________________^H
M                      "C___________________+
M      "0___________________O%@                    !]________
M____________/@                    !L____________________:0
M                  !:____________________F0
M  !)____________________TA8                    Y____________
M_________U@                    I_____________________Z(
M               9______________________56                   $
M______________________^[+P                  ^/______________
M________JRD                 S________________________\E'
M  <3("X^4FB$[?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________35R?______________
M______________K2L))W74(H#   2O_______________________\5]11<
M            $=C____________________$4                    )__
M_________________Z(,                     &C_________________
M_Y0                      #;__________________]H
M          ?L__________________\5                      #$____
M______________](                      "B__________________]U
M                      "#__________________^=
M      !I___________________#                      !2________
M___________G#P                     ^____________________,P
M                   K____________________6
M   8____________________@0                     %____________
M________K                       ____________________WB(
M                \O___________________UP
MW____________________Y\                     S/______________
M_____^A*                    M_____________________^@%@
M            G/______________________>@(                 =___
M_____________________WH+               %3/__________________
M______^B5VAT@(V<J[S0Y_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________MX___
M________________________TJ-Z6#HI(QP6#@8  )__________________
M____K%(.                 &G__________________^1#
M         #3__________________WD                       #C____
M_____________\T                       "R__________________\3
M                      "%__________________]/
M      !=__________________^#                       Z________
M__________^R                       <___________________; P
M                   "____________________*@
M    ^___________________3P                      Y___________
M________=                       U/__________________FP
M                P/__________________Q <
MK?__________________\#,                     FO______________
M_____V<                     AO___________________Z,
M            <O___________________^-$                    7/__
M__________________^1!@                  0?__________________
M___K7P                  '?______________________RDL
M         /_______________________\M7   ,&"0Q/TY@=(NGQ_______
M____________________U^?R____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________Z]3-Q\*^NK>SL*VIJ*7_____
M_______________=?E,_,",9$0D"          #;_________________W8
M                      "G_________________[H
M      !U__________________\'                      !&________
M__________].                       :__________________^,
M                    _?_________________!
M    V__________________Q&0                      OO__________
M________1                       I/__________________:P
M                C?__________________D0
M>?__________________MP                      9O______________
M____WB$                     4____________________TH
M            /____________________W<                     *___
M_________________ZP*                    %O__________________
M_^=%                     /____________________^*
M         /_____________________630                   /W_____
M________________IRX                  -7_____________________
M_Y@J           &&"U%8.#_______________________^H8W2!CYRKN\WB
M^O__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
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M P$1  (1 0,1 ?_$ !X   ,  @,! 0$            )"@<( P8+! 4!_\0
M51   0(% @0#! 4%"@83     00% @,&!Q$((0 )$C$4%4$3%B)1"B0E87$7
M(X&A\"8R,S4X0U*1L<$8)S1"=-$9&C8W.49'2%-66&1U>)?6X>+Q_\0 ' $
M 04! 0$               0%!@<( P$"_\0 2!$  @$"!0($ P0'! @$!P
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M<V(L9P@K430*B()DJ)F9GR^BD]XL/6X)R$(81VA [;D?/\=_Q!QCCG)]<?,
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M-]<?%E(Q4^U+'1S5!,C\:L"-H2'QJX> 2=SL3$!GL>-8:AG<A3R;97465!M
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MO11K&=A@=JR6 C<1-@"9DDE0)$ D,08.VD_#SI!>K>L"[[Q1HTS5K%8#"FK
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MM.587$$J#ZRTGG\;6'TPZ#Z.!@:0KW8/_.+="-]]K56P.?QSOM^K;BIO%?\
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M\O7VY##"^C$-)ZIJV>ZASA.=,2( "Q ))CF;W4D&2"29F^4M?U[.]8ZXU74
M%9B%5!Y5IJ+*B@?L*/D!+%R-Q)>3BG7EL:?W:P6GI%(J-#.;:OKM?[[/[>I3
MQIE;=$X(D21M9U4.((9:]O9TDB%S;Q',#8[^VAQ#!T117;TSH^9TC25IFU1O
M,18&"0O(O$$\P%8 02#&NO#+IMNFNFZ.6JJ5K5'^-46"&56 "(2+R%!;88(+
MD$!@PQ*OSYH@.8I7F,?[@K:1#)SD14]\/IC< '&?3Y<;0\(J^6_T:?(5 0QJ
MUF@\":K[;WX !!_.0<7_ *0OVC22H-E ![&P,\@3<WGDF\B<.>^C>QB'23>B
M8>T&HAV)P1W-N;7PXVW/8X^_UQQ6?BX)ZE(X_4=X'-0VB?41_488==09<H/^
M<_F(GZ^8>T^V% <\[2(\V*U6/-Z6II4FU>H=4:F1N28X2-%SPCB%7LRU61F%
MQ7+0:W;80/MF<\QR]C#'BQ/"WJ;)YK1CT]GN:7D!/>G(V$ -(4HH63 ^(E0
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M8=6FEA.$Z:4.J 0$P1CU&_ZL]CG'<_,<6+&8$1!%Y)@Q]]N_UQ<JA:0^$ 1
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M5\,LG(,8UKQ9T73F;,:4OQJP!)4&*0)X^)6@HJD@!BOQ*B_,*;1A%5UC[*1
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E A"2%)< $LT"2[V@@")5ZP8R!: /-' $R8M?<01)G:/,;1__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
